10-Q

UNITED STATES 

SECURITIES AND EXCHANGE COMMISSION 

Washington, DC 20549

FORM 10-Q

☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the quarterly period ended September 30, 2023

OR

☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the transition period from __________ to __________  

Commission File Number: 001-36242

DMK PHARMACEUTICALS CORPORATION  

(Exact name of registrant as specified in its charter)

Delaware	82-0429727
(State or other jurisdiction  of incorporation or organization)	(I.R.S. Employer  Identification Number)

11622 El Camino Real, Suite 100, San Diego, CA 92130

(Address of principal executive offices, including zip code) 

(858) 997-2400

(Registrant’s telephone number, including area code)

Securities registered pursuant to Section 12(b) of the Act: 

Title of each class	Trading Symbol(s)	Name of each exchange on which registered
Common Stock	DMK	NASDAQ Capital Market

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Sections 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes ☒  No ☐

Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). Yes ☒  No ☐

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.

Large accelerated filer	☐	Accelerated filer	☐
Non-accelerated filer	☒	Smaller reporting company	☒
		Emerging growth company	☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes ☐  No ☒

The number of shares outstanding of the issuer’s common stock, par value $0.0001 per share, as of November 13, 2023, was 10,102,050.

DMK PHARMACEUTICALS CORPORATION AND SUBSIDIARIES

CONTENTS OF QUARTERLY REPORT ON FORM 10-Q

		Page
PART I FINANCIAL INFORMATION
Item 1.	Financial Statements (Unaudited):
	Condensed Consolidated Balance Sheets at September 30, 2023 (Unaudited) and December 31, 2022	3
	Condensed Consolidated Statements of Operations (Unaudited) for the Three Months and Nine Months Ended September 30, 2023 and 2022	4
	Condensed Consolidated Statements of Mezzanine Equity and Stockholders’ Deficit (Unaudited) for the Three Months and Nine Months Ended September 30, 2023 and 2022	5
	Condensed Consolidated Statements of Cash Flows (Unaudited) for the Nine Months Ended September 30, 2023 and 2022	6-7
	Notes to Condensed Consolidated Financial Statements (Unaudited)	8
Item 2.	Management’s Discussion and Analysis of Financial Condition and Results of Operations	25
Item 3.	Quantitative and Qualitative Disclosure of Market Risk	33
Item 4.	Controls and Procedures	33
PART II OTHER INFORMATION
Item 1.	Legal Proceedings	34
Item 1A.	Risk Factors	36
Item 2.	Unregistered Sales of Equity Securities, Use of Proceeds and Issuer Purchases of Equity Securities	56
Item 3.	Defaults Upon Senior Securities	56
Item 4.	Mine Safety Disclosures	56
Item 5.	Other Information	56
Item 6.	Exhibits	57
Signatures		58

2   

PART I FINANCIAL INFORMATION

Item 1. Financial Statements

DMK PHARMACEUTICALS CORPORATION AND SUBSIDIARIES 

UNAUDITED CONDENSED CONSOLIDATED BALANCE SHEETS

	September 30, 2023			December 31, 2022
ASSETS
CURRENT ASSETS
Cash and Cash Equivalents	$	6,663,921		$	1,081,364
Restricted Cash		—			30,068
Accounts Receivable, net		—			1,054,058
Inventories		662,962			1,238,778
Prepaid Expenses and Other Current Assets		539,772			1,914,966
Current Assets of Discontinued Operations		5,406			3,952,916
Total Current Assets		7,872,061			9,272,150
LONG TERM ASSETS
Fixed Assets, net		1,075,676			1,288,894
Right-of-Use Assets		—			317,622
Other Non-Current Assets		9,674			52,174
Total Assets	$	8,957,411		$	10,930,840
LIABILITIES, MEZZANINE EQUITY AND STOCKHOLDERS’ DEFICIT
CURRENT LIABILITIES
Accounts Payable	$	9,973,413		$	7,937,493
Deferred Revenue, current portion (including $145,000 and $0 associated with variable interest entity at September 30, 2023 and December 31, 2022, respectively)		172,779			27,779
Accrued Other Expenses		2,323,738			1,510,053
Product Recall Liability		—			305,806
Lease Liabilities, current portion		63,209			342,562
Current Liabilities of Discontinued Operations		929,328			1,272,173
Total Current Liabilities		13,462,467			11,395,866
LONG TERM LIABILITIES
Deferred Revenue, net of current portion		157,413			178,247
Warrant Liabilities, at fair value		302,170			7,492
Total Liabilities		13,922,050			11,581,605
COMMITMENTS AND CONTINGENCIES (Note 13)
MEZZANINE EQUITY
Convertible Preferred Stock - Par Value $0.0001;  10,000,000 Shares Authorized: Series C Preferred Stock 3,000 Shares Authorized, liquidation preference $110 per share; 3,000 Issued and Outstanding at September 30, 2023 and December 31, 2022, respectively.		330,000			157,303
STOCKHOLDERS’ DEFICIT
Convertible Preferred Stock - Par Value $0.0001; 10,000,000 Shares Authorized; Series E Preferred Stock 1,941.2 Shares Authorized, 1,212 Issued and Outstanding at September 30, 2023 and no Shares Authorized, Issued and Outstanding at December 31, 2022		—			—
Common Stock - Par Value $0.0001; 200,000,000 Shares Authorized; 10,102,050 and 2,150,051 Issued, 10,094,580 and 2,142,581 Outstanding at September 30, 2023 and December 31, 2022, respectively.		1,010			215
Additional Paid-in Capital		318,178,762			303,761,053
Accumulated Deficit		(323,469,161	)		(304,564,086	)
Treasury Stock - 7,470 Shares, at cost		(5,250	)		(5,250	)
Total Stockholders’ Deficit		(5,294,639	)		(808,068)
Total Liabilities, Mezzanine Equity and Stockholders’ Deficit	$	8,957,411		$	10,930,840

The accompanying notes are an integral part of these Condensed Consolidated Financial Statements

3   

DMK PHARMACEUTICALS CORPORATION AND SUBSIDIARIES 

UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS

	Three Months Ended September 30,						Nine Months Ended September 30,
	2023			2022			2023			2022
Revenue, net	$	9,062		$	1,505,683		$	1,469,007		$	2,605,396
Costs of goods sold		338,488			1,647,585			2,487,948			3,705,697
Gross Loss		(329,426	)		(141,902	)		(1,018,941	)		(1,100,301	)
OPERATING EXPENSES
Selling, General and Administrative		2,517,161			2,508,176			11,332,333			10,096,807
Research and Development		418,518			1,977,939			2,106,004			9,520,118
Acquired In-Process Research and Development (IPR&D)		—			—			6,539,675			—
Loss from Operations		(3,265,105	)		(4,628,017	)		(20,996,953	)		(20,717,226	)
OTHER INCOME (EXPENSE)
Interest Income		13,835			19,699			14,549			40,021
Interest Expense		(29,465	)		—			(135,808	)		—
Other Income (Expense)		773,764			278,419			1,183,781			(419,413	)
Loss on PPP2 loan		—			—			—			(1,787,417	)
Excess of March 2023 Warrant Fair Value over Offering Proceeds		—			—			(2,476,109	)		—
Change in Fair Value of Warrants		770,723			58,690			4,656,292			87,618
Total Other Income (Expense), net		1,528,857			356,808			3,242,705			(2,079,191	)
Net Loss from Continuing Operations		(1,736,248	)		(4,271,209	)		(17,754,248	)		(22,796,417	)
DISCONTINUED OPERATIONS
Net Income(Loss) from Discontinued Operations		348,202			(127,692	)		(1,150,827	)		(354,320	)
Net Loss Applicable to Common Stock	$	(1,388,046	)	$	(4,398,901	)	$	(18,905,075	)	$	(23,150,737	)
Basic and Diluted Loss Per Share:
Continuing Operations	$	(0.25	)	$	(1.99	)	$	(4.53	)	$	(10.65	)
Discontinued Operations	$	0.05		$	(0.06	)	$	(0.29	)	$	(0.17	)
Basic and Diluted Loss Per share	$	(0.20	)	$	(2.05	)	$	(4.82	)	$	(10.82	)
Basic and Diluted Weighted Average Shares Outstanding		7,065,673			2,142,618			3,957,733			2,140,097

The accompanying notes are an integral part of these Condensed Consolidated Financial Statements

4   

DMK PHARMACEUTICALS CORPORATION AND SUBSIDIARIES

UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF MEZZANINE EQUITY AND STOCKHOLDERS’ DEFICIT  

For the Three Months Ended September 30, 2023	(Mezzanine Equity) Convertible Preferred Stock				Convertible Preferred Stock					Common Stock				Additional  Paid-In			Treasury Stock					Accumulated			Stockholders'
	Shares		Amount		Shares			Amount		Shares		Amount		Capital			Shares		Amount			Deficit			Deficit Total
Balance June 30, 2023		3,000	$	330,00		1,941.2		$	—		2,797,865	$	280	$	310,260,759			7,470	$	(5,250	)	$	(322,081,115	)	$	(11,825,326	)
Issuance of Common Stock and Warrants in August 2023 Financing, net of issuance costs of $912,751		—		—		—			—		4,800,000		480		7,092,156			—		—			—			7,092,636
Conversion of Series E Preferred Stock into Common Stock		—		—		(729.2	)		—		729,200		73		(73	)		—		—			—			—
Issuance of Common Stock upon exercise of Prefunded Warrants		—		—		—			—		1,129,985		113		(73	)		—		—			—			40
Issuance of Common Stock upon exercise of Common Stock Warrants		—		—		—			—		645,000		64		870,686			—		—			—			870,750
Share Based Compensation		—		—							—		—		(44,693	)										(44,693	)
Net Loss		—		—		—			—		—		—		—			—		—			(1,388,046	)		(1,388,046	)
Balance September 30, 2023		3,000	$	330,000		1,212.0		$	—		10,102,050	$	1,010	$	318,178,762			7,470	$	(5,250	)	$	(323,469,161	)	$	(5,294,639	)
For the Nine Months Ended September 30, 2023
Balance December 31, 2022		3,000	$	157,303		—		$	—		2,150,051	$	215	$	303,761,053			7,470	$	(5,250	)	$	(304,564,086	)	$	(808,068	)
March 2023 Offering		—		—		—			—		235,714		24		(24	)		—		—			—			—
Accretion of Series C Preferred Stock		—		172,697		—			—		—		—		(172,697	)		—		—			—			(172,697	)
Issuance of Series E Preferred Stock pursuant to DMK Merger		—		—		1,941.2			—		—		—		4,853,000			—		—			—			4,853,000
Common Stock Issuance pursuant to DMK Merger		—		—		—			—		302,815		30		757,008			—		—			—			757,038
Assumption of DMK options pursuant to DMK Merger		—		—		—			—		—		—		415,809			—		—			—			415,809
Issuance of Common Stock and Warrants in the August 2023 Financing, net of issuance costs of $912,751		—		—		—			—		4,800,000		480		7,092,156			—		—			—			7,092,636
Issuance of Common Stock upon Exercise of Pre-funded Warrants		—		—		—			—		1,237,127		124		525,045			—		—			—			525,169
Issuance of Common Stock upon Exercise of Common Stock Warrants		—		—		—			—		645,000		64		870,686			—		—			—			870,750
Issuance of Common Stock upon Vesting of Restricted Stock Units (RSUs)		—		—		—			—		2,143		—		—			—		—			—			—
Conversion of Series E Preferred Stock into Common Stock		—		—		(729.2	)		—		729,200		73		(73	)		—		—			—			—
Stock Based Compensation		—		—		—			—						76,799			—		—			—			76,799
Net Loss		—		—		—			—						—			—		—			(18,905,075	)		(18,905,075	)
Balance September 30, 2023		3,000	$	330,000		1,212		$	—		10,102,050	$	1,010	$	318,178,762			7,470	$	(5,250	)	$	(323,469,161	)	$	(5,294,639	)
For the Three Months Ended September 30, 2022
Balance June 30, 2022		—	$	—		—		$	—		2,150,051	$	215	$	303,884,827			7,470	$	(5,250	)	$	(296,837,649	)	$	7,042,143
Issuance of Series C Preferred Stock, net of issuance costs of $8,300		3,000		157,303		—			—		—		—		—			—		—			—			—
Issuance of 750,000 Warrants, pursuant to the Series C Preferred Stock issuance, net of issuance costs of $6,700		—		—		—			—						127,697			—		—			—			127,697
Stock Based Compensation															74,488			—		—			—			74,488
Net Loss		—		—		—			—						—			—		—			(4,398,901	)		(4,398,901	)
Balance September 30, 2022		3,000	$	157,303		—		$	—		2,150,051	$	215	$	304,087,012			7,470	$	(5,250	)	$	(301,236,550	)	$	2,845,427
For the Nine Months Ended September 30, 2022
Balance December 31, 2021		—	$	—		—		$	—		2,144,494	$	214	$	303,973,627			7,470	$	(5,250	)	$	(278,085,813	)	$	25,882,778
Issuance of Series C Preferred Stock, net of issuance costs of $8,300		3,000		157,303		—			—		—		—		—			—		—			—			—
Issuance of 750,000 Warrants, pursuant to the Series C Preferred Stock issuance, net of issuance costs of $6,700		—		—		—			—		—		—		127,697			—		—			—			127,697
Issuance of Common Stock upon Vesting of Restricted Stock Units (RSUs)		—		—		—			—		5,557		1		(1	)		—		—			—			—
Share Based Compensation		—		—		—			—						(14,311	)		—		—			—			(14,311	)
Net Loss		—		—		—			—						—			—		—			(23,150,737	)		(23,150,737	)
Balance September 30, 2022		3,000	$	157,303		—		$	—		2,150,051	$	215	$	304,087,012			7,470	$	(5,250	)	$	(301,236,550	)	$	2,845,427

The accompanying notes are an integral part of these Condensed Consolidated Financial Statements      

5   

DMK PHARMACEUTICALS CORPORATION AND SUBSIDIARIES 

UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS

	Nine Months Ended September 30,
	2023			2022
CASH FLOWS FROM OPERATING ACTIVITIES
Net Loss	$	(18,905,075	)	$	(23,150,737	)
Less: Loss from Discontinued Operations		1,150,827			354,320
Adjustments to Reconcile Net Loss to Net
Cash Used in Operating Activities:
Acquired IPR&D		6,539,675			—
Stock Based Compensation		76,799			(14,311	)
Excess of March 2023 Warrant Fair Value over Offering Proceeds		2,476,109			—
Change in Fair Value of Warrant Liability		(4,656,292	)		(87,618	)
Cash Payments in Excess of Lease Expense		(78,665	)		(12,081	)
Impairment of Right-of-Use Assets		116,934			—
Depreciation Expense		264,012			1,111,495
Receivable from Fagron		—			919,413
Change in Operating Assets and Liabilities:
Accounts Receivable		1,054,058			(490,940	)
Inventories		575,816			(673,838	)
Prepaid Expenses and Other Current & Non-Current Assets		1,318,090			567,094
Accounts Payable		1,580,139			1,319,707
Product Recall Liability		(305,806	)		(1,591,870	)
Deferred Revenue (including $145,000 and $0 associated with variable interest entity for the nine months ended September 30, 2023 and 2022, respectively)		(22,952	)		(637,030	)
Accrued Other Expenses		1,108,448			(1,552,766	)
Net Cash Used in Operating Activities of Continuing Operations		(7,707,883	)		(23,939,162	)
Net Cash Used in Operating Activities of Discontinued Operations		(145,429	)		(439,301	)
Net Cash Used in Operating Activities		(7,853,312	)		(24,378,463	)
CASH FLOWS FROM INVESTING ACTIVITIES
Purchase of Equipment		—			(588,923	)
Cash Acquired in DMK Acquisition		136,089			—
Proceeds from Receivable from Fagron		12,104			3,917,530
Net Cash Provided by Investing Activities of Continuing Operations		148,193			3,328,607
Net Cash Provided by Investing Activities of Discontinued Operations		2,599,267			—
Net Cash Provided by Investing Activities		2,747,460			3,328,607
CASH FLOWS FROM FINANCING ACTIVITIES
Proceeds from March 2023 Offering related to Common Stock Warrant		2,099,862			—
Proceeds from March 2023 Offering related to Prefunded Warrant		899,388			—
March 2023 Offering Issuance Costs		(275,000	)		—
Proceeds from Exercise of Prefunded Warrant		790			—
Proceeds from August 2023 Financing		8,005,387			—
August 2023 Financing Issuance Costs		(912,751	)		—
Proceeds from Exercise of August 2023 Common Stock Warrants		870,750			—
Proceeds from Issuance of Preferred Stock and Warrants, net		—			285,000
Net Cash Provided by Financing Activities of Continuing Operations		10,688,426			285,000
Net Cash Provided by Financing Activities of Discontinued Operations		—			—
Net Cash Provided by Financing Activities		10,688,426			285,000
Increase (Decrease) in Cash and Cash Equivalents and Restricted Cash		5,582,574			(20,764,856	)
Cash and Cash Equivalents, and Restricted Cash
Beginning Balance		1,111,432			23,250,793
Decrease in Cash and Restricted Cash Equivalents of Discontinued Operations		(30,085	)		(35,921	)
Ending Balance	$	6,663,921		$	2,450,016

The accompanying notes are an integral part of these Condensed Consolidated Financial Statements

6   

DMK PHARMACEUTICALS CORPORATION AND SUBSIDIARIES 

UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS

	Nine Months Ended September 30,
	2023			2022
	(Unaudited)			(Unaudited)
RECONCILIATION OF CASH & CASH EQUIVALENTS AND RESTRICTED CASH
Cash & Cash Equivalents	$	6,663,921		$	2,419,960
Restricted Cash		—			(30,056	)
Total Cash & Cash Equivalents and Restricted Cash	$	6,663,921		$	2,450,016
SUPPLEMENTAL DISCLOSURE OF CASH FLOW INFORMATION
Cash Paid for Income Taxes	$	—		$	3,625
SUPPLEMENTAL DISCLOSURE OF NONCASH INVESTING ACTIVITIES
Liabilities of DMK assumed from DMK Merger	$	157,461		$	—
Issuance of common stock for DMK Merger	$	(757,038	)	$	—
Issuance of Series E preferred stock for DMK Merger	$	(4,853,000	)	$	—
DMK options assumed and replaced by the Company in connection with the DMK Merger	$	(415,809	)	$	—
Fixed asset additions included in accrued expenses	$	—		$	217,340
SUPPLEMENTAL DISCLOSURE OF NONCASH FINANCING ACTIVITIES
Accretion on Series C Preferred Stock	$	172,697		$	—
Conversion of Series E Preferred Stock to Common Stock	$	73		$	—
Cashless Exercise of August 2023 Prefunded Warrants	$	73		$	—
Exercise of March 2023 Prefunded Warrants	$	524,379		$	—

The accompanying notes are an integral part of these Condensed Consolidated Financial Statements

7   

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (UNAUDITED)

Note 1: Organization and Description of the Business

DMK Pharmaceuticals Corporation (“DMK” or the “Company”) is a specialty biopharmaceutical company focused on developing and commercializing products in the substance use disorder space including treatment of opioid use disorder. Effective September 6, 2023, pursuant to a certificate of amendment to the Company’s restated certificate of incorporation, the Company changed its name from Adamis Pharmaceuticals Corporation to DMK Pharmaceuticals Corporation.

Reverse Stock Split

Effective May 22, 2023, the Company effected a 1-for-70 reverse stock split of its outstanding common stock (the “Reverse Stock Split”). Pursuant to the Reverse Stock Split, every 70 shares of issued and outstanding common stock were automatically combined into one share of common stock, without any change in the par value per share. The Company did not issue any fractional shares in the Reverse Stock Split. The number of authorized shares of common stock under the Company’s restated certificate of incorporation remained unchanged at 200,000,000 shares. Unless otherwise indicated, share numbers, per share data and earnings per share data throughout this Report have been recast retroactively to reflect the Reverse Stock Split.

DMK Merger

On February 24, 2023, the Company entered into an Agreement and Plan of Reorganization (the “Merger Agreement”) with DMK Pharmaceuticals Corporation, a New Jersey corporation (“Legacy DMK”), and Aardvark Merger Sub, Inc. (“Merger Sub”), a Delaware corporation and a wholly-owned subsidiary of the Company (“Merger Sub”). The Merger Agreement provided for the merger (the “Merger”) of Legacy DMK with and into Merger Sub, with Merger Sub surviving as a wholly-owned subsidiary of the Company. Prior to the Merger, Legacy DMK was a privately-held, clinical stage biotechnology company focused on the development and commercialization of potential products for a variety of central nervous disorders. Pursuant to the Merger, each share of common stock of Legacy DMK was converted into the right to receive a number of shares of the Company’s common stock and, in the case of certain Legacy DMK stockholders, shares of our Series E Convertible Preferred Stock, or Series E Preferred.

On May 25, 2023, following a special meeting of stockholders of the Company, the Merger was completed in accordance with the terms of the Merger Agreement. In connection with the Merger, the name of Merger Sub as the surviving corporation was changed to DMK Pharmaceuticals Corporation. In connection with the September 2023 change of the Company’s corporate name, Merger Sub’s corporate name was changed to Adamis Pharmaceuticals Corporation.

As a result of the consummation of the Merger, and after giving effect to the Reverse Stock Split, effective at the closing of the Merger (the “Effective Time”), the shares of Legacy DMK common stock then outstanding were canceled and automatically converted into and became the right to receive a total of 302,815 shares of the Company’s common stock and, with respect to certain former Legacy DMK stockholders, 1,941.2 shares of Series E Convertible Preferred Stock (“Series E Preferred”) of the Company. The Series E Preferred is convertible into shares of the Company’s common stock at a conversion rate of 1,000 common shares for one Series E Preferred share (subject to beneficial ownership limitations of 9.99%).

Note 2: Summary of Significant Accounting Policies

Basis of Presentation and Principles of Consolidation

The accompanying unaudited interim condensed consolidated financial statements have been prepared in accordance with U.S. generally accepted accounting principles for interim financial information and with the instructions to Form 10-Q and Article 8 of Regulation S-X promulgated by the Securities and Exchange Commission (“SEC”). Accordingly, certain information and footnote disclosures normally included in annual financial statements have been condensed or omitted. In the opinion of management, the accompanying unaudited interim condensed consolidated financial statements reflect all adjustments (including normal recurring adjustments and the elimination of intercompany accounts) considered necessary for a fair statement of all periods presented. The results of operations of the Company for any interim periods are not necessarily indicative of the results of operations for any other interim periods or for a full fiscal year. These unaudited interim condensed consolidated financial statements should be read in conjunction with the audited consolidated financial statements and footnotes thereto included in the Company’s Annual Report on Form 10-K for the year ended December 31, 2022 (the “2022 Form 10-K”).

Principles of Consolidation

The condensed consolidated financial statements include the accounts of DMK and its wholly-owned and controlled subsidiaries, Merger Sub (a variable interest entity wherein the Company is the primary beneficiary) and US Compounding, Inc (a discontinued operation) (“USC”). All significant intercompany accounts and transactions have been eliminated in consolidation.

Prior Periods Reclassifications

Certain amounts in prior periods have been reclassified to conform with current period presentation related to the receivable from Fagron included in prepaid expenses and other current assets in the accompanying condensed consolidated balance sheets. Such reclassification had no effect on the total current assets as of December 31, 2022. The reclassification had no effect on the condensed consolidated statement of operations or condensed consolidated statement of cash flows for the periods ended September 30, 2022.

Certain amounts in prior periods have been reclassified to conform with current period presentation related to interest income which was presented separately from the other income (expenses) on the accompanying condensed consolidated statements of operations. Such reclassification had no effect on the total other income (expense), net for the three and nine months ended September 30, 2022. The reclassification had no effect on the condensed consolidated balance sheet as of December 31, 2022 or condensed consolidated statement of cash flows for the periods ended September 30, 2022.

8   

Variable Interest Entity

The purpose of the Merger with Legacy DMK is to expand the Company’s potential product pipeline. The Company intends to focus on developing therapies with novel mechanisms of action to treat conditions, including substance abuse disorders.

The Company has 100% ownership of Merger Sub. In the event Merger Sub requires additional funding to support its operations, the Company would provide such financial support; and any benefits from the development of any of the potential product candidates would be realized by the Company. Additionally, as with any product development program there are risks that could materially impact the Company’s financial condition negatively. Conversely, positive outcomes during product development and/or achieving regulatory approval on a product or drug could materially impact the Company’s financial condition positively. See Note 3, DMK Merger for additional information regarding the VIE.

Assets recognized as a result of consolidating Merger Sub do not represent additional assets that could be used to satisfy claims against the Company’s general assets. Cash specifically must be utilized based on the specific terms of the respective grant in which the monies were received; and any unspent grant funds would be required to be returned at the end of the respective grant term. Conversely, liabilities recognized as a result of consolidating Merger Sub do not represent additional claims of the Company’s general assets; they represent claims against the specific assets of Merger Sub. 

               Assets Held for Sale

The Company considers assets to be held for sale when management approves and commits to a plan to actively market the assets for sale at a reasonable price in relation to its fair value, the assets are available for immediate sale in their present condition, an active program to locate a buyer and other actions required to complete the sale have been initiated, the sale of the assets is expected to be completed within one year and it is unlikely that significant changes will be made to the plan. Upon designation as held for sale, the Company ceases to record depreciation and amortization expenses and measures the assets at the lower of their carrying value or estimated fair value less costs to sell. Assets held for sale are included as other current assets in the Company’s consolidated balance sheets and the gain or loss from sale of assets held for sale is included in the Company’s general and administrative expenses. 

Accrued Other Expenses

Accrued Other Expenses consists of the following as of September 30, 2023 and December 31, 2022:

	September 30, 2023		December 31, 2022
Accrued Expenses – R&D	$	145,806	$	42,400
Accrued Expenses – COGS		1,392,810		1,099,571
Accrued Expenses - Other		601,000		200,363
Accrued PTO		184,122		167,719
Total Accrued Other Expenses	$	2,323,738	$	1,510,053

                Going Concern

The Company’s cash and cash equivalents were approximately $6.7 million and $1.1 million at September 30, 2023 and December 31, 2022, respectively.  

The condensed consolidated financial statements were prepared under the assumption that the Company will continue operations as a going concern, which contemplates the realization of assets and the satisfaction of liabilities during the normal course of business. In preparing these condensed consolidated financial statements, consideration was given to the Company’s future business as described below, which may preclude the Company from realizing the value of certain assets.    

The Company has incurred substantial recurring losses from continuing operations, negative cash flows from operations, and is dependent on additional financing to fund operations. The Company incurred a net loss of approximately $1.4 million and $18.9 million for the three months and nine months ended September 30, 2023, respectively. As of September 30, 2023, the Company had an accumulated deficit of approximately $323.5 million. These conditions raise substantial doubt about the Company’s ability to continue as a going concern within one year after the date the financial statements are issued. The accompanying unaudited condensed consolidated financial statements do not include any adjustments relating to the recoverability and classification of recorded asset amounts and classification of liabilities that might be necessary should the Company be unable to continue in existence.

Management’s plans include attempting to secure additional required funding through equity or debt financing, if available, seeking to enter into a partnership or other strategic agreement regarding, or sales or out-licensing of, its commercial products, product candidates or intellectual property assets or other assets, revenues relating to supply and sale of SYMJEPI and ZIMHI products and share of net profits received relating to sales in the U.S. of our SYMJEPI and ZIMHI products, seeking partnerships or commercialization agreements with other pharmaceutical companies or third parties to co-develop and fund research and development or commercialization efforts of its products.  There can be no assurance that we will be able to obtain required funding in the future. If the Company does not obtain required funding, the Company’s cash resources will be depleted in the near term and the Company would be required to materially reduce or suspend operations, which would likely have a material adverse effect on the Company’s business, stock price and our relationships with third parties with whom the Company have business relationships. If the Company does not have sufficient funds to continue operations, the Company could be required to seek bankruptcy protection, dissolution or liquidation, or other alternatives that could result in the Company’s stockholders losing some or all of their investment in us. The Company has implemented expense reduction measures including, without limitation, employee headcount reductions and the reduction or discontinuation of certain product development programs. Additionally, the Company is not in compliance with certain listing standards of the Nasdaq National Market and there can be no assurance that the Company will be successful in curing the deficiencies and regaining compliance by the applicable cure dates. (See Note 11 for additional information).

9   

 Basic and Diluted Loss per Share 

Under ASC 260, the Company is required to apply the two-class method to compute earnings per share (“EPS”). Under the two-class method both basic and diluted EPS are calculated for each class of common stock and participating security considering both dividends declared (or accumulated) and participation rights in undistributed earnings. The two-class method results in an allocation of all undistributed earnings as if all those earnings were distributed. Considering the Company has generated losses in each reporting period since its inception through September 30, 2023, the Company also considered the guidance related to the allocation of the undistributed losses under the two-class method. The contractual rights and obligations of the preferred stock shares and the warrants were evaluated to determine if they have an obligation to share in the losses of the Company. As there is no obligation for the preferred stock shareholders or the holders of the warrants to fund the losses of the Company nor is the contractual principal or redemption amount of the preferred stock shares or the warrants reduced as a result of losses incurred by the Company, under the two-class method, the undistributed losses are allocated entirely to the common stock securities.

The Company computes basic loss per share by dividing the loss attributable to holders of common stock for the period by the weighted average number of shares of common stock outstanding during the period. Adjustments to the loss attributable to holders of common stock include the accretion on Series C Preferred treated as a dividend. During the three and nine months ended September 30, 2023, the Series C Preferred was accreted $0 and $172,697, respectively. As of September 30, 2023, the carrying value of the Series C Preferred stock represents its full redemption value of $330,000. The numerator in calculating the loss attributable to the holders of common stock was adjusted as follows:

	Three Months Ended September 30, 2023			Nine Months Ended September 30, 2023
Net loss	$	(1,388,046	)	$	(18,905,075	)
Accretion on Series C Preferred		—			(172,697	)
Adjusted Net Loss	$	(1,388,046	)	$	(19,077,772	)

The Series E common stock equivalents are not included in the calculation of diluted EPS as this would be anti-dilutive (since the Company generates net losses). The diluted loss per share calculation is based on the if-converted method for convertible preferred shares and gives effect to dilutive if-converted shares and the treasury stock method and gives effect to dilutive options, warrants and other potentially dilutive common stock. The preferred stock is not considered potentially dilutive due to the contingency on the conversion feature not being tied to stock price or price of the convertible instrument.

Common share equivalents outstanding, determined using the treasury stock method, are comprised of shares that may be issued under the Company’s stock option and warrant agreements. For the warrants accounted as liabilities, at each reporting period the Company evaluates the combined effect of the adjustment to the numerator (assumed beginning of the period exercise) and inclusion of the warrants in the denominator, with the warrants included for the purposes of diluted EPS calculation if such effect is dilutive. The warrants and options were determined to be anti-dilutive for all periods presented.

Potentially dilutive securities, which are not included in diluted weighted average shares outstanding for the period ended September 30, 2023 and 2022, consist of the following (in common stock equivalents):

	September 30,  2023		September 30, 2022
Outstanding Warrants		6,184,323		213,612
Outstanding Options		33,886		63,377
Legacy DMK Options assumed by the Company		231,490		—
Outstanding Restricted Stock Units		7,143		9,286
Series C Preferred stock (if converted)		697,674		—
Series E Preferred stock (if converted)		1,212,000		—

Stock-based compensation

The Company accounts for transactions in which the Company receives services in exchange for restricted stock units (“RSUs”) or options to purchase common stock as stock-based compensation cost based on estimated fair value. Stock-based compensation cost for RSUs is measured based on the closing fair market value of the Company’s common stock on the date of grant. Stock-based compensation cost for stock options is estimated at the grant date based on each option’s fair-value as calculated by the Black-Scholes option-pricing model. The Company accounts for forfeitures as they occur and will reduce compensation cost at the time of forfeiture.

Discontinued Operations

In accordance with ASC 205-20 Presentation of Financial Statements: Discontinued Operations, the Company reports a disposal of a component of an entity or a group of components of an entity as discontinued operations if the disposal represents a strategic shift that has (or will have) a major effect on the Company’s operations and financial results when the component/s meets the criteria in paragraph 205-20-45-10. In the period in which the component meets held-for-sale or discontinued operations criteria, the Company reports the major current assets, noncurrent assets, current liabilities, and noncurrent liabilities as components of total assets and liabilities separate from those balances of the continuing operations. At the same time, the Company reports the results of all discontinued operations, less applicable income taxes, as components of net loss separate from the net loss of continuing operations.

10   

 Note 3: DMK Merger

On May 25, 2023, the Company completed the merger transaction with Legacy DMK. The Company determined that the acquired group, Legacy DMK, is a variable interest entity, or VIE, as Legacy DMK's total equity at risk is not sufficient to permit Legacy DMK to finance its activities without additional subordinated financial support. In accordance with FASB Accounting Standards Codification (“ASC”) Topic 805 “Business Combinations”, the consolidation of Legacy DMK was considered an asset acquisition as substantially all of the fair value of the gross assets acquired were concentrated in DPI-125, a single identifiable asset. The Company was determined to be the primary beneficiary of Legacy DMK (as the Company holds 100% equity ownership in Legacy DMK post-merger, will receive the returns from its operations and is also obligated to absorb any losses of Legacy DMK). Based on applicable accounting guidance, the Company was required to record Legacy DMK's assets and liabilities at fair value. At acquisition date, based on the provisions of ASC Topic 730 "Research and Development", the Company expensed the purchase consideration allocated to the early-stage acquired in-process research and development (acquired IPR&D) because there is no alternative future use related to DPI-125 asset in IPR&D stage. The Company incurred approximately $1.4 million of transaction costs that were included within selling, general and administrative expenses on the condensed consolidated statement of operations.

           The fair value of the acquired IPR&D was determined based upon the income approach using a multi period excess earnings model which included a forecast of the expected cash flows of DPI-125. The discount rate associated with this forecast was 27%.

           The purchase price, or total consideration transferred, to acquire Legacy DMK in the Merger was comprised of the following:

Fair Value of the Company's Common Stock issued to Legacy DMK shareholders	$	757,038
Fair Value of the Company's Series E Preferred issued to Legacy DMK shareholders		4,853,000
Fair Value of Legacy DMK options assumed and replaced by the Company		415,809
Legacy DMK incurred Merger-related costs paid for by the Company		492,456
Total Consideration Transferred	$	6,518,303

The fair value of the  302,815 shares of common stock issued in connection with the Merger is based on the closing price of the Company's common stock on the date of acquisition multiplied by the number of common shares issued.

The fair value of the  1,941.2 shares of Series E Preferred issued in connection with the Merger is based on inputs that are observable or can be corroborated by observable market data (the Company’s closing stock price), and, as such, qualify as Level 2 measurement. The fair value of the Series E Preferred is based on the closing price of the Company's common stock as the Series E Preferred have no preferences over common stock.

Pursuant to the Merger Agreement, at the effective time, the outstanding Legacy DMK stock options to purchase shares of Legacy DMK common stock were assumed by the Company and became options to purchase a total of  231,490 shares of the Company’s common stock, with proportionate adjustments to the exercise prices per share of such options based on the exchange ratio determined pursuant to the Merger Agreement. The assumed options continue to be governed by the terms of the Legacy DMK 2016 Stock Plan, which was assumed by the Company in connection with the closing of the Merger. The assumed options were fully vested and the fair value of the replacement awards was treated as additional purchase price consideration.

The fair value of the replacement awards is based primarily on inputs that are observable or can be corroborated by observable market data (such as the Company’s closing stock price and the published treasury par yield curves from the US Department of the Treasury). The estimated fair value of the replacement options of  $415,809 at the merger closing date was calculated using the Black Scholes Option Pricing Model. The valuation assumptions include the volatility of  119.5%, the Company’s stock price on the date of closing of  $2.50, expected dividend yield of  0.0%, and the terms ranging from  2.37 years to  4.37 years and average risk-free interest rate of 4.06%.

The allocation of the total purchase price is estimated as follows:

Assets Acquired:
Cash	$	136,089
Total assets acquired		136,089
Liabilities Assumed:
Accounts Payable		30
Due to Related Party		1,698
Accrued Expenses		8,615
Deferred Grant Revenue		147,118
Total liabilities assumed		157,461
Net Liabilities acquired		(21,372	)
Acquired IPR&D (DPI-125)		6,539,675
Total Purchase Price	$	6,518,303

11   

Note 4: Discontinued Operations

In July 2021, the Company approved a restructuring process to wind down and cease the remaining operations at USC, with the remaining USC assets to be sold, liquidated or otherwise disposed of.

In August 2021, the Company entered into a purchase agreement with Fagron Compounding Services, LLC (“Fagron”) to sell to Fagron certain assets of USC, related to its human compounding pharmaceutical business including certain customer information and information on products sold to such customers by USC, including related formulations, know-how, and expertise regarding the compounding of pharmaceutical preparations, clinical support knowledge and other data and certain other information relating to the customers and products. Fagron made monthly payments to the Company based on formulas related to the amounts actually collected by Fagron or its affiliates for sales of products or services made through July 30, 2022. As of September 30, 2023, the total amount received in connection with this purchase agreement was approximately $5.5 million. At September 30, 2023, the remaining receivable from Fagron was approximately $19,000.

Discontinued operations comprise those activities that were disposed of during the period, abandoned or which were classified as held for sale at the end of the period and represent a separate major line of business or geographical area that was previously distinguished as Compounded Pharmaceuticals segment for operational and financial reporting purposes in prior reported financial statements.

The major assets and liabilities associated with discontinued operations included in our condensed consolidated balance sheets are as follows:

	September 30, 2023		December 31, 2022
Cash and Cash Equivalents	$	—	$	30,085
Fixed Assets held for sale		—		6,719,252
Other assets		5,406		5,407
Loss recognized on classification as held for sale		—		(2,801,828	)
Total assets of the disposal group classified as held for sale in the statement of financial position	$	5,406	$	3,952,916
Carrying amounts of major classes of liabilities included as part of discontinued operations
Accounts Payable	$	673,335	$	649,633
Accrued Other Expenses		55,959		75,602
Lease Liabilities		200,034		243,008
Contingent Loss Liability		—		50,000
Other Current Liabilities		—		208,000
Deferred Tax Liability		—		45,930
Total liabilities of the disposal group classified as held for sale in the statement of financial position	$	929,328	$	1,272,173

12   

In January 2023, the Company received approximately $832,000 from the sale of certain fixed assets to a third party. This amount plus the $208,000 of earnest money received as a deposit in December 2022 (previously recorded as other current liability), resulted in the recognition of a gain of $68,339 which was recorded as a gain on sale of fixed assets in discontinued operations during the three month period ended March 31, 2023.

During the second quarter of 2023, in connection with a third party’s offer to purchase USC’s land and building (the “USC Property”) for $1,525,000, the Company recorded an impairment charge of approximately $1.5 million (inclusive of broker commissions) to bring the carrying value of the USC property down to its net sales price. On July 25, 2023, the Company received net proceeds of approximately $1.5 million from the sale of USC’s land and building. On July 25, 2023, the Company sold previously impaired USC equipment and received the net proceeds of approximately $349,000. During the three months ended September 30, 2023, the Company recorded the gain on disposal of fixed assets in discontinued operations of $20,500 and $348,500, on the sale of the USC Property and USC equipment, respectively, representing the excess of the net proceeds over the carrying value of the equipment.

               The revenues and expenses associated with discontinued operations included in our consolidated statements of operations were as follows:

	Three Months Ended September 30,
	2023			2022
Major line items constituting pretax loss of discontinued operations:
Selling, General and Administrative Expenses	$	(20,798	)	$	(125,722	)
Interest Income		—			22
Gain (Loss) on Disposal of Assets		369,000			(1,992	)
Gain (Loss) from discontinued operations before income taxes		348,202			(127,692	)
Income Tax Benefit		—			—
Gain (Loss) from discontinued operations	$	348,202		$	(127,692	)

	Nine Months Ended September 30,
	2023			2022
Major line items constituting pretax loss of discontinued operations:
Selling, General and Administrative Expenses	$	(83,721	)	$	(390,105	)
Impairment Expense - USC Property		(1,512,263	)		—
Other Income		7,818			8,647
Gain on Disposal of Assets		437,339			27,138
Loss from discontinued operations before income taxes		(1,150,827	)		(354,320	)
Income tax benefit		—			—
Loss from discontinued operations	$	(1,150,827	)	$	(354,320	)

13   

Note 5: Revenues 

Revenues are related to the sales of the Company's commercial products which include: ZIMHI^® (naloxone HCL Injection, USP) 5 mg/0.5 mL, which was approved by the U.S. Food and Drug Administration, or FDA, for the treatment of opioid overdose; SYMJEPI^® (epinephrine) Injection 0.3mg, which was approved by the FDA for use in the emergency treatment of acute allergic reactions, including anaphylaxis, for patients weighing 66 pounds or more; and SYMJEPI (epinephrine) Injection 0.15mg, which was approved by the FDA for use in the treatment of anaphylaxis for patients weighing 33-65 pounds.

            Exclusive Distribution and Commercialization Agreement for SYMJEPI^™ and ZIMHI^™ with US WorldMeds (“USWM”)

             On May 11, 2020 (the “Effective Date”) the Company entered into an exclusive distribution and commercialization agreement (the “USWM Agreement”) with USWM for the United States commercial rights for the SYMJEPI products, as well as for the Company’s ZIMHI (naloxone HCI Injection, USP) 5mg/0.5mL product intended for the emergency treatment of opioid overdose. The Company’s revenues relating to its FDA approved products SYMJEPI and ZIMHI are dependent on the USWM Agreement.

            Under the terms of the USWM Agreement, the Company appointed USWM as the exclusive (including as to the Company) distributor of SYMJEPI in the United States and related territories (“Territory”) effective upon the termination of a Distribution and Commercialization Agreement previously entered into with Sandoz Inc., and of the ZIMHI product approved by the U.S. Food and Drug Administration (“FDA”) for marketing, and granted USWM an exclusive license under the Company’s patent and other intellectual property rights and know-how to market, sell, and otherwise commercialize and distribute the products in the Territory, subject to the provisions of the USWM Agreement, in partial consideration of an initial payment by USWM and potential regulatory and commercial based milestone payments totaling up to $26 million, if the milestones are achieved. There can be no assurances that any of these milestones will be met or that any milestone payments will be paid to the Company. The Company retains rights to the intellectual property subject to the USWM Agreement and to commercialize both products outside of the Territory. In addition, the Company may continue to use the licensed intellectual property (excluding certain of the licensed trademarks) to develop and commercialize other products (with certain exceptions), including products that utilize the Company’s Symject™ syringe product platform.

            The initial term for the USWM Agreement began on the Effective Date and continues for a period of 10 years from the launch by USWM of the first product in the United States pursuant to the agreement, unless terminated earlier in accordance with its terms.

Revenue Recognition

            The Company evaluated the USWM Agreement under ASC Topic 606, “Revenue from Contracts with Customers” (ASC 606). 

           The Company has determined that there are multiple performance obligations in the contract which are the following: the manufacture and supply of SYMJEPI™ and ZIMHI™ products to USWM, the license to distribute and commercialize SYMJEPI™ and ZIMHI™ products in the United States and the clinical development of ZIMHI™.

            The Company utilized significant judgement to develop estimates of the stand-alone selling price for each distinct performance obligation based upon the relative stand-alone selling price. The transaction price allocated to the clinical development of ZIMHI was immaterial.

            Revenues from the manufacture and supply of SYMJEPI™ and ZIMHI™ are recognized at a point in time upon delivery to the carrier. The licenses to distribute and commercialize SYMJEPI™ and ZIMHI™ products in the United States is distinct from the other performance obligations identified in the arrangement and has stand-alone functionality; the Company recognizes revenues from non-refundable, upfront fees allocated to the license when the license is transferred to the licensee and the licensee is able to benefit from the license.

        Payments received under USWM Agreement may include non-refundable fees at the inception of the arrangements, milestone payments for specific achievements and net-profit sharing payments based on certain percentages of net profit generated from the sales of products over a given quarter. At the inception of arrangements that include milestone payments, the Company uses judgement to evaluate whether the milestones are probable of being achieved and estimates the amount to include in the transaction price utilizing the most likely amount method. If it is probable that a significant revenue reversal will not occur, the estimated amount is included in the transaction price. Milestone payments that are not within the Company or the licensee’s control, such as regulatory approvals are not included in the transaction price until those approvals are received. At the end of each reporting period, the Company re-evaluates the probability of achievement of development milestones and any related constraint and adjusts the estimate of the overall transaction price, if necessary. The Company recognizes aggregate sales-based milestones, and net-profit sharing as royalties from product sales at the later of when the related sales occur or when the performance obligation to which the sales-based milestone or royalty has been allocated has been satisfied. The amounts receivable from USWM have a payment term of Net 30.

            Revenues do not include any state or local taxes collected from customers on behalf of governmental authorities. The Company made the accounting policy election to continue to exclude these amounts from revenues. 

Product Recall   

           On March 21, 2022, the Company announced a voluntary recall of four lots of SYMJEPI (epinephrine) Injection 0.15 mg (0.15 mg/0.3 mL) and 0.3 mg (0.3 mg/0.3 mL) Pre-Filled Single-Dose Syringes to the consumer level, due to the potential clogging of the needle preventing the dispensing of epinephrine. In February 2023, the Company received notice from the FDA that the FDA considers the voluntary recall of our SYMJEPI products to be terminated. Such notice does not preclude the FDA from taking action in the future related to the recall, and the Company remains responsible for compliance with applicable laws relating to the product and the recall.

          As of September 30, 2023 and December 31, 2022, the recall liability was $0 and $0.3 million, respectively. During the three and nine months ended September 30, 2023, the Company expensed $25,000 and $81,000, respectively, in product recall costs, which were included in selling, general and administrative expenses. During the three and nine months ended September 30, 2022, the Company expensed $388,000 and $2.4 million, respectively, in product recall costs, which were included in selling, general and administrative expenses. Total product recall costs from inception of the recall through September 30, 2023, were approximately $2.6 million.

14   

Note 6: Inventories

Inventories at September 30, 2023 and December 31, 2022 were as follows: 

	September 30, 2023		December 31, 2022
Finished Goods	$	—	$	267,554
Work-in-Process		—		261,720
Raw Materials		662,962		709,504
Inventories	$	662,962	$	1,238,778

Note 7: Fixed Assets, net

Fixed assets, net at September 30, 2023 and December 31, 2022 were as follows: 

Description	Useful Life (Years)		September 30,  2023			December 31, 2022
Machinery and Equipment		3 - 7	$	5,156,377		$	5,209,575
Less: Accumulated Depreciation				(4,080,701	)		(4,665,067	)
Construction In Progress - Equipment				—			744,386
Fixed Assets, net			$	1,075,676		$	1,288,894

Depreciation expense for the three months ended September 30, 2023 and 2022 was approximately $67,000 and $399,000, respectively, included in costs of goods sold and Selling, General and Administrative in the accompanying condensed consolidated statements of operations. Depreciation expense for the nine months ended September 30, 2023 and 2022 was approximately $264,000 and $1,111,000, respectively, included in costs of goods sold and Selling, General and Administrative in the accompanying condensed consolidated statements of operations.  

Note 8: Paycheck Protection Program (PPP) Loan    

On March 15, 2021, the Company entered into a Note (the “PPP2 Note”) in favor of Arvest Bank (the “Bank”), as lender, in the principal amount of $1,765,495 relating to funding under a Second Draw loan (the “Second PPP Loan”) pursuant to the terms of the Paycheck Protection Program (the “PPP”), established pursuant to the Coronavirus Aid, Relief, and Economic Security Act (the “CARES Act”) and administered by the U.S. Small Business Administration (“SBA”), and the Economic Aid to Hard-Hit Small Businesses, Nonprofits, and Venues Act enacted in December 2020. The Company applied for forgiveness and received notification through the Bank that as of September 28, 2021, the Second Draw PPP Loan, including principal and interest thereon, was fully forgiven by the SBA. The Company recognized $1,765,495, the amount forgiven, as other income in the third quarter of 2021. In March 2022 the Company was informed that the Civil Division of the U.S. Attorney’s Office for the Southern District of New York was investigating the Company’s Second Draw PPP Loan and eligibility for that loan. In June 2022, following the inquiry, the Company paid a total of $1,787,417 in repayment of the Second Draw PPP Loan principal and such related interest and fees.

15   

Note 9: Fair Value Measurement

Fair value is defined as the exchange price that would be received for an asset or an exit price paid to transfer a liability in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. Valuation techniques used to measure fair value must maximize the use of observable inputs and minimize the use of unobservable inputs.

The fair value hierarchy defines a three-level valuation hierarchy for disclosure of fair value measurements as follows: 

Level 1:	Unadjusted quoted prices in active markets for identical assets or liabilities;
Level 2:	Inputs other than quoted prices included within Level 1 that are observable, unadjusted quoted prices in markets that are not active, or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the related assets or liabilities; and
Level 3:	Unobservable inputs that are supported by little or no market activity for the related assets or liabilities.

The carrying value of the Company’s cash and cash equivalents, prepaid expenses and other current assets, accounts payable and accrued liabilities, approximate fair value due to the short-term nature of these items. 

The categorization of a financial instrument within the valuation hierarchy is based upon the lowest level of input that is significant to the fair value measurement.

The following table sets forth the Company’s financial instruments that were measured at fair value on a recurring basis by level within the fair value hierarchy: 

		Fair Value Measurements at September 30, 2023
	Total		Level 1		Level 2		Level 3
Liabilities
2020 Warrant Liability	$	Less than $1	$	—	$	Less than $1	$	—
March 2023 Common Stock Warrants		302,170		—		302,170		—
Total Common Stock Warrants Liabilities	$	302,170	$	—	$	302,170	$	—

		Fair Value Measurements at December 31, 2022
	Total		Level 1		Level 2		Level 3
Liabilities
2020 Warrant Liability	$	7,492	$	—	$	7,492	$	—

16   

The fair value measurement of the warrants issued by the Company in February 2020 (“2020 Warrant Liability”) and March 16, 2023 Common Stock Warrant ("March 2023 Common Stock Warrants") are based on inputs that are observable or can be corroborated by observable market data (such as the Company’s daily closing stock price and the published treasury par yield curves from the US Department of the Treasury), and, as such, qualify as Level 2 measurement. The fair value of the warrant liabilities was calculated using the Black Scholes Option Pricing Model.

As of September 30, 2023, the valuation assumptions include the expected volatility of the Company’s stock ranging from approximately 70% - 134.65%, the Company’s stock price at valuation date of $0.69, expected dividend yield of 0.0%, expected term ranging from 1.93 to 4.96 years and average risk-free interest rate ranging from 4.721% - 5.253%.

As of December 31, 2022, the valuation assumptions include the expected volatility of the Company’s stock of approximately 70% (based on calculated volatility and management’s judgement), the Company’s stock price at valuation date of $11.90, expected dividend yield of 0.0%, expected term of 2.68 years and risk-free interest rate of approximately 4.362%. 

17   

Note 10: Prepaid Expenses and Other Current Assets

Prepaid expenses and other current assets were as follows:

	September 30, 2023		December 31, 2022
Employee Retention Credit	$	—	$	875,307
Prepaid Insurance		86,436		323,143
Prepaid - Research and Development		326,854		588,354
Other Prepaid		59,275		78,590
Other Current Assets		67,207		49,572
	$	539,772	$	1,914,966

Employee Retention Credit

The Company applied for the Employee Retention Credit (ERC) which was available under the CARES Act. The ERC is a fully refundable tax credit for employers equal to 50 percent of qualified wages (including allocable qualified health plan expenses) that eligible employers paid their employees. The ERC applied to wages paid after March 12, 2020 and before January 1, 2021. The Company received the full amount from the original ERC from the Department of Treasury in January 2023. The Company amended its ERC application due to its repayment of the PPP loans (discussed in Note 7) and was subsequently awarded an additional refund of approximately $463,000, which the Company received in full during the second quarter of 2023, and is included in other income in the condensed consolidated statement of operations for the nine months ended September 30, 2023.

18   

Note 11: Legal Proceedings

The Company may from time to time become party to actions, claims, suits, investigations or proceedings arising from the ordinary course of business, including actions with respect to intellectual property claims, breach of contract claims, labor and employment claims and other matters. The Company may also become party to litigation in federal and state courts relating to opioid drugs. Any litigation could divert management time and attention from the Company, could involve significant amounts of legal fees and other fees and expenses, or could result in an adverse outcome having a material adverse effect on the Company’s financial condition, cash flows or results of operations. Actions, claims, suits, investigations and proceedings are inherently uncertain and their results cannot be predicted with certainty. Except as described below, the Company is not currently involved in any legal proceedings that the Company believes are, individually or in the aggregate, material to our business, results of operations or financial condition. However, regardless of the outcome, litigation can have an adverse impact on the Company because of associated cost and diversion of management time.

            Investigations 

           On May 11, 2021, each of the Company and its USC subsidiary received a grand jury subpoena from the U.S. Attorney’s Office for the Southern District of New York (the “USAO”) issued in connection with a criminal investigation, requesting a broad range of documents and materials relating to, among other matters, certain veterinary products sold by the Company’s USC subsidiary, certain practices, agreements and arrangements relating to products sold by USC, including veterinary products, and certain regulatory and other matters relating to the Company and USC. The Audit Committee of the Board engaged outside counsel to conduct an independent internal investigation to review these and other matters. The Company has also received requests from the Securities and Exchange Commission (“SEC”) that the Company voluntarily provide documents and information in connection with the SEC’s investigation relating to certain matters including matters arising from the subject matter of the subpoenas from the USAO. The Company has produced and will continue to produce and provide documents in response to the subpoenas and requests as needed. Additionally, on March 16, 2022, the Company was informed that the Civil Division of the USAO (“Civil Division”) is investigating the Company’s Second Draw PPP Loan application disclosed in previous reports. The Audit Committee of the Board engaged outside counsel to conduct an internal inquiry into the matter. In June 2022, following the inquiry the Company paid a total of $1,787,417 in repayment of the Second Draw PPP Loan principal and such related interest and fees. The Company intends to continue cooperating with the USAO and the SEC, and has continued to engage in communications with the SEC and USAO regarding their investigations. The Company has received additional requests for production of documents from the SEC and the USAO, have responded to those requests, could receive additional requests from the USAO, SEC, or other authorities, and continue to engage in communications with the SEC and the USAO regarding their investigations.  Additional issues or facts could arise or be determined, which may expand the scope, duration, or outcome of the investigation. The Company is unable to predict the duration, scope, or final outcome of the investigations by the USAO, SEC, or other agencies; what, if any, proceedings the USAO, SEC, or other federal or state authorities may initiate; what penalties, payments, by the Company, remedies or remedial measures the USAO, SEC, or other federal or state authorities may seek or may require in order to resolve the investigations; what, if any, impact the foregoing matters may have on the Company’s business, financial condition, previously reported financial results, financial results included in this Report, or future financial results; or what proceedings the USAO, SEC, or other federal or state authorities may initiate if the foregoing matters are not resolved. However, in connection with resolution of these matters, the Company or its USC subsidiary may be found to have violated one or more laws arising from the subject matter of the subpoenas, and to resolve the matters and investigations with the USAO and the SEC the Company may be required to pay material amounts in penalties or other payments, and to agree to other remedies or remedial measures. Payment of material amounts in connection with resolution of the foregoing matters would reduce the amount of financial resources that the Company has available to support product development programs and commercialization activities and would adversely impact the Company’s development programs. Depending in part on the amount and timing of any payments that the Company may be required to make or other remedial measures that may be implemented in connection with resolution of these matters, a resolution of these matters with the USAO or SEC could have a material and adverse impact on the company. The foregoing matters have diverted and will likely continue to divert management’s attention, have caused the company to suffer reputational harm, have required and will continue to require the company to devote significant financial resources, could subject the company, one or more of its subsidiaries, or its officers and directors to civil or criminal proceedings, and depending on the resolution of the matters or any proceedings, could result in fines, penalties, payments, or financial remedies in amounts that would have a material adverse effect on the Company’s financial condition, or equitable remedies, and adversely affect the company’s business, previously reported financial results, financial results included or incorporated by reference herein, or future financial results.

Nasdaq Compliance     

              On October 4, 2023, the Company received notice (the “Prior Notice”) from the Listing Qualifications Department (the “Staff”) of The Nasdaq Stock Market LLC (“Nasdaq”) notifying the Company that it failed to evidence a minimum closing bid price of $1.00 per share, as required by Nasdaq Listing Rule 5550(a)(2) (the “Bid Price Rule”), for the previous 30 consecutive days and that the Company was provided a grace period of 180 calendar days from the date of the Prior Notice, or until April 1, 2024, to regain compliance with the Bid Price Rule, in accordance with Listing Rule 5810(c)(3)(A).  Also as previously disclosed, on October 11, 2023, the Company received notice from the Staff that, due to the Company’s failure to regain compliance with the minimum $35 million market value of listed securities (“MVLS”) requirement set forth in Nasdaq Listing Rule 5550(b)(2) (the “MVLS Rule”) during the 180-day grace period previously granted to the Company that expired on October 9, 2023, the Company’s common stock was subject to delisting unless the Company timely requested a hearing before the Nasdaq Hearings Panel (the “Panel”).

                In response, the Company timely requested a hearing before the Panel, which request stayed any further action by Nasdaq at least until the hearing is held and any extension the Panel may grant to the Company following the hearing expires.

              On October 18, 2023, the Company received a superseding notice from the Staff (the “Subsequent Notice”), indicating that the Prior Notice was issued in error. The Subsequent Notice indicated that because the Company was subject to a one-year Mandatory Panel Monitor as a result of a prior hearing before the Panel, the Company was not eligible for the automatic 180-day compliance grace period provided by Listing Rule 5810(c)(3)(A) and that the Company’s non-compliance with the Bid Price Rule serves as an additional basis for delisting from Nasdaq.

At the hearing before the Panel, the Company will address its plan to regain compliance with both the Bid Price Rule and the MVLS Rule as well as its continued compliance with all other applicable criteria for continued listing on The Nasdaq Capital Market. There can be no assurance, however, that the Panel will grant the Company’s request for continued listing or that the Company will evidence compliance with the listing rules prior to the expiration of any extension that may be granted by the Panel following the hearing.

19   

 Jerald Hammann       

On June 8, 2021, Jerald Hammann filed a complaint against the Company and each of its directors in the Court of Chancery of the State of Delaware, captioned Jerald Hammann v. Adamis Pharmaceuticals Corporation et al., C.A. No. 2021-0506-PAF (the “Complaint”), seeking injunctive and declaratory relief.  The Complaint alleges, among other things, that the defendants (i) violated Rule 14a-5(f) and 14a-9(a) of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), in connection with the Company’s 2021 annual meeting of stockholders—which was subsequently held on July 16, 2021 (the “2021 annual meeting”)—and disseminated false and misleading information in the Company’s proxy materials relating to the 2021 annual meeting, (ii) violated certain provisions of the Company’s bylaws relating to the 2021 annual meeting, (iii) violated section 220 of the Delaware General Corporation Law (“DGCL”) in connection with a request for inspection of books and records submitted by the plaintiff, and (iv) breached their fiduciary duties of disclosure and loyalty, including relating to establishing and disclosing the date of the Company’s 2021 annual meeting and to the Company’s determination that a solicitation notice delivered to the Company by plaintiff was not timely and was otherwise deficient.  On April 4, 2022, the plaintiff filed a motion to amend the Complaint. The proposed amended Complaint added additional allegations relating to the manner in which the defendants established and disclosed the date of the Company’s 2021 annual meeting of stockholders and to statements the defendants made about the plaintiff to the Company’s stockholders. On April 28, 2022, the Court granted the motion. Trial on the merits of the plaintiff’s claims was held on March 16, 2023.  On August 23, 2023, the Court entered its opinion rendering judgment in favor of the Company and the other defendants and against the plaintiff as to all of the plaintiff’s claims.  On August 30, 2023, the plaintiff filed a motion for re-argument.  On October 16, 2023, the Court denied the plaintiff’s motion except with respect to an issue of nominal damages but concluded that nominal damages were not warranted.  On October 9, 2023, the plaintiff filed a motion for a temporary restraining order seeking to enjoin the defendants from distributing proxy materials and holding the Company’s 2023 annual meeting of stockholders.  On October 12, 2023, the Court denied the plaintiff’s motion for a temporary restraining order, and on October 16, 2023, the Court issued an order denying the plaintiff’s motion for re-argument. On November 3, 2023, plaintiff filed a notice of appeal to the Supreme Court of the State of Delaware.

CVI Investments

On October 19, 2023, a purported shareholder of the Company filed a complaint against the Company in the Supreme Court of the State of New York, County of New York, captioned CVI Investments vs. DMK Pharmaceuticals Corporation f/k/a Adamis Pharmaceuticals Corporation, Index No. 655184/2023 (the “Complaint”).  The Complaint alleges that the Company breached two warrant agreements that Plaintiff entered into with the Company in connection with Plaintiff’s previous purchases of shares of Adamis stock.  Specifically, the Complaint alleges that the Company failed to repurchase two warrants previously issued to the Plaintiff for the repurchase price specified in the warrants, allegedly in violation of the terms of the warrants that provide for the repurchase of the warrants following timely notice from the warrant holder following the occurrence of certain specified events. The Complaint seeks (i) actual and compensatory damages from the purported breaches, (ii) reasonable attorneys’ fees and other costs and expenses incurred in connection with the Complaint, and (iii) pre- and post-judgment interest.  The Company’s deadline to respond to the Complaint is November 22, 2023. The Company disputes that it was obligated to repurchase the warrants and intends to vigorously dispute the claim.

Arbitration

On October 20, 2023, David J. Marguglio, a former executive officer of the Company, filed a demand for arbitration with Judicial Arbitration and Mediation Services, Inc. (JAMS) challenging the grounds of the separation of his employment, alleging that he is entitled to severance under the terms of his employment agreement, and demanding that the Company pay the costs of the arbitration.  The Company contends that Mr. Marguglio is not entitled to severance under the terms of his employment agreement.

Turbare Real Estate Holdings

On May 26, 2023, Turbare Real Estate Holdings, LLC filed a complaint against the Company in the Circuit Court of Faulkner County Arkansas, captioned Turbare Real Estate Holdings, LLC v Adamis Pharmaceutical Corporation 23CV-23-796. The suit alleges breach of contract, seeking $1,414,943.08, with additional amounts still being incurred, plus costs and attorney fees, for alleged required repairs under a lease agreement between the parties.  The Company has filed a counter suit, alleging as to Turbare Real Estate Holdings, LLC, claims for breach of lease agreement, conversion, civil conspiracy for conversion, replevin, and unjust enrichment.  Additionally, the Company has added, as third party defendant, Turbare Manufacturing, LLC, alleging claims of breach of an access agreement for the leased real estate, conversion, civil conspiracy for conversion, replevin, tortious interference with contract, and unjust enrichment. On November 3, 2023, plaintiff filed a notice of appeal to the Supreme Court of the State of Delaware.

Supplemental Proxy Disclosures

On April 11, 2023, a purported stockholder of the Company filed a complaint against the Company and each of its directors in the United States District Court for the Southern District of New York, captioned Lapin vs. Adamis Pharmaceuticals Corporation, Case No. 1:23-cv-03023 (the “Complaint”). The Complaint alleged that the defendants violated Sections 14(a) and 20(a) of the Securities Exchange Act of 1934, as amended, by causing a materially incomplete and misleading Preliminary Proxy Statement to be filed with the SEC. Specifically, the Complaint alleged that the Preliminary Proxy Statement contains materially incomplete and misleading information concerning the sales process, financial projections prepared by management, as well as the financial analysis conducted by Raymond James & Associates, Inc., the Company’s financial advisor. The Complaint sought, among other things, (i) injunctive relief preventing the consummation of the transactions contemplated by the Merger Agreement or the filing of a definitive proxy statement with the SEC or causing a definitive proxy statement to be disseminated to the Company’s stockholders unless and until the material information described in the Complaint is included in the definitive proxy statement or otherwise disseminated to the Company’s stockholders, and (ii) in the event that the Merger transaction is consummated without the alleged material omissions referenced in the Complaint being remedied, damages and costs and disbursements of the action including reasonable plaintiff’s attorneys’ and experts’ fees and expenses. On July 6, 2023, the plaintiff filed a notice of voluntary dismissal, dismissing the claims in the complaint without prejudice, which was entered by the court on July 7, 2023.

In addition, the Company has received additional demand letters from counsel (the “Demand Letters”), each representing a purported stockholder of the Company, asserting that the Preliminary Proxy Statement and/or Proxy Statement was deficient and demanding that the alleged deficiencies be rectified. The Demand Letters allege, among other matters, that the Proxy Statements contain materially incomplete and misleading information concerning the sales process, financial projections prepared by the Company's management, and the financial analysis conducted by Raymond James & Associates, Inc. In addition, each purported shareholder has reserved his or her rights, including the right to alter or amend the demands at any time, and/or seek monetary damages following the consummation of the Merger.

The Company believes that the allegations in the Complaint and the Demand Letters are without merit and that the disclosures set forth in the Proxy Statement comply fully with applicable law. However, in order to moot the unmeritorious claims, avoid nuisance and possible expense and delay, and to provide additional information to the Company’s shareholders, the Company provided a voluntary supplement to the Proxy Statement with the supplemental disclosures filed with the SEC on May 5, 2023. Nothing in the Supplemental Disclosures shall be deemed an admission of the legal necessity or materiality under applicable laws of any of the disclosures set forth in the Supplemental Disclosures. To the contrary, the Company specifically denies all allegations that any additional disclosure was or is required. Nevertheless, resolution of these matters may involve payments by the Company to the parties submitting the Demand Letters or other claims.

The Company records accruals for loss contingencies associated with legal matters when the Company determines it is probable that a loss has been or will be incurred and the amount of the loss can be reasonably estimated. Where a material loss contingency is reasonably possible and the reasonably possible loss or range of possible loss can be reasonably estimated, U.S. GAAP requires the Company to disclose an estimate of the reasonably possible loss or range of loss or make a statement that such an estimate cannot be made. The Company has not accrued any amount in respect of the matters described under the headings “Investigation,” “Jerald Hammann,” “Supplemental Proxy Disclosures,” “CVI Investments,” “Arbitration,” or “Turbare Real Estate Holdings,” as the Company cannot estimate the probable loss or the range of probable losses that the Company may incur. The Company is unable to make such an estimate because (i) with respect to the matters described under the heading “Investigation,” the Company is unable to predict whether any proceedings will be initiated by the USAO, SEC or other authorities arising from such matters, what, if any, relief, remedies or remedial measures the USAO, SEC, or other authorities may seek if proceedings are commenced, and the duration, scope, or outcome of any such proceedings, if they are commenced, (ii) litigation, arbitration, and other proceedings are inherently uncertain and unpredictable, and (iii) with respect to the “Supplemental Proxy Disclosures” the Demand Letters have not specified any amount for monetary damages and a reasonably possible loss or range of loss cannot be estimated. Because legal proceedings and investigations are uncertain and unpredictable and unfavorable results could occur, assessing contingencies is highly subjective and requires significant judgments about future events, including determining both the probability and reasonably estimated amount of a possible loss or range of loss. The amount of any ultimate loss may differ from any accruals or estimates that the Company may make.

20   

Note 12: Stockholders' Equity

Common Stock

             On March 14, 2023, the Company entered into a Securities Purchase Agreement or, SPA, with an investor providing for the purchase and sale of (i) an aggregate of 235,714 common stock shares, at a price of $8.75 per share, (ii) a warrant to purchase up to an aggregate of 685,714 shares of the Company’s common stock at an exercise price of $9.66 per share (the “Common Stock Warrants”), and (iii) a prefunded warrant at a price of $8.74 per share to purchase up to an aggregate of 107,143 shares of the Company’s common stock (the “Prefunded Warrants” and, collectively with the Common Stock Warrant, the “Warrants”), which represents the per share price for the shares less the $0.0007 per share exercise price for the Prefunded Warrant, pursuant to a previously filed and effective registration statement in a registered direct offering (the “March 2023 Offering”). Gross proceeds from the March 2023 Offering were approximately $3.0 million, before deducting offering expenses of approximately $0.3 million.

The Prefunded Warrants are immediately exercisable and will expire five years from the date of issuance. The Common Stock Warrants are exercisable on or after the six month and one day anniversary of the date of issuance and will expire five years and six months from the date of issuance. The terms of the Warrants provide that at the request of the holder following a change of control or certain other fundamental transactions, the Company or the successor entity, has to purchase the Warrant from the holder for an amount in cash equal to the Black Scholes Value (as defined in the Warrant). Due to this cash redemption feature, the Company determined that the Warrants should be classified as liabilities based on the authoritative guidance in ASC 480 “Distinguishing Liabilities from Equity” (“ASC 480”). The liability-classified Warrants are measured initially and subsequently at fair value each reporting period, with the changes in fair value recorded in the income statement.

             At the closing of the Offering on March 16, 2023, the Company determined the fair value of the Warrants (based on the Black Scholes Option Pricing Model) was in excess of the proceeds and, as such, a day-one loss was recognized in earnings. The issuance costs of $225,000 were fully allocated to the Warrants and expensed in the condensed consolidated statement of operations.

The following table provides the initial allocation of the offering proceeds between the common stock and the Warrants issued:

	Allocation
235,714 Common Stock Issued	$	—
107,142 Prefunded Warrant Issued		899,388
685,714 Common Stock Warrant Issued		4,575,971
Day-one Loss due to Excess Warrant Fair Value		(2,476,109	)
Gross Proceeds	$	2,999,250

In May 2023, the Prefunded Warrants were exercised in full, which resulted in the reclassification of the fair value of the Prefunded Warrants of $524,379, net of the cash proceeds of $750, at the exercise date into equity.

August 2023 Offering

On August 4, 2023, the Company completed an offering of (i) 4,800,000 shares of the common stock, (ii) pre-funded warrants to purchase up to 1,130,000 shares of Common Stock (the “August 2023 Prefunded Warrants”), and (iii) common stock purchase warrants to purchase up to 5,930,000 shares of the Company’s common stock (the “August 2023 Common Stock Warrants” and together with the August 2023 Prefunded Warrants, the “August 2023 Warrants”) (the “August 2023 Offering”). The Company received net proceeds of approximately $7.1 million from the August 2023 Offering, net of approximately $0.9 million of placement agent commissions and other offering expenses.

The August 2023 Prefunded Warrants are immediately exercisable at $0.0001 per share and do not expire until exercised in full. All August 2023 Prefunded Warrants were exercised in full on August 4, 2023. Of the 1,130,000 August 2023 Prefunded Warrants exercised on August 4, 2023, 395,000 resulted in cash proceeds of approximately $40, representing the par value of the 395,000 Common Stock shares issued. The remaining 735,000 of the August 2023 Prefunded Warrants were exercised on a cashless basis, resulting in the issuance of 734,985 Common Stock shares. 

The August 2023 Common Stock Warrants are exercisable at $1.35 per share beginning on the issuance date, and expire five years from the issuance date. During the three months ended September 30, 2023, 645,000 August 2023 Common Stock Warrants were exercised, resulting in cash proceeds of $870,750. 

The August 2023 Warrants were accounted for as equity instruments as they meet all of the requirements for equity classification under ASC Topic 815 “Derivatives and Hedging” (“ASC 815").

Series C Convertible Preferred Stock

On July 5, 2022, the Company entered into a private placement transaction with Lincoln Park Capital Fund, LLC, (“Lincoln Park”) pursuant to which the Company issued an aggregate of 3,000 shares of Series C Convertible Preferred Stock, par value $0.0001 per share (the “Series C Preferred”), together with warrants (the “July Warrants”) to purchase up to an aggregate of 10,714 shares of common stock of the Company, at an exercise price of $32.90 per share (subject to adjustment as provided in the July Warrants). Gross proceeds were $300,000, excluding transaction costs, fees and expenses of $15,000. The July Warrants become exercisable commencing January 3, 2023 and have a term ending on January 5, 2028.

Subsequent to the issuance of the Series C Preferred, in connection with the Company’s 2022 annual meeting of stockholders, in September 2022 the Company’s stockholders voted on a reverse stock split proposal, and the proposal was not approved. Pursuant to the Series C Preferred transaction agreements, the Company paid $15,000 to Lincoln Park resulting from the failure of the reverse stock split proposal to be approved at the meeting.  In connection the approval of the Reverse Stock Split in May 2023 at the Company's special meeting of stockholders, redemption of the Series C Preferred became probable. As a result, the Company recorded accretion of approximately $173,000 in the second quarter of 2023, which is reflected in the accompanying condensed consolidated statements of mezzanine equity and stockholders’ deficit for the nine months ended September 30, 2023. As of September 30, 2023, neither the holder nor the Company have elected to redeem the Series C Preferred and the Series C Preferred stock is reflected on the condensed consolidated balance sheet at the 110% redemption value of $330,000.

21   

Series E Preferred Stock

Pursuant to the DMK Merger, 1,941.2 shares of Series E Preferred were issued to former Legacy DMK shareholders. The Series E Preferred is convertible into shares of the Company’s common stock at a conversion rate of 1,000 common shares for 1 Series E Preferred share, and conversion is subject to certain beneficial ownership limitations. During the three and nine months ended September 30, 2023, 729.2 Series E Preferred shares have been converted into 729,200 shares of Common Stock.

Stock Options

The Company’s 2020 Equity Incentive Plan (the “2020 Plan”) provides for the grant of incentive stock options, non-statutory stock options, restricted stock awards, restricted stock unit awards, stock appreciation rights, performance stock awards, and other forms of equity compensation (collectively “stock awards”). In addition, the 2020 Plan provides for the grant of cash awards. The initial aggregate number of shares of common stock that may be issued initially pursuant to stock awards under the 2020 Plan is 28,571 shares. The number of shares of common stock reserved for issuance automatically increases on January 1 of each calendar year during the term of the 2020 Plan, commencing January 1, 2021, by 5.0% of the total number of shares of common stock outstanding on December 31 of the preceding calendar year, or a lesser number of shares of common stock determined by the Company’s board of directors before the start of a calendar year for which an increase applies. In December 2022, the Board determined and resolved, that the 2020 Plan share reserve shall not be increased effective January 1, 2023, and that there shall not be any increase in share reserve for the 2023 year by virtue of the annual share reserve increase. No awards had been made pursuant to the 2020 Plan as of September 30, 2023.

The Company had a 2009 Equity Incentive Plan (the “2009 Plan”). The 2009 Plan terminated effective February 2019 and no new awards may be made under the 2009 Plan. The maximum contractual term for options is 10 years.

The following table summarizes the outstanding stock option activity under the 2009 Equity Incentive Plan for the nine months ended September 30, 2023:

	2009 Equity Incentive Plan			Weighted-Average Exercise Price		Weighted-Average Remaining Contract Life
Outstanding Vested and Expected to Vest as of December 31, 2022		61,525		$	291.41		2.09 years
Cancelled/Expired		(29,068	)		280.26		—
Outstanding and Vested as of September 30, 2023		32,457			306.44		2.44 years

As of September 30, 2023, the unamortized compensation expense related to 2009 Plan awards was $0.

The aggregate intrinsic value (the difference between the Company’s closing stock price on the last trading day of the period and the exercise price, multiplied by the number of in-the-money options) of all options outstanding at September 30, 2023 and December 31, 2022 was $0.

The following table summarizes the outstanding stock option activity for the non-plan awards for the nine months ended September 30, 2023:

	Non-Plan Awards			Weighted-Average Exercise Price			Weighted-Average Remaining Contract Life
Outstanding as of December 31, 2022		1,857			$	43.40		9.13 years
Cancelled		(429	)			43.40		—
Outstanding as of September 30, 2023		1,428				43.40		8.38 years
Vested and Expected to Vest at September 30, 2023		952				43.40		8.38 years

22   

Non-plan awards are granted pursuant to Rule 5635(c)(4) of the Nasdaq Listing Rules, as a material inducement to the willingness of such person to join the Company as a new employee, effective upon the effective date of Board of Director-approved resolutions to grant nonqualified stock options to such person (an inducement grant). Inducement grants, although granted outside of the Company’s 2020 Plan, are subject to the terms and conditions set forth in that plan. The terms of inducement grants are generally the same as terms would be under the 2020 Plan, wherein the exercise price of the options is equal to the fair value of the Company’s common stock at date of grant, with vesting commencing on date of grant, and a vesting schedule consisting of one-sixth (1/6) of the options becoming exercisable six (6) months after vesting commences, and one thirty-sixth (1/36) of the options on becoming exercisable each subsequent monthly anniversary of the vesting commencement date, such that the option is exercisable in full after three years from the vesting commencement date of the option grant, subject to the option holder providing continuous service.

As of September 30, 2023, the unamortized compensation expense related to non-plan awards was $0.

              Pursuant to the Merger Agreement with Legacy DMK, the Company assumed the outstanding options of Legacy DMK.  Based on the conversion mechanism in the Merger Agreement, the Company assumed 231,490 options with an exercise price of $2.90. The assumed options were fully vested and will continue to be governed by the terms of the DMK 2016 Stock Plan, which was assumed by the Company in connection with the closing of the Merger. Additionally, the assumed options were converted into an equivalent option to acquire shares of the Company’s common stock. The DMK 2016 Stock Plan provides for the grant of incentive stock options ("ISOs"), nonstatutory stock options, stock bonus and opportunities to make direct purchase of the Company’s common stock to employees and directors. The total number of shares of common stock reserved for the Stock Plan is 249,501.

The aggregate intrinsic value (the difference between the Company’s closing stock price on the last trading day of the period and the exercise price, multiplied by the number of in-the-money options) of all options outstanding at September 30, 2023 and December 31, 2022, was $0.

 Restricted Stock Units

The following table summarizes the RSUs outstanding at September 30, 2023: 

	Number of Shares/Units			Weighted Average Grant Date Fair Value
Non-vested as of December 31, 2022		9,286		$	325.13
Vested during the period		(2,143	)		592.20
Forfeited during the period		—			—
Non-vested as of September 30, 2023		7,143			245.00
Expected to vest as of September 30, 2023		7,143		$	245.00

The RSU's have cliff vesting after seven years of continuous service or upon change of control from date of grant or upon death or disability. As of September 30, 2023, the unamortized compensation expense related to RSUs was approximately $42,000 and will be recognized over 0.42 years.

Stock-Based Compensation

The following summarizes stock-based compensation recognized for the three months ended September 30, 2023 and 2022:

	For the Three Months Ended September 30,
	2023			2022
Research and Development	$	(69,835	)	$	3,654
Selling, General and Administrative		25,142			70,834
Total	$	(44,693	)	$	74,488

The following summarizes stock-based compensation recognized as R&D costs and SG&A costs for the nine months ended September 30, 2023 and 2022:

	For the Nine Months Ended September 30,
	2023			2022
Research and Development	$	(69,835	)	$	122,746
Selling, General and Administrative		146,634			(137,057	)
Total	$	76,799		$	(14,311	)

23   

     Warrants 

The following table summarizes warrants issued and outstanding as of September 30, 2023:   

	Warrant   Shares		Exercise Price   Per Share		Date   Issued	Expiration   Date
Old Adamis Warrants		840	$	595.00	November 15, 2007	November 15, 2023
2019 Warrants		197,055	$	80.50	August 5, 2019	August 5, 2024
2020 Warrants		5,000	$	49.00	February 25, 2020	September 3, 2025
Series C Preferred Warrants		10,714	$	32.90	July 5, 2022	January 5, 2028
March 2023 Common Stock Warrants		685,714	$	9.66	March 16, 2023	September 16, 2028
August 2023 Common Stock Warrants		5,285,000	$	1.35	August 4, 2023	August 4, 2028
Total		6,184,323

Shares Reserved

As of September 30, 2023, the Company has reserved shares of common stock for issuance upon exercise of outstanding options, warrants including all of the warrants in the table above and restricted stock units, as follows:

Warrants	6,184,323
Restricted Stock Units	7,143
Non-Plan Awards	1,428
2009 Equity Incentive Plan	32,457
Legacy DMK Options Assumed by the Company	231,490
Conversion of Series C Preferred stock	697,674
Conversion of Series E Preferred stock	1,212,000
Total Shares Reserved	8,366,515

 Note 13: Commitments and Contingencies

Firm Purchase Commitments

The Company has a production threshold commitment to a manufacturer of our SYMJEPI Products where the Company would be required to pay for maintenance fees if it does not meet certain periodic purchase order minimums. Any such maintenance fees would be prorated as a percentage of the required minimum production threshold. For the three and nine month periods ended September 30, 2023 and 2022, there were no purchases under firm purchase commitments. The maintenance fees for the three and nine months ended September 30, 2023 were approximately $268,000 and $804,000, respectively, and were recorded as cost of sales in the condensed consolidated statement of operations. There were no maintenance fees incurred during the three and nine months ended September 30, 2022.

Abandonment of ROU Assets

The Company has one operating lease for an office space in San Diego, CA with the lease term through November 30, 2023 and base rent of $32,000 per month. The Company ceased the use of this space in August 2023 and the related right-of-use asset was deemed abandoned. The ROU asset was reduced to its salvage value of zero as of its cease-use date which resulted in an impairment charge of $116,934 included in general and administrative expenses in the condensed consolidated statements of operations for the three and nine months ended September 30, 2023.

 Note 14: Income Taxes

The Company did not record any income tax provision or benefit for the three and nine months ended September 30, 2023 and 2022. The Company has evaluated the positive and negative evidence bearing upon its ability to realize the deferred tax assets. Management has considered the Company’s history of cumulative net losses incurred since inception and its history of gross losses and has concluded that it is not more likely than not that the Company will realize the benefits of the deferred tax assets. Accordingly, a full valuation allowance has been established against the deferred tax assets as of September 30, 2023 and December 31, 2022. Management reevaluates the positive and negative evidence at each reporting period.

24   

ITEM 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations

The following discussion and analysis of financial condition and results of operations should be read together with the consolidated financial statements and accompanying notes of the Company appearing elsewhere in this Quarterly Report on Form 10-Q (this “Report”) and the audited consolidated financial statements and accompanying notes included in our Annual Report on Form 10-K for the year ended December 31, 2022 (the “2022 Form 10-K”). Our financial results for the three- and nine- months ended September 30, 2023, are not necessarily indicative of results that may occur in future interim periods or for the full fiscal year.  

Information Relating to Forward-Looking Statements

This Report, and the discussion of our financial condition and results of operations, contain and include forward-looking statements. Such statements are not historical facts, but are based on our current expectations, estimates and beliefs about our business and industry. Such forward-looking statements may include, without limitation, statements about our strategies, objectives and our future achievements; our expectations for growth; estimates of future revenue; our current or future expenses, obligations or liabilities; our sources and uses of cash; our liquidity needs; our current or planned clinical trials or research and development activities; anticipated completion dates for clinical trials; product development timelines; anticipated dates for commercial introduction of products; our future products; regulatory matters; our expectations concerning the timing of regulatory actions relating to our products and product candidates; anticipated dates for meetings with regulatory authorities and submissions to obtain required regulatory marketing approvals; expense, profit, cash flow, or balance sheet items or any other guidance regarding future periods; the impact of broad-based business or economic disruptions, including relating to the health emergencies, on our ongoing business and prospects; our expectations concerning the outcome of proceedings discussed in this Report under Item 1 of Part II of this Report under the caption “Legal Proceedings”; and other statements concerning our future operations and activities.  Such forward-looking statements include those that express plans, anticipation, intent, contingencies, goals, targets or future development and/or otherwise are not statements of historical fact.  These forward-looking statements are based on our current expectations and projections about future events, and they are subject to risks and uncertainties, known and unknown, that could cause actual results and developments to differ materially from those expressed or implied in such statements. In some cases, you can identify forward-looking statements by terminology, such as “believe,” “will,” “expect,” “may,” “anticipate,” “estimate,” “intend,” “plan,” “should,” and “would,” or the negative of such terms or other similar expressions. Any forward-looking statements are qualified in their entirety by reference to the factors discussed throughout this Report. These forward-looking statements are not guarantees of future performance and concern matters that could subsequently differ materially from those described in the forward-looking statements. Actual events or results may differ materially from those discussed in this Report. In addition, many forward-looking statements concerning our anticipated future business activities assume that we have or are able to obtain sufficient funding to support such activities and continue our operations and planned activities. As discussed elsewhere in this Report, we will require additional funding to continue operations, and there are no assurances that such funding will be available. Failure to timely obtain required funding would adversely affect and could delay or prevent our ability to realize the results contemplated by such forward-looking statements. New factors emerge from time to time, and it is not possible for us to predict which factors will arise.  In addition, we cannot assess the impact of each factor on our business or the extent to which any factor, or combination of factors, may cause actual results to differ materially from those contained in any forward-looking statements.  Because factors referred to elsewhere in this Report and in our 2022 Form 10-K, including without limitation the “Risk Factors” section in this Report and in the 2022 Form 10-K, could cause actual results or outcomes to differ materially from those expressed in any forward-looking statements made by us, you should not place undue reliance on any forward-looking statements.  Further, any forward-looking statement speaks only as of the date on which it is made, and except as may be required by applicable law, we undertake no obligation to release publicly the results of any revisions to these forward-looking statements or to reflect events or circumstances arising after the date of this Report. Important risks and factors that could cause actual results to differ materially from those in these forward-looking statements are disclosed in this Report including, without limitation, under the headings “Part II, Item 1A. Risk Factors,” and “Part I, Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations,” and in our 2022 Form 10-K, including, without limitation, under the headings “Part I, Item 1A. Risk Factors,” “Part I, Item 1. Business,” and “Part II, Item 7. Management’s Discussion and Analysis of Financial Condition and Results of Operations,” as well as in our subsequent filings with the Securities and Exchange Commission, press releases and other communications. 

Unless the context otherwise requires, the terms “we,” “our,” “the company” and “the Company” refer to DMK Pharmaceuticals Corporation, a Delaware corporation, and its subsidiaries.

Investors and others should note that we may announce material information to our investors using our website (www.dmkpharmaceuticals.com), SEC filings, press releases, public conference calls and webcasts, as well as social media and blogs.  We use these channels as a means of disclosing material non-public information and making disclosures pursuant to Regulation FD, and to communicate with our members and the public about our company. It is possible that the information we post on our website or social media and blogs could be deemed to be material information. Therefore, we encourage investors, the media, and others interested in our company to review the information we post on our website social media channels and blogs listed on our investor relations website.

General

Company Overview

We are a specialty biopharmaceutical company focused on developing and commercializing products in the substance use disorder space including treatment of opioid use disorder. Our two commercial products are designed to treat opioid overdose and anaphylactic shock. The first is ZIMHI® (naloxone HCL Injection, USP) 5 mg/0.5 mL, which was approved by the U.S. Food and Drug Administration, or FDA, for the treatment of opioid overdose, and the second is SYMJEPI® (epinephrine) Injection 0.3mg, which was approved by the FDA for use in the emergency treatment of acute allergic reactions, including anaphylaxis, for patients weighing 66 pounds or more, and SYMJEPI (epinephrine) Injection 0.15mg, which was approved by the FDA for use in the treatment of anaphylaxis for patients weighing 33-65 pounds. The foundation of our development pipeline is a proprietary portfolio of approximately 750 small molecule neuropeptide analogues. Our lead clinical-stage product candidate is for the treatment opioid use disorder and acute and chronic pain. The portfolio also has the potential to generate other compounds for treatment of various substance use disorders and compounds for life cycle management and backup molecules.

On May 25, 2023, we completed a merger transaction, or the Merger, with DMK Pharmaceuticals Corporation, a New Jersey corporation (“Legacy DMK”), pursuant to an Agreement and Plan of Merger and Reorganization dated as of February 24, 2023, or the Merger Agreement, by and among the Company, Legacy DMK, Aardvark Merger Sub, Inc., a Delaware corporation and a wholly-owned subsidiary of the Company (“Merger Sub”). The Merger Agreement provided for the merger (the “Merger”) of Legacy DMK with and into Merger Sub, with Merger Sub surviving as a wholly-owned subsidiary of the Company. Prior to the Merger, Legacy DMK was a privately-held, clinical stage biotechnology company focused on the development and commercialization of potential products for a variety of central nervous disorders. Pursuant to the Merger, each share of common stock of Legacy DMK was converted into the right to receive a number of shares of the Company’s common stock and, in the case of certain Legacy DMK stockholders, shares of our Series E Convertible Preferred Stock, or Series E Preferred. Additionally, Merger Sub changed its name to DMK Pharmaceuticals Corporation.

Effective September 6, 2023, pursuant to a certificate of amendment to the Company’s restated certificate of incorporation, Adamis Pharmaceuticals Corporation changed its name to DMK Pharmaceuticals Corporation. In connection with the change of the Company’s corporate name, Merger Sub’s corporate name was changed to Adamis Pharmaceuticals Corporation.

25   

Our US Compounding Inc. subsidiary, or USC, which we acquired in April 2016, is a discontinued operation, was previously registered as a human drug compounding outsourcing facility under Section 503B of the FDCA and the U.S. Drug Quality and Security Act, or DQSA, and provided prescription compounded medications, including compounded sterile preparations and nonsterile compounds, to patients, physician clinics, hospitals, surgery centers and other clients throughout most of the United States.  In July 2021, we sold certain assets relating to USC’s human compounding pharmaceutical business and approved a restructuring process to wind down the remaining USC business and sell, liquidate or otherwise dispose of the remaining USC assets.  Effective October 31, 2021, USC surrendered its Arkansas retail pharmacy permit and wholesaler/outsourcer permit and is no longer selling compounded pharmaceutical or veterinary products.

            To achieve our goals and support our overall strategy, we will need to raise additional funding to sustain operations, satisfy our obligations and liabilities and enable further product development.

Products and Product Candidates

Opioid Overdose; ZIMHI (naloxone) Injection

Naloxone is an opioid antagonist used to treat narcotic overdoses. Naloxone, which is generally considered the drug of choice for immediate administration for opioid overdose, blocks or reverses the effects of the opioid, including extreme drowsiness, slowed breathing, or loss of consciousness and eventually, death. Common opioids include morphine, heroin, tramadol, oxycodone, hydrocodone and fentanyl. Since the COVID-19 pandemic, the opioid crisis has become significantly worse, and this increase has disproportionately affected adolescents. According to Bloomberg industry data, the U.S. naloxone market grew by about 15% in 2022 and according to the December 31, 2022 Form 10-K of Emergent BioSolutions, Inc. filed in March 2023, sales of Narcan®, the leading naloxone product for treatment of opioid overdoses, were approximately $374 million for 2022.

The Centers for Disease Control and Prevention, or CDC, estimates that between 1999 and 2020 more than 932,000 people have died of drug overdoses, with annual deaths increasing during the COVID-19 pandemic. More recent statistics published by the CDC reported that drug overdoses resulted in approximately 107,081 deaths in the United States during the 12-month period ending December 2022, which was an approximately 51% increase over the approximately 71,030 deaths for the 12-month period ending December 2019. Overdose deaths involving opioids (including both prescription and synthetic) accounted for 81,045 of the overdose deaths in 2022 and are now the leading cause of death for Americans under age 50. More powerful synthetic opioids, like fentanyl and its analogues, are responsible for approximately 90% of those opioid deaths. These statistics are even more stark for adolescents according to the CDC. Comparing July-December 2019 to July-December 2021, overdose deaths among youngsters aged 10 to 19 years increased by 109% and in that same time period, deaths involving illicitly manufactured fentanyl increased by 182% in the same age group. In June 2021, the National Institute on Drug Abuse; National Institutes of Health; U.S. Department of Health and Human Services, published the policy brief, “Naloxone for Opioid Overdose: Life-Saving Science,” which reported that statistical modeling suggests that high rates of naloxone distribution among laypersons and emergency personnel could avert approximately 21% of opioid deaths. The brief also stated that overdoses involving highly potent synthetic opioids such as fentanyl or large quantities of opioids may require multiple doses of naloxone, and if respiratory function does not improve, naloxone doses may be repeated every two to three minutes. With the increasing prevalence of illicit fentanyl on the streets, we believe the need for ZIMHI as a product that results in rapid increase in higher blood levels of naloxone is becoming ever more important.

On October 18, 2021, we announced that the FDA had approved ZIMHI (naloxone hydrocholoride 5mg) for the treatment of opioid overdose, and it was commercially launched in the U.S. on March 31, 2022. 

The results of a study sponsored by the FDA was recently presented by Dr. David Strauss, M.D., Ph.D. Dr. Straus at a virtual public meeting of the Reagan–Udall Foundation addressing fatal overdoses. Dr. Straus is the Director of the Division of Applied Regulatory Science at the Center for Drug Evaluation and Research. The current standard of care is a single intranasal 4mg dose of naloxone, as contained in Narcan. Given the fentanyl crisis, the investigators tested this single dose against two and four doses to reverse a simulated fentanyl overdose. They showed that the most effective reversal was achieved by four administrations of 4mg intranasal naloxone given within 2.5 minutes. We believe that this data from the FDA sponsored study suggests that rapid delivery of naloxone is necessary to help counter a fentanyl overdose and that a single administration of ZIMHI, based on its pharmacokinetic profile, could be an effective agent to counter a fentanyl overdose.

On July 28, 2023, we issued a press release announcing that we had committed to fund an unrestricted research grant to the Leiden University Medical Center Anesthesia and Pain Research Unit. The funding will support the work of Albert Dahan, MD, PhD, an expert on opioid-induced respiratory depression (opioid overdose) and professor of anesthesiology at the University. Dr. Dahan has been working with the FDA to understand better methods of reversing fentanyl overdoses. The objective of the work will be to assess the efficacy of the Company’s ZIMHI product compared to 4mg of intranasal naloxone, and the respective number of doses required to reverse fentanyl-induced respiratory depression.

Anaphylaxis; SYMJEPI; Epinephrine Injection Pre-Filled Single Dose Syringe

The American Academy of Allergy Asthma and Immunology, or AAAAI, defines anaphylaxis as a serious life-threatening allergic reaction. The most common anaphylactic reactions are to foods, insect stings, medications and latex. According to information published by AAAAI reporting on findings from a 2009-2010 study, up to 8% of U.S. children under the age of 18 had a food allergy, and approximately 38% of those with a food allergy had a history of severe reactions. Anaphylaxis requires immediate medical treatment, with epinephrine as the first course of treatment to open airways and maintain blood pressure.

We estimate that sales of prescription epinephrine products were more than approximately $1.75 billion in 2022, based on assumptions and estimates using industry data. While we cannot provide any assurances concerning whether annual prescription sales will decline or grow, we believe that the epinephrine market has the potential to grow in the future, based in part on the prevalence of medical conditions, such as anaphylaxis, cardiovascular diseases, respiratory diseases (asthma), and the increased awareness about the treatment options for the management of these diseases. The market for prescription epinephrine products is competitive. Our SYMJEPI (epinephrine) Injection 0.15mg and 0.3mg products allow users to administer a pre-measured epinephrine dose quickly with a device that we believe, based on human factors studies, to be intuitive to use. 

On June 15, 2017, the FDA approved our SYMJEPI (epinephrine) Injection 0.3mg product for the emergency treatment of allergic reactions (Type I) including anaphylaxis. SYMJEPI (epinephrine) Injection 0.3mg is intended to deliver a dose of epinephrine, which is used for emergency, immediate administration in acute anaphylactic reactions to insect stings or bites, allergic reaction to certain foods, drugs and other allergens, as well as idiopathic or exercise-induced anaphylaxis for patients weighing 66 pounds or more. On September 27, 2018, the FDA approved our lower dose SYMJEPI (epinephrine) Injection 0.15mg product, for the emergency treatment of allergic reactions (Type I) including anaphylaxis in patients weighing 33 to 66 pounds. Our SYMJEPI injection products were fully launched in July 2019 by our then-commercialization partner Sandoz Inc. Our SYMJEPI products are currently marketed and sold by USWM, LLC, or USWM or US WorldMeds, with which we entered into an exclusive distribution and commercialization agreement, or the USWM Agreement, in May 2020 for the United States commercial rights for the SYMJEPI products, as well as for our ZIMHI product.

SYMJEPI is manufactured and tested for us by Catalent Belgium S.A. During Catalent’s routine testing, a small number of syringes with clogged needles were identified. On March 21, 2022, we announced a voluntary recall of four lots of SYMJEPI (epinephrine) Injection 0.15 mg (0.15 mg/0.3 mL) and 0.3 mg (0.3 mg/0.3 mL) due to the potential clogging of the needle preventing the dispensing of epinephrine. The recall was conducted with the knowledge of the FDA, and USWM handled the recall process for the Company, with Company oversight. As of the date of this Report, neither USWM nor we have received, nor are aware of, any adverse events related to this recall and in February 2023, the Company received notice from the FDA that the agency considers the voluntary recall of our SYMJEPI products to be terminated. Such notice does not preclude the FDA from taking action in the future related to the recall, and we remain responsible for compliance with applicable laws relating to the product and the recall. Catalent’s investigation determined the steel used in a specific stainless steel needle batch as the root cause for the clogged syringes observed. The Company worked with Catalent to develop corrective and preventive actions. However, despite the corrective actions and sourcing syringes which used a different batch of steel for the needles, Catalent’s attempt to resume manufacturing of SYMJEPI at its Belgium facility has resulted in similar product defects. Therefore, as of the date of this Report, the Company remains unable to manufacture product. While we are committed to returning SYMJEPI to the market, we will not do so until we are satisfied that sufficient corrective actions have been implemented to avoid a repeat of the circumstances which led to the voluntary recall. We are evaluating a range of options to restore SYMJEPI production, including a critical assessment of Catalent.

26   

Product Candidates

As a result of our Merger with Legacy DMK, we acquired a portfolio of approximately 750 novel small molecule neuropeptide analogues and a number of product candidates and technologies in development for opioid use disorder and other neuro-based disorders. We intend to focus on developing therapies with novel mechanisms of action to treat these important conditions where patients are currently underserved, including substance abuse disorders. We intend to develop mono, bi- and tri-functional small molecules that simultaneously modulate critical networks in the nervous system with the goal of creating treatments that are efficacious, safe, and tolerable and could address several unmet or underserved medical needs by taking the novel approach to integrate with the body’s own efforts to regain balance of disrupted physiology. By designing small molecule analogs of neuropeptides, one or multiple receptors can be targeted by a single molecule to support a transition back to a balanced neurophysiological state.

Our lead clinical stage product candidate, DPI-125, is being developed as a potential novel treatment for opioid use disorder, or OUD. We also plan to study this compound for the treatment of moderate to severe pain, where it could potentially offer a product with competitive advantages compared to currently marketed opioids (pain killers) and hence help prevent opioid addiction. Other product candidates include DPI-221, for treating bladder control problems, and DPI-289 for treating severe end stage Parkinson’s disease. We generally intend to focus on the development programs that target substance use disorder described above and to seek to out-license product candidates targeting indications outside of this focus.

DPI-125

DPI-125 is a small molecule that is currently being developed for two potential uses. The first is for the rapid stabilization of OUD patients actively using prescription or street opioids, including deadly fentanyl and its analogues. The second potential use is as a potent, acute analgesic, with a potentially reduced risk of respiratory depression and addiction compared to currently marketed opioids. 

We have completed a human Phase 1 dose escalation study with DPI-125, and the pharmacokinetic data showed that the drug was well tolerated in the human study, with no serious adverse events, deaths or dropouts. The next anticipated development step, assuming available funding and no unexpected developments, will be human proof of concept studies, which will attempt to confirm what has been demonstrated in preclinical studies in terms of reduced or absent respiratory depression and abuse liability. Following these proof-of-concept studies, we believe that the next development step, assuming available funding and no unexpected developments, will be to proceed into Phase 2 trials for the treatment of OUD and acute pain, where the focus of the trials will not only be on efficacy, but also safety and tolerability. We believe that the same characteristics and mechanism of action that may make DPI-125 a useful product in the fight against addiction could also make it a significant alternative to currently marketed opioids used for treating pain.

DPI-221

DPI-221 is a small molecule as what we believe is a unique alternative to surgery for benign prostatic hyperplasia, or BPH, by reestablishing bladder control. BPH is a common problem with approximately six million men seeking treatment annually, with an estimated market size of approximately $5.4 billion annually in the United States. BPH is a common, chronic disease caused by an enlarged prostate. DPI-221 may offer a novel approach to the treatment of BPH by acting on the central nervous system to suppress abnormal activity without interfering with normal bladder function. In preclinical studies, DPI-221 was effective at reestablishing neural control of the bladder, which returns the bladder to more normal function, allowing coordinated bladder contractions and efficient voiding.

A first-in-human Phase 1 oral dose escalation study, showed that the drug was safe and tolerable in the study. There were no serious adverse events, deaths or study dropouts. The pharmacokinetic, or PK, characteristics have allowed planning of a proof-of-concept study, which, assuming available funding and no unexpected developments, is anticipated to be a human urodynamic study to determine the efficacious dose that will inform dosing in a subsequent Phase 2 study. We believe that if successfully developed, this medication could prevent or reduce the need for BPH surgery.

DPI-289

DPI-289, also a small molecule, has been developed to treat patients suffering from severe Parkinson’s disease, or PD. Many of these patients will have been treated with a current leading treatment product called levodopa, or L-DOPA. Unfortunately, after a few years of treatment, the duration of effect is markedly curtailed (reduced “on-time”) and patients can exhibit severe abnormal movements called levodopa induced dyskinesia, or LID, which make it difficult or impossible to lead a normal life. Preclinical studies have demonstrated DPI-289’s ability to treat parkinsonian disability in rodent and non-human primate models to dramatically increase on-time without causing dyskinesia. Our initial goal with respect to this product candidate is to target patients late in their disease who require deep brain stimulation (DBS-brain surgery) to prevent such surgeries and also treat those patients who are not eligible for DBS. Given this target population, we plan to seek orphan drug status from the FDA and international regulatory agencies. Initially, assuming available funding and no unexpected developments, we intend to develop the compound as monotherapy, but we anticipate that future studies will examine its utility in PD patients as combination therapy with L-DOPA to increase “on-time” without increasing the debilitating side effect of dyskinesia.

We anticipate that the next step for this program, assuming adequate funding and no unexpected developments, will be to carry out IND-enabling toxicology studies to allow the filing of an Investigational New Drug Application, or IND, for the first in-person studies. If orphan drug status is conferred by the FDA or other international regulatory bodies, the cost and duration of the clinical development program may be significantly reduced, allowing for approval in an accelerated time frame.

Other

In June 2020, we entered into a license agreement with a third-party entity to in-license rights under patents, patent applications and related know-how of licensor relating to Tempol, an investigational drug. In September 2021 we commenced patient dosing in a Phase 2/3 clinical trial to examine the safety and efficacy of Tempol in COVID-19 patients. The Data Safety Monitoring Board, or DSMB, overseeing the Phase 2/3 clinical trial met in March and June 2022 to evaluate interim clinical and safety data and, following its evaluation, recommended that the study continue as planned. On September 21, 2022, we announced that the DSMB’s third interim analysis of the Phase 2/3 clinical trial, which was the first interim review where the DSMB evaluated the primary efficacy endpoint, determined that the trial did not achieve its primary endpoint and recommended that the study be halted early due to lack of efficacy. Based on the recommendation from the DSMB, we halted the trial and stopped all further development of Tempol in October 2022.

Going Concern and Management Plan 

            The financial statements included elsewhere herein for the three and nine months ended September 30, 2023 and 2022, were prepared under the assumption that we would continue our operations as a going concern, which contemplates the realization of assets and the satisfaction of liabilities during the normal course of business. However, as of September 30, 2023, we had cash and cash equivalents of approximately $6.7 million, an accumulated deficit of approximately $323.5 million, and liabilities of approximately $13.9 million. We have incurred substantial recurring losses from continuing operations, have used, rather than provided, cash in our continuing operations, and are dependent on additional financing to fund operations. These conditions raise substantial doubt about our ability to continue as a going concern within one year after the date the financial statements are issued. The financial statements included elsewhere herein do not include any adjustments to reflect the possible future effects on the recoverability and classification of assets or the amounts and classification of liabilities that may result from the outcome of this uncertainty.

           Our management intends to attempt to secure additional required funding through equity or debt financing if available, seeking to enter into a partnership or other strategic agreement regarding, or sales or out-licensing of, our commercial products, product candidates or intellectual property assets or other assets, revenues relating to supply and sale of ZIMHI and SYMJEPI products and share of net profits received relating to sales in the U.S. of our ZIMHI and SYMJEPI products, seeking partnerships or commercialization agreements with other pharmaceutical companies or third parties to co-develop and fund research and development or commercialization efforts of our products.  There can be no assurance that we will be successful in obtaining the required funding. If we do not obtain required funding, our cash resources will be depleted in the near term and we would be required to materially reduce or suspend operations, which would likely have a material adverse effect on our business, stock price and our relationships with third parties with whom we have business relationships. If we do not have sufficient funds to continue operations, we could be required to seek bankruptcy protection, dissolution or liquidation, or other alternatives that could result in our stockholders losing some or all of their investment in us. We have implemented expense reduction measures including, without limitation, employee headcount reductions and the reduction or discontinuation of certain product development programs. 

27   

Results of Operations                

Our consolidated results of operations are presented for the three and nine months ended September 30, 2023 and 2022. Certain financial results (revenues and expenses) relating to the business formerly conducted by USC are reflected in Note 4, Discontinued Operations and Assets Held for Sale, of the notes to the condensed consolidated financial statements appearing elsewhere in this Report.  Unless otherwise noted, the discussion below, and the revenue and expense amounts discussed below, are based on and relate to the continuing operations of the Company, which includes the operations of Legacy DMK from the date of acquisition.       

The following table summarizes the significant items within our results of operations for the three and nine months ended September 30, 2023 and 2022 (in thousands):

	Three Months Ended September 30,				Increase (Decrease)		Nine Months Ended September 30,				Increase (Decrease)
	2023		2022				2023		2022
Revenue, net	$	9	$	1,506	$	(1,497)	$	1,469	$	2,605	$	(1,136)
Cost of goods sold	338		1,648		(1,310)		2,488		3,706		(1,218)
Gross loss	(329)		(142)		(187)		(1,019)		(1,101)		82
Selling, general and administrative expenses	2,517		2,508		9		11,332		10,097		1,235
Research and development expenses	419		1,978		(1,559)		2,106		9,520		(7,414)
Acquired in-process research & development (IPR&D)	—		—		—		6,540		—		6,540
Other income (expense), net	1,529		357		1,172		3,243		(2,079)		5,322
Net loss from continuing operations	(1,736)		(4,271)		2,535		(17,754)		(22,797)		5,043
Net income (loss) from discontinued operations	348		(128)		476		(1,151)		(354)		(797)
Net Loss Applicable to Common Stock	(1,388)		(4,399)		(3,011)		(18,905)		(23,151)		(4,246)

28   

Three Months Ended September 30, 2023 and 2022

Revenues. Revenues were approximately $9,000 and $1,506,000 for the three months ended September 30, 2023 and 2022, respectively. The revenues recognized during the three months ended September 30, 2023 represent license fees received in relation to the USWM Agreement, which are recognized as revenue ratably over the term of the license. The revenues recognized during the three months ended September 30, 2022 were primarily attributable to approximately $1.3 million of sales of ZIMHI to USWM recognized in that quarter and approximately $0.6 million in recognition of deferred revenue due to the Company's reassessment of performance obligations met under the USWM Agreement, offset by product recall costs of approximately $0.4 million, which were recorded as contra-revenue. There were no product revenues for SYMJEPI or ZIMHI during the three months ended September 30, 2023 due to continued sourcing issues with the syringes for SYMJEPI, and due to the lack of orders for ZIMHI from USWM. The Company has been evaluating the disappointing results of USWM’s commercialization efforts in creating market access and sales for ZIMHI and has taken additional steps to bolster USWM’s work. As of the date of this Report, the Company remains unable to manufacture SYMJEPI. While we are committed to returning SYMJEPI to the market, we will not do so until we are satisfied that sufficient corrective actions have been implemented to avoid a repeat of the circumstances which led to the voluntary recall.

Cost of Goods Sold. Our cost of goods sold includes direct and indirect costs to manufacture formulations and sell products, including active pharmaceutical ingredients, personnel costs, packaging, storage, shipping and handling costs, the write-off of obsolete inventory, assembly line depreciation and other related expenses. Cost of goods sold was approximately $338,000 and $1,648,000 for the three months ended September 30, 2023 and 2022, respectively. The gross loss for the three months ended September 30, 2023 was approximately $329,000 compared to approximately $142,000 for the three months ended September 30, 2022. Cost of goods sold for the third quarter of 2023 compared to the third quarter of 2022 decreased approximately $1.3 million primarily due to a decrease in assembly line depreciation of approximately $0.4 million which was fully depreciated in May 2023, a decrease in ZIMHI production costs of approximately $1.2 million, offset by an increase in maintenance fees to USWM of approximately $0.3 million due to the lack of product production. 

Selling, General and Administrative Expenses. Selling, general and administrative, or SG&A, expenses consist primarily of consulting and employee compensation, professional fees which include legal, accounting and audit fees, and fixed assets depreciation and amortization expenses. SG&A expenses for the three months ended September 30, 2023 and 2022 were approximately $2,517,000 and $2,508,000, respectively. The increase in SG&A expenses of approximately $9,000 was primarily due to an increase in legal expenses of approximately $0.1 million, offset by a decrease in compensation and accounting related expenses of approximately $0.1 million.  

Research and Development Expenses. Our research and development, or R&D, costs are expensed as incurred and include costs to conduct clinical trials, contract research costs, R&D consulting and R&D employee compensation and R&D supplies. Non-refundable advance payments for goods and services to be used in future research and development activities are recorded as an asset and are expensed when the research and development activities are performed. R&D expenses were approximately $419,000 and $1,978,000 for the three months ended September 30, 2023 and 2022, respectively. The decrease of approximately $1.6 million was primarily attributable to a decrease in costs of approximately $1.6 million related to the Tempol product candidate clinical trial that was halted in the third quarter of fiscal year 2022. The research and development expenses of approximately $0.4 million incurred during the three months ended September 30, 2023 is primarily attributable to continued development of our ZIMHI product.

Other Income or Expense. Other Income or Expense consists primarily of interest income, interest expense, penalty fees, changes to the fair value of warrant liabilities, and other miscellaneous transactions. Other income was approximately $1,529,000 and $357,000 for the three months ended September 30, 2023 and 2022, respectively. The increase in Other Income of approximately $1.2 million is primarily due to the increase in the gains from the revaluation of the warrant liabilities of approximately $0.7 million and an increase of approximately $0.2 million in insurance proceeds received related to a legal matter. Additionally, an Other Expense of approximately $0.3 million related to the loss on Fagron variable consideration was recognized in the prior year’s third quarter, compared to $0 in the third quarter of 2023.

Income (Loss) from Discontinued Operations. The Company recorded a net income (loss) from discontinued operations, after taxes, of approximately $348,000 and $(128,000) for the three months ended September 30, 2023 and 2022, respectively.  The increase in income from discontinued operations of approximately $0.5 million during the three months ended September 30, 2023, compared to the three months ended September 30, 2022, was primarily due to the gain on asset disposal of approximately $0.4 million recorded upon the sale of the USC land, building, and equipment during the third quarter of 2023. Additionally, the SG&A costs attributable to the discontinued operations decreased approximately $0.1 million in the third quarter of 2023 as compared to the third quarter of 2022 as the Company continues the winding down of USC's former business operations. 

29   

Nine Months Ended September 30, 2023 and 2022 

Revenues. Revenues were approximately $1,469,000 and $2,605,000 for the nine months ended September 30, 2023 and 2022, respectively. The decrease of approximately $1.1 million was primarily attributable to a decrease in sales of ZIMHI to USWM of approximately $0.9 million, offset by a decrease in product recall costs of approximately $0.4 million, which were recorded as contra-revenue during the nine months ended September 30, 2022. The Company has been evaluating the disappointing results of USWM’s commercialization efforts in creating market access and sales for ZIMHI and has taken additional steps to bolster USWM’s work. Additionally, a decrease of approximately $0.6 million is attributable to the recognition of deferred revenue during the nine months ended September 30, 2022, due to the Company's reassessment of performance obligations met under the USWM Agreement.

Cost of Goods Sold. Our cost of goods sold includes direct and indirect costs to manufacture formulations and sell products, including active pharmaceutical ingredients, personnel costs, packaging, storage, shipping and handling costs, the write-off of obsolete inventory, assembly line depreciation and other related expenses. Cost of goods sold was approximately $2,488,000 and $3,706,000 for the nine months ended September 30, 2023 and 2022, respectively. The gross loss for the nine months ended September 30, 2023 was approximately $1,019,000 compared to approximately $1,101,000 for the nine months ended September 30, 2022. Cost of goods sold for the nine months ended September 30, 2023, compared to the nine months ended September 30, 2022 decreased by approximately $1.2 million, primarily due to a decrease in assembly line depreciation of approximately $0.9 million, a decrease in defective and obsolete inventory expenses of approximately $0.2 million, and a decrease of approximately $0.9 million in ZIMHI production costs, offset by an increase in maintenance fees of approximately $0.8 million due to the lack of product production.  

Selling, General and Administrative Expenses. Selling, general and administrative, or SG&A, expenses consist primarily of consulting and employee compensation, professional fees which include legal, accounting and audit fees, and fixed assets depreciation and amortization. SG&A expenses for the nine months ended September 30, 2023 and 2022 were approximately $11,332,000 and $10,097,000 respectively. The increase in SG&A expenses of approximately $1.2 million was primarily attributable to increases of approximately $1.4 million of the costs related to the Merger, approximately $0.9 million related to legal expenses, offset by a decrease in compensation and employment separation expenses of approximately $1.1 million.

Research and Development Expenses. Our research and development, or R&D, costs are expensed as incurred and include costs to conduct clinical trials, contract research costs, R&D consulting and R&D employee compensation and R&D supplies. Non-refundable advance payments for goods and services to be used in future research and development activities are recorded as an asset and are expensed when the research and development activities are performed. R&D expenses were approximately $2,106,000 and $9,520,000 for the nine months ended September 30, 2023 and 2022, respectively. The decrease of approximately $7.4 million was primarily attributable to a decrease in development spending on the Tempol product candidate in which the related clinical trial was halted in the third quarter of 2022 of approximately $5.5 million, a decrease in other development spending of approximately $0.4 million on other product candidates, and a decrease in compensation expenses for research and development employees of approximately $1.5 million primarily due to the reduction in work force. 

Acquired In-Process Research & Development (IPR&D). We elected to expense the fair value of the Acquired IPR&D from the DMK Merger due to its early stage and its lack of alternative future use. Acquired IPR&D was approximately $6,540,000 and $0, for the nine months ended September 30, 2023 and 2022, respectively.  There was no asset acquisition completed during the nine months ended September 30, 2022.

Other Income or Expense. Other Income (Expense) consists primarily of interest income, interest expense, changes to the fair value of warrant liabilities, and other transactions. Other income (expense) totaled approximately $3,243,000 and $(2,079,000) for the nine months ended September 30, 2023 and 2022, respectively. The increase in other income (expense) of approximately $5.3 million was primarily attributable to the increase in the gain recognized from the change in the fair value of warrants of approximately $4.6 million, an increase in the gain recognized due to additional Employee Retention Credit received during the second quarter of 2023 of approximately $0.5 million, and an increase in insurance proceeds received of approximately $0.3 million. This increase in other income (expense) was offset by an increase of approximately $0.3 million in interest expense and contingent loss liability related to the USC lease, and approximately $2.5 million in losses related to the excess of the fair value of the March 2023 warrants over the proceeds received from that transaction. Additionally, for the nine months ended September 30, 2022, losses on Fagron variable consideration of approximately $0.9 million were recorded, and a contingent accrual loss related to the PPP2 loan of approximately $1.8 million was recorded, as compared to no such losses recorded during the nine months ended September 30, 2023.

Loss from Discontinued Operations. The company recorded a net loss from discontinued operations of approximately $1,151,000 and $354,000 for the nine months ended September 30, 2023, and 2022, respectively. The increase in loss from discontinued operations of approximately $0.8 million during the nine months ended September 30, 2023, compared to the nine months ended September 30, 2022, primarily attributable to the impairment charge taken on the USC land and building of approximately $1.5 million during the second quarter of 2023 to reduce the carrying value of the property to the anticipated sales price less commissions, offset by the gain on asset disposal of approximately $0.4 million recorded upon the sale of the USC land, building, and equipment during the nine months ended September 30, 2023, as well as the decrease of approximately $0.3 million in SG&A expenses as the Company continues the winding down of USC's former business operations. 

30   

Liquidity and Capital Resources 

We have incurred net losses from our continuing and discontinued operations of approximately $18.9 million and $23.2 million for the nine months ended September 30, 2023 and 2022, respectively. Since inception, and through September 30, 2023, we have an accumulated deficit of approximately $323.5 million. Since inception and through September 30, 2023, we have financed operations principally through product sales, public and private issuances of common stock, preferred stock and warrants and through debt financing. On July 25, 2023, we closed a transaction involving the sale of a building and real property located in Conway, Arkansas, formerly utilized by our discontinued USC compounding pharmacy business, as well as certain related personal property equipment and assets and intellectual property, to an unaffiliated third-party purchaser, for total aggregate net proceeds of approximately $1.8 million. In addition, on August 4, 2023, we completed an offering of 4,800,000 shares of our common stock, 1,130,000 prefunded warrants and common stock purchase warrants to purchase up to 5,930,000 shares of our common stock and received net proceeds of approximately $7.1 million. However, we will need additional funding in the future to satisfy our existing and future obligations, liabilities and working capital needs, to support commercialization of our products and conduct clinical and regulatory work to develop our product candidates, to begin building working capital reserves, and for other purposes. We intend to seek to finance future cash needs primarily through proceeds from equity or debt financings, loans, share of profits anticipated to be received relating to sales in the U.S. of our SYMJEPI and ZIMHI products, sales of assets, out-licensing transactions, and/or collaborative agreements with corporate partners. 

We will need additional funding in the future to satisfy our existing and future obligations and liabilities and working capital needs, to support commercialization of our products and conduct clinical and regulatory work to develop our product candidates, to begin building working capital reserves, and for other purposes. We intend to seek to finance future cash needs primarily through proceeds from equity or debt financings, loans, share of profits anticipated to be received relating to sales in the U.S. of our SYMJEPI and ZIMHI products, sales of assets, out-licensing transactions, and/or collaborative agreements with corporate partners.

As of September 30, 2023, we had cash and cash equivalents of approximately $6.7 million.

The following table provides a summary of the net cash flow activity for each of the periods set forth below (in thousands):

	For the Nine Months Ended September 30,
	2023			2022
Net cash used in operating activities	$	(7,853	)	$	(24,378	)
Net cash provided by investing activities		2,747			3,329
Net cash provided by financing activities		10,688			285
Increase (decrease) in cash, cash equivalents and restricted cash	$	5,582		$	(20,764	)

Net cash used in operating activities for the nine months ended September 30, 2023 and 2022, was approximately $7.9 million and $24.4 million, respectively. Our net cash used in operating activities decreased by approximately $16.5 million primarily due to a decrease in our net losses of approximately 4.3 million, an increase in noncash expenses of approximately $3.3 million, and a decrease in net operating assets. 

              Net cash provided by investing activities for the nine months ended September 30, 2023 and 2022, was approximately $2.7 million and $3.3 million, respectively. Net cash provided by investing activities decreased by approximately $0.6 million. Net cash provided by investing activities for the nine months ended September 30, 2023 is primarily related to the proceeds of approximately $2.6 million related to the sale of certain fixed assets which were classified in discontinued operations, and approximately $0.1 million of cash acquired in the DMK Merger. Net cash provided by investing activities for the nine months ended September 30, 2022 is primarily related to the proceeds of approximately $3.9 million received from the sale of USC assets to Fagron in the first half of 2022, offset by the purchases of equipment of approximately $0.6 million during the nine months ended September 30, 2022.

Net cash provided by financing activities was approximately $10.7 million $0.3 million for the nine months ended September 30, 2023 and 2022, respectively. Net cash provided by financing activities increased by approximately $10.4 million due to the net proceeds of approximately $2.7 million from the March 2023 Offering, net proceeds of approximately $7.1 million from the August 2023 Offering, and approximately $0.9 million of proceeds received upon the exercise of common stock warrants. During the nine months ended September 30, 2022, net cash provided by financing activities included approximately $0.3 million of proceeds received from the issuance of preferred stock and warrants.

As noted above under the heading “Going Concern and Management Plan,” through September 30, 2023, we have incurred substantial losses.  We will be required to devote significant cash resources to support our intended development programs and sustain operations and activities.  The availability of any required additional funding cannot be assured.  In addition, an adverse outcome in legal or regulatory proceedings in which we are or in the future could be involved could adversely affect our liquidity and financial position.  See Note 11 of the notes to our consolidated financial statements included elsewhere herein.  If in the future we are not able to obtain additional required equity or debt funding, our cash resources could be depleted, and we could be required to suspend operations or seek bankruptcy protection.  No assurance can be given as to the timing or ultimate success of obtaining future funding.  Even if we are successful in obtaining required additional funding to permit us to continue operations at the levels that we desire, substantial time may pass before we obtain regulatory marketing approval for any additional pharmaceutical products and begin to realize revenues from sales of such additional products. No assurance can be given as to the timing or ultimate success of obtaining any required future funding. In addition, there can be no assurance that deterioration in credit and financial markets will not occur, which would make it more difficult, or more costly or dilutive, to obtain any necessary debt or equity financing.  In addition, as disclosed elsewhere in this Report, on May 11, 2021, both the USAO and the SEC have initiated investigations of the company relating to, among other matters, certain veterinary products sold by the company’s USC subsidiary, certain practices, agreements and arrangements relating to products sold by USC, including veterinary products, and certain regulatory and other matters relating to the company and USC. We have received additional requests for production of documents from the SEC and the USAO and continue to engage in communications with the SEC and the USAO regarding their investigations. We or our USC subsidiary may be found to have violated one or more laws arising from the subject matter of the subpoenas. There can be no assurance that any resolution of these matters and investigations with the USAO or SEC will not have a material and adverse effect on the company. The foregoing matters could subject the company and its officers and directors to civil or criminal proceedings, and depending on the resolution of the matters or any proceedings, could result in fines, payments, or financial remedies in amounts that may be material to our financial condition, or equitable remedies, and materially and affect the company’s business, previously reported financial results, financial results included in this Report, or future financial results.   The occurrence of any of these events could have a material adverse effect on the company’s business, financial condition and results of operations.

31   

Material Cash Requirements

           Based on our current and anticipated level of operations, we do not believe that our cash and cash equivalents together with anticipated revenues from operations and cash inflows from other sources and amounts that we expect to receive as a result of our sales of assets relating to our former USC business, will be sufficient to meet our anticipated operating expenses, capital expenditures and obligations for at least 12 months from the date of this Report. Even giving effect to our sale of the building and real property in Conway, Arkansas, for total aggregate estimated net proceeds of approximately $1.8 million and the net proceeds of approximately $7.1 million from our equity offering completed in August 2023, we will require additional funding in the near term to satisfy our substantial accounts payable balance and sustain operations. We will seek to raise additional funds or seek funding from a variety of sources including proceeds from equity or debt financings if available, loans, revenues relating to sales of our SYMJEPI product (after relaunch) and our ZIMHI product, sales or out-licensing of intellectual property assets or other assets, products, product candidates or technologies. Additional required capital may not be available on a timely basis, on favorable terms, or at all, and such funding, if raised, may not be sufficient to meet our obligations or enable us to continue to implement our long-term business strategy. In addition, obtaining additional funding or entering into other strategic transactions could result in significant dilution to our stockholders. If we do not receive required funding and are not able to engage in a merger, sale or other strategic transaction, we would likely be required to reduce or cease operations or seek dissolution and liquidation or bankruptcy protection.

           We have entered into arrangements with clinical sites and clinical research organizations, or CROs, for the conduct of our clinical trials. We make payments to these clinical sites and CROs based in part on the number of eligible patients enrolled, the length of their participation in the clinical trials and activities undertaken by the clinical sites and CROs. At this time, the close-out of the Phase 2/3 clinical trial relating to Tempol was substantially completed in December 2022, and we are in the process of completing the final reconciliation of costs related to the Tempol clinical trial. In addition, we have entered into agreements and arrangements with third parties for the manufacture and supply of clinical and commercial materials and drug products, including for our SYMJEPI and ZIMHI products and our halted clinical trial for our Tempol product candidate. In some of our agreements with manufacturers, we have a production threshold commitment where we would be required to pay for maintenance fees if we do not meet certain periodic purchase order minimums or we have firm purchase commitments we would be liable for. Maintenance fees for the nine months ended September 30, 2023 and 2022 were approximately $804,000 and $0, respectively. There were no purchases under the firm purchase commitments for the three or nine months ended September 30, 2023 and 2022. Under certain of these agreements, we may be subject to penalties in the event that we prematurely terminate these agreements. We intend to use our current financial resources to fund our obligations under these commitments. As disclosed elsewhere in this Report, on March 21, 2022, we announced a voluntary recall of four lots of SYMJEPI (epinephrine) Injection 0.15 mg (0.15 mg/0.3 mL) and 0.3 mg (0.3 mg/0.3 mL) Pre-Filled Single-Dose Syringes to the consumer level, due to the potential clogging of the needle preventing the dispensing of epinephrine. USWM is handling the recall process for the company, with company oversight. SYMJEPI is manufactured and tested for us by Catalent Belgium S.A. The ultimate costs of the recall and the allocation of costs of the recall, including the costs to us resulting from the recall, are unknown as of the date of this Report; however, the FDA has notified us that the FDA considers the voluntary recall terminated. Additionally, the recall could cause the company to suffer reputational harm, depending on the resolution of matters relating to the recall could result in the company incurring additional financial costs and expenses which could be material, has adversely affected and could continue to adversely affect the supply of SYMJEPI products until manufacturing is resumed, and depending on the resolution of matters relating to the recall could have a material adverse effect on our business, financial condition, and results of operations.   

Critical Accounting Estimates 

The discussion and analysis of our financial condition and results of operations are based on our unaudited condensed consolidated financial statements, which have been prepared in accordance with accounting principles generally accepted in the United States. The preparation of these unaudited condensed consolidated financial statements requires us to make estimates and judgments that affect the reported amounts of assets, liabilities, revenues, expenses, and related disclosure of contingent assets and liabilities. We evaluate our estimates on an ongoing basis. We base our estimates on historical experience and on other assumptions that we believe to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities that are not readily apparent from other sources. Actual results may differ from these estimates under different assumptions or conditions.

Critical accounting estimates related to the DMK Merger are as follows:

We determined that the acquired group, DMK, is a variable interest entity, or VIE, as DMK’s total equity at risk is not sufficient to permit DMK to finance its activities without additional subordinated financial support. Additionally, DMK did not constitute a business because substantially all of the fair value of the gross assets acquired were concentrated in a single identifiable asset (DP-125). In accordance with accounting guidance, the consolidation of DMK (the VIE) is considered an asset acquisition. Additionally, we determined that we were the primary beneficiary and legal acquirer. Based on applicable accounting guidance, we were required to record DMK’s assets and liabilities at fair value. At acquisition date, we elected to expense the purchase consideration allocated to the early-stage acquired in-process research and development (acquired IPR&D) because there is no alternative future use related to the acquired IPR&D, and, as such, no further impairment assessments would be necessary for these assets. The Company incurred approximately $1.4 million of transaction costs were recorded within selling, general and administrative expenses on the condensed consolidated statement of operations.

The fair value of the acquired IPR&D was determined based upon the income approach using a multi period excess earnings model which included a forecast of the expected cash flows of DPI-125. The discount rate associated with this forecast was 27%.

The purchase price, or total consideration transferred, to acquire DMK in the Merger was comprised of the following:

Fair Value of the Company's Common Stock issued to Legacy DMK shareholders	$	757,038
Fair Value of the Company's Series E Preferred issued to Legacy DMK shareholders		4,853,000
Fair Value of Legacy DMK options assumed and replaced by the Company		415,809
Legacy DMK incurred Merger-related costs paid for by the Company		492,456
Total Consideration Transferred	$	6,518,303

32   

The fair value of the 302,815 shares of common stock issued in connection with the Merger was based on the closing price of our common stock on the date of acquisition multiplied by the number of common shares issued.

The fair value of the 1,941.2 shares of Series E Preferred issued in connection with the Merger was based on the closing price of our common stock on the date of acquisition multiplied by the number of common shares the Series E preferred stock is convertible into (1,941,200). The same fair value basis was utilized as our common stock for the Series E Preferred because the Series E Preferred have no preferences over common stock.

Pursuant to the Merger agreement, at the effective time, the outstanding DMK stock options to purchase shares of DMK common stock were assumed by us and became options to purchase a total of 231,490 shares of the Company’s common stock, with proportionate adjustments to the exercise prices per share of such options based on the exchange ratio determined pursuant to the Merger Agreement. The assumed options continue to be governed by the terms of the DMK 2016 Stock Plan, which was assumed by us in connection with the closing of the Merger. The assumed options were fully vested and the replacement awards was treated as additional purchase price consideration paid by us.

The fair value of the replacement awards is based primarily on inputs that are observable or can be corroborated by observable market data (such as our closing stock price and the published treasury par yield curves from the US Department of the Treasury). The estimated fair value of the replacement options of $415,809 was calculated using the Black Scholes Option Pricing Model. Key inputs at the date of closing, include expected volatility of 119.5% based on a 50/50 weighting of calculated volatility of our stock of approximately 107% (based on calculated volatility) and DMK's implied volatility of 132%, our stock price on the date of closing of $2.50, expected dividend yield of 0.0%, expected term ranging from 2.3699 years to 4.3726 years and average risk-free interest rate (based on the published treasury par yield curves from the US Department of Treasury) of approximately 4.06%.

  Recent Accounting Pronouncements

We periodically monitor and review all current accounting pronouncements and standards from the Financial Accounting Standards Board for applicability to our operations. We do not expect the adoption of accounting pronouncements recently issued during the third quarter of calendar year 2023 to have a significant impact on our results of operations, financial position or cash flow.

ITEM 3. Quantitative and Qualitative Disclosure of Market Risk

Not required.

ITEM 4. Controls and Procedures

We maintain disclosure controls and procedures that are designed to ensure that information required to be disclosed in our reports, filed under the Securities Exchange Act of 1934, is recorded, processed, summarized and reported within the time periods specified in the SEC’s rules and forms, and that such information is accumulated and communicated to our management, including our chief executive officer and chief financial officer, as appropriate, to allow timely decisions regarding required disclosure.  In designing and evaluating the disclosure controls and procedures, management recognized that any controls and procedures, no matter how well designed and operated, can provide only reasonable assurance and not absolute assurance of achieving their objectives.  In reaching a reasonable level of assurance, management necessarily was required to apply its judgment in evaluating the cost-benefit relationship of possible controls and procedures.  In addition, the design of any system of controls also is based in part upon certain assumptions about the likelihood of future events, and there can be no assurance that any design will succeed in achieving its stated goals under all potential future conditions.  Over time, a control may become inadequate because of changes in conditions or the degree of compliance with policies or procedures may deteriorate.  Because of the inherent limitations in a cost-effective control system, misstatements due to error or fraud may occur and not be detected.

            As required by the SEC Rule 13a-15(b), we carried out an evaluation under the supervision and with the participation of our management, including our chief executive officer and chief financial officer, of the effectiveness of the design and operation of our disclosure controls and procedures as of the end of the period covered by this Report.  Based on the foregoing, our chief executive officer and chief financial officer concluded that our disclosure controls and procedures were effective at the reasonable assurance level as of September 30, 2023.

Limitations on the Effectiveness of Controls

            Because of their inherent limitations, our disclosure controls and procedures and our internal control over financial reporting may not prevent material errors or fraud. All internal control systems, no matter how well designed, have inherent limitations and can provide only reasonable, not absolute, assurance that the objectives of the control system are met. Further, the design of a control system must reflect the fact that there are resource constraints, and the benefits of controls must be considered relative to their costs. The effectiveness of our disclosure controls and procedures and our internal control over financial reporting is subject to risks, including that the controls may become inadequate because of changes in conditions or that the degree of compliance with our policies or procedures may deteriorate. Because of the inherent limitations in all control systems, no evaluation of controls can provide absolute assurance that all control issues and instances of fraud, if any, within our company have been detected. 

Changes in Internal Controls Over Financial Reporting 

There were no changes in our internal control over financial reporting identified in management’s evaluation pursuant to Rules 13a-15(d) or 15d-15(d) of the Exchange Act that occurred during the quarter ended September 30, 2023 that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting. 

33   

PART II OTHER INFORMATION

ITEM 1. Legal Proceedings

We may from time to time become party to actions, claims, suits, investigations or proceedings arising from the ordinary course of our business, including actions with respect to intellectual property claims, breach of contract claims, labor and employment claims and other matters. We may also become party to litigation in federal and state courts relating to opioid drugs. Any litigation could divert management time and attention from the Company, could involve significant amounts of legal fees and other fees and expenses, or could result in an adverse outcome having a material adverse effect on our financial condition, cash flows or results of operations. Actions, claims, suits, investigations and proceedings are inherently uncertain and their results cannot be predicted with certainty. Except as described below, we are not currently involved in any legal proceedings that we believe are, individually or in the aggregate, material to our business, results of operations or financial condition. However, regardless of the outcome, litigation can have an adverse impact on us because of associated cost and diversion of management time.

Investigations 

            On May 11, 2021, each of the Company and its USC subsidiary received a grand jury subpoena from the U.S. Attorney’s Office for the Southern District of New York (the “USAO”) issued in connection with a criminal investigation, requesting a broad range of documents and materials relating to, among other matters, certain veterinary products sold by the Company’s USC subsidiary, certain practices, agreements and arrangements relating to products sold by USC, including veterinary products, and certain regulatory and other matters relating to the Company and USC. The Audit Committee of the Board engaged outside counsel to conduct an independent internal investigation to review these and other matters. The Company has also received requests from the Securities and Exchange Commission (“SEC”) that the Company voluntarily provide documents and information in connection with the SEC’s investigation relating to certain matters including matters arising from the subject matter of the subpoenas from the USAO. The Company has produced and will continue to produce and provide documents in response to the subpoenas and requests as needed. Additionally, on March 16, 2022, we were informed that the Civil Division of the USAO (“Civil Division”) is investigating the Company’s Second Draw PPP Loan application disclosed in previous reports. The Audit Committee of the Board engaged outside counsel to conduct an internal inquiry into the matter. In June 2022, following the inquiry the Company paid a total of $1,787,417 in repayment of the Second Draw PPP Loan principal and such related interest and fees. The Company intends to continue cooperating with the USAO and the SEC, and has continued to engage in communications with the SEC and USAO regarding their investigations. We have received additional requests for production of documents from the SEC and the USAO, have responded to those requests, could receive additional requests from the USAO, SEC, or other authorities, and continue to engage in communications with the SEC and the USAO regarding their investigations.  Additional issues or facts could arise or be determined, which may expand the scope, duration, or outcome of the investigation. We are unable to predict the duration, scope, or final outcome of the investigations by the USAO, SEC, or other agencies; what, if any, proceedings the USAO, SEC, or other federal or state authorities may initiate; what penalties, payments, by the Company, remedies or remedial measures the USAO, SEC, or other federal or state authorities may seek or may require in order to resolve the investigations; what, if any, impact the foregoing matters may have on the Company’s business, financial condition, previously reported financial results, financial results included in this Report, or future financial results; or what proceedings the USAO, SEC, or other federal or state authorities may initiate if the foregoing matters are not resolved. However, in connection with resolution of these matters, we or our USC subsidiary may be found to have violated one or more laws arising from the subject matter of the subpoenas, and to resolve the matters and investigations with the USAO and the SEC we may be required to pay material amounts in penalties or other payments, and to agree to other remedies or remedial measures. Payment of material amounts in connection with resolution of the foregoing matters would reduce the amount of financial resources that we have available to support our product development programs and commercialization activities and would adversely impact our development programs. Depending in part on the amount and timing of any payments that we may be required to make or other remedial measures that may be implemented in connection with resolution of these matters, a resolution of these matters with the USAO or SEC could have a material and adverse impact on the company. The foregoing matters have diverted and will likely continue to divert management’s attention, have caused the company to suffer reputational harm, have required and will continue to require the company to devote significant financial resources, could subject the company, one or more of its subsidiaries, or its officers and directors to civil or criminal proceedings, and depending on the resolution of the matters or any proceedings, could result in fines, penalties, payments, or financial remedies in amounts that would have a material adverse effect on our financial condition, or equitable remedies, and adversely affect the company’s business, previously reported financial results, financial results included or incorporated by reference herein, or future financial results.

Nasdaq Compliance

As previously disclosed, on October 4, 2023, the Company received notice (the “Prior Notice”) from the Listing Qualifications Department (the “Staff”) of The Nasdaq Stock Market LLC (“Nasdaq”) notifying the Company that it failed to evidence a minimum closing bid price of $1.00 per share, as required by Nasdaq Listing Rule 5550(a)(2) (the “Bid Price Rule”), for the previous 30 consecutive days and that the Company was provided a grace period of 180 calendar days from the date of the Prior Notice, or until April 1, 2024, to regain compliance with the Bid Price Rule, in accordance with Listing Rule 5810(c)(3)(A).  Also as previously disclosed, on October 11, 2023, the Company received notice from the Staff that, due to the Company’s failure to regain compliance with the minimum $35 million market value of listed securities (“MVLS”) requirement set forth in Nasdaq Listing Rule 5550(b)(2) (the “MVLS Rule”) during the 180-day grace period previously granted to the Company that expired on October 9, 2023, the Company’s common stock was subject to delisting unless the Company timely requested a hearing before the Nasdaq Hearings Panel (the “Panel”).

                In response, the Company timely requested a hearing before the Panel, which request stayed any further action by Nasdaq at least until the hearing is held and any extension the Panel may grant to the Company following the hearing expires.

                On October 18, 2023, the Company received a superseding notice from the Staff (the “Subsequent Notice”), indicating that the Prior Notice was issued in error. The Subsequent Notice indicated that because the Company was subject to a one-year Mandatory Panel Monitor as a result of a prior hearing before the Panel, the Company was not eligible for the automatic 180-day compliance grace period provided by Listing Rule 5810(c)(3)(A) and that the Company’s non-compliance with the Bid Price Rule serves as an additional basis for delisting from Nasdaq.

At the hearing before the Panel, the Company will address its plan to regain compliance with both the Bid Price Rule and the MVLS Rule as well as its continued compliance with all other applicable criteria for continued listing on The Nasdaq Capital Market. There can be no assurance, however, that the Panel will grant the Company’s request for continued listing or that the Company will evidence compliance with the listing rules prior to the expiration of any extension that may be granted by the Panel following the hearing. 

34   

Jerald Hammann

On June 8, 2021, Jerald Hammann filed a complaint against the Company and each of its directors in the Court of Chancery of the State of Delaware, captioned Jerald Hammann v. Adamis Pharmaceuticals Corporation et al., C.A. No. 2021-0506-PAF (the “Complaint”), seeking injunctive and declaratory relief.  The Complaint alleges, among other things, that the defendants (i) violated Rule 14a-5(f) and 14a-9(a) of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), in connection with the Company’s 2021 annual meeting of stockholders—which was subsequently held on July 16, 2021 (the “2021 annual meeting”)—and disseminated false and misleading information in the Company’s proxy materials relating to the 2021 annual meeting, (ii) violated certain provisions of the Company’s bylaws relating to the 2021 annual meeting, (iii) violated section 220 of the Delaware General Corporation Law (“DGCL”) in connection with a request for inspection of books and records submitted by the plaintiff, and (iv) breached their fiduciary duties of disclosure and loyalty, including relating to establishing and disclosing the date of the Company’s 2021 annual meeting and to the Company’s determination that a solicitation notice delivered to the Company by plaintiff was not timely and was otherwise deficient.  On April 4, 2022, the plaintiff filed a motion to amend the Complaint. The proposed amended Complaint added additional allegations relating to the manner in which the defendants established and disclosed the date of the Company’s 2021 annual meeting of stockholders and to statements the defendants made about the plaintiff to the Company’s stockholders. On April 28, 2022, the Court granted the motion. Trial on the merits of the plaintiff’s claims was held on March 16, 2023.  On August 23, 2023, the Court entered its opinion rendering judgment in favor of the Company and the other defendants and against the plaintiff as to all of the plaintiff’s claims.  On August 30, 2023, the plaintiff filed a motion for re-argument.  On October 16, 2023, the Court denied the plaintiff’s motion except with respect to an issue of nominal damages but concluded that nominal damages were not warranted.  On October 9, 2023, the plaintiff filed a motion for a temporary restraining order seeking to enjoin the defendants from distributing proxy materials and holding the Company’s 2023 annual meeting of stockholders.  On October 12, 2023, the Court denied the plaintiff’s motion for a temporary restraining order, and on October 16, 2023, the Court issued an order denying the plaintiff’s motion for re-argument. On November 3, 2023, plaintiff filed a notice of appeal to the Supreme Court of the State of Delaware.

CVI Investments

On October 19, 2023, a purported shareholder of the Company filed a complaint against the Company in the Supreme Court of the State of New York, County of New York, captioned CVI Investments vs. DMK Pharmaceuticals Corporation f/k/a Adamis Pharmaceuticals Corporation, Index No. 655184/2023 (the “Complaint”).  The Complaint alleges that the Company breached two warrant agreements Plaintiff entered into with the Company in connection with Plaintiff’s previous purchases of shares of Adamis stock.  Specifically, the Complaint alleges that the Company failed to repurchase two warrants previously issued to the Plaintiff for the repurchase price specified in the warrants, allegedly in violation of the terms of the warrants that provide for the repurchase of the warrants following timely notice from the warrant holder following the occurrence of certain specified events. The Complaint seeks (i) actual and compensatory damages from the purported breaches, (ii) reasonable attorneys’ fees and other costs and expenses incurred in connection with the Complaint, and (iii) pre- and post-judgment interest.  The Company’s deadline to respond to the Complaint is November 22, 2023. The Company disputes that it was obligated to repurchase the warrants and intends to vigorously dispute the claim.

Arbitration

On October 20, 2023, David Marguglio filed a demand for arbitration with Judicial Arbitration and Mediation Services, Inc. (JAMS) challenging the grounds of the separation of his employment, alleging that he is entitled to severance under the terms of his employment agreement, and demanding that the Company pay the costs of the arbitration.  The Company contends that Mr. Marguglio is not entitled to severance under the terms of his employment agreement. 

Turbare Real Estate Holdings

On May 26, 2023, Turbare Real Estate Holdings, LLC filed a complaint against the Company in the Circuit Court of Faulkner County Arkansas, captioned Turbare Real Estate Holdings, LLC v Adamis Pharmaceutical Corporation 23CV-23-796. The suit alleges breach of contract, seeking $1,414,943.08, with additional amounts still being incurred, plus costs and attorney fees, for alleged required repairs under a lease agreement between the parties.  The Company has filed a counter suit, alleging as to Turbare Real Estate Holdings, LLC, claims for breach of lease agreement, conversion, civil conspiracy for conversion, replevin, and unjust enrichment.  Additionally, the Company has added, as third party defendant, Turbare Manufacturing, LLC, alleging claims of breach of an access agreement for the leased real estate, conversion, civil conspiracy for conversion, replevin, tortious interference with contract, and unjust enrichment. On November 3, 2023, plaintiff filed a notice of appeal to the Supreme Court of the State of Delaware.

Supplemental Proxy Disclosures

On April 11, 2023, a purported stockholder of the Company filed a complaint against the Company and each of its directors in the United States District Court for the Southern District of New York, captioned Lapin vs. Adamis Pharmaceuticals Corporation, Case No. 1:23-cv-03023 (the “Complaint”). The Complaint alleged that the defendants violated Sections 14(a) and 20(a) of the Securities Exchange Act of 1934, as amended, by causing a materially incomplete and misleading Preliminary Proxy Statement to be filed with the SEC. Specifically, the Complaint alleged that the Preliminary Proxy Statement contains materially incomplete and misleading information concerning the sales process, financial projections prepared by management, as well as the financial analysis conducted by Raymond James & Associates, Inc., the Company’s financial advisor. The Complaint sought, among other things, (i) injunctive relief preventing the consummation of the transactions contemplated by the Merger Agreement or the filing of a definitive proxy statement with the SEC or causing a definitive proxy statement to be disseminated to the Company’s stockholders unless and until the material information described in the Complaint is included in the definitive proxy statement or otherwise disseminated to the Company’s stockholders, and (ii) in the event that the Merger transaction is consummated without the alleged material omissions referenced in the Complaint being remedied, damages and costs and disbursements of the action including reasonable plaintiff’s attorneys’ and experts’ fees and expenses. On July 6, 2023, the plaintiff filed a notice of voluntary dismissal, dismissing the claims in the complaint without prejudice, which was entered by the court on July 7, 2023.

In addition, the Company has received additional demand letters from counsel (the “Demand Letters”), each representing a purported stockholder of the Company, asserting that the Preliminary Proxy Statement and/or Proxy Statement was deficient and demanding that the alleged deficiencies be rectified. The Demand Letters allege, among other matters, that the Proxy Statements contain materially incomplete and misleading information concerning the sales process, financial projections prepared by the Company's management, and the financial analysis conducted by Raymond James & Associates, Inc. In addition, each purported shareholder has reserved his or her rights, including the right to alter or amend the demands at any time, and/or seek monetary damages following the consummation of the Merger.

The Company believes that the allegations in the Complaint and the Demand Letters are without merit and that the disclosures set forth in the Proxy Statement comply fully with applicable law. However, in order to moot the unmeritorious claims, avoid nuisance and possible expense and delay, and to provide additional information to our shareholders, the Company provided a voluntary supplement to the Proxy Statement with the supplemental disclosures filed with the SEC on May 5, 2023. Nothing in the Supplemental Disclosures shall be deemed an admission of the legal necessity or materiality under applicable laws of any of the disclosures set forth in the Supplemental Disclosures. To the contrary, the Company specifically denies all allegations that any additional disclosure was or is required. Nevertheless, resolution of these matters may involve payments by the Company to the parties submitting the Demand Letters or other claims.

35   

Item 1A. Risk Factors

   You should consider carefully the following information about the risks described below, together with the other information contained in this Quarterly Report on Form 10-Q and in our other public filings in evaluating our business. The risk factors set forth below with an asterisk (*) next to the title contain substantive changes to the risk factors associated with our business previously disclosed in Item 1A of our Annual Report on Form 10-K for the year ended December 31, 2022.  Our business, financial condition, results of operations and future prospects could be materially and adversely affected by these risks if any of them actually occurs.  In these circumstances, the market price of our common stock would likely decline.  The risks and uncertainties described below are not the only ones we face.  Additional risks not currently known to us or other factors not perceived by us to present significant risks to our business at this time also may impair our business. 

Risks Related to Our Financial Condition 

There is substantial doubt about our ability to continue as a going concern, which may hinder out ability to obtain further financing.   

Our consolidated financial statements are prepared using the generally accepted accounting principles applicable to a going concern, which contemplates the realization of assets and liquidation of liabilities in the normal course of business. However, as shown in our consolidated financial statements for the year ended December 31, 2022, included in our Annual Report on Form 10-K for the year ended December 31, 2022 and the condensed consolidated financial statements included in this Report, we have sustained substantial recurring losses from operations, have a substantial accumulated deficit, have limited cash resources and significant liabilities. In addition, we have used, rather than provided, cash in our continuing operations. The above conditions raise substantial doubt about our ability to continue as a going concern within one year after such date. Our consolidated financial statements do not include any adjustments relating to the recoverability and classification of recorded asset amounts and classification of liabilities that might be necessary should we be unable to continue in existence. Uncertainty concerning our ability to continue as a going concern, among other factors, may hinder our ability to obtain future financing. Continued operations and our ability to continue as a going concern are dependent, among other factors, on our ability to successfully develop and commercialize products, the market acceptance and success of our products and our ability to obtain additional required funding in the near term and thereafter. If we cannot continue as a viable entity, we might be required to reduce or cease operations or seek dissolution and liquidation or bankruptcy protection, and our stockholders would likely lose most or all of their investment in us.

Our ability to obtain required financing will be subject to a number of factors, including without limitation market conditions, our capitalization, our operating performance and investor sentiment. If we are unable to raise additional capital when required or on acceptable terms, we may have to significantly delay, scale back or discontinue the development or commercialization of one or more of our product candidates, restrict our operations or attempt to obtain funds by entering into agreements on unattractive terms, which would likely have a material adverse effect on our business, stock price and our relationships with third parties with whom we have business relationships, and which could result in additional dilution to our stockholders. If we do not have sufficient funds to continue operations, we could be required to seek bankruptcy protection or other alternatives that would likely result in our stockholders losing some or all of their investment in us.

36

We have incurred losses since our inception, and we anticipate that we will continue to incur losses. We may never achieve or sustain profitability.

We incurred significant net losses for the periods covered in this Report. We expect that these losses will continue as we continue our research and development activities, support commercialization of our approved products, and continue to conduct our business. These losses will cause, among other things, our stockholders’ equity and working capital to decrease. Any future earnings and cash flow from operations of our business are dependent on our ability to further develop our products and on revenue and profitability from sales of products. There can be no assurance that we will be able to generate sufficient revenue and amounts payable to us under our commercialization agreement relating to our SYMJEPI and ZIMHI products or other commercialization agreements that we may enter into to become profitable at all or on a sustained basis. We expect to have quarter-to-quarter fluctuations in revenue and expenses, some of which could be significant. If our products do not achieve market acceptance, we may never become profitable. As we commercialize and market products, we may incur expenses for product marketing and brand awareness and conduct significant research, development, testing and regulatory compliance activities that, together with general and administrative expenses, could result in substantial operating losses for the foreseeable future. Even if we do achieve profitability, we may not be able to sustain or increase profitability on a quarterly or annual basis.

We will require additional funding to continue as a going concern.

Our continued operations and the development of our business will require additional capital. Based on our current and anticipated level of operations, we do not believe that our cash, cash equivalents and short-term investments, together with anticipated revenues from operations and amounts that we have received or expect to receive as a result of our sales of assets relating to our former U.S. Compounding, Inc. business or from other sources, will be sufficient to meet our anticipated operating expenses, liabilities and obligations for at least 12 months from the date of this Report. We will require additional funds to sustain operations, satisfy our obligations and liabilities, fund our ongoing operations, or for other purposes. There are no assurances that required funding will be available at all or will be available in sufficient amounts or on reasonable terms. In addition to product revenues, we have historically relied upon sales of our equity or debt securities to fund our operations. We currently have no available balance in our credit facility or committed sources of capital, and a number of factors may limit or prevent our current ability to access capital markets to obtain any required equity or debt funding. Delays in obtaining, or the inability to obtain, required funding from revenues relating to sales of our commercial products, debt or equity financings, sales of assets, sales or out-licenses of intellectual property assets, products, product candidates or technologies, or other transactions or sources, would materially and adversely affect our ability to satisfy our current and future liabilities and obligations, and would materially and adversely affect our ability to continue operations.

Our ability to obtain required debt or equity financing or funds from other transactions will be subject to a number of factors, including without limitation market conditions, our capitalization, our operating performance and investor sentiment. The terms of any such funding, or the terms of any strategic transaction that we might enter into, could result in significant dilution to our stockholders. If we are unable to raise additional funds when required or on acceptable terms, we may have to significantly restrict our operations or seek to obtain funds by entering into agreements on unattractive terms, which would likely have a material adverse effect on our business, stock price and our relationships with third parties with whom we have business relationships, and which could result in additional dilution to our stockholders. If we do not have sufficient funds to continue operations, we could be required to seek dissolution and liquidation, bankruptcy protection or other alternatives that would likely result in our stockholders losing some or all of their investment in us.

37

Statements in this Report concerning our future plans and operations are dependent on our ability to secure adequate funding and the absence of unexpected delays or adverse developments. We may not be able to secure required funding.   

Any statements contained in this Report concerning future events or developments or our future activities, such as concerning research and development activities or regulatory matters, commercial introduction of any products that we may develop in the future, anticipated outcome of any legal proceedings in which we are involved, and other statements concerning our future operations and activities, are forward-looking statements that in each instance assume that we have or are able to obtain sufficient funding to support such activities and continue our operations and satisfy our liability and obligations in a timely manner. There can be no assurance that this will be the case. Also, such statements assume that there are no significant unexpected developments or events that delay or prevent such activities from occurring. Failure to timely obtain any required additional funding, or unexpected developments or events, could delay the occurrence of such events or prevent the events described in any such statements from occurring which could adversely affect our business, financial condition and results of operations.

38

We have received grand jury subpoenas issued in connection with a criminal investigation and are subject to other investigations and legal proceedings.

As we have previously disclosed, on May 11, 2021, each of the company and its USC subsidiary received a grand jury subpoena from the U.S. Attorney’s Office for the Southern District of New York (the “USAO”) issued in connection with a criminal investigation, requesting a broad range of documents and materials relating to, among other matters, certain veterinary products sold by the company’s USC subsidiary, certain practices, agreements and arrangements relating to products sold by USC, including veterinary products, and certain regulatory and other matters relating to the company and USC. The Audit Committee of the Board engaged outside counsel to conduct an independent internal investigation to review these and other matters. The company has also received requests from the SEC that the company voluntarily provide documents and information in connection with the SEC’s investigation relating to certain matters including matters arising from the subject matter of the subpoenas from the USAO. The company has produced and will continue to produce and provide documents in response to the subpoenas and requests. The company intends to continue cooperating with the USAO and the SEC, and has continued to engage in communications with the SEC and USAO regarding their investigations. We could receive additional requests from the USAO, SEC, or other authorities, which may require further investigation, and additional issues or facts could arise or be determined, which could expand the scope, duration or outcome of the investigation. We are unable to predict the duration, scope, or final outcome of the investigations by the USAO, SEC, or other agencies or what proceedings the USAO, SEC, or other federal or state authorities may initiate if the foregoing matters are not resolved. However, in connection with resolution of these matters, we or our USC subsidiary may be found to have violated one or more laws arising from the subject matter of the subpoenas, and to resolve the matters and investigations with the USAO and the SEC we may be required to pay material amounts in penalties or other payments, and to agree to other remedies or remedial measures. Payment of material amounts in connection with resolution of the foregoing matters would reduce the amount of financial resources that we have available to support our product development programs and commercialization activities and would adversely impact our development programs. Depending in part on the amount and timing of any payments that we may be required to make or other remedial measures that may be implemented in connection with resolution of these matters, a resolution of these matters with the USAO or SEC could have a material and adverse impact on the company. The foregoing matters have diverted and will likely continue to divert management’s attention, have caused the company to suffer reputational harm, have required and will continue to require the company to devote significant financial resources, could subject the company, one or more of its subsidiaries, or its officers and directors to civil or criminal proceedings, and depending on the resolution of the matters or any proceedings, could result in fines, penalties, payments, or financial remedies in amounts that would have a material adverse effect on our financial condition, or equitable remedies, and adversely affect the company’s business, previously reported financial results, financial results included or incorporated by reference herein, or future financial results.

The above matters, or the resolutions of other matters discussed in this Report under the heading of “Legal Proceedings,” or other legal proceedings that may arise, could require the Company to spend material amounts to defend, settle or resolve, and an adverse outcome in one or more of these proceedings could have a material adverse effect on the Company’s business and financial position.

Our PPP loans may be audited or reviewed by federal or state regulatory authorities.  

We applied for and obtained loan funding under the PPP pursuant to an initial PPP loan and PPP note, the balance of which has been forgiven, and under the Second Draw PPP Loan and PPP2 Note in the principal amount of $1,765,495, the balance of which was initially forgiven. However, in connection with an investigation by the Civil Division, in June 2022 we paid a total of $1,787,417 in repayment of our Second Draw PPP Loan principal and related interest and fees. Our PPP loans and applications for forgiveness of loan amounts remain subject to future review and audit by SBA for compliance with program requirements set forth in the PPP Interim Final Rules and in the Borrower Application Form, including without limitation the required economic necessity certification by the company that was part of the PPP loan application process. Accordingly, the company is subject to audit or review by federal or state regulatory authorities as a result of applying for and obtaining the PPP Loan or obtaining forgiveness of that loan. If we were to be audited or reviewed and receive an adverse determination or finding in such audit or review, we could be required to return or repay the full amount of the applicable loan and could be subject to additional fines or penalties, which could reduce our liquidity and adversely affect our business, financial condition and results of operations.

Certain of our securities issued in prior offerings include a right to receive the Black-Scholes value of the unexercised portion of those securities in the event of a fundamental transaction, which payment could be significant.

Most of our outstanding warrants to purchase shares of common stock issued by us in prior offerings provide that, in the event of a “fundamental transaction,” as defined in the applicable warrant, including, among other things, certain mergers or consolidations of our company, sale of all or substantially all of our assets or a sale of a certain percentage of our common stock, the holders of such warrants have the option, subject to the terms of the applicable warrant, to require us to pay to such holders an amount of cash equal to the Black-Scholes value of the warrants. Such amount could be significantly more than the warrant holders would otherwise receive if they were to exercise their warrants and receive the same consideration as the other holders of common stock, which in turn could reduce the consideration that holders of common stock would be concurrently entitled to receive in such fundamental transaction. Additionally, any future equity financing that we conduct may require us to issue securities that have a similar feature.

Risk Relating to Our Business and Industry

We may never commercialize additional product candidates that are subject to regulatory approval or earn a profit.   

Except for our SYMJEPI and ZIMHI products, we have not received regulatory approval for any drugs or products. We may never be able to commercialize any additional product candidates that are subject to regulatory approval or be able to generate revenue from sales of such products. Because of the risks and uncertainties associated with developing and commercializing our specialty pharmaceuticals and other product candidates, we are unable to predict when we may commercially introduce such products, the extent of any future losses or when we will become profitable, if ever.

Our development plans concerning product candidates are affected by many factors, the outcome of which are difficult to predict.

The development of new pharmaceutical products is a highly risky undertaking. Any potential product that we might determine to research or develop in the future may require significant additional research and development before any commercial introduction, and our development plans concerning any such product candidate will be affected by many factors, many of which are difficult to predict. Some of the factors that could affect development plans concerning any product candidates that we might determine to research or develop in the future include: general market conditions and developments in the marketplace including the introduction of potentially competing new products by our competitors; the availability of adequate funding to support product development efforts and sales and marketing efforts for approved products; the regulatory pathway for the product candidate; the time required to conduct required clinical trials and unexpected delays in the anticipated timing of the commencement, conduct or completion of clinical trials; the outcome and results of pre-clinical or clinical trials; the FDA’s review of NDAs that we may file concerning any such product candidate; any unexpected difficulties in licensing or sublicensing intellectual property rights that may be required for other components of the product; patent infringement lawsuits relating to Paragraph IV certifications as part of any Section 505(b)(2) or ANDA filings; any unexpected difficulties in the ability of our suppliers to timely supply quantities for commercial launch of the product; and our ability to successfully market and sell our products or enter into commercialization arrangements with third parties to market our products. There can be no assurance that future research, development or clinical trial efforts, if any, will be successful or result in viable products or meet efficacy standards. We cannot assure you that any testing or clinical trials will show potential products to be safe and efficacious or that any such product will be approved for a specific indication. Further, the results from preclinical studies and early clinical trials may not be indicative of the results that will be obtained in later-stage clinical trials. Delays or setbacks in development efforts that we might determine to undertake could have a material adverse effect on our ability to achieve our financial goals.

39

Business or economic disruptions or global health concerns could harm our business.

Business or economic disruptions or global health concerns could adversely affect our business. We could experience delays in obtaining products or services from our third-party manufacturers or suppliers as a result of the impact of the pandemic or other similar health emergencies on such parties. The extent to which health emergencies will impact our business is difficult to predict and subject to change. In addition, a severe or prolonged economic downturn or political disruption could result in a variety of risks to our business, including our ability to raise capital when needed on acceptable terms, if at all. A weak or declining economy or political disruption could also strain our manufacturers or suppliers, possibly resulting in supply disruption, or cause our customers to delay making purchases or payments for our products. Any of the foregoing could harm our business. Any future health emergencies could result in significant governmental measures being implemented to control the spread of the virus, including, at various times, quarantines, shelter-in-place or work-from-home orders or policies, travel restrictions, social distancing and business shutdowns. The effects of any future governmental measures implemented to control the spread of health emergencies could negatively impact productivity of our employees and disrupt our business activities, the magnitude of which will depend, in part, on the length and severity of the restrictions and our ability to conduct business in the ordinary course.

We intend to rely on third parties to conduct any clinical trials that we may conduct in the future. If these third parties do not successfully carry out their contractual duties or meet expected deadlines, we may be unable to obtain, or may experience delays in obtaining, trial results or regulatory approval.

Like many companies our size, we do not have the ability to conduct preclinical or clinical studies for product candidates that we may in the future determine to develop without the assistance of third parties who conduct the studies on our behalf. These third parties are often toxicology facilities and clinical research organizations, or CROs, that have significant resources and experience in the conduct of pre-clinical and clinical studies. The toxicology facilities conduct the pre-clinical safety studies as well as associated tasks connected with these studies. The CROs typically perform patient recruitment, project management, data management, statistical analysis, and other reporting functions. In the past we have relied on third parties to conduct clinical trials of our product candidates and to use third party toxicology facilities and CROs for our pre-clinical and clinical studies, and if we undertake clinical trials for any product candidate that we may in the future develop we similarly intend to rely on such third parties. We may also rely on academic institutions or clinical research organizations to conduct, supervise or monitor some or all aspects of any clinical trials that we might undertake in the future. Our reliance on these third parties for development activities will reduce our control over these activities.  If these third parties do not successfully carry out their contractual duties or obligations or meet expected deadlines, or if the quality or accuracy of the clinical data they obtain is compromised due to the failure to adhere to our clinical protocols or for other reasons, we may be required to replace them, and our clinical trials may be extended, delayed or terminated.  Although we believe there are a number of third party contractors that we could engage to conduct or continue these activities, replacing a third party contractor may result in a delay of the affected trials.  

If there are injuries or deaths associated with use of our products, or if there is a product recall affecting one or more of our products, we may be exposed to significant liabilities, or a prolonged failure to supply, one or more of our products, we may be exposed to significant liabilities.

The testing of human product candidates entails an inherent risk of allegations of clinical trial liability, while the marketing and sale of approved products entails an inherent risk of allegations of product liability and associated adverse publicity. The production, manufacturing, labeling of pharmaceutical products and compounded pharmaceutical preparations is inherently risky. We could be adversely affected if any of our products prove to be, or are asserted to be, harmful to patients. There are a number of factors that could result in the injury or death of a patient who receives one of our products, including quality issues, manufacturing or labeling flaws, improper packaging or unanticipated or improper uses of the products, any of which could result from human or other error. Any of these situations could lead to a recall of, safety alert, or other proceedings or actions, relating to one or more of such products. On March 21, 2022, we announced a voluntary recall of four lots of SYMJEPI (epinephrine) Injection 0.15 mg (0.15 mg/0.3 mL) and 0.3 mg (0.3 mg/0.3 mL) Pre-Filled Single-Dose Syringes, due to the potential clogging of the needle preventing the dispensing of epinephrine. Our consolidated financial statements for the year ended December 31, 2021, included in our annual report on Form 10-K for the year ended December 31, 2021, included and reflected a reserve of approximately $2.0 million associated with the SYMJEPI recall. As of the date of this Report, the manufacturing of SYMJEPI is on hold.  There can be no assurance concerning the timing of resumption of manufacturing or resupplying USWM with product to enable a relaunch of SYMJEPI.  Under the terms of our commercial agreement with USWM, if after a prolonged period of time we are unable to resume the supply of SYMJEPI to USWM, USWM may elect to terminate the agreement and we may be required to make certain payments to USWM, which could be material. If adverse events or deaths or a product recall, either voluntarily or as required by the FDA or a state board of pharmacy, were associated with our products, we could become subject to product and professional liability lawsuits or other proceedings, including enforcement actions by state and federal authorities or other healthcare self-regulatory bodies or product liability claims or lawsuits. In addition, such matters could result in indemnification claims by third parties or claims relating to the product recall or associated expenses, including third parties that have purchased our SYMJEPI products or that may purchase our ZIMHI product, or to which we have sold certain assets of USC, including claims pursuant to our agreements with third parties. The recall may have an adverse effect on the amount or the timing of our revenues, and on our financial results and liquidity. In addition, current or future insurance coverage may prove insufficient to cover any liability claims brought against us with respect to the SYMJEPI recall, products previously sold by USC, or other matters. Any of the foregoing matters could result in a material adverse effect on our business, results of operations, financial condition and liquidity.

40

We are subject to the risk of clinical trial and product liability lawsuits.  

The testing of human health care product candidates entails an inherent risk of allegations of clinical trial liability, while the marketing and sale of approved products entails an inherent risk of allegations of product liability and associated adverse publicity. We currently maintain liability insurance. However, such insurance policies are expensive, may not provide sufficient coverage, and may not be available in the future on acceptable terms, or at all. If we conduct additional clinical trials and introduce products into the United States market, the risk of adverse events will increase and our requirements for liability insurance coverage are likely to increase. We are subject to the risk that substantial liability claims from the testing or marketing of pharmaceutical products could be asserted against us in the future. There can be no assurance that we will be able to obtain or maintain insurance on acceptable terms, particularly in overseas locations, for clinical and commercial activities or that any insurance obtained will provide adequate protection against potential liabilities. An inability to obtain sufficient insurance coverage on reasonable terms or to otherwise protect against potential product liability claims could inhibit our business.  

Moreover, our current and future coverages may not be adequate to protect us from all of the liabilities that we may incur. If losses from liability claims exceed our insurance coverage, we may incur substantial liabilities that exceed our financial resources. In addition, a product or clinical trial liability action against us would be expensive and time-consuming to defend, even if we ultimately prevailed. If we are required to pay a claim, we may not have sufficient financial resources and our business and results of operations may be harmed. A product liability claim brought against us in excess of our insurance coverage, if any, could have a material adverse effect upon our business, financial condition and results of operations.    

We do not have commercial-scale manufacturing capability, and we lack commercial manufacturing experience. We will likely rely on third parties to manufacture and supply our commercial products and our product candidates for which we will be seeking FDA approval.  

We do not own or operate manufacturing facilities for clinical or commercial production of pharmaceutical products and product candidates, we do not have any experience in drug formulation or manufacturing, and we lack the resources and the capability to manufacture any of our product candidates on a clinical or commercial scale. Accordingly, we expect to depend on third-party contract manufacturers for the foreseeable future. Any performance failure on the part of our contract manufacturers could delay clinical development, regulatory approval or commercialization of our current or future product candidates, or result in product recalls or shortages or manufacturing halts or delays, depriving us of potential product revenue and resulting in additional losses. Any manufacturing problem or the loss of a contract manufacturer could be disruptive to our operations and result in lost sales.  Additionally, we rely on third parties to supply the raw materials needed to manufacture our existing and potential products.  Any business interruptions resulting from geopolitical actions, including war and terrorism, adverse public health developments such as pandemic or other health emergencies, or natural disasters including earthquakes, typhoons, floods and fires, could adversely affect our supply chain.  Any reliance on suppliers may involve several risks, including a potential inability to obtain critical materials and reduced control over production costs, delivery schedules, reliability and quality.  Any unanticipated disruption to our manufacturers or suppliers could delay shipment of any of our products, increase our cost of goods sold and result in lost sales.  

The manufacture of pharmaceutical products requires significant expertise and capital investment, including the development of advanced manufacturing techniques and process controls. Manufacturers of pharmaceutical products often encounter difficulties in production, particularly in scaling up initial production. These problems can include difficulties with production costs and yields, quality control (including stability of the product candidate and quality assurance testing), shortages of qualified personnel, and compliance with strictly enforced federal, state and foreign regulations. If our third-party contract manufacturers were to encounter any of these difficulties or otherwise fail to comply with their obligations or under applicable regulations, our ability to provide product candidates to patients in our clinical trials or to provide commercial products would be jeopardized. If we file an application for marketing approval of the product and the FDA grants marketing approval, any delay or interruption in the supply of product could delay the commercial launch of the product or impair our ability to meet demand for the product. Difficulties in supplying products for clinical trials could increase the costs associated with our clinical trial programs and, depending upon the period of delay, require us to commence new trials or qualify new manufacturers at significant additional expense, possibly causing commercial delays or termination of the trials.

These problems can include difficulties with production costs and yields, quality control (including stability of the product candidate and quality assurance testing), shortages of qualified personnel, and compliance with strictly enforced federal, state and foreign regulations. If our third-party contract manufacturers were to encounter any of these difficulties or otherwise fail to comply with their obligations or under applicable regulations, our ability to provide product candidates to patients in our clinical trials or commercially would be jeopardized. If we file an application for marketing approval of the product and the FDA grants marketing approval, any delay or interruption in the supply of product could delay the commercial launch of the product or impair our ability to meet demand for the product. Difficulties in supplying products for clinical trials could increase the costs associated with our clinical trial programs and, depending upon the period of delay, require us to commence new trials or qualify new manufacturers at significant additional expense, possibly causing commercial delays or termination of the trials.

Our products can only be manufactured in a facility that has undergone a satisfactory inspection by the FDA and other relevant regulatory authorities. For these reasons, we may not be able to replace manufacturing capacity for our products quickly if we or our contract manufacturer(s) were unable to use manufacturing facilities as a result of a fire, natural disaster (including an earthquake), equipment failure, or other difficulty, or if such facilities were deemed not in compliance with the regulatory requirements and such non-compliance could not be rapidly rectified. An inability or reduced capacity to manufacture our products could have a material adverse effect on our business, financial condition, and results of operations.  

41

We are subject to substantial government regulation, which could materially adversely affect our business. If we do not receive regulatory approvals, we may not be able to develop and commercialize our technologies.   

We need FDA approval to market our products in the United States that are subject to regulatory approval, and similar approvals from foreign regulatory authorities to market products outside the United States. The production and marketing of such products and potential products and our ongoing research and development, pre-clinical testing and clinical trial activities are subject to extensive regulation and review by numerous governmental authorities in the United States and will face similar regulation and review for overseas approval and sales from governmental authorities outside of the United States. The regulatory review and approval process, which may include evaluation of preclinical studies and clinical trials of our products that are subject to regulatory review, as well as the evaluation of manufacturing processes and contract manufacturers’ facilities, is lengthy, expensive and uncertain. We have limited experience in filing and pursuing applications necessary to gain regulatory approvals. Many of the product candidates that we are currently developing must undergo rigorous pre-clinical and clinical testing and an extensive regulatory approval process before they can be marketed. This process makes it longer, more difficult and more costly to bring our potential products to market, and we cannot guarantee that any of our potential products will be approved. Many products for which FDA approval has been sought by other companies have never been approved for marketing. In addition to testing and approval procedures, extensive regulations also govern marketing, manufacturing, distribution, labeling, and record-keeping procedures. If we or our collaboration partners do not comply with applicable regulatory requirements, such violations could result in non-approval, suspensions of regulatory approvals, civil penalties and criminal fines, product seizures and recalls, operating restrictions, injunctions, and criminal prosecution.  

Regulatory authorities generally have substantial discretion in the approval process and may either refuse to accept an application, or may decide after review of an application that the data submitted is insufficient to allow approval of the proposed product, as we have experienced with previous Complete Response Letters that we have received from the FDA. If regulatory authorities do not accept or approve our applications, they may require that we conduct additional clinical, preclinical or manufacturing studies and submit that data before regulatory authorities will reconsider such application. We may need to expend substantial resources to conduct further studies to obtain data that regulatory authorities believe is sufficient. Depending on the extent of these studies, acceptance or approval of applications may be delayed by several years, or may require us to expend more resources than we may have available. It is also possible that additional studies may not suffice to make applications approvable. If any of these outcomes occur, we may be forced to abandon our applications for approval.

Failure to obtain FDA or other required regulatory approvals, or withdrawal of previous approvals, would adversely affect our business. Even if regulatory approval of a product is granted, this approval may entail limitations on uses for which the product may be labeled and promoted, or may prevent us from broadening the uses of products for different applications.  

Following regulatory approval of any of our drug candidates, we will be subject to ongoing regulatory obligations and restrictions, which may result in significant expense and limit our ability to commercialize our potential products.  

With regard to our drug candidates that are approved by the FDA or by another regulatory authority, we are held to extensive regulatory requirements over product manufacturing, labeling, packaging, adverse event reporting, storage, advertising, promotion and record keeping. Regulatory approvals may also be subject to significant limitations on the indicated uses or marketing of the drug candidates. Potentially costly follow-up or post-marketing clinical studies may be required as a condition of approval to further substantiate safety or efficacy, or to investigate specific issues of interest to the regulatory authority. Previously unknown problems with the drug candidate, including adverse events of unanticipated severity or frequency, may result in restrictions on the marketing of the drug, and could include withdrawal of the drug from the market. In addition, the law or regulatory policies governing pharmaceuticals may change. New statutory requirements may be enacted or additional regulations may be enacted that could prevent or delay regulatory approval of our drug candidates. We cannot predict the likelihood, nature or extent of adverse government regulation that may arise from future legislation or administrative action, either in the United States or elsewhere. If we are not able to maintain regulatory compliance, we might not be permitted to market our drugs and our business could suffer.

42

If we fail to obtain acceptable prices or appropriate reimbursement for our products, our ability to successfully commercialize our products will be impaired.

Government and insurance reimbursements for healthcare expenditures play an important role for all healthcare providers, including physicians and pharmaceutical companies such as the Company, that plan to offer various products in the United States and other countries in the future. Physicians and patients may decide not to order our products unless third- party payors, such as managed care organizations as well as government payors such as Medicare and Medicaid, pay a substantial portion of the price of the products. Market acceptance and sales of our products and potential products will depend in part on the extent to which reimbursement for the costs of such products will be available from government health administration authorities, private health coverage insurers, managed care organizations, and other organizations. In the United States, our ability to have our products eligible for Med

an important factor in determining the ultimate success of our products. If, for any reason, Medicare, Medicaid or the insurance companies decline to provide reimbursement for our products, our ability to commercialize our products would be adversely affected.

Third-party payors may challenge the price of medical and pharmaceutical products. Reimbursement by a third-party payor may depend on a number of factors, including a payor’s determination that our product candidates are experimental or not effective, medically necessary, appropriate for the specific patient, cost-effective, supported by peer-reviewed publications, or included in clinical practice guidelines.

If purchasers or users of our products and related treatments are not able to obtain appropriate reimbursement for the cost of using such products, they may forego or reduce such use. Significant uncertainty exists as to the reimbursement status of newly approved pharmaceutical products, and there can be no assurance that adequate third- party coverage will be available for any of our products. Even if our products are approved for reimbursement by Medicare, Medicaid and private insurers, of which there can be no assurance, the amount of reimbursement may be reduced at times or even eliminated, which could have a material adverse effect on our business, financial condition and results of operations.

Legislative or regulatory reform of the healthcare system may affect our ability to sell our products profitably. 

In both the United States and certain foreign jurisdictions, there have been and are expected to be a number of legislative and regu

icare, Medicaid or private insurance reimbursement will be latory changes to the healthcare system in ways that could impact our ability to sell our products profitably. The impact of these changes on the biotechnology and pharmaceutical industries and our business is uncertain.

On August 16, 2022, President Biden signed the Inflation Reduction Act, or IRA, into law, which sets forth meaningful changes to drug product reimbursement by Medicare. Among other actions, the IRA permits HHS to engage in price-capped negotiation to set the price of certain drugs and biologics reimbursed under Medicare Part D. The IRA also establishes a rebate obligation for drug manufacturers that increase prices of Medicare Part D covered drugs at a rate greater than the rate of inflation. The inflation rebates may require us to pay rebates if we increase the cost of a covered Medicare Part D approved product faster than the rate of inflation. In addition, the law eliminates the “donut hole” under Medicare Part D beginning in 2025 by significantly lowering the beneficiary maximum out-of-pocket cost and requiring manufacturers to subsidize, through a newly established manufacturer discount program, 10% of Part D enrollees’ prescription costs for brand drugs below the out-of-pocket maximum and 20% once the out-of-pocket maximum has been reached. Our cost-sharing responsibility for any approved product covered by Medicare Part D could be significantly greater under the newly designed Part D benefit structure compared to the pre-IRA benefit design. Additionally, manufacturers that fail to comply with certain provisions of the IRA may be subject to penalties, including civil monetary penalties. The IRA is anticipated to have significant effects on the pharmaceutical industry and may reduce the prices we can charge and reimbursement we can receive for our products, among other effects.

The U.S. Congress continues to consider issues relating to the healthcare system, and future legislation or regulations may affect our ability to market and sell products on favorable terms, which would affect our results of operations, as well as our ability to raise capital, obtain additional collaborators or profitably market our products. Such legislation or regulation may reduce our revenues, increase our expenses or limit the markets for our products. In particular, we expect to experience pricing pressures in connection with the sale of our products due to the influence of health maintenance and managed health care organizations and additional legislative proposals.

We are subject to a variety of federal, state and local laws and regulations relating to the general healthcare industry, which are subject to frequent change.

Participants in the healthcare industry, including the company and, before the discontinuance of its business, USC, are subject to a variety of federal, state, and local laws and regulations. Laws and regulations in the healthcare industry are extremely complex and, in many instances, industry participants do not have the benefit of significant regulatory or judicial interpretation. Such laws and regulations are subject to change and often are uncertain in their application. There can be no assurance that we will not be subject to scrutiny or challenge under one or more of these laws or regulations or that any such challenge would not be successful. Any such challenge, whether or not successful, could adversely affect our business, financial condition or results of operations.

Laws that may affect our ability to operate include, but are not limited to, the federal Anti-Kickback Statute, federal civil and criminal false claims laws, state anti-kickback and false claims laws, HIPAA, as amended by HITECH, and the federal Physician Payments Sunshine Act, created under the ACA and its implementing regulations. Violations of these laws can result in imprisonment, civil or criminal fines, fines and disciplinary actions relating to our state licensure, disgorgement, exclusion of products from reimbursement under U.S. federal or state healthcare programs, additional reporting requirements and/or oversight if we become subject to a corporate integrity agreement or similar agreement to resolve allegations of non-compliance with these laws, and the curtailment or restructuring of our operations. Moreover, any violation or alleged violation of such federal or state laws could harm our reputation, customer relationships or otherwise have a material adverse effect on our business, financial condition and results of operations.

We have limited sales, marketing and distribution experience. 

We have limited experience in the sales, marketing, and distribution of pharmaceutical products. There can be no assurance that we will be able to establish sales, marketing, and distribution capabilities or make arrangements with collaborators or others to perform such activities or that such efforts will be successful. If we decide to market any products directly ourselves, we would be required to either acquire or internally develop a marketing and sales force with technical expertise and with supporting distribution capabilities. The acquisition or development of a sales, marketing and distribution infrastructure would require substantial resources, which may not be available to us or, even if available, could divert the attention of our management and key personnel and have a negative impact on further product development efforts.

We may seek to enter into arrangements to develop and commercialize our products. These collaborations, even if secured, may not be successful. 

We have entered and sought to enter into arrangements with third parties regarding development or commercialization of some of our products or product candidates and may in the future seek to enter into collaborative arrangements to develop and commercialize some of our potential products both in North America and international markets. There can be no assurance that we will be able to negotiate commercialization or collaborative arrangements on favorable terms or at all or that our current or future collaborative arrangements will be successful. The amount and timing of resources such third parties will devote to these activities may not be within our control. There can be no assurance that such parties will perform their obligations as expected. There can be no assurance that our collaborators will devote adequate resources to our products.  

43

Even if they are approved and commercialized, if our potential products are unable to compete effectively with current and future products targeting similar markets as our potential products, our commercial opportunities will be reduced or eliminated.

The markets for our SYMJEPI products and ZIMHI product, and our other product candidates, are intensely competitive and characterized by rapid technological progress. We face competition from numerous sources, including major biotechnology and pharmaceutical companies worldwide. Many of our competitors have substantially greater financial and technical resources, and development, production and marketing capabilities, than we do. Our SYMJEPI product competes with a number of other currently marketed epinephrine products for use in the emergency treatment of acute allergic reactions, including anaphylaxis.

Our ZIMHI product competes with a number of other currently marketed products utilizing naloxone, for the treatment of acute opioid overdose. Certain companies have established technologies that may be competitive with our products and any future product candidates that we may determine to develop or acquire. Some of these products may use different approaches or means to obtain results, which could be more effective or less expensive than our products for similar indications. In addition, many of these companies have more experience than we do in pre-clinical testing, performance of clinical trials, manufacturing, and obtaining FDA and foreign regulatory approvals. They may also have more brand name exposure and expertise in sales and marketing. We also compete with academic institutions, governmental agencies and private organizations that are conducting research in the same fields.

Competition among these entities to recruit and retain highly qualified scientific, technical and professional personnel and consultants is also intense. As a result, there is a risk that one or more of our competitors will develop a more effective product for the same indications for which we are developing a product or, alternatively, bring a similar product to market before we can do so. Failure to successfully compete will adversely impact the ability to raise additional capital and ultimately achieve profitable operations.

Our product candidates may not gain acceptance among physicians, patients, or the medical community, thereby limiting our potential to generate revenue, which will undermine our future growth prospects. 

Even if our pharmaceutical product candidates are approved for commercial sale by the FDA or other regulatory authorities, the degree of market acceptance of any approved product candidate by physicians, health care professionals and third-party payors, and our profitability and growth will depend on a number of factors, including:  

● the ability to provide acceptable evidence of safety and efficacy;

● pricing and cost effectiveness, which may be subject to regulatory control;

● our ability to obtain sufficient third-party insurance coverage or reimbursement;

● effectiveness of our or our collaborators’ sales and marketing strategy;

● relative convenience and ease of administration;

● the prevalence and severity of any adverse side effects; and

● availability of alternative treatments.

If any product candidate that we develop does not provide a treatment regimen that is at least as beneficial as the current standard of care or otherwise does not provide some additional patient benefit over the current standard of care, that product will likely not achieve market acceptance and we will not generate sufficient revenues to achieve profitability.

If we suffer negative publicity concerning the safety of our products in development, our sales may be harmed and we may be forced to withdraw such products.

If concerns should arise about the safety of any of our products that are marketed, regardless of whether or not such concerns have a basis in generally accepted science or peer-reviewed scientific research, such concerns could adversely affect the market for these products. Similarly, negative publicity could result in an increased number of product liability claims, whether or not these claims are supported by applicable law.  

44

Our failure to adequately protect or to enforce our intellectual property rights or secure rights to third party patents could materially harm our proprietary position in the marketplace or prevent the commercialization of our products. 

Our success depends in part on our ability to obtain and maintain protection in the United States and other countries for the intellectual property covering or incorporated into our technologies and products. The patents and patent applications in our existing patent portfolio are either owned by us or licensed to us. Our ability to protect our product candidates from unauthorized use or infringement by third parties depends substantially on our ability to obtain and maintain, or license, valid and enforceable patents. Due to evolving legal standards relating to the patentability, validity and enforceability of patents covering pharmaceutical inventions and the scope of claims made under these patents, our ability to obtain and enforce patents is uncertain and involves complex legal and factual questions for which important legal principles are unresolved.

There is a substantial backlog of patent applications at the United States Patent and Trademark Office, or USPTO. There can be no assurance that any patent applications relating to our products or methods will be issued as patents, or, if issued, that the patents will not be challenged, invalidated or circumvented or that the rights granted thereunder will provide a competitive advantage.  We may not be able to obtain patent rights on products, treatment methods or manufacturing processes that we may develop or to which we may obtain license or other rights.  Even if we do obtain or license patent rights, rights under any issued patents may not provide us with sufficient protection for our product candidates or provide sufficient protection to afford us a commercial advantage against our competitors or their competitive products or processes.  Patents and intellectual property that we own or license may not afford us the rights that we anticipate.  It is possible that no patents will be issued from any pending or future patent applications owned by us or licensed to us.  Others may challenge, seek to invalidate, infringe or circumvent any patents we own or license.  Alternatively, we may in the future be required to initiate litigation against third parties to enforce our intellectual property rights.  The defense and prosecution of patent and intellectual property claims are both costly and time consuming, even if the outcome is favorable to us.  Any adverse outcome could subject us to significant liabilities, require us to license disputed rights from others, or require us to cease selling our future products.

In addition, many other organizations are engaged in research and product development efforts that may overlap with our products. Such organizations may currently have, or may obtain in the future, legally blocking proprietary rights, including patent rights, in one or more products or methods under development or consideration by us. These rights may prevent us from commercializing technology, or may require us to obtain a license from the organizations to use the technology. We may not be able to obtain any such licenses that may be required on reasonable financial terms, if at all, and we cannot be sure that the patents underlying any such licenses will be valid or enforceable. As with other companies in the pharmaceutical industry, we are subject to the risk that persons located in other countries will engage in development, marketing or sales activities of products that would infringe our patent rights if such activities were conducted in the United States.  

Our patents also may not afford protection against competitors with similar technology. We may not have identified all patents, published applications or published literature that affect our business either by blocking our ability to commercialize our product candidates, by preventing the patentability of our products or by covering the same or similar technologies that may affect our ability to market or license our product candidates. Many companies have encountered difficulties in protecting and defending their intellectual property rights in foreign jurisdictions. If we encounter such difficulties or are otherwise precluded from effectively protecting our intellectual property rights in either the United States or foreign jurisdictions, our business prospects could be substantially harmed. In addition, we may not have adequate cash funding to devote the resources that might be necessary to prepare or pursue patent applications, either at all or in all jurisdictions in which we might desire to obtain patents, or to maintain already-issued patents.  

We may become involved in patent litigation or other intellectual property proceedings relating to our future product approvals, which could result in liability for damages or delay or stop our development and commercialization efforts. 

The pharmaceutical industry has been characterized by significant litigation and other proceedings regarding patents, patent applications, trademarks, and other intellectual property rights. The situations in which we may become parties to such litigation or proceedings may include any third parties initiating litigation claiming that our products infringe their patent or other intellectual property rights, or that one of our trademarks or trade names infringes the third party’s trademark rights; in such case, we will need to defend against such proceedings. For example, the field of generic pharmaceuticals is characterized by frequent litigation that occurs in connection with the regulatory filings under Section 505(b)(2) of the FDCA and attempts to invalidate the patent of the reference drug.   

The costs of resolving any patent litigation or other intellectual property proceeding, even if resolved in our favor, could be substantial. Many of our potential competitors will be able to sustain the cost of such litigation and proceedings more effectively than we can because of their substantially greater resources. Uncertainties resulting from the initiation and continuation of patent litigation or other intellectual property proceedings could have a material adverse effect on our ability to compete in the marketplace. Patent litigation and other intellectual property proceedings may also consume significant management time.  

In the event that a competitor infringes upon our patent or other intellectual property rights, enforcing those rights may be costly, difficult, and time-consuming. Even if successful, litigation to enforce our intellectual property rights or to defend our patents against challenge could be expensive and time-consuming and could divert our management’s attention. We may not have sufficient resources to enforce our intellectual property rights or to defend our patent or other intellectual property rights against a challenge. If we are unsuccessful in enforcing and protecting our intellectual property rights and protecting our products, it could materially harm our business.  

45

We are subject to certain data privacy and security requirements, which are very complex and difficult to comply with at times. Any failure to ensure adherence to these requirements could subject us to fines and penalties, and damage our reputation.  

We are required to comply, as applicable, with numerous federal and state laws, including state security breach notification laws, state health information privacy laws and federal and state consumer protection laws, which govern the collection, use and disclosure of personal information. Other countries also have, or are developing, laws governing the collection, use and transmission of personal information. In addition, most healthcare providers who may prescribe products we may sell in the future and from whom we may obtain patient health information are subject to privacy and security requirements under HIPAA and comparable state laws. These laws could create liability for us or increase our cost of doing business, and any failure to comply could result in harm to our reputation, and potentially fines and penalties.  

There are significant limitations on our ability in the future to utilize any net operating loss carryforwards for federal and state income tax purposes.

At December 31, 2022, we had federal and state net operating loss carryforwards, or NOLs, and credit carryforwards which, subject to certain limitations, we may use to reduce future taxable income or offset income taxes due. Insufficient future taxable income will adversely affect our ability to utilize these NOLs and credit carryforwards. Pursuant to Internal Revenue Code Section 382, the annual use of the NOLs and research and development tax credits could be limited by any greater than 50% ownership change during any three-year testing period. As noted in Note 20 of the audited consolidated financial statements appearing in our Annual Report on Form 10-K for the year ended December 31, 2022, our existing NOLs are subject to limitations arising from previous ownership changes, and if we undergo additional ownership changes, our ability to use our NOLs could be further limited by Section 382 of the Code. As a result of these limitations, we may be materially limited in our ability to utilize our NOLs and credit carryforward.

46

Risks Related to Our Former Compounding Pharmacy Business  

We discontinued our former compounding pharmacy business conducted by USC and have sold a substantial portion of the assets relating to that former business. We may incur significant costs in connection with the transfer or disposal of the remaining assets related to that former business.

As previously disclosed in our reports with the SEC and as disclosed elsewhere in this Report, we have sold and transferred certain assets relating to the human compounding pharmaceutical business of USC and have agreed to a variety of restrictive covenants preventing us from engaging in certain business and competitive activities relating to the human compounding pharmaceutical business. The remaining operations and business of USC have been wound down and terminated, and remaining assets relating to USC’s business have been sold or will be otherwise transferred or disposed of. Effective October 31, 2021, USC surrendered its Arkansas retail pharmacy permit and wholesaler/outsourcer permit and is no longer engaged in the human or veterinary compounding pharmaceutical business.

Other matters may arise relating to the former USC business, USC assets, or USC employees, or arising out of the restructuring, winding down and winding up activities, that could require us to pay amounts in the future. The process of winding down and winding up the remaining business of USC could require us to incur significant expenses or pay significant amounts in connection with or relating to the termination of employment of USC’s employees, the disposition of remaining USC assets, the termination of agreements relating to the USC business, or the resolution of outstanding obligations, liabilities, or current or future claims or proceedings. In addition, we could be required to pay significant fines, penalties or other amounts as a result of proceedings by federal or state regulatory authorities relating to the former business and operations of USC. The compounding pharmaceuticals business formerly conducted by USC is subject to federal, state and local laws, regulations and administrative practices. There can be no assurance that we or USC have been or are compliant in material respects with applicable federal and state regulatory requirements. Failure to comply with FDA requirements and other federal or state governmental laws and regulations can result in fines, disgorgement, unanticipated compliance expenditures, recall or seizure of products, exposure to product liability claims, total or partial suspension of production or distribution, enforcement actions, injunctions and civil or criminal prosecution, any of which could have a material adverse effect on our business, financial condition or results of operations.

47

Risks Related to Our Common Stock 

Provisions of our charter documents could discourage an acquisition of our company that would benefit our stockholders and may have the effect of entrenching, and making it difficult to remove, management. 

Provisions of our restated certificate of incorporation and bylaws may make it more difficult for a third party to acquire control of us, even if a change of control would benefit our stockholders. For example, shares of our preferred stock may be issued in the future without further stockholder approval, and upon such terms and conditions, and having such rights, privileges and preferences, as our board of directors may determine, including, for example, rights to convert into our common stock. The rights of the holders of our common stock will be subject to, and may be adversely affected by, the rights of the holders of any of our preferred stock that may be issued in the future. The issuance of our preferred stock could have the effect of making it more difficult for a third party to acquire control of us. This could limit the price that certain investors might be willing to pay in the future for shares of our common stock and discourage those investors from acquiring a majority of our common stock. Similarly, our bylaws include a prohibition on stockholder action by written consent, which means that all stockholder action must be taken at an annual or special meeting of stockholders. Moreover, our charter documents do not provide for cumulative voting in the election of directors, which limits the ability of minority stockholders to elect director candidates. Our bylaws require that any stockholder proposals or nominations for election to our board of directors must meet specific advance notice requirements and procedures, which make it more difficult for our stockholders to make proposals or director nominations. The existence of these charter provisions could have the effect of entrenching management and making it more difficult to change our management. Furthermore, because we are incorporated in Delaware, we are governed by the provisions of Section 203 of the Delaware General Corporation Law. These provisions may prohibit or restrict large stockholders, in particular those owning 15% or more of our outstanding voting stock, from merging or combining with us, unless one or more exemptions from such provisions apply. These provisions under Delaware law could discourage potential takeover attempts and could reduce the price that investors might be willing to pay for shares of our common stock in the future.

The price of our common stock may be volatile. 

The market price of our common stock may fluctuate substantially. For example, from January 2022 to September 30, 2023, the market price of our common stock has fluctuated between approximately $0.48 and $59.32, as adjusted by and giving effect to the Reverse Stock Split.  Market prices for securities of early-stage pharmaceutical, biotechnology and other life sciences companies have historically been particularly volatile. Some of the factors that may cause the market price of our common stock to fluctuate include:  

● relatively low trading volume, which can result in significant volatility in the market price of our common stock based on a relatively smaller number of trades and dollar amount of transactions;

● the timing and results of our current and any future preclinical or clinical trials of our product candidates;

● the entry into or termination of key agreements, including, among others, key collaboration and license agreements;

● the results and timing of regulatory reviews relating to the approval of our product candidates;

● the timing of, or delay in the timing of, commercial introduction of any of our products;

● the initiation of, material developments in, or conclusion of, litigation to enforce or defend any of our intellectual property rights;

● failure of any of our product candidates, if approved, to achieve commercial success;

● general and industry-specific economic conditions that may affect our research and development expenditures;

● the results of clinical trials conducted by others on products that would compete with our product candidates;

● issues in manufacturing our product candidates or any approved products;

● the loss of key employees;

● the introduction of technological innovations or new commercial products by our competitors;

● changes in estimates or recommendations by securities analysts, if any, who cover our common stock;

● future sales of our common stock;

● publicity or announcements regarding regulatory developments relating to our products;

● period-to-period fluctuations in our financial results, including our cash and cash equivalents balance, operating expenses, cash burn rate or revenue levels;

● common stock sales in the public market by one or more of our larger stockholders, officers or directors;

● our filing for protection under federal bankruptcy laws;

● a negative outcome in any litigation or legal proceeding; 

● effects of public health crises, pandemics and epidemics, such as the COVID-19 outbreak; or

● other potentially negative financial announcements, such as a review of any of our filings by the SEC, changes in accounting treatment or restatement of previously reported financial results or delays in our filings with the SEC.

The stock markets in general have experienced substantial volatility that has often been unrelated to the operating performance of individual companies. These broad market fluctuations may also adversely affect the trading price of our common stock. In the past, following periods of volatility in the market price of a company’s securities, stockholders have often instituted class action securities litigation against those companies. Such litigation, if instituted, could result in substantial costs and diversion of management attention and resources, which could significantly harm our profitability and reputation. Furthermore, market volatility may lead to increased shareholder activism if we experience a market valuation that activists believe is not reflective of our intrinsic value. Activist campaigns that contest or conflict with our strategic direction or seek changes in the composition of our board of directors could have an adverse effect on our operating results and financial condition.

48

Trading of our common stock is limited.

Trading of our common stock is limited, and trading restrictions imposed on us by applicable regulations may further reduce our trading, making it difficult for our stockholders to sell their shares.  

The foregoing factors may result in lower prices for our common stock than might otherwise be obtained and could also result in a larger spread between the bid and asked prices for our common stock. In addition, without a large public float, our common stock is less liquid than the stock of companies with broader public ownership, and as a result, the trading price of our common stock may be more volatile. In the absence of an active public trading market, an investor may be unable to liquidate his or her investment in our common stock. Trading of a relatively small volume of our common stock may have a greater impact on the trading price of our stock than would be the case if our public float were larger. We cannot predict the price at which our common stock will trade at any given time.  

Our failure to meet the continued listing requirements of Nasdaq could result in a delisting of our common stock, which could negatively impact the market price and liquidity of our common shares and our ability to access the capital markets.

Our common stock is currently listed on the Nasdaq Capital Market. If we fail to satisfy the continued listing requirements of Nasdaq, such as the corporate governance requirements, the minimum closing bid price requirement, or applicable market capitalization or shareholder equity requirements, Nasdaq may take steps to delist our common stock. Such a delisting would have a negative effect on the price of our common stock, impair the ability to sell or purchase our common stock when persons wish to do so, and could materially and adversely affect our ability to raise capital or pursue strategic restructuring, refinancing or other transactions on acceptable terms, or at all. Delisting from the Nasdaq Capital Market could also have other negative results, including the potential loss of institutional investor interest and fewer business development opportunities. In the event of a delisting, we would attempt to take actions to restore our compliance with Nasdaq’s listing requirements, but we can provide no assurance that any such action taken by us would allow our common stock to become listed again, stabilize the market price or improve the liquidity of our common stock, prevent our common stock from dropping below the Nasdaq minimum bid price requirement or prevent future non-compliance with Nasdaq’s listing requirements.

As previously disclosed, on October 4, 2023, the Company received notice (the “Prior Notice”) from the Listing Qualifications Department (the “Staff”) of The Nasdaq Stock Market LLC (“Nasdaq”) notifying the Company that it failed to evidence a minimum closing bid price of $1.00 per share, as required by Nasdaq Listing Rule 5550(a)(2) (the “Bid Price Rule”), for the previous 30 consecutive days and that the Company was provided a grace period of 180 calendar days from the date of the Prior Notice, or until April 1, 2024, to regain compliance with the Bid Price Rule, in accordance with Listing Rule 5810(c)(3)(A). Also as previously disclosed, on October 11, 2023, the Company received notice from the Staff that, due to the Company’s failure to regain compliance with the minimum $35 million market value of listed securities (“MVLS”) requirement set forth in Nasdaq Listing Rule 5550(b)(2) (the “MVLS Rule”) during the 180-day grace period previously granted to the Company that expired on October 9, 2023, the Company’s common stock was subject to delisting unless the Company timely requested a hearing before the Nasdaq Hearings Panel (the “Panel”).

In response, the Company timely requested a hearing before the Panel, which request stayed any further action by Nasdaq at least until the hearing is held and any extension the Panel may grant to the Company following the hearing expires.

On October 18, 2023, the Company received a superseding notice from the Staff (the “Subsequent Notice”), indicating that the Prior Notice was issued in error. The Subsequent Notice indicated that because the Company was subject to a one-year Mandatory Panel Monitor as a result of a prior hearing before the Panel, the Company was not eligible for the automatic 180-day compliance grace period provided by Listing Rule 5810(c)(3)(A) and that the Company’s non-compliance with the Bid Price Rule serves as an additional basis for delisting from Nasdaq.

At the hearing before the Panel, the Company will address its plan to regain compliance with both the Bid Price Rule and the MVLS Rule as well as its continued compliance with all other applicable criteria for continued listing on The Nasdaq Capital Market. There can be no assurance, however, that the Panel will grant the Company’s request for continued listing or that the Company will evidence compliance with the listing rules prior to the expiration of any extension that may be granted by the Panel following the hearing.   

49

Our common stock could become subject to additional trading restrictions as a “penny stock,” which could adversely affect the liquidity and price of such stock. If our common stock became subject to the SEC’s penny stock rules, broker-dealers may experience difficulty in completing customer transactions and trading activity in our securities may be adversely affected.    

If our common stock was delisted from the NASDAQ Capital Market and began to trade on the OTCQB or other trading platform, such trading platforms are viewed by most investors as a less desirable, and less liquid, marketplace. As a result, an investor could find it more difficult to purchase, dispose of or obtain accurate quotations as to the value of our common stock.

Unless our common stock is listed on a national securities exchange, such as the NASDAQ Capital Market, our common stock may also be subject to the regulations regarding trading in “penny stocks,” which are those securities trading for less than $5.00 per share, and that are not otherwise exempted from the definition of a penny stock under other exemptions provided for in the applicable regulations.  The following is a list of the general restrictions on the sale of penny stocks:  

● Before the sale of penny stock by a broker-dealer to a new purchaser, the broker-dealer must determine whether the purchaser is suitable to invest in penny stocks. To make that determination, a broker-dealer must obtain, from a prospective investor, information regarding the purchaser’s financial condition and investment experience and objectives. Subsequently, the broker-dealer must deliver to the purchaser a written statement setting forth the basis of the suitability finding and obtain the purchaser’s signature on such statement.

● A broker-dealer must obtain from the purchaser an agreement to purchase the securities. This agreement must be obtained for every purchase until the purchaser becomes an “established customer.”

● The Securities Exchange Act of 1934, or the Exchange Act, requires that before effecting any transaction in any penny stock, a broker-dealer must provide the purchaser with a “risk disclosure document” that contains, among other things, a description of the penny stock market and how it functions, and the risks associated with such investment. These disclosure rules are applicable to both purchases and sales by investors.

● A dealer that sells penny stock must send to the purchaser, within 10 days after the end of each calendar month, a written account statement including prescribed information relating to the security.

These requirements can severely limit the liquidity of securities in the secondary market because fewer brokers or dealers are likely to be willing to undertake these compliance activities. If our common stock is not listed on a national securities exchange, the rules and restrictions regarding penny stock transactions may limit an investor’s ability to sell to a third party and our ability to raise additional capital. We make no guarantee that market-makers will make a market in our common stock, or that any market for our common stock will continue.  

Our stockholders may experience significant dilution as a result of any additional financing using our securities, or as the result of the exercise or conversion of our outstanding securities. 

In the future, to the extent that we raise additional funds by issuing equity securities or securities convertible into or exercisable for equity securities, our stockholders may experience significant dilution. In addition, conversion or exercise of other outstanding options, warrants or convertible securities could result in there being a significant number of additional shares outstanding and dilution to our stockholders. If additional funds are raised through the issuance of preferred stock, holders of preferred stock could have rights that are senior to the rights of holders of our common stock, and the agreements relating to any such issuance could contain covenants that would restrict our operations.  

We have not paid cash dividends on our common stock in the past and do not expect to pay cash dividends on our common stock for the foreseeable future. Any return on investment may be limited to the value of our common stock. 

No cash dividends have been paid on our common stock, and we do not expect to pay cash dividends on our common stock in the foreseeable future. Payment of dividends would depend upon our profitability at the time, cash available for those dividends, and other factors as our board of directors may consider relevant. If we do not pay dividends, our common stock may be less valuable because a return on a stockholder investment will only occur if our stock price appreciates. 

50

The rights of the holders of common stock may be impaired by the potential issuance of preferred stock.  

Our restated certificate of incorporation gives our board of directors the right to create new series of preferred stock. As a result, the board of directors may, without stockholder approval, issue preferred stock with voting, dividend, conversion, liquidation or other rights which could adversely affect the voting power and equity interest of the holders of common stock. Preferred stock, which could be issued with the right to more than one vote per share, could be utilized as a method of discouraging, delaying or preventing a change of control. The possible impact on takeover attempts could adversely affect the price of our common stock.

Future sales of substantial amounts of our common stock, or the possibility that such sales could occur, could adversely affect the market price of our common stock. 

If in the future we sell additional equity securities to help satisfy funding requirements, those securities may be subject to registration rights or may include warrants with anti-dilutive protective provisions. Future sales in the public market of our common stock, or shares issued upon exercise of our outstanding stock options, warrants or convertible securities, or the perception by the market that these issuances or sales could occur, could lower the market price of our common stock or make it difficult for us to raise additional capital. Our stockholders may experience substantial dilution and a reduction in the price that they are able to obtain upon the sale of their shares. Also, new equity securities issued may have greater rights, preferences or privileges than our existing common stock.

Exercise of our outstanding warrants may result in dilution to our stockholders. 

We have outstanding warrants to purchase a significant number of shares of our comment stock, which were issued in connection with previous offering financing transactions. Exercise of some or all of these outstanding warrants in the future may result in additional dilution to our stockholders.

51

Our Bylaws provide that the Court of Chancery of the State of Delaware is the sole and exclusive forum for a wide variety of disputes between us and our stockholders, and that the federal district courts of the United States of the America are the sole and exclusive forum for the resolution of any complaint asserting a cause of action arising under the Securities Act. Exclusive forum provisions in our Bylaws could limit our stockholders’ ability to obtain a favorable judicial forum for disputes with us or our directors, officers or employees.

Our Bylaws, as amended, provide that, unless we consent in writing to the selection of an alternative forum, to the fullest extent permitted by law, the Court of Chancery of the State of Delaware will be the sole and exclusive forum for most legal actions involving actions brought against us by stockholders, including (i) any derivative action or proceeding brought on behalf of the company; (ii) any action asserting a claim of breach of a fiduciary duty owed by any director, officer or other employee of the company to the company or the company’s stockholders; (iii) any action asserting a claim against the company or any director or officer or other employee of the company arising pursuant to any provision of the Delaware General Corporation Law, the certificate of incorporation or the Bylaws of the company, or as to which the Delaware General Corporation Law confers jurisdiction on the Courts of Chancery of the State of Delaware; or (iv) any action asserting a claim against the company or any director or officer or other employee of the company governed by the internal affairs doctrine, in all cases subject to the court’s having personal jurisdiction over the indispensable parties named as defendants (including without limitation as a result of the consent of such indispensable party to the personal jurisdiction of such court). The Bylaws provide that the foregoing provisions do not apply to actions or suits brought to enforce any liability or duty created by the Securities Act of 1933, as amended (the “Securities Act”), the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or any other claim for which the federal courts have exclusive jurisdiction. Section 27 of the Exchange Act creates exclusive federal jurisdiction over all suits brought to enforce any duty or liability created by the Exchange Act or the rules and regulations thereunder. As a result, the exclusive forum provision will not apply to suits brought to enforce any duty or liability created by the Exchange Act or any other claim for which the federal courts have exclusive jurisdiction. Our Bylaws do not relieve us of our duties to comply with federal securities laws and the rules and regulations thereunder, and our stockholders will not be deemed to have waived our compliance with these laws, rules and regulations. In addition, our Bylaws, as amended, provide that, unless we consent in writing to the selection of an alternative forum, to the fullest extent permitted by law, the federal district courts of the United States of America shall be the sole and exclusive forum for the resolution of any complaint asserting a cause of action arising under the Securities Act. Any person or entity purchasing or otherwise acquiring or holding any interest in any of our securities shall be deemed to have notice of and to have consented to these provisions.

Under the Securities Act, federal and state courts have concurrent jurisdiction over all suits brought to enforce any duty or liability created by the Securities Act. There is uncertainty as to whether a court (other than state courts in the State of Delaware, where the Supreme Court of the State of Delaware decided in March 2020 that exclusive forum provisions for causes of action arising under the Securities Act are facially valid under Delaware law) would enforce forum selection provisions and whether investors can waive compliance with the federal securities laws and the rules and regulations thereunder. We believe the forum selection provisions in Bylaws, as amended, may benefit us by providing increased consistency in the application of Delaware law and federal securities laws by chancellors and judges, as applicable, particularly experienced in resolving corporate disputes, efficient administration of cases on a more expedited schedule relative to other forums and protection against the burdens of multi-forum litigation. However, these provisions may have the effect of discouraging lawsuits against us and/or our directors, officers and employees as it may limit any stockholder’s ability to bring a claim in a judicial forum that such stockholder finds favorable for disputes with us or our directors, officers or employees. In addition, stockholders who do bring a claim in the Court of Chancery in the State of Delaware could face additional litigation costs in pursuing any such claim, particularly if they do not reside in or near Delaware. The enforceability of similar choice of forum provisions in other companies’ charter documents has been challenged in legal proceedings, and it is possible that, in connection with any applicable action brought against us, a future court could find the choice of forum provisions contained in our Bylaws to be inapplicable or unenforceable in such action. If a court were to find the choice of forum provision contained in our Bylaws to be inapplicable or unenforceable in an action, we may incur additional costs associated with resolving such action in other jurisdictions, which could adversely affect our business, financial condition or results of operations.

If we fail to comply with the rules under the Sarbanes-Oxley Act of 2002 related to disclosure controls and procedures, identify or discover material weaknesses in our internal control over financial reporting or fail to effectively remediate any identified material weaknesses, our business and financial condition could be materially and adversely affected and our stock price could decline.

Our management is responsible for establishing and maintaining an adequate system of internal control over financial reporting, designed to provide reasonable assurance regarding the reliability of financial reporting and the preparation of consolidated financial statements for external purposes in accordance with U.S. GAAP. Our management is likewise required, on a quarterly basis, to evaluate the effectiveness of our internal controls and to disclose any material changes and weaknesses identified through such evaluation. A material weakness is a deficiency, or a combination of deficiencies, in internal control over financial reporting, such that there is a reasonable possibility that a material misstatement of our annual or interim financial statements will not be prevented or detected on a timely basis. If we fail to comply with the rules under the Sarbanes-Oxley Act of 2002 related to disclosure controls and procedures, or, if we discover material weaknesses and other deficiencies in our internal control and accounting procedures, our stock price could decline significantly and our business and financial condition could be adversely affected. If material weaknesses or significant deficiencies are discovered or if we otherwise fail to achieve and maintain the adequacy of our internal control, we may not be able to ensure that we can conclude on an ongoing basis that we have effective internal controls over financial reporting in accordance with Section 404 of the Sarbanes-Oxley Act. Moreover, effective internal controls are necessary for us to produce reliable financial reports and are important to helping prevent financial fraud. If we cannot provide reliable financial reports or prevent fraud, our business and operating results could be harmed, investors could lose confidence in our reported financial information, and the trading price of our common stock could decline significantly.

We take responsive actions to address identified material weaknesses in our internal control over financial reporting. However, we can give no assurance that such measures will remediate any material weakness that are identified or that any additional material weaknesses or restatements of financial results will not arise in the future. In the future, our management may determine that our disclosure controls and procedures are ineffective or that there are one or more material weaknesses in our internal controls over financial reporting, resulting in a reasonable possibility that a material misstatement to the annual or interim financial statements would not have been prevented or detected. Accordingly, a material weakness increases the risk that the financial information we report contains material errors. Any system of internal controls, however well designed and operated, is based in part on certain assumptions and can provide only reasonable, not absolute, assurances that the objectives of the system are met. Efforts to correct any material weaknesses or deficiencies that may be identified could require significant financial resources to address. Moreover, if remedial measures are insufficient to address the deficiencies that are determined to exist, we may fail to meet our future reporting obligations on a timely basis, our consolidated financial statements could contain material misstatements, we could be required to restate our prior period financial results, our operating results may be harmed, and we could become subject to class action litigation or investigations or proceedings from regulatory authorities. Any of these matters could adversely affect our business, reputation, revenues, results of operations, financial condition and stock price.

52

General Risk Factors

We depend on our officers. If we are unable to retain our key employees or to attract additional qualified personnel, our product operations and development efforts may be seriously jeopardized.   

Our success will be dependent upon the efforts of our management team and staff, including Ebrahim Versi, our Chief Executive Officer. We currently do not have key person life insurance policies covering any of our executive officers or key employees. If key individuals leave us, we could be adversely affected if suitable replacement personnel are not quickly recruited. There is competition for qualified personnel in all functional areas, which makes it difficult to attract and retain the qualified personnel necessary for the operation of our business. Our success also depends in part on our ability to attract and retain highly qualified scientific, commercial and administrative personnel. If we are unable to attract new employees and retain existing key employees, the development and commercialization of our product candidates could be delayed or negatively impacted. In addition, any staffing interruptions resulting from geopolitical actions, including war and terrorism, adverse public health.

53

We may experience difficulties in managing growth.

We are a small company.  Any significant growth in the future could impose significant added responsibilities on members of management, including the need to identify, attract, retain, motivate and integrate highly skilled personnel.   Our future financial performance and our ability to compete effectively may depend, in part, on our ability to manage any future growth effectively.  To that end, we must be able to:  

● manage our clinical studies effectively;

● integrate additional management, administrative, manufacturing and regulatory personnel;

● maintain sufficient administrative, accounting and management information systems and controls; and

● hire and train additional qualified personnel.

We may not be able to accomplish these tasks, and our failure to accomplish any of them could harm our financial results.  

Our business and operations would suffer in the event of cybersecurity or other system failures. Our business depends on complex information systems, and any failure to successfully maintain these systems or implement new systems to handle our changing needs could materially harm our operations.

In the ordinary course of our business, we collect and store sensitive data, including intellectual property, our proprietary business information and that of our suppliers, as well as personally identifiable information of employees. Similarly, our third-party providers possess certain of our sensitive data. The secure maintenance of this information is material to our operations and business strategy. Despite our security measures, our information technology and infrastructure may be vulnerable to attacks by hackers or breached due to employee error, malfeasance or other disruptions. Any such breach could compromise our networks and the information stored there could be accessed, publicly disclosed, lost or stolen. The legislative and regulatory landscape for privacy and data protection continues to evolve, and there has been an increasing amount of focus on privacy and data protection issues with the potential to affect our business, including recently enacted laws in a majority of states requiring security breach notification. Thus, any access, disclosure or other loss of information, including our data being breached at our partners or third-party providers, could result in legal claims or proceedings and liability under laws that protect the privacy of personal information, disrupt our operations, and damage our reputation which could adversely affect our business.

54

A sale of a substantial number of shares of our common stock may cause the price of our common stock to decline and may impair our ability to raise capital in the future. 

There have been and may continue to be periods when our common stock could be considered “thinly-traded,” meaning that the number of persons interested in purchasing our common stock at or near bid prices at any given time may be relatively small or non-existent.  Finance transactions resulting in a large amount of newly issued shares that become readily tradable, conversion of outstanding convertible notes or exercise of outstanding warrants and sale of the shares issuable upon conversion of such notes or exercise of such warrants, issuance of shares following vesting of outstanding restricted stock units, or other events that cause stockholders to sell shares, could place downward pressure on the trading price of our stock.  In addition, the lack of a robust resale market may require a stockholder who desires to sell a large number of shares of common stock to sell the shares in increments over time to mitigate any adverse impact of the sales on the market price of our stock.  If our stockholders sell, or the market perceives that our stockholders intend to sell for various reasons, substantial amounts of our common stock in the public market, the market price of our common stock could decline.  Sales of a substantial number of shares of our common stock may make it more difficult for us to sell equity or equity-related securities in the future at a time and price that we deem reasonable or appropriate.  

If securities or industry analysts do not publish research or reports about our business, or if they change their recommendations regarding our stock adversely, our stock price and trading volume could decline.  

The trading market for our common stock will be influenced by the research and reports that industry or securities analysts publish about us or our business.  We may never obtain substantial research coverage by industry or financial analysts.  If no or few analysts commence or continue coverage of us, the trading price of our stock would likely decrease.  Even if we do obtain analyst coverage, if one or more of the analysts who cover us downgrade our stock, our stock price would likely decline.  If one or more of these analysts cease coverage of our company or fail to regularly publish reports on us, we could lose visibility in the financial markets, which in turn could cause our stock price or trading volume to decline.

55

ITEM  2. Unregistered Sales of Equity Securities, Use of Proceeds and Issuer Purchases of Equity Securities

              Information concerning our sales of unregistered securities during the quarter ended September 30, 2023, has previously been reported in reports on Form 8-K that we filed during that quarter.

ITEM 3. Defaults Upon Senior Securities

None.

ITEM 4. Mine Safety Disclosures

Not Applicable.

ITEM 5. Other Information

None.

56

ITEM 6. Exhibits

The following exhibits are attached hereto or incorporated herein by reference.

3.1	Certificate of Amendment to Restated Certificate of Incorporation. (Incorporated by reference to Exhibit 3.1 to the Company’s Report on Form 8-K filed September 8, 2023)
3.2	Amended and Restated Bylaws of the Registrant.  (Incorporated by reference to Exhibit 3.2 to the Company’s Report on Form 8-K filed September 8, 2023)
4.1	Common Stock Purchase Warrant.#
4.2	Form of Pre-Funded Warrant.  (Incorporated by reference to Exhibit 4.13 to the Registration Statement on Form S-1 (File No. 333-273233 on July 13, 2023)
4.3	Warrant Agency Agreement.#
10.1	Securities Purchase Agreement.   (Incorporated by reference to Exhibit 10.1 to the Company’s Current Report on Form 8-K filed August 3, 2023)
10.2	Placement Agency Agreement.  (Incorporated by reference to Exhibit 1.1 to the Company’s Current Report on Form 8-K filed August 3, 2023)
10.3	Executive Employment Agreement between the Company and Ebrahim Versi dated as of August 23, 2023.*  (Incorporated by reference to Exhibit 10.1 to the Company’s Report on Form 8-K filed August 29, 2023)
10.4	Purchase and Sale Agreement.+/**** (Incorporated by reference to Exhibit 10.1 to the Company’s Report on Form 8-K filed July 24, 2023)
10.5	Sales Agreement. + (Incorporated by reference to Exhibit 10.2 to the Company’s Report on Form 8-K filed July 24, 2023)
10.6	Employment Agreement between the Company and Seth A. Cohen.* (Incorporated by reference to Exhibit 10.1 to the Company’s Report on Form 8-K filed October 19, 2023)
10.7	Employment Agreement between the Company and John W. Dorbin, Jr.*#
10.8	Inducement Stock Option Award Agreement dated as of October 16, 2023.+* (Incorporated by reference to Exhibit 10.3 to the Company’s Report on Form 8-K filed October 19, 2023)
10.9	Form of Inducement Stock Option Award Agreement.+* (Incorporated by reference to Exhibit 10.4 to the Company’s Report on Form 8-K filed October 19, 2023)

31.1	Certification of Chief Executive Officer pursuant to Section 302 of the Sarbanes-Oxley Act of 2002
31.2	Certification of Chief Financial Officer pursuant to Section 302 of the Sarbanes-Oxley Act of 2002
32.1	Certification of Chief Executive Officer pursuant to Section 906 of the Sarbanes-Oxley Act of 2002
32.2	Certification of Chief Financial Officer pursuant to Section 906 of the Sarbanes-Oxley Act of 2002

101.INS	XBRL Instance Document.  The instance document does not appear in the Interactive Data File because its XBRL tags are embedded within the Inline XBRL document.
101.SCH	XBRL Taxonomy Extension Schema Document
101.CAL	XBRL Taxonomy Extension Calculation Linkbase Document
101.DEF	XBRL Taxonomy Extension Definition Linkbase Document
101.LAB	XBRL Taxonomy Extension Label Linkbase Document
101.PRE	XBRL Taxonomy Extension Presentation Linkbase Document
104	Cover Page Interactive Data File (formatted as inline XBRL and contained in Exhibit 101)
+	Exhibits and/or schedules have been omitted pursuant to Item 601(a)(5) of Regulation S-K. The Registrant hereby undertakes to furnish supplemental copies of any of the omitted schedules and exhibits upon request by SEC.
*	Represents a management contract or compensatory arrangement.
**	We have received confidentiality treatment for certain portions of this exhibit.
***	Certain marked information (indicated by “[***]” has been omitted as the registrant has determined it is both not material and is the type that the registrant customarily and actually treats as private or confidential.
****	Certain marked information has been omitted from this exhibit because it is both not material and would be competitively harmful if publicly disclosed.
#	Filed herewith.

57

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

	DMK PHARMACEUTICALS CORPORATION
Date: November 14, 2023	By:	/s/ Ebrahim Versi
		Ebrahim Versi
		Chief Executive Officer
Date: November 14, 2023	By:	/s/ Seth A. Cohen
		Seth A. Cohen
		Chief Financial Officer

58

EX-4.1

DMK Pharmaceuticals Corporation 10-Q

Exhibit 4.1

COMMON STOCK PURCHASE WARRANT

ADAMIS PHARMACEUTICALS CORPORATION

Warrant Shares: 5,930,000 Issue Date: August 4, 2023

THIS COMMON STOCK PURCHASE WARRANT (the “Warrant”) certifies that, for value received, Cede & Co., a nominee of The Depository Trust Company or its assigns (the “Holder”) is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at any time on or after August 4, 2023 (the “Initial Exercise Date”) and on or prior to 5:00 p.m. (New York City time) on August 4, 2028 (the “Termination Date”), but not thereafter, to subscribe for and purchase from Adamis Pharmaceuticals Corporation, a Delaware corporation (the “Company”), up to 5,930,000 shares (as subject to adjustment hereunder, the “Warrant Shares”) of Common Stock. The purchase price of one share of Common Stock under this Warrant shall be equal to the Exercise Price, as defined in Section 2(b). This Warrant shall initially be issued and maintained in the form of a security held in book-entry form and the Depository Trust Company or its nominee (“DTC”) shall initially be the sole registered holder of this Warrant, subject to a Holder’s right to elect to receive a Warrant in certificated form pursuant to the terms of the Warrant Agency Agreement, in which case this sentence shall not apply.

Section 1.            Definitions. Capitalized terms used and not otherwise defined herein shall have the meanings set forth in that certain Securities Purchase Agreement (the “Purchase Agreement”), dated August 1, 2023, among the Company and the purchasers signatory thereto.

Section 2. Exercise.

a)           Exercise of Warrant. Exercise of the purchase rights represented by this Warrant may be made, in whole or in part, at any time or times on or after the Initial Exercise Date and on or before the Termination Date by delivery to the Company or the Warrant Agent of a duly executed PDF copy submitted by e-mail (or e-mail attachment) of the Notice of Exercise in the form annexed hereto (the “Notice of Exercise”). Within the earlier of (i) two (2) Trading Days and (ii) the number of Trading Days comprising the Standard Settlement Period (as defined in Section 2(d)(i) herein) following the date of exercise as aforesaid, the Holder shall deliver the aggregate Exercise Price for the shares specified in the applicable Notice of Exercise by wire transfer or cashier’s check drawn on a United States bank unless the cashless exercise procedure specified in Section 2(c) below is specified in the applicable Notice of Exercise. No ink-original Notice of Exercise shall be required, nor shall any medallion guarantee (or other type of guarantee or notarization) of any Notice of Exercise be required. Notwithstanding anything herein to the contrary, the Holder shall not be required to physically surrender this Warrant to the Company or the Warrant Agent until the Holder has purchased all of the Warrant Shares available hereunder and the Warrant has been exercised in full, in which case, the Holder shall surrender this Warrant to the Company or the Warrant Agent for cancellation within three (3) Trading Days of the date on which the final Notice of Exercise is delivered to the Company or the Warrant Agent. Partial exercises of this Warrant resulting in purchases of a portion of the total number of Warrant Shares available hereunder shall have the effect of lowering the outstanding number of Warrant Shares purchasable hereunder in an amount equal to the applicable number of Warrant Shares purchased as set forth in the applicable Notice(s) of Exercise. The Holder and the Company (or its Warrant Agent) shall maintain records showing the number of Warrant Shares purchased and the date of such purchases. The Company or the Warrant Agent shall deliver any objection to any Notice of Exercise within one (1) Business Day of receipt of such notice. The Holder and any assignee, by acceptance of this Warrant, acknowledge and agree that, by reason of the provisions of this paragraph, following the purchase of a portion of the Warrant Shares hereunder, the number of Warrant Shares available for purchase hereunder at any given time may be less than the amount stated on the face hereof. Notwithstanding the foregoing in this Section 2(a), a holder whose interest in this Warrant is a beneficial interest in certificate(s) representing this Warrant held in book-entry form through DTC (or another established clearing corporation performing similar functions), shall effect exercises made pursuant to this Section 2(a) by delivering to DTC (or such other clearing corporation, as applicable) the appropriate instruction form for exercise, complying with the procedures to effect exercise that are required by DTC (or such other clearing corporation, as applicable), subject to a Holder’s right to elect to receive a Definitive Certificate (as defined in the Warrant Agency Agreement) pursuant to the terms of the Warrant Agency Agreement, in which case this sentence shall not apply.

b)           Exercise Price. The exercise price per share of Common Stock under this Warrant shall be $1.35, subject to adjustment hereunder (the “Exercise Price”).

c)           Cashless Exercise. If at the time of exercise hereof there is no effective registration statement registering the resale of the Warrant Shares by, or the prospectus contained therein is not available for the resale of the Warrant Shares by, the Holder, then this Warrant may also be exercised, in whole or in part, at such time by means of a “cashless exercise” in which the Holder shall be entitled to receive a number of Warrant Shares equal to the quotient obtained by dividing [(A-B) (X)] by (A), where:

(A) = as applicable: (i) the VWAP on the Trading Day immediately preceding the date of the applicable Notice of Exercise if such Notice of Exercise is (1) both executed and delivered pursuant to Section 2(a) hereof on a day that is not a Trading Day or (2) both executed and delivered pursuant to Section 2(a) hereof on a Trading Day prior to the opening of “regular trading hours” (as defined in Rule 600(b) of Regulation NMS promulgated under the federal securities laws) on such Trading Day, (ii) at the option of the Holder, either (y) the VWAP on the Trading Day immediately preceding the date of the applicable Notice of Exercise or (z) the Bid Price of the Common Stock on the principal Trading Market as reported by Bloomberg L.P. (“Bloomberg”) as of the time of the Holder’s execution of the applicable Notice of Exercise if such Notice of Exercise is executed during “regular trading hours” on a Trading Day and is delivered within two (2) hours thereafter (including until two (2) hours after the close of “regular trading hours” on a Trading Day) pursuant to Section 2(a) hereof or (iii) the VWAP on the date of the applicable Notice of Exercise if the date of such Notice of Exercise is a Trading Day and such Notice of Exercise is both executed and delivered pursuant to Section 2(a) hereof after the close of “regular trading hours” on such Trading Day;

(B) = the Exercise Price of this Warrant, as adjusted hereunder; and

(X) = the number of Warrant Shares that would be issuable upon exercise of this Warrant in accordance with the terms of this Warrant if such exercise were by means of a cash exercise rather than a cashless exercise.

If Warrant Shares are issued in such a cashless exercise, the parties acknowledge and agree that in accordance with Section 3(a)(9) of the Securities Act, the holding period of the Warrant Shares being issued may be tacked on to the holding period of this Warrant. The Company agrees not to take any position contrary to this Section 2(c), except to the extent required by applicable law, rules, or regulations.

“Bid Price” means, for any date, the price determined by the first of the following clauses that applies: (a) if the Common Stock is then listed or quoted on a Trading Market, the bid price of the Common Stock for the time in question (or the nearest preceding date) on the Trading Market on which the Common Stock is then listed or quoted as reported by Bloomberg (based on a Trading Day from 9:30 a.m. (New York City time) to 4:02 p.m. (New York City time)), (b) if OTCQB or OTCQX is not a Trading Market, the volume weighted average price of the Common Stock for such date (or the nearest preceding date) on OTCQB or OTCQX as applicable, (c) if the Common Stock is not then listed or quoted for trading on OTCQB or OTCQX and if prices for the Common Stock are then reported on The Pink Open Market (or a similar organization or agency succeeding to its functions of reporting prices), the most recent bid price per share of the Common Stock so reported, or (d) in all other cases, the fair market value of a share of Common Stock as determined by an independent appraiser selected in good faith by the Purchasers of a majority in interest of the Securities then outstanding and reasonably acceptable to the Company, the fees and expenses of which shall be paid by the Company.

“Trading Day” means any day on which the Trading Market is open for trading, including any day on which the Trading Market is open for trading for a period of time less than the customary time.

“VWAP” means, for any date, the price determined by the first of the following clauses that applies: (a) if the Common Stock is then listed or quoted on a Trading Market, the daily volume weighted average price of the Common Stock for such date (or the nearest preceding date) on the Trading Market on which the Common Stock is then listed or quoted as reported by Bloomberg (based on a Trading Day from 9:30 a.m. (New York City time) to 4:02 p.m. (New York City time)), (b) if OTCQB or OTCQX is not a Trading Market, the volume weighted average price of the Common Stock for such date (or the nearest preceding date) on OTCQB or OTCQX as applicable, (c) if the Common Stock is not then listed or quoted for trading on OTCQB or OTCQX and if prices for the Common Stock are then reported on The Pink Open Market (or a similar organization or agency succeeding to its functions of reporting prices), the most recent bid price per share of the Common Stock so reported, or (d) in all other cases, the fair market value of a share of Common Stock as determined by an independent appraiser selected in good faith by the Purchasers of a majority in interest of the Securities then outstanding and reasonably acceptable to the Company, the fees and expenses of which shall be paid by the Company.

Notwithstanding anything herein to the contrary, if the amount determined pursuant to subparagraph “(A)” above is higher than the Exercise Price, then, on the Termination Date, this Warrant shall be automatically exercised via cashless exercise pursuant to this Section 2(c).

d) Mechanics of Exercise.

i.          Delivery of Warrant Shares Upon Exercise. The Company shall cause the Warrant Shares purchased hereunder to be transmitted by the Transfer Agent to the Holder by crediting the account of the Holder’s or its designee’s balance account with The Depository Trust Company through its Deposit or Withdrawal at Custodian system (“DWAC”) if the Company is then a participant in such system and either (A) there is an effective registration statement permitting the issuance of the Warrant Shares to or resale of the Warrant Shares by the Holder or (B) this Warrant is being exercised via cashless exercise, and otherwise by physical delivery of a certificate, registered in the Company’s share register in the name of the Holder or its designee, for the number of Warrant Shares to which the Holder is entitled pursuant to such exercise to the address specified by the Holder in the Notice of Exercise by the date that is the earliest of (i) two (2) Trading Days after the delivery to the Company or the Warrant Agent of the Notice of Exercise, (ii) one (1) Trading Day after delivery of the aggregate Exercise Price to the Company and (iii) the number of Trading Days comprising the Standard Settlement Period after the delivery to the Company or the Warrant Agent of the Notice of Exercise (such date, the “Warrant Share Delivery Date”). Upon delivery of the Notice of Exercise, the Holder shall be deemed for all corporate purposes to have become the holder of record of the Warrant Shares with respect to which this Warrant has been exercised, irrespective of the date of delivery of the Warrant Shares, provided that payment of the aggregate Exercise Price (other than in the case of a cashless exercise) is received within the earlier of (i) two (2) Trading Days and (ii) the number of Trading Days comprising the Standard Settlement Period following delivery of the Notice of Exercise. If the Company fails for any reason to deliver or cause the delivery to the Holder the Warrant Shares subject to a Notice of Exercise by the Warrant Share Delivery Date, the Company shall pay to the Holder, in cash, as liquidated damages and not as a penalty, for each $1,000 of Warrant Shares subject to such exercise (based on the VWAP of the Common Stock on the date of the applicable Notice of Exercise), $10 per Trading Day (increasing to $20 per Trading Day on the third Trading Day after the Warrant Share Delivery Date) for each Trading Day after such Warrant Share Delivery Date until such Warrant Shares are delivered or Holder rescinds such exercise. Notwithstanding the foregoing, the Warrant Agent under the Warrant Agency Agreement shall not, in any event, be subject to, or responsible for, liquidated damages as contemplated by this Section 2(d)(i). The Company agrees to maintain a transfer agent that is a participant in the FAST program so long as this Warrant remains outstanding and exercisable. As used herein, “Standard Settlement Period” means the standard settlement period, expressed in a number of Trading Days, on the Company’s primary Trading Market with respect to the Common Stock as in effect on the date of delivery of the Notice of Exercise. Notwithstanding the foregoing, with respect to any Notice(s) of Exercise delivered on or prior to 12:00 p.m. (New York City time) on the Initial Exercise Date, which may be delivered at any time after the time of execution of the Purchase Agreement, the Company agrees to deliver the Warrant Shares subject to such notice(s) by 4:00 p.m. (New York City time) on the Initial Exercise Date and the Initial Exercise Date shall be the Warrant Share Delivery Date for purposes hereunder, provided that payment of the aggregate Exercise Price (other than in the case of a cashless exercise) is received by such Warrant Share Delivery Date.

ii.          Delivery of New Warrants Upon Exercise. If this Warrant shall have been exercised in part, the Company shall, at the request of a Holder and upon surrender of this Warrant certificate, at the time of delivery of the Warrant Shares, deliver to the Holder a new Warrant evidencing the rights of the Holder to purchase the unpurchased Warrant Shares called for by this Warrant, which new Warrant shall in all other respects be identical with this Warrant.

iii.         Rescission Rights. If the Company fails to cause the Transfer Agent to transmit to the Holder the Warrant Shares pursuant to Section 2(d)(i) by the Warrant Share Delivery Date, then the Holder will have the right to rescind such exercise.

iv.         Compensation for Buy-In on Failure to Timely Deliver Warrant Shares Upon Exercise. In addition to any other rights available to the Holder, if the Company fails to cause the Transfer Agent to transmit to the Holder the Warrant Shares in accordance with the provisions of Section 2(d)(i) above pursuant to an exercise on or before the Warrant Share Delivery Date, and if after such date the Holder is required by its broker to purchase (in an open market transaction or otherwise) or the Holder’s brokerage firm otherwise purchases, shares of Common Stock to deliver in satisfaction of a sale by the Holder of the Warrant Shares which the Holder anticipated receiving upon such exercise (a “Buy-In”), then the Company shall (A) pay in cash to the Holder the amount, if any, by which (x) the Holder’s total purchase price (including brokerage commissions, if any) for the shares of Common Stock so purchased exceeds (y) the amount obtained by multiplying (1) the number of Warrant Shares that the Company was required to deliver to the Holder in connection with the exercise at issue times (2) the price at which the sell order giving rise to such purchase obligation was executed, and (B) at the option of the Holder, either reinstate the portion of the Warrant and equivalent number of Warrant Shares for which such exercise was not honored (in which case such exercise shall be deemed rescinded) or deliver to the Holder the number of shares of Common Stock that would have been issued had the Company timely complied with its exercise and delivery obligations hereunder. For example, if the Holder purchases Common Stock having a total purchase price of $11,000 to cover a Buy-In with respect to an attempted exercise of shares of Common Stock with an aggregate sale price giving rise to such purchase obligation of $10,000, under clause (A) of the immediately preceding sentence the Company shall be required to pay the Holder $1,000. The Holder shall provide the Company written notice indicating the amounts payable to the Holder in respect of the Buy-In and, upon request of the Company, evidence of the amount of such loss. Nothing herein shall limit a Holder’s right to pursue any other remedies available to it hereunder, at law or in equity including, without limitation, a decree of specific performance and/or injunctive relief with respect to the Company’s failure to timely deliver shares of Common Stock upon exercise of the Warrant as required pursuant to the terms hereof. Notwithstanding the foregoing, the Warrant Agent under the Warrant Agency Agreement shall not, in any event, be subject to, or responsible for, Buy-In penalties contemplated by this Section 2(d)(iv).

v.          No Fractional Shares or Scrip. No fractional shares or scrip representing fractional shares shall be issued upon the exercise of this Warrant. As to any fraction of a share which the Holder would otherwise be entitled to purchase upon such exercise, the Company shall, at its election, either pay a cash adjustment in respect of such final fraction in an amount equal to such fraction multiplied by the Exercise Price or round up to the next whole share.

vi.         Charges, Taxes and Expenses. Issuance of Warrant Shares shall be made without charge to the Holder for any issue or transfer tax or other incidental expense in respect of the issuance of such Warrant Shares, all of which taxes and expenses shall be paid by the Company, and such Warrant Shares shall be issued in the name of the Holder or in such name or names as may be directed by the Holder; provided, however, that, in the event that Warrant Shares are to be issued in a name other than the name of the Holder, this Warrant when surrendered for exercise shall be accompanied by the Assignment Form attached hereto duly executed by the Holder and the Company may require, as a condition thereto, the payment of a sum sufficient to reimburse it for any transfer tax incidental thereto. The Company shall pay all Transfer Agent fees required for processing of any Notice of Exercise and all fees to the Depository Trust Company (or another established clearing corporation performing similar functions) required for electronic delivery of the Warrant Shares.

vii.        Closing of Books. The Company will not close its stockholder books or records in any manner which prevents the timely exercise of this Warrant, pursuant to the terms hereof.

e) Holder’s Exercise Limitations. The Company shall not effect any exercise of this Warrant, and a Holder shall not have the right to exercise any portion of this Warrant, pursuant to Section 2 or otherwise, to the extent that after giving effect to such issuance after exercise as set forth on the applicable Notice of Exercise, the Holder (together with the Holder’s Affiliates, and any other Persons acting as a group together with the Holder or any of the Holder’s Affiliates (such Persons, “Attribution Parties”)), would beneficially own in excess of the Beneficial Ownership Limitation (as defined below). For purposes of the foregoing sentence, the number of shares of Common Stock beneficially owned by the Holder and its Affiliates and Attribution Parties shall include the number of shares of Common Stock issuable upon exercise of this Warrant with respect to which such determination is being made, but shall exclude the number of shares of Common Stock which would be issuable upon (i) exercise of the remaining, nonexercised portion of this Warrant beneficially owned by the Holder or any of its Affiliates or Attribution Parties and (ii) exercise or conversion of the unexercised or nonconverted portion of any other securities of the Company (including, without limitation, any other Common Stock Equivalents) subject to a limitation on conversion or exercise analogous to the limitation contained herein beneficially owned by the Holder or any of its Affiliates or Attribution Parties. Except as set forth in the preceding sentence, for purposes of this Section 2(e), beneficial ownership shall be calculated in accordance with Section 13(d) of the Exchange Act and the rules and regulations promulgated thereunder, it being acknowledged by the Holder that the Company is not representing to the Holder that such calculation is in compliance with Section 13(d) of the Exchange Act and the Holder is solely responsible for any schedules required to be filed in accordance therewith. To the extent that the limitation contained in this Section 2(e) applies, the determination of whether this Warrant is exercisable (in relation to other securities owned by the Holder together with any Affiliates and Attribution Parties) and of which portion of this Warrant is exercisable shall be in the sole discretion of the Holder, and the submission of a Notice of Exercise shall be deemed to be the Holder’s determination of whether this Warrant is exercisable (in relation to other securities owned by the Holder together with any Affiliates and Attribution Parties) and of which portion of this Warrant is exercisable, in each case subject to the Beneficial Ownership Limitation, the Company shall have no obligation to verify or confirm the accuracy of such determination, and a submission of a Notice of Exercise shall be deemed a representation and warranty by the Holder of the foregoing determination. In addition, a determination as to any group status as contemplated above shall be determined in accordance with Section 13(d) of the Exchange Act and the rules and regulations promulgated thereunder. For purposes of this Section 2(e), in determining the number of outstanding shares of Common Stock, a Holder may rely on the number of outstanding shares of Common Stock as reflected in (A) the Company’s most recent periodic or annual report filed with the Commission, as the case may be, (B) a more recent public announcement by the Company or (C) a more recent written notice by the Company or the Transfer Agent setting forth the number of shares of Common Stock outstanding. Upon the written or oral request of a Holder, the Company shall within one Trading Day confirm orally and in writing to the Holder the number of shares of Common Stock then outstanding. In any case, the number of outstanding shares of Common Stock shall be determined after giving effect to the conversion or exercise of securities of the Company, including this Warrant, by the Holder or its Affiliates or Attribution Parties since the date as of which such number of outstanding shares of Common Stock was reported. The “Beneficial Ownership Limitation” shall be 4.99% (or, upon election by a Holder prior to the issuance of any Warrants, 9.99%) of the number of shares of the Common Stock outstanding immediately after giving effect to the issuance of shares of Common Stock issuable upon exercise of this Warrant. The Holder, upon notice to the Company, may increase or decrease the Beneficial Ownership Limitation provisions of this Section 2(e), provided that the Beneficial Ownership Limitation shall in no event ever exceed 9.99% of the number of shares of the Common Stock outstanding immediately after giving effect to the issuance of shares of Common Stock upon exercise of this Warrant held by the Holder and the provisions of this Section 2(e) shall continue to apply. Any increase in the Beneficial Ownership Limitation will not be effective until the 61^st day after such notice is delivered to the Company. The provisions of this paragraph shall be construed and implemented in a manner otherwise than in strict conformity with the terms of this Section 2(e) to correct this paragraph (or any portion hereof) which may be defective or inconsistent with the intended Beneficial Ownership Limitation herein contained or to make changes or supplements necessary or desirable to properly give effect to such limitation. The limitations contained in this paragraph shall apply to a successor holder of this Warrant.

Section 3. Certain Adjustments.

a)          Stock Dividends and Splits. If the Company, at any time while this Warrant is outstanding: (i) pays a stock dividend or otherwise makes a distribution or distributions on shares of its Common Stock or any other equity or equity equivalent securities payable in shares of Common Stock (which, for avoidance of doubt, shall not include any shares of Common Stock issued by the Company upon exercise of this Warrant), (ii) subdivides outstanding shares of Common Stock into a larger number of shares, (iii) combines (including by way of reverse stock split) outstanding shares of Common Stock into a smaller number of shares, or (iv) issues by reclassification of shares of the Common Stock any shares of capital stock of the Company, then in each case the Exercise Price shall be multiplied by a fraction of which the numerator shall be the number of shares of Common Stock (excluding treasury shares, if any) outstanding immediately before such event and of which the denominator shall be the number of shares of Common Stock outstanding immediately after such event, and the number of shares issuable upon exercise of this Warrant shall be proportionately adjusted such that the aggregate Exercise Price of this Warrant shall remain unchanged. Any adjustment made pursuant to this Section 3(a) shall become effective immediately after the record date for the determination of stockholders entitled to receive such dividend or distribution and shall become effective immediately after the effective date in the case of a subdivision, combination or re-classification.

b)          Reserved.

c)          Subsequent Rights Offerings. In addition to any adjustments pursuant to Section 3(a) above, if at any time the Company grants, issues or sells any Common Stock Equivalents or rights to purchase stock, warrants, securities or other property pro rata to the record holders of any class of shares of Common Stock (the “Purchase Rights”), then the Holder will be entitled to acquire, upon the terms applicable to such Purchase Rights, the aggregate Purchase Rights which the Holder could have acquired if the Holder had held the number of shares of Common Stock acquirable upon complete exercise of this Warrant (without regard to any limitations on exercise hereof, including without limitation, the Beneficial Ownership Limitation) immediately before the date on which a record is taken for the grant, issuance or sale of such Purchase Rights, or, if no such record is taken, the date as of which the record holders of shares of Common Stock are to be determined for the grant, issue or sale of such Purchase Rights (provided, however, that, to the extent that the Holder’s right to participate in any such Purchase Right would result in the Holder exceeding the Beneficial Ownership Limitation, then the Holder shall not be entitled to participate in such Purchase Right to such extent (or beneficial ownership of such shares of Common Stock as a result of such Purchase Right to such extent) and such Purchase Right to such extent shall be held in abeyance for the Holder until such time, if ever, as its right thereto would not result in the Holder exceeding the Beneficial Ownership Limitation).

d)          Pro Rata Distributions. During such time as this Warrant is outstanding, if the Company shall declare or make any dividend or other distribution of its assets (or rights to acquire its assets) to holders of shares of Common Stock, by way of return of capital or otherwise (including, without limitation, any distribution of cash, stock or other securities, property or options by way of a dividend, spin off, reclassification, corporate rearrangement, scheme of arrangement or other similar transaction) (a “Distribution”), at any time after the issuance of this Warrant, then, in each such case, the Holder shall be entitled to participate in such Distribution to the same extent that the Holder would have participated therein if the Holder had held the number of shares of Common Stock acquirable upon complete exercise of this Warrant (without regard to any limitations on exercise hereof, including without limitation, the Beneficial Ownership Limitation) immediately before the date of which a record is taken for such Distribution, or, if no such record is taken, the date as of which the record holders of shares of Common Stock are to be determined for the participation in such Distribution (provided, however, that, to the extent that the Holder’s right to participate in any such Distribution would result in the Holder exceeding the Beneficial Ownership Limitation, then the Holder shall not be entitled to participate in such Distribution to such extent (or in the beneficial ownership of any shares of Common Stock as a result of such Distribution to such extent) and the portion of such Distribution shall be held in abeyance for the benefit of the Holder until such time, if ever, as its right thereto would not result in the Holder exceeding the Beneficial Ownership Limitation). To the extent that this Warrant has not been partially or completely exercised at the time of such Distribution, such portion of the Distribution shall be held in abeyance for the benefit of the Holder until the Holder has exercised this Warrant.

e)          Fundamental Transaction. If, at any time while this Warrant is outstanding, (i) the Company, directly or indirectly, in one or more related transactions effects any merger or consolidation of the Company with or into another Person pursuant to which (A) shares of Common Stock held by the Company’ stockholders immediately before such merger or consolidation are converted into or exchanged for other securities, cash or property or (B) the Company’s stockholders immediately before the consummation of such merger or consolidation do not hold, immediately after the consummation of such transaction, more than 50% of the outstanding shares of Common Stock, (ii) the Company or any Subsidiary, directly or indirectly, effects any sale, lease, license, assignment, transfer, conveyance or other disposition of all or substantially all of the assets of the Company and all of its Subsidiaries, taken as a whole, in one or a series of related transactions, (iii) any, direct or indirect, purchase offer, tender offer or exchange offer (whether by the Company or another Person) is completed pursuant to which holders of Common Stock are permitted to sell, tender or exchange their shares for other securities, cash or property and has been accepted by the holders of 50% or more of the outstanding Common Stock, (iv) the Company, directly or indirectly, in one or more related transactions effects any reclassification, reorganization or recapitalization of the Common Stock or any compulsory share exchange pursuant to which the Common Stock is effectively converted into or exchanged for other securities, cash or property, or (v) the Company, directly or indirectly, in one or more related transactions, other than in a transaction or transactions primarily for the purpose of financing, consummates a stock or share purchase agreement or other business combination (including, without limitation, a reorganization, recapitalization, spin-off, merger or scheme of arrangement) with another Person or group of Persons whereby such other Person or group acquires more than 50% of the outstanding shares of Common Stock (not including any shares of Common Stock held by the other Person or other Persons making or party to, or associated or affiliated with the other Persons making or party to, such stock or share purchase agreement or other business combination) (each a “Fundamental Transaction”), then, upon any subsequent exercise of this Warrant, the Holder shall have the right to receive, for each Warrant Share that would have been issuable upon such exercise immediately prior to the occurrence of such Fundamental Transaction, at the option of the Holder (without regard to any limitation in Section 2(e) on the exercise of this Warrant), the number of shares of Common Stock of the successor or acquiring corporation or of the Company, if it is the surviving corporation, and any additional consideration (the “Alternate Consideration”) receivable as a result of such Fundamental Transaction by a holder of the number of shares of Common Stock for which this Warrant is exercisable immediately prior to such Fundamental Transaction (without regard to any limitation in Section 2(e) on the exercise of this Warrant). For purposes of any such exercise, the determination of the Exercise Price shall be appropriately adjusted to apply to such Alternate Consideration based on the amount of Alternate Consideration issuable in respect of one share of Common Stock in such Fundamental Transaction, and the Company shall apportion the Exercise Price among the Alternate Consideration in a reasonable manner reflecting the relative value of any different components of the Alternate Consideration. If holders of Common Stock are given any choice as to the securities, cash or property to be received in a Fundamental Transaction, then the Holder shall be given the same choice as to the Alternate Consideration it receives upon any exercise of this Warrant following such Fundamental Transaction. Notwithstanding anything to the contrary, in the event of a Fundamental Transaction, the Company or any Successor Entity (as defined below) shall, at the Holder’s option, exercisable at any time concurrently with, or within 30 days after, the consummation of the Fundamental Transaction (or, if later, the date of the public announcement of the applicable Fundamental Transaction), purchase this Warrant from the Holder by paying to the Holder an amount of cash equal to the Black Scholes Value (as defined below) of the remaining unexercised portion of this Warrant on the date of the consummation of such Fundamental Transaction; provided, however, that, if the Fundamental Transaction is not within the Company’s control, including not approved by the Company’s Board of Directors, Holder shall only be entitled to receive from the Company or any Successor Entity the same type or form of consideration (and in the same proportion), at the Black Scholes Value of the unexercised portion of this Warrant, that is being offered and paid to the holders of Common Stock of the Company in connection with the Fundamental Transaction, whether that consideration be in the form of cash, stock or any combination thereof, or whether the holders of Common Stock are given the choice to receive from among alternative forms of consideration in connection with the Fundamental Transaction; provided, further, that if holders of Common Stock of the Company are not offered or paid any consideration in such Fundamental Transaction, such holders of Common Stock will be deemed to have received common stock of the Successor Entity (which Entity may be the Company following such Fundamental Transaction) in such Fundamental Transaction. “Black Scholes Value” means the value of this Warrant based on the Black-Scholes Option Pricing Model obtained from the “OV” function on Bloomberg determined as of the day of consummation of the applicable Fundamental Transaction for pricing purposes and reflecting (A) a risk-free interest rate corresponding to the U.S. Treasury rate for a period equal to the time between the date of the public announcement of the applicable Fundamental Transaction and the Termination Date, (B) an expected volatility equal to the greater of 100% and the 100 day volatility obtained from the HVT function on Bloomberg (determined utilizing a 365 day annualization factor) as of the Trading Day immediately following the public announcement of the applicable Fundamental Transaction, (C) the underlying price per share used in such calculation shall be the greater of (i) the sum of the price per share being offered in cash, if any, plus the value of any non-cash consideration, if any, being offered in such Fundamental Transaction and (ii) the highest VWAP during the period beginning on the Trading Day immediately preceding the public announcement of the applicable Fundamental Transaction (or the consummation of the applicable Fundamental Transaction, if earlier) and ending on the Trading Day of the Holder’s request pursuant to this Section 3(e) and (D) a remaining option time equal to the time between the date of the public announcement of the applicable Fundamental Transaction and the Termination Date and (E) a zero cost of borrow. The payment of the Black Scholes Value will be made by wire transfer of immediately available funds (or such other consideration) within the later of (i) five Business Days of the Holder’s election and (ii) the date of consummation of the Fundamental Transaction. The Company shall cause any successor entity in a Fundamental Transaction in which the Company is not the survivor (the “Successor Entity”) to assume in writing all of the obligations of the Company under this Warrant and the other Transaction Documents in accordance with the provisions of this Section 3(e) pursuant to written agreements in form and substance reasonably satisfactory to the Holder and approved by the Holder (without unreasonable delay) prior to such Fundamental Transaction and shall, at the option of the Holder, deliver to the Holder in exchange for this Warrant a security of the Successor Entity evidenced by a written instrument substantially similar in form and substance to this Warrant which is exercisable for a corresponding number of shares of capital stock of such Successor Entity (or its parent entity) equivalent to the shares of Common Stock acquirable and receivable upon exercise of this Warrant (without regard to any limitations on the exercise of this Warrant) prior to such Fundamental Transaction, and with an exercise price which applies the exercise price hereunder to such shares of capital stock (but taking into account the relative value of the shares of Common Stock pursuant to such Fundamental Transaction and the value of such shares of capital stock, such number of shares of capital stock and such exercise price being for the purpose of protecting the economic value of this Warrant immediately prior to the consummation of such Fundamental Transaction), and which is reasonably satisfactory in form and substance to the Holder. Upon the occurrence of any such Fundamental Transaction, the Successor Entity shall succeed to, and be substituted for (so that from and after the date of such Fundamental Transaction, the provisions of this Warrant and the other Transaction Documents referring to the “Company” shall refer instead to the Successor Entity), and may exercise every right and power of the Company and shall assume all of the obligations of the Company under this Warrant and the other Transaction Documents with the same effect as if such Successor Entity had been named as the Company herein. A determination as to any group for purposes of this paragraph shall be determined in accordance with Section 13(d) of the Exchange Act and the rules and regulations promulgated thereunder.

f)          Calculations. All calculations under this Section 3 shall be made to the nearest cent or the nearest 1/100th of a share, as the case may be. For purposes of this Section 3, the number of shares of Common Stock deemed to be issued and outstanding as of a given date shall be the sum of the number of shares of Common Stock (excluding treasury shares, if any) issued and outstanding.

g)          Notice to Holder.

i.          Adjustment to Exercise Price. Whenever the Exercise Price is adjusted pursuant to any provision of this Section 3, the Company shall promptly deliver to the Holder by email a notice setting forth the Exercise Price after such adjustment and any resulting adjustment to the number of Warrant Shares and setting forth a brief statement of the facts requiring such adjustment.

ii.          Notice to Allow Exercise by Holder. If (A) the Company shall declare a dividend (or any other distribution in whatever form) on the Common Stock, (B) the Company shall declare a special nonrecurring cash dividend on or a redemption of the Common Stock, (C) the Company shall authorize the granting to all holders of the Common Stock rights or warrants to subscribe for or purchase any shares of capital stock of any class or of any rights, (D) the approval of any stockholders of the Company shall be required in connection with any reclassification of the Common Stock, any consolidation or merger to which the Company (or any of its Subsidiaries) is a party pursuant to which that holders of the Common Stock of record will be entitled to exchange their shares of Common Stock for securities, cash or other property deliverable upon such consolidation or merger, sale, any sale or transfer of all or substantially all of the assets of the Company and its Subsidiaries, taken as a whole, or any compulsory share exchange whereby the Common Stock is converted into other securities, cash or property, or (E) the Company shall authorize the voluntary or involuntary dissolution, liquidation or winding up of the affairs of the Company, then, in each case, the Company shall cause to be delivered by email to the Holder at its last email address as it shall appear upon the Warrant Register of the Company or the Warrant Agent, at least 20 calendar days prior to the anticipated applicable record or effective date hereinafter specified, a notice stating (x) the anticipated date on which a record is to be taken for the purpose of such dividend, distribution, redemption, rights or warrants, or if a record is not to be taken, the date as of which the holders of the Common Stock of record to be entitled to such dividend, distributions, redemption, rights or warrants are to be determined or (y) the date (if known) on which such reclassification, consolidation, merger, sale, transfer or share exchange is expected to become effective or close, and the date as of which it is expected that holders of the Common Stock of record shall be entitled to exchange their shares of the Common Stock for securities, cash or other property deliverable upon such reclassification, consolidation, merger, sale, transfer or share exchange; provided that the failure to deliver such notice or any defect therein or in the delivery thereof shall not affect the validity of the corporate action required to be specified in such notice. To the extent that any notice provided in this Warrant constitutes, or contains, material, non-public information regarding the Company or any of the Subsidiaries as determined by the Company in consultation with Company Counsel, the Company shall simultaneously file such notice with the Commission pursuant to a Current Report on Form 8-K. The Holder shall remain entitled to exercise this Warrant during the period commencing on the date of such notice to the effective date of the event triggering such notice except as may otherwise be expressly set forth herein.

Section 4. Transfer of Warrant.

a)          Transferability. Subject to compliance with applicable securities laws and the conditions set forth in Section 4(d) hereof and to the provisions of Section 4.1 of the Purchase Agreement, this Warrant and all rights hereunder (including, without limitation, any registration rights) are transferable, in whole or in part, upon surrender of this Warrant at the principal office of the Company or its designated agent, together with a written assignment of this Warrant substantially in the form attached hereto duly executed by the Holder or its agent or attorney and funds sufficient to pay any transfer taxes payable upon the making of such transfer. Upon such surrender and, if required, such payment, the Company shall execute and deliver a new Warrant or Warrants in the name of the assignee or assignees, as applicable, and in the denomination or denominations specified in such instrument of assignment, and shall issue to the assignor a new Warrant evidencing the portion of this Warrant not so assigned, and this Warrant shall promptly be cancelled. Notwithstanding anything herein to the contrary, the Holder shall not be required to physically surrender this Warrant to the Company unless the Holder has assigned this Warrant in full, in which case, the Holder shall surrender this Warrant to the Company within three (3) Trading Days of the date on which the Holder delivers an assignment form to the Company assigning this Warrant in full. The Warrant, if properly assigned in accordance herewith, may be exercised by a new holder for the purchase of Warrant Shares without having a new Warrant issued.

b)          New Warrants. If this Warrant is not held in global form through DTC (or any successor depositary) this Warrant may be divided or combined with other Warrants upon presentation hereof at the aforesaid office of the Company, together with a written notice specifying the names and denominations in which new Warrants are to be issued, signed by the Holder or its agent or attorney. Subject to compliance with Section 4(a), as to any transfer which may be involved in such division or combination, the Company shall execute and deliver a new Warrant or Warrants in exchange for the Warrant or Warrants to be divided or combined in accordance with such notice. All Warrants issued on transfers or exchanges shall be dated the initial issuance date of this Warrant and shall be identical with this Warrant except as to the number of Warrant Shares issuable pursuant thereto.

c)          Warrant Register. The Warrant Agent (or, in the event a Holder elects to receive a Definitive Certificate, the Company) shall register this Warrant, upon records to be maintained by the Warrant Agent (or, in the event a Holder elects to receive a Definitive Certificate, the Company) for that purpose (the “Warrant Register”), in the name of the record Holder hereof from time to time. The Company and the Warrant Agent may deem and treat the registered Holder of this Warrant as the absolute owner hereof for the purpose of any exercise hereof or any distribution to the Holder, and for all other purposes, absent actual notice to the contrary.

d)          Transfer Restrictions. If, at the time of the surrender of this Warrant in connection with any transfer of this Warrant, the transfer of this Warrant shall not be either (i) registered pursuant to an effective registration statement under the Securities Act and under applicable state securities or blue sky laws or (ii) eligible for resale without volume or manner-of-sale restrictions or current public information requirements pursuant to Rule 144, the Company may require, as a condition of allowing such transfer, that the Holder or transferee of this Warrant, as the case may be, comply with the provisions of Section 5.7 of the Purchase Agreement.

Section 5. Miscellaneous.

a)           No Rights as Stockholder Until Exercise; No Settlement in Cash. This Warrant does not entitle the Holder to any voting rights, dividends or other rights as a stockholder of the Company prior to the exercise hereof as set forth in Section 2(d)(i), except as expressly set forth in Section 3. Without limiting any rights of a Holder to receive Warrant Shares on a “cashless exercise” pursuant to Section 2(c) or to receive cash payments pursuant to Section 2(d)(i) and Section 2(d)(iv) herein, in no event shall the Company be required to net cash settle an exercise of this Warrant.

b)          Loss, Theft, Destruction or Mutilation of Warrant. The Company covenants that upon receipt by the Company of evidence reasonably satisfactory to it of the loss, theft, destruction or mutilation of this Warrant or any stock certificate relating to the Warrant Shares, and in case of loss, theft or destruction, of indemnity or security reasonably satisfactory to it (which, in the case of the Warrant, shall not include the posting of any bond), and upon surrender and cancellation of such Warrant or stock certificate, if mutilated, the Company will make and deliver a new Warrant or stock certificate of like tenor and dated as of such cancellation, in lieu of such Warrant or stock certificate.

c)          Saturdays, Sundays, Holidays, etc. If the last or appointed day for the taking of any action or the expiration of any right required or granted herein shall not be a Trading Day, then such action may be taken or such right may be exercised on the next succeeding Trading Day.

d)          Authorized Shares.

The Company covenants that, during the period the Warrant is outstanding, it will reserve from its authorized and unissued Common Stock a sufficient number of shares to provide for the issuance of the Warrant Shares upon the exercise of any purchase rights under this Warrant. The Company further covenants that its issuance of this Warrant shall constitute full authority to its officers who are charged with the duty of issuing the necessary Warrant Shares upon the exercise of the purchase rights under this Warrant. The Company will take all such reasonable action as may be necessary to assure that such Warrant Shares may be issued as provided herein without violation of any applicable law or regulation, or of any requirements of the Trading Market upon which the Common Stock may be listed. The Company covenants that all Warrant Shares which may be issued upon the exercise of the purchase rights represented by this Warrant will, upon exercise of the purchase rights represented by this Warrant and payment for such Warrant Shares in accordance herewith, be duly authorized, validly issued, fully paid and nonassessable and free from all taxes, liens and charges created by the Company in respect of the issue thereof (other than taxes in respect of any transfer occurring contemporaneously with such issue).

Except and to the extent as waived or consented to by the Holder, the Company shall not by any action, including, without limitation, amending its certificate of incorporation or through any reorganization, transfer of assets, consolidation, merger, dissolution, issue or sale of securities or any other voluntary action, avoid or seek to avoid the observance or performance of any of the terms of this Warrant, but will at all times in good faith assist in the carrying out of all such terms and in the taking of all such actions as may be necessary or appropriate to protect the rights of Holder as set forth in this Warrant against impairment. Without limiting the generality of the foregoing, the Company will (i) not increase the par value of any Warrant Shares above the amount payable therefor upon such exercise immediately prior to such increase in par value, (ii) take all such action as may be necessary or appropriate in order that the Company may validly and legally issue fully paid and nonassessable Warrant Shares upon the exercise of this Warrant and (iii) use commercially reasonable efforts to obtain all such authorizations, exemptions or consents from any public regulatory body having jurisdiction thereof, as may be, necessary to enable the Company to perform its obligations under this Warrant.

Before taking any action which would result in an adjustment in the number of Warrant Shares for which this Warrant is exercisable or in the Exercise Price, the Company shall obtain all such authorizations or exemptions thereof, or consents thereto, as may be necessary from any public regulatory body or bodies having jurisdiction thereof.

e)          Jurisdiction. All questions concerning the construction, validity, enforcement and interpretation of this Warrant shall be determined in accordance with the provisions of the Purchase Agreement.

f)           Restrictions. The Holder acknowledges that the Warrant Shares acquired upon the exercise of this Warrant, if not registered, and the Holder does not utilize cashless exercise, will have restrictions upon resale imposed by state and federal securities laws.

g)          Nonwaiver and Expenses. No course of dealing or any delay or failure to exercise any right hereunder on the part of Holder shall operate as a waiver of such right or otherwise prejudice the Holder’s rights, powers or remedies. Without limiting any other provision of this Warrant or the Purchase Agreement, if the Company willfully and knowingly fails to comply with any provision of this Warrant, which results in any material damages to the Holder, the Company shall pay to the Holder such amounts as shall be sufficient to cover any costs and expenses including, but not limited to, reasonable attorneys’ fees, including those of appellate proceedings, incurred by the Holder in collecting any amounts due pursuant hereto or in otherwise enforcing any of its rights, powers or remedies hereunder.

h)          Notices. Any notice, request or other document required or permitted to be given or delivered to the Holder by the Company shall be delivered in accordance with the notice provisions of the Purchase Agreement.

i)           Limitation of Liability. No provision hereof, in the absence of any affirmative action by the Holder to exercise this Warrant to purchase Warrant Shares, and no enumeration herein of the rights or privileges of the Holder, shall give rise to any liability of the Holder for the purchase price of any Common Stock or as a stockholder of the Company, whether such liability is asserted by the Company or by creditors of the Company.

j)           Remedies. The Holder, in addition to being entitled to exercise all rights granted by law, including recovery of damages, will be entitled to specific performance of its rights under this Warrant. The Company agrees that monetary damages would not be adequate compensation for any loss incurred by reason of a breach by it of the provisions of this Warrant and hereby agrees to waive and not to assert the defense in any action for specific performance that a remedy at law would be adequate.

k)          Successors and Assigns. Subject to applicable securities laws, this Warrant and the rights and obligations evidenced hereby shall inure to the benefit of and be binding upon the successors and permitted assigns of the Company and the successors and permitted assigns of Holder. The provisions of this Warrant are intended to be for the benefit of any Holder from time to time of this Warrant and shall be enforceable by the Holder or holder of Warrant Shares.

l)           Amendment. This Warrant may be modified or amended or the provisions hereof waived with the written consent of the Company and the Holder.

m)         Severability. Wherever possible, each provision of this Warrant shall be interpreted in such manner as to be effective and valid under applicable law, but if any provision of this Warrant shall be prohibited by or invalid under applicable law, such provision shall be ineffective to the extent of such prohibition or invalidity, without invalidating the remainder of such provisions or the remaining provisions of this Warrant.

n)          Headings. The headings used in this Warrant are for the convenience of reference only and shall not, for any purpose, be deemed a part of this Warrant.

o)          Warrant Agency Agreement. If this Warrant is held in global form through DTC (or any successor depositary), this Warrant is issued subject to the Warrant Agency Agreement. To the extent any provision of this Warrant conflicts with the express provisions of the Warrant Agency Agreement, the provisions of this Warrant shall govern and be controlling.

********************

(Signature Page Follows)

IN WITNESS WHEREOF, the Company has caused this Warrant to be executed by its officer thereunto duly authorized as of the date first above indicated.

ADAMIS PHARMACEUTICALS CORPORATION
By:	/s/ David J. Marguglio
	Name: David J. Marguglio
	Title: President & Chief Operating Officer

[Signature Page to Warrant]

NOTICE OF EXERCISE

TO: ADAMIS PHARMACEUTICALS CORPORATION

(1) The undersigned hereby elects to purchase ________ Warrant Shares of the Company pursuant to the terms of the attached Warrant (only if exercised in full), and tenders herewith payment of the exercise price in full, together with all applicable transfer taxes, if any.

(2) Payment shall take the form of (check applicable box):

[   ] in lawful money of the United States; or

[   ] if permitted the cancellation of such number of Warrant Shares as is necessary, in accordance with the formula set forth in subsection 2(c), to exercise this Warrant with respect to the maximum number of Warrant Shares purchasable pursuant to the cashless exercise procedure set forth in subsection 2(c).

(3) Please issue said Warrant Shares in the name of the undersigned or in such other name as is specified below:

_______________________________

The Warrant Shares shall be delivered to the following DWAC Account Number:

_______________________________

_______________________________

_______________________________

ASSIGNMENT FORM

(To assign the foregoing Warrant, execute this form and supply required information. Do not use this form to purchase shares.)

FOR VALUE RECEIVED, the foregoing Warrant and all rights evidenced thereby are hereby assigned to

Name:
	(Please Print)
Address:
	(Please Print)
Phone Number:
Email Address:
Dated: _______________ __, ______
Holder’s Signature:
Holder’s Address:

EX-4.3

DMK Pharmaceuticals Corporation 10-Q

Exhibit 4.3

ADAMIS PHARMACEUTICALS CORPORATION

and

EQUINITI TRUST COMPANY, LLC, as

Warrant Agent

Warrant Agency Agreement

Dated as of August 4, 2023

WARRANT AGENCY AGREEMENT

WARRANT AGENCY AGREEMENT, dated as of August 4, 2023 (“Agreement”), between Adamis Pharmaceuticals Corporation, a corporation organized under the laws of the State of Delaware (the “Company”), and Equiniti Trust Company, LLC (the “Warrant Agent”).

W I T N E S S E T H

WHEREAS, pursuant to a registered offering by the Company of 5,930,000 Units (the “Offering”), with each Unit consisting of one share of the Company’s common stock, par value $0.0001 per share (the “Common Stock”) (or one pre-funded warrant (the “Pre-Funded Warrants”) and one warrant (the “Warrants”) to purchase one share of Common Stock (the “Warrant Shares”) at a price of $1.35 per share (or 100% of the price of each share of Common Stock sold in the Offering); and

WHEREAS, upon the terms and subject to the conditions hereinafter set forth and pursuant to an effective registration statement on Form S-1, as amended (File No. 333-273233) (the “Registration Statement”), and the terms and conditions of the Warrant Certificate, the Company wishes to issue the Warrants in book entry form entitling the respective holders of the Warrants (the “Holders,” which term shall include a Holder’s transferees, successors and assigns and “Holder” shall include, if the Warrants are held in “street name,” a Participant (as defined below) or a designee appointed by such Participant); and

WHEREAS, the shares of Common Stock (or Pre-Funded Warrants) and Warrants to be issued in connection with the Offering shall be immediately separable and will be issued separately, but will be purchased together in the Offering; and

WHEREAS, the Company wishes the Warrant Agent to act on behalf of the Company, and the Warrant Agent is willing so to act, in connection with the issuance, registration, transfer, exchange, exercise and replacement of the Warrants and, in the Warrant Agent’s capacity as the Company’s transfer agent, the delivery of the Warrant Shares (as defined below).

NOW, THEREFORE, in consideration of the premises and the mutual agreements herein set forth, the parties hereby agree as follows:

Section 1. Certain Definitions. For purposes of this Agreement, all capitalized terms not herein defined shall have the meanings hereby indicated:

(a)“Affiliate” has the meaning ascribed to it in Rule 12b-2 under the Securities Exchange Act of 1934, as amended (the “Exchange Act”).

(b)“Close of Business” on any given date means 5:00 p.m., New York City time, on such date; provided, however, that if such date is not a Business Day it means 5:00 p.m., New York City time, on the next succeeding Business Day.

(c)“Person” means an individual, corporation, association, partnership, limited liability company, joint venture, trust, unincorporated organization, government or political subdivision thereof or governmental agency or other entity.

(d)“Warrant Certificate” means the certificate in substantially the form attached as Exhibit 1 hereto, representing such number of Warrant Shares as is indicated therein, provided that any reference to the delivery of a Warrant Certificate in this Agreement shall include delivery of a Definitive Certificate or a Global Warrant (each as defined below).

All other capitalized terms used but not otherwise defined herein shall have the meaning ascribed to such terms in the Warrant Certificate (including any defined terms set forth in the Purchase Agreement (as defined in the Warrant Certificate)).

Section 2. Appointment of Warrant Agent. The Company hereby appoints the Warrant Agent to act as agent for the Company in accordance with the terms and conditions hereof, and the Warrant Agent hereby accepts such appointment.

Section 3. Global Warrants.

(a)The Warrants shall be registered securities and shall be evidenced by a global warrant with respect to the Warrants (the “Global Warrants”), in the form of the Warrant Certificate, which shall be deposited with the Warrant Agent and registered in the name of Cede & Co., a nominee of The Depository Trust Company (the “Depositary”), or as otherwise directed by the Depositary. Ownership of beneficial interests in the Warrants shall be shown on, and the transfer of such ownership shall be effected through, records maintained by (i) the Depositary or its nominee for each Global Warrant or (ii) institutions that have accounts with the Depositary (such institution, with respect to a Warrant in its account, a “Participant”).

(b)If the Depositary subsequently ceases to make its book-entry settlement system available for the Warrants, the Company may instruct the Warrant Agent regarding other arrangements for book-entry settlement. In the event that the Warrants are not eligible for, or it is no longer necessary to have the Warrants available in, book-entry form, the Warrant Agent shall provide written instructions to the Depositary to deliver to the Warrant Agent for cancellation each Global Warrant, and the Company shall instruct the Warrant Agent to deliver to each Holder a Warrant Certificate.

(c)A Holder has the right to elect at any time or from time to time a Warrant Exchange (as defined below) pursuant to a Warrant Certificate Request Notice (as defined below). Upon written notice by a Holder to the Company and the Warrant Agent for the exchange of some or all of such Holder’s Global Warrants for a separate certificate in the form attached hereto as Exhibit 1 (such separate certificate, a “Definitive Certificate”) evidencing the same number of Warrants, which request shall be in the form attached hereto as Exhibit 2 (a “Warrant Certificate Request Notice” and the date of delivery of such Warrant Certificate Request Notice by the Holder, the “Warrant Certificate Request Notice Date” and the surrender by the Holder to the Warrant Agent of a number of Global Warrants for the same number of Warrants evidenced by a Warrant Certificate, a “Warrant Exchange”), the Company and the Warrant Agent shall promptly effect the Warrant Exchange and the Company and the Warrant Agent shall promptly issue and deliver to the Holder a Definitive Certificate for such number of Warrants in the name set forth in the Warrant Certificate Request Notice. Such Definitive Certificate shall be dated the original issue date of the Warrants, shall be executed by facsimile by an authorized signatory of the Company, shall be in the form attached hereto as Exhibit 1, and shall be reasonably acceptable in all respects to such Holder. In connection with a Warrant Exchange, the Company agrees to deliver the Definitive Certificate to the Holder within ten(10) Business Days of the Warrant Certificate Request Notice pursuant to the delivery instructions in the Warrant Certificate Request Notice (“Warrant Certificate Delivery Date”). If the Company and the Warrant Agent fail for any reason to deliver to the Holder the Definitive Certificate subject to the Warrant Certificate Request Notice by the Warrant Certificate Delivery Date, the Company shall pay to the Holder, in cash, as liquidated damages and not as a penalty, for each $1,000 of Warrant Shares evidenced by such Definitive Certificate (based on the VWAP (as defined in the Warrants) of the Common Stock on the Warrant Certificate Request Notice Date), $10 per Business Day for each Business Day after such Warrant Certificate Delivery Date until such Definitive Certificate is delivered or, prior to delivery of such Warrant Certificate, the Holder rescinds such Warrant Exchange. The Company covenants and agrees that, upon the date of delivery of the Warrant Certificate Request Notice, the Holder shall be deemed to be the holder of the Definitive Certificate and, notwithstanding anything to the contrary set forth herein, the Definitive Certificate shall be deemed for all purposes to contain all of the terms and conditions of the Warrants evidenced by such Warrant Certificate and the terms of this Agreement, other than Sections 3(c), 3(d) and 9 herein, shall not apply to the Warrants evidenced by the Definitive Certificate. Notwithstanding anything herein to the contrary, the Warrant Agent shall act as warrant agent with respect to any Definitive Certificate requested and issued pursuant to this section. Notwithstanding anything to the contrary contained in this Agreement, in the event of inconsistency between any provision in this Agreement and any provision in a Definitive Certificate, as it may from time to time be amended, the terms of such Definitive Certificate shall control.

(d) A Holder of a Definitive Certificate (pursuant to a Warrant Exchange or otherwise) has the right to elect at any time or from time to time a Global Warrants Exchange (as defined below) pursuant to a Global Warrants Request Notice (as defined below). Upon written notice by a Holder to the Company and the Warrant Agent for the exchange of some or all of such Holder’s Warrants evidenced by a Definitive Certificate for a beneficial interest in Global Warrants held in book-entry form through the Depositary evidencing the same number of Warrants, which request shall be in the form attached hereto as Exhibit 3 (a “Global Warrants Request Notice” and the date of delivery of such Global Warrants Request Notice by the Holder, the “Global Warrants Request Notice Date” and the surrender upon delivery by the Holder of the Warrants evidenced by Definitive Certificates for the same number of Warrants evidenced by a beneficial interest in Global Warrants held in book-entry form through the Depositary, a “Global Warrants Exchange”), the Warrant Agent shall promptly effect the Global Warrants Exchange and shall promptly issue and deliver to the Holder Global Warrants for such number of Warrants in the Global Warrants Request Notice, which beneficial interest in such Global Warrants shall be delivered by the Depositary’s Deposit or Withdrawal at Custodian system to the Holder pursuant to the instructions in the Global Warrants Request Notice. In connection with a Global Warrants Exchange, the Warrant shall deliver the beneficial interest in such Global Warrants to the Holder within ten (10) Business Days of the Global Warrants Request Notice pursuant to the delivery instructions in the Global Warrant Request Notice (“Global Warrants Delivery Date”). If the Company fails for any reason to deliver to the Holder Global Warrants subject to the Global Warrants Request Notice by the Global Warrants Delivery Date, the Company shall pay to the Holder, in cash, as liquidated damages and not as a penalty, for each $1,000 of Warrant Shares evidenced by such Global Warrants (based on the VWAP (as defined in the Warrants) of the Common Stock on the Global Warrants Request Notice Date), $10 per Business Day for each Business Day after such Global Warrants Delivery Date until such Global Warrants are delivered or, prior to delivery of such Global Warrants, the Holder rescinds such Global Warrants Exchange. The Company covenants and agrees that, upon the date of delivery of the Global Warrants Request Notice, the Holder shall be deemed to be the beneficial holder of such Global Warrants.

Section 4. Form of Warrant Certificates. The Warrant Certificate, together with the form of election to purchase Common Stock (“Notice of Exercise”) and the form of assignment to be printed on the reverse thereof, shall be in the form of Exhibit 1 hereto.

Section 5. Countersignature and Registration. The Global Warrants shall be executed on behalf of the Company by its Chief Executive Officer, Chief Operating Officer or President, by facsimile signature, and have affixed thereto the Company’s seal or a facsimile thereof (in each case only if the Company has a seal) which shall be attested by the Secretary or an Assistant Secretary of the Company, by facsimile signature. The Global Warrants shall be countersigned by the Warrant Agent by facsimile signature and shall not be valid for any purpose unless so countersigned. In case any officer of the Company who shall have signed any of the Global Warrants shall cease to be such officer of the Company before countersignature by the Warrant Agent and issuance and delivery by the Company, such Global Warrant, nevertheless, may be countersigned by the Warrant Agent, issued and delivered with the same force and effect as though the person who signed such Global Warrants had not ceased to be such officer of the Company; and any Global Warrant may be signed on behalf of the Company by any person who, at the actual date of the execution of such Global Warrant, shall be a proper officer of the Company to sign such Global Warrants, although at the date of the execution of this Warrant Agreement any such person was not such an officer.

The Warrant Agent will keep or cause to be kept, at one of its offices, or at the office of one of its agents, books for registration and transfer of the Global Warrants issued hereunder. Such books shall show the names and addresses of the respective Holders of the Global Warrant, the number of warrants evidenced on the face of each of such Global Warrant and the date of each of such Global Warrant. The Warrant Agent will create a special account for the issuance of Global Warrants. The Warrant Agent will keep or cause to be kept at one of its offices, books for the registration and transfer of any Definitive Certificates issued hereunder. Such Warrant Agent books shall show the names and addresses of the respective Holders of the Definitive Certificates, the number of warrants evidenced on the face of each such Definitive Certificate and the date of each such Definitive Certificate.

Section 6. Transfer, Split Up, Combination and Exchange of Warrant Certificates; Mutilated, Destroyed, Lost or Stolen Warrant Certificates. With respect to the Global Warrants, subject to the provisions of the Warrant Certificate and the last sentence of this first paragraph of Section 6 and subject to applicable law, rules or regulations, or any “stop transfer” instructions the Company may give to the Warrant Agent, at any time after the closing date of the Offering, and at or prior to the Close of Business on the Termination Date (as such term is defined in the Warrant Certificate), any Global Warrant or Global Warrants may be transferred, split up, combined or exchanged for another Global Warrant or Global Warrants, entitling the Holder to purchase a like number of shares of Common Stock as the Global Warrant or Global Warrants surrendered then entitled such Holder to purchase. Any Holder desiring to transfer, split up, combine or exchange any Global Warrant shall make such request in writing delivered to the Warrant Agent, and shall surrender the Global Warrant to be transferred, split up, combined or exchanged at the principal office of the Warrant Agent. Any requested transfer of Warrants, whether in book-entry form or certificate form, shall be accompanied by reasonable evidence of authority of the party making such request that may be required by the Warrant Agent. Thereupon the Warrant Agent shall, subject to the last sentence of this first paragraph of Section 6, countersign and deliver to the Person entitled thereto a Global Warrant or Global Warrants, as the case may be, as so requested. The Company may require payment from the Holder of a sum sufficient to cover any tax or governmental charge or any bond or other fees required by the Warrant Agent that may be imposed in connection with any transfer, split up, combination or exchange of Global Warrants. The Company shall compensate the Warrant Agent per the fee schedule mutually agreed upon by the parties hereto and provided separately on the date hereof. 

Upon receipt by the Warrant Agent of evidence reasonably satisfactory to it of the loss, theft, destruction or mutilation of a Warrant Certificate, which evidence shall include an affidavit of loss, or in the case of mutilated certificates, the certificate or portion thereof remaining, and, in case of loss, theft or destruction, of indemnity in customary form and amount (but, with respect to any Definitive Certificates, shall not include the posting of any bond by the Holder), and satisfaction of any other reasonable requirements established by Section 8-405 of the Uniform Commercial Code as in effect in the State of Delaware, and reimbursement to the Company and the Warrant Agent of all reasonable expenses incidental thereto, and upon surrender to the Warrant Agent and cancellation of the Warrant Certificate if mutilated, the Company will make and deliver a new Warrant Certificate of like tenor to the Warrant Agent for delivery to the Holder in lieu of the Warrant Certificate so lost, stolen, destroyed or mutilated.

Section 7. Exercise of Warrants; Exercise Price; Termination Date.

(a)The Warrants shall be exercisable commencing on the Initial Exercise Date. The Warrants shall cease to be exercisable and shall terminate and become void as set forth in the Warrant Certificate. Subject to the foregoing and to Section 7(b) below, the Holder of a Warrant may exercise the Warrant in whole or in part upon surrender of the Warrant Certificate, if required, with the executed Notice of Exercise and payment of the Exercise Price, which may be made, at the option of the Holder, by wire transfer or by certified or official bank check in United States dollars, to the Warrant Agent at the principal office of the Warrant Agent or to the office of one of its agents as may be designated by the Warrant Agent from time to time. In the case of the Holder of a Global Warrant, the Holder shall deliver the executed Notice of Exercise and the payment of the Exercise Price as described herein. Notwithstanding any other provision in this Agreement, a holder whose interest in a Global Warrant is a beneficial interest in a Global Warrant held in book-entry form through the Depositary (or another established clearing corporation performing similar functions), shall effect exercises by delivering to the Depositary (or such other clearing corporation, as applicable) the appropriate instruction form for exercise, complying with the procedures to effect exercise that are required by the Depositary (or such other clearing corporation, as applicable). The Company acknowledges that the bank accounts maintained by the Warrant Agent in connection with the services provided under this Agreement will be in its name and that the Warrant Agent may receive investment earnings in connection with the investment at Warrant Agent risk and for its benefit of funds held in those accounts from time to time. Neither the Company nor the Holders will receive interest on any deposits or Exercise Price. No ink-original Notice of Exercise shall be required, nor shall any medallion guarantee (or other type of guarantee or notarization) of any Notice of Exercise be required. The Company hereby acknowledges and agrees that, with respect to a holder whose interest in a Global Warrant is a beneficial interest in a Global Warrant held in book-entry form through the Depositary (or another established clearing corporation performing similar functions), upon delivery of irrevocable instructions to such holder’s Participant to exercise such warrants, that solely for purposes of Regulation SHO that such holder shall be deemed to have exercised such warrants.

(b)Upon receipt of a Notice of Exercise for a Cashless Exercise, provided the requirements for a Cashless Exercise have been met, the Company will promptly calculate and transmit to the Warrant Agent the number of Warrant Shares issuable in connection with such Cashless Exercise and deliver a copy of the Notice of Exercise to the Warrant Agent, which shall issue such number of Warrant Shares in connection with such Cashless Exercise.

(c)Upon the exercise of the Warrant Certificate pursuant to the terms of Section 2 of the Warrant Certificate, the Warrant Agent shall cause the Warrant Shares underlying such Warrant Certificate or Global Warrant to be delivered to or upon the order of the Holder of such Warrant Certificate or Global Warrant, registered in such name or names as may be designated by such Holder, no later than the Warrant Share Delivery Date (as such term is defined in the Warrant Certificate). If the Company is then a participant in the DWAC system of the Depositary and either (A) there is an effective registration statement permitting the issuance of the Warrant Shares to or resale of the Warrant Shares by Holder or (B) the Warrant is being exercised via Cashless Exercise, then the certificates for Warrant Shares shall be transmitted by the Warrant Agent to the Holder by crediting the account of the Holder’s broker with the Depositary through its DWAC system. For the avoidance of doubt, if the Company becomes obligated to pay any amounts to any Holders pursuant to Section 2(d)(i) or 2(d)(iv) of the Warrant Certificate, such obligation shall be solely that of the Company and not that of the Warrant Agent. Notwithstanding anything else to the contrary in this Agreement, except in the case of a Cashless Exercise, if any Holder fails to duly deliver payment to the Warrant Agent of an amount equal to the aggregate Exercise Price of the Warrant Shares to be purchased upon exercise of such Holder’s Warrant as set forth in Section 7(a) hereof by the Warrant Share Delivery Date, the Warrant Agent will not obligated to deliver such Warrant Shares (via DWAC or otherwise) until following receipt of such payment, and the applicable Warrant Share Delivery Date shall be deemed extended by one day for each day (or part thereof) until such payment is delivered to the Warrant Agent.

(d)The Warrant Agent shall deposit all funds received by it in payment of the Exercise Price for all Warrants in the account of the Company maintained with the Warrant Agent for such purpose (or to such other account as directed by the Company in writing) and shall advise the Company via email at the end of each day on which notices of exercise are received or funds for the exercise of any Warrant are received of the amount so deposited to its account.

Section 8. Cancellation and Destruction of Warrant Certificates. All Warrant Certificates surrendered for the purpose of exercise, transfer, split up, combination or exchange shall, if surrendered to the Company or to any of its agents, be delivered to the Warrant Agent for cancellation or in canceled form, or, if surrendered to the Warrant Agent, shall be canceled by it, and no Warrant Certificate shall be issued in lieu thereof except as expressly permitted by any of the provisions of this Agreement. The Company shall deliver to the Warrant Agent for cancellation and retirement, and the Warrant Agent shall so cancel and retire, any other Warrant Certificate purchased or acquired by the Company otherwise than upon the exercise thereof. The Warrant Agent shall destroy such canceled Warrant Certificates, subject to any applicable law, rule or regulation requiring the Warrant Agent to retain such canceled certificates or subject to any applicable policies of the Warrant Agent.

Section 9. Certain Representations; Reservation and Availability of Shares of Common Stock or Cash.

(a)This Agreement has been duly authorized, executed and delivered by the Company and, assuming due authorization, execution and delivery hereof by the Warrant Agent, constitutes a valid and legally binding obligation of the Company enforceable against the Company in accordance with its terms, and the Warrants have been duly authorized, executed and issued by the Company and, assuming due authentication thereof by the Warrant Agent pursuant hereto and payment therefor by the Holders as provided in the Registration Statement, constitute valid and legally binding obligations of the Company enforceable against the Company in accordance with their terms and entitled to the benefits hereof; in each case except as enforceability may be limited by bankruptcy, insolvency, reorganization, moratorium and other similar laws relating to or affecting creditors’ rights generally or by general equitable principles (regardless of whether such enforceability is considered in a proceeding in equity or at law).

(b)As of the date hereof, the authorized capital stock of the Company consists of (i) 200,000,000 shares of Common Stock, of which approximately 2,790,396 shares of Common Stock are issued and outstanding as of August 4, 2023, and 5,930,000 shares of Common Stock are reserved for issuance upon exercise of the Warrants, and (ii) 10,000,000 shares of preferred stock, par value $0.0001 per share, of which 3,000 shares of Series C Convertible Preferred Stock and 1,941.2 shares of Series E Convertible Preferred Stock are issued and outstanding as of August 4, 2023. Except as disclosed in the Registration Statement, there are no other outstanding obligations, warrants, options or other rights to subscribe for or purchase from the Company any class of capital stock of the Company.

(c)The Company covenants and agrees that it will cause to be reserved and kept available out of its authorized and unissued shares of Common Stock or its authorized and issued shares of Common Stock held in its treasury, free from preemptive rights, the number of shares of Common Stock that will be sufficient to permit the exercise in full of all outstanding Warrants.

(d)The Warrant Agent will create a special account for the issuance of Common Stock upon the exercise of Warrants.

(e)The Company further covenants and agrees that it will pay when due and payable any and all federal and state transfer taxes and charges which may be payable in respect of the original issuance or delivery of the Warrant Certificates or certificates evidencing Common Stock upon exercise of the Warrants. The Company shall not, however, be required to pay any tax or governmental charge which may be payable in respect of any transfer involved in the transfer or delivery of Warrant Certificates or the issuance or delivery of certificates for Common Stock in a name other than that of the Holder of the Warrant Certificate evidencing Warrants surrendered for exercise or to issue or deliver any certificate for shares of Common Stock upon the exercise of any Warrants until any such tax or governmental charge shall have been paid (any such tax or governmental charge being payable by the Holder of such Warrant Certificate at the time of surrender) or until it has been established to the Company’s reasonable satisfaction that no such tax or governmental charge is due.

Section 10. Common Stock Record Date. Each Person in whose name any certificate for shares of Common Stock is issued (or to whose broker’s account is credited shares of Common Stock through the DWAC system) upon the exercise of Warrants shall for all purposes be deemed to have become the holder of record for the Common Stock represented thereby on, and such certificate shall be dated, the date on which submission of the Notice of Exercise was made, provided that the Warrant Certificate evidencing such Warrant is duly surrendered (but only if required herein) and payment of the Exercise Price (and any applicable transfer taxes) is received on or prior to the Warrant Share Delivery Date; provided, however, that if the date of submission of the Notice of Exercise is a date upon which the Common Stock transfer books of the Company are closed, such Person shall be deemed to have become the record holder of such shares on, and such certificate shall be dated, the next succeeding day on which the Common Stock transfer books of the Company are open.

Section 11. Adjustment of Exercise Price, Number of Shares of Common Stock or Number of the Company Warrants. The Exercise Price, the number of shares covered by each Warrant and the number of Warrants outstanding are subject to adjustment from time to time as provided in Section 3 of the Warrant Certificate. In the event that at any time, as a result of an adjustment made pursuant to Section 3 of the Warrant Certificate, the Holder of any Warrant thereafter exercised shall become entitled to receive any shares of capital stock of the Company other than shares of Common Stock, thereafter the number of such other shares so receivable upon exercise of any Warrant shall be subject to adjustment from time to time in a manner and on terms as nearly equivalent as practicable to the provisions with respect to the shares contained in Section 3 of the Warrant Certificate and the provisions of Sections 7, 11 and 12 of this Agreement with respect to the shares of Common Stock shall apply on like terms to any such other shares. All Warrants originally issued by the Company subsequent to any adjustment made to the Exercise Price pursuant to the Warrant Certificate shall evidence the right to purchase, at the adjusted Exercise Price, the number of shares of Common Stock purchasable from time to time hereunder upon exercise of the Warrants, all subject to further adjustment as provided herein.

Section 12. Certification of Adjusted Exercise Price or Number of Shares of Common Stock. Whenever the Exercise Price or the number of shares of Common Stock issuable upon the exercise of each Warrant is adjusted as provided in Section 11 or 13, the Company shall (a) promptly prepare a certificate setting forth the Exercise Price of each Warrant as so adjusted, and a brief statement of the facts accounting for such adjustment, (b) promptly file with the Warrant Agent and with each transfer agent for the Common Stock a copy of such certificate and (c) instruct the Warrant Agent to send a brief summary thereof to each Holder of a Warrant Certificate.

Section 13. Fractional Shares of Common Stock.

(a)The Company shall not issue fractions of Warrants or distribute Warrant Certificates which evidence fractional Warrants. Whenever any fractional Warrant would otherwise be required to be issued or distributed, the actual issuance or distribution shall reflect a rounding of such fraction to the nearest whole Warrant (rounded down).

(b)The Company shall not issue fractions of shares of Common Stock upon exercise of Warrants or distribute stock certificates which evidence fractional shares of Common Stock. Whenever any fraction of a share of Common Stock would otherwise be required to be issued or distributed, the actual issuance or distribution in respect thereof shall be made in accordance with Section 2(d)(v) of the Warrant Certificate.

Section 14. Conditions of the Warrant Agent’s Obligations. The Warrant Agent accepts its obligations herein set forth upon the terms and conditions hereof, including the following to all of which the Company agrees and to all of which the rights hereunder of the Holders from time to time of the Warrant Certificates shall be subject:

(a)Compensation and Indemnification. The Company agrees promptly to pay the Warrant Agent the compensation detailed on Exhibit 4 hereto for all services rendered by the Warrant Agent and to reimburse the Warrant Agent for reasonable out-of-pocket expenses (including reasonable counsel fees) incurred without gross negligence or willful misconduct finally adjudicated to have been directly caused by the Warrant Agent in connection with the services rendered hereunder by the Warrant Agent. The Company also agrees to indemnify the Warrant Agent for, and to hold it harmless against, any loss, liability or expense incurred without gross negligence, or willful misconduct on the part of the Warrant Agent, finally adjudicated to have been directly caused by Warrant Agent hereunder, including the reasonable costs and expenses of defending against any claim of such liability. The Warrant Agent shall be under no obligation to institute or defend any action, suit, or legal proceeding in connection herewith or to take any other action likely to involve the Warrant Agent in expense, unless first indemnified to the Warrant Agent’s satisfaction. The indemnities provided by this paragraph shall survive the resignation or discharge of the Warrant Agent or the termination of this Agreement. Anything in this Agreement to the contrary notwithstanding, in no event shall the Warrant Agent be liable under or in connection with the Agreement for indirect, special, incidental, punitive or consequential losses or damages of any kind whatsoever, including but not limited to lost profits, whether or not foreseeable, even if the Warrant Agent has been advised of the possibility thereof and regardless of the form of action in which such damages are sought, and the Warrant Agent’s aggregate liability to the Company, or any of the Company’s representatives or agents, under this Section 14(a) or under any other term or provision of this Agreement, whether in contract, tort, or otherwise, is expressly limited to, and shall not exceed in any circumstances, one (1) year’s fees received by the Warrant Agent as fees and charges under this Agreement, but not including reimbursable expenses previously reimbursed to the Warrant Agent by the Company hereunder.

(b)Agent for the Company. In acting under this Warrant Agreement and in connection with the Warrant Certificates, the Warrant Agent is acting solely as agent of the Company and does not assume any obligations or relationship of agency or trust for or with any of the Holders of Warrant Certificates or beneficial owners of Warrants.

(c)Counsel. The Warrant Agent may consult with counsel satisfactory to it, which may include counsel for the Company, and the written advice of such counsel shall be full and complete authorization and protection in respect of any action taken, suffered or omitted by it hereunder in good faith and in accordance with the advice of such counsel.

(d)Documents. The Warrant Agent shall be protected and shall incur no liability for or in respect of any action taken or omitted by it in reliance upon any Warrant Certificate, notice, direction, consent, certificate, affidavit, statement or other paper or document reasonably believed by it to be genuine and to have been presented or signed by the proper parties.

(e)Certain Transactions. The Warrant Agent, and its officers, directors and employees, may become the owner of, or acquire any interest in, Warrants, with the same rights that it or they would have if it were not the Warrant Agent hereunder, and, to the extent permitted by applicable law, it or they may engage or be interested in any financial or other transaction with the Company and may act on, or as depositary, trustee or agent for, any committee or body of Holders of Warrant Securities or other obligations of the Company as freely as if it were not the Warrant Agent hereunder. Nothing in this Warrant Agreement shall be deemed to prevent the Warrant Agent from acting as trustee under any indenture to which the Company is a party.

(f)No Liability for Interest. Unless otherwise agreed with the Company, the Warrant Agent shall have no liability for interest on any monies at any time received by it pursuant to any of the provisions of this Agreement or of the Warrant Certificates.

(g)No Liability for Invalidity. The Warrant Agent shall have no liability with respect to any invalidity of this Agreement or the Warrant Certificates (except as to the Warrant Agent’s countersignature thereon).

(h)No Responsibility for Representations. The Warrant Agent shall not be responsible for any of the recitals or representations herein or in the Warrant Certificate (except as to the Warrant Agent’s countersignature thereon), all of which are made solely by the Company.

(i)No Implied Obligations. The Warrant Agent shall be obligated to perform only such duties as are herein and in the Warrant Certificates specifically set forth and no implied duties or obligations shall be read into this Agreement or the Warrant Certificates against the Warrant Agent. The Warrant Agent shall not be under any obligation to take any action hereunder which may tend to involve it in any expense or liability, the payment of which within a reasonable time is not, in its reasonable opinion, assured to it. The Warrant Agent shall not be accountable or under any duty or responsibility for the use by the Company of any of the Warrant Certificates authenticated by the Warrant Agent and delivered by it to the Company pursuant to this Agreement or for the application by the Company of the proceeds of the Warrant Certificate. The Warrant Agent shall have no duty or responsibility in case of any default by the Company in the performance of its covenants or agreements contained herein or in the Warrant Certificates or in the case of the receipt of any written demand from a Holder of a Warrant Certificate with respect to such default, including, without limiting the generality of the foregoing, any duty or responsibility to initiate or attempt to initiate any proceedings at law.

Section 15. Purchase or Consolidation or Change of Name of Warrant Agent. Any corporation into which the Warrant Agent or any successor Warrant Agent may be merged or with which it may be consolidated, or any corporation resulting from any merger or consolidation to which the Warrant Agent or any successor Warrant Agent shall be party, or any corporation succeeding to the corporate trust business of the Warrant Agent or any successor Warrant Agent, shall be the successor to the Warrant Agent under this Agreement without the execution or filing of any paper or any further act on the part of any of the parties hereto, provided that such corporation would be eligible for appointment as a successor Warrant Agent under the provisions of Section 17. In case at the time such successor Warrant Agent shall succeed to the agency created by this Agreement any of the Warrant Certificates shall have been countersigned but not delivered, any such successor Warrant Agent may adopt the countersignature of the predecessor Warrant Agent and deliver such Warrant Certificates so countersigned; and in case at that time any of the Warrant Certificates shall not have been countersigned, any successor Warrant Agent may countersign such Warrant Certificates either in the name of the predecessor Warrant Agent or in the name of the successor Warrant Agent; and in all such cases such Warrant Certificates shall have the full force provided in the Warrant Certificates and in this Agreement.

In case at any time the name of the Warrant Agent shall be changed and at such time any of the Warrant Certificates shall have been countersigned but not delivered, the Warrant Agent may adopt the countersignature under its prior name and deliver such Warrant Certificates so countersigned; and in case at that time any of the Warrant Certificates shall not have been countersigned, the Warrant Agent may countersign such Warrant Certificates either in its prior name or in its changed name; and in all such cases such Warrant Certificates shall have the full force provided in the Warrant Certificates and in this Agreement.

Section 16. Duties of Warrant Agent. The Warrant Agent undertakes the duties and obligations imposed by this Agreement upon the following terms and conditions, by all of which the Company, by its acceptance hereof, shall be bound:

(a)The Warrant Agent may consult with legal counsel reasonably acceptable to the Company (who may be legal counsel for the Company), and the opinion of such counsel shall be full and complete authorization and protection to the Warrant Agent as to any action taken or omitted by it in good faith and in accordance with such opinion.

(b)Whenever in the performance of its duties under this Agreement the Warrant Agent shall deem it necessary or desirable that any fact or matter be proved or established by the Company prior to taking or suffering any action hereunder, such fact or matter (unless other evidence in respect thereof be herein specifically prescribed) may be deemed to be conclusively proved and established by a certificate signed by the Chief Executive Officer, Chief Financial Officer or Vice President of the Company; and such certificate shall be full authentication to the Warrant Agent for any action taken or suffered in good faith by it under the provisions of this Agreement in reliance upon such certificate.

(c)Subject to the limitation set forth in Section 14, the Warrant Agent shall be liable hereunder only for its own gross negligence or willful misconduct, or for a breach by it of this Agreement.

(d) The Warrant Agent shall not be liable for or by reason of any of the statements of fact or recitals contained in this Agreement or in the Warrant Certificate (except its countersignature thereof) by the Company or be required to verify the same, but all such statements and recitals are and shall be deemed to have been made by the Company only.

(e)The Warrant Agent shall not be under any responsibility in respect of the validity of this Agreement or the execution and delivery hereof (except the due execution hereof by the Warrant Agent) or in respect of the validity or execution of any Warrant Certificate (except its countersignature thereof); nor shall it be responsible for any breach by the Company of any covenant or condition contained in this Agreement or in any Warrant Certificate; nor shall it be responsible for the adjustment of the Exercise Price or the making of any change in the number of shares of Common Stock required under the provisions of Section 11 or 13 or responsible for the manner, method or amount of any such change or the ascertaining of the existence of facts that would require any such adjustment or change (except with respect to the exercise of Warrants evidenced by the Warrant Certificates after actual notice of any adjustment of the Exercise Price); nor shall it by any act hereunder be deemed to make any representation or warranty as to the authorization or reservation of any shares of Common Stock to be issued pursuant to this Agreement or any Warrant Certificate or as to whether any shares of Common Stock will, when issued, be duly authorized, validly issued, fully paid and nonassessable.

(f)Each party hereto agrees that it will perform, execute, acknowledge and deliver or cause to be performed, executed, acknowledged and delivered all such further and other acts, instruments and assurances as may reasonably be required by the other party hereto for the carrying out or performing by any party of the provisions of this Agreement.

(g)The Warrant Agent is hereby authorized to accept instructions with respect to the performance of its duties hereunder from the Chief Executive Officer, President, Chief Financial Officer or Vice President of the Company, and to apply to such officers for advice or instructions in connection with its duties, and it shall not be liable and shall be indemnified and held harmless for any action taken or suffered to be taken by it in good faith in accordance with instructions of any such officer, provided Warrant Agent carries out such instructions without gross negligence or willful misconduct.

(h)The Warrant Agent and any shareholder, director, officer or employee of the Warrant Agent may buy, sell or deal in any of the Warrants or other securities of the Company or become pecuniarily interested in any transaction in which the Company may be interested, or contract with or lend money to the Company or otherwise act as fully and freely as though it were not Warrant Agent under this Agreement. Nothing herein shall preclude the Warrant Agent from acting in any other capacity for the Company or for any other legal entity.

(i)The Warrant Agent may execute and exercise any of the rights or powers hereby vested in it or perform any duty hereunder either itself or by or through its attorney or agents, and the Warrant Agent shall not be answerable or accountable for any act, default, neglect or misconduct of any such attorney or agents or for any loss to the Company resulting from any such act, default, neglect or misconduct, provided reasonable care was exercised in the selection and continued employment thereof.

Section 17. Change of Warrant Agent. The Warrant Agent may resign and be discharged from its duties under this Agreement upon 30 days’ notice in writing sent to the Company and to each transfer agent of the Common Stock, and to the Holders of the Warrant Certificates. The Company may remove the Warrant Agent or any successor Warrant Agent upon 30 days’ notice in writing, sent to the Warrant Agent or successor Warrant Agent, as the case may be, and to each transfer agent of the Common Stock, and to the Holders of the Warrant Certificates. If the Warrant Agent shall resign or be removed or shall otherwise become incapable of acting, the Company shall appoint a successor to the Warrant Agent. If the Company shall fail to make such appointment within a period of 30 days after such removal or after it has been notified in writing of such resignation or incapacity by the resigning or incapacitated Warrant Agent or by the Holder of a Warrant Certificate (who shall, with such notice, submit his Warrant Certificate for inspection by the Company), then the Holder of any Warrant Certificate may apply to any court of competent jurisdiction for the appointment of a new Warrant Agent, provided that, for purposes of this Agreement, the Company shall be deemed to be the Warrant Agent until a new warrant agent is appointed. Any successor Warrant Agent, whether appointed by the Company or by such a court, shall be a corporation organized and doing business under the laws of the United States or of a state thereof, in good standing, which is authorized under such laws to exercise corporate trust powers and is subject to supervision or examination by federal or state authority and which has at the time of its appointment as Warrant Agent a combined capital and surplus of at least $50,000,000. After appointment, the successor Warrant Agent shall be vested with the same powers, rights, duties and responsibilities as if it had been originally named as Warrant Agent without further act or deed; but the predecessor Warrant Agent shall deliver and transfer to the successor Warrant Agent any property at the time held by it hereunder, and execute and deliver any further assurance, conveyance, act or deed necessary for the purpose. Not later than the effective date of any such appointment, the Company shall file notice thereof in writing with the predecessor Warrant Agent and each transfer agent of the Common Stock, and mail a notice thereof in writing to the Holders of the Warrant Certificates. However, failure to give any notice provided for in this Section 17, or any defect therein, shall not affect the legality or validity of the resignation or removal of the Warrant Agent or the appointment of the successor Warrant Agent, as the case may be.

Section 18. Issuance of New Warrant Certificates. Notwithstanding any of the provisions of this Agreement or of the Warrants to the contrary, the Company may, at its option, issue new Warrant Certificates evidencing Warrants in such form as may be approved by its Board of Directors to reflect any adjustment or change in the Exercise Price per share and the number or kind or class of shares of stock or other securities or property purchasable under the several Warrant Certificates made in accordance with the provisions of this Agreement.

Section 19. Notices. Notices or demands authorized by this Agreement to be given or made (i) by the Warrant Agent or by the Holder of any Warrant Certificate to or on the Company, (ii) subject to the provisions of Section 17, by the Company or by the Holder of any Warrant Certificate to or on the Warrant Agent or (iii) by the Company or the Warrant Agent to the Holder of any Warrant Certificate shall be deemed given (a) on the date delivered, if delivered personally, (b) on the first Business Day following the deposit thereof with Federal Express or another recognized overnight courier, if sent by Federal Express or another recognized overnight courier, (c) on the fourth Business Day following the mailing thereof with postage prepaid, if mailed by registered or certified mail (return receipt requested), and (d) the date of transmission, if such notice or communication is delivered via facsimile or email attachment at or prior to 5:30 p.m. (New York City time) on a Business Day and (e) the next Business Day after the date of transmission, if such notice or communication is delivered via facsimile or email attachment on a day that is not a Business Day or later than 5:30 p.m. (New York City time) on any Business Day, in each case to the parties at the following addresses (or at such other address for a party as shall be specified by like notice):

(a)	If to the Company, to:
	Adamis Pharmaceuticals Corporation 11455 El Camino Real, Suite 300 San Diego, CA 92130 Attention: David J. Marguglio  E-mail Address: dmarguglio@adamispharma.com

(b)	If to the Warrant Agent, to: Equiniti Trust Company, LLC 6201 15th Avenue
	Brooklyn, NY 11219  Attention: Corporate Actions – Warrants  E-mail Address: ReorgWarrants@equiniti.com

For any notice delivered by email to be deemed given or made, such notice must be followed by notice sent by overnight courier service to be delivered on the next business day following such email, unless the recipient of such email has acknowledged via return email receipt of such email.

(c) If to the Holder of any Warrant Certificate to the address of such Holder as shown on the registry books of the Company. Any notice required to be delivered by the Company to the Holder of any Warrant may be given by the Warrant Agent on behalf of the Company. Notwithstanding any other provision of this Agreement, where this Agreement provides for notice of any event to a Holder of any Warrant, such notice shall be sufficiently given if given to the Depositary (or its designee) pursuant to the procedures of the Depositary or its designee.

Section 20. Supplements and Amendments.

(a)The Company and the Warrant Agent may from time to time supplement or amend this Agreement without the approval of any Holders of Global Warrants in order to (i) add to the covenants and agreements of the Company for the benefit of the Holders of the Global Warrants, (ii) to surrender any rights or power reserved to or conferred upon the Company in this Agreement, (iii) to cure any ambiguity, (iv) to correct or supplement any provision contained herein which may be defective or inconsistent with any other provisions herein, or (v) to make any other provisions with regard to matters or questions arising hereunder which the Company and the Warrant Agent may deem necessary or desirable, provided that such addition, correction or surrender shall not adversely affect the interests of the Holders of the Global Warrants or Warrant Certificates in any material respect.

(b)In addition to the foregoing, with the consent of Holders of Warrants entitled, upon exercise thereof, to receive not less than a majority of the shares of Common Stock issuable thereunder, the Company and the Warrant Agent may modify this Agreement for the purpose of adding any provisions to or changing in any manner or eliminating any of the provisions of this Warrant Agreement or modifying in any manner the rights of the Holders of the Global Warrants; provided, however, that no modification of the terms (including but not limited to the adjustments described in Section 11) upon which the Warrants are exercisable or the rights of holders of Warrants to receive liquidated damages or other payments in cash from the Company or reducing the percentage required for consent to modification of this Agreement may be made without the consent of the Holder of each outstanding Warrant Certificate affected thereby; provided further, however, that no amendment hereunder shall affect any terms of any Warrant Certificate issued in a Warrant Exchange. As a condition precedent to the Warrant Agent’s execution of any amendment, the Company shall deliver to the Warrant Agent a certificate from a duly authorized officer of the Company that states that the proposed amendment complies with the terms of this Section 20.

Section 21. Successors. All covenants and provisions of this Agreement by or for the benefit of the Company or the Warrant Agent shall bind and inure to the benefit of their respective successors and assigns hereunder.

Section 22. Benefits of this Agreement. Nothing in this Agreement shall be construed to give any Person other than the Company, the Holders of Warrant Certificates and the Warrant Agent any legal or equitable right, remedy or claim under this Agreement. This Agreement shall be for the sole and exclusive benefit of the Company, the Warrant Agent and the Holders of the Warrant Certificates. Notwithstanding anything to the contrary contained herein, to the extent any provision of a Warrant Certificate conflicts with any provision of this Agreement, the provisions of the Warrant Certificate shall govern and be controlling.

Section 23. Governing Law. This Agreement and each Warrant Certificate and Global Warrant issued hereunder shall be governed by, and construed in accordance with, the laws of the State of New York without giving effect to the conflicts of law principles thereof.

Section 24. Counterparts. This Agreement may be executed in any number of counterparts and each of such counterparts shall for all purposes be deemed to be an original, and all such counterparts shall together constitute but one and the same instrument.

Section 25. Captions. The captions of the sections of this Agreement have been inserted for convenience only and shall not control or affect the meaning or construction of any of the provisions hereof.

Section 26. Information. The Company agrees to promptly provide to the Holders of the Warrants any information it provides to the holders of the Common Stock, except to the extent any such information is publicly available on the EDGAR system (or any successor thereof) of the Securities and Exchange Commission.

[Signature page follows]

IN WITNESS WHEREOF, the parties hereto have caused this Agreement to be duly executed as of the day and year first above written.

ADAMIS PHARMACEUTICALS CORPORATION
By:	/s/ Ebrahim Versi
	Name:Ebrahim Versi
	Title: Chief Executive Officer
EQUINITI TRUST COMPANY, LLC
By:	/s/ Michael Legregin
	Name:Michael Legregin
	Title: Senior Vice President

Exhibit 1

Form of Warrant Certificate

Exhibit 2

Form of Warrant Certificate Request Notice

WARRANT CERTIFICATE REQUEST NOTICE

To: EQUINITI TRUST COMPANY, LLC, as Warrant Agent for ADAMIS PHARMACEUTICALS CORPORATION (the “Company”)

The undersigned Holder of Common Stock Purchase Warrants (“Warrants”) in the form of Global Warrants issued by the Company hereby elects to receive a Warrant Certificate evidencing the Warrants held by the Holder as specified below:

1. Name of Holder of Warrants in form of Global Warrants:                                                                         

2. Name of Holder in Warrant Certificate (if different from name of Holder of Warrants in form of Global Warrants):                                    

3. Number of Warrants in name of Holder in form of Global Warrants:                            

4. Number of Warrants for which Warrant Certificate shall be issued:                            

5. Number of Warrants in name of Holder in form of Global Warrants after issuance of Warrant Certificate, if any:                            

6. Warrant Certificate shall be delivered to the following address:

The undersigned hereby acknowledges and agrees that, in connection with this Warrant Exchange and the issuance of the Warrant Certificate, the Holder is deemed to have surrendered the number of Warrants in form of Global Warrants in the name of the Holder equal to the number of Warrants evidenced by the Warrant Certificate.

[SIGNATURE OF HOLDER]

Name of Investing Entity:

Signature of Authorized Signatory of Investing Entity:

Name of Authorized Signatory:

Title of Authorized Signatory:

Date:

Exhibit 3

Form of Global Warrant Request Notice

GLOBAL WARRANT REQUEST NOTICE

To: EQUINITI TRUST COMPANY, LLC, as Warrant Agent for ADAMIS PHARMACEUTICALS CORPORATION (the “Company”)

The undersigned Holder of Common Stock Purchase Warrants (“Warrants”) in the form of Warrants Certificates issued by the Company hereby elects to receive a Global Warrant evidencing the Warrants held by the Holder as specified below:

1. Name of Holder of Warrants in form of Warrant Certificates:                                                                         

2. Name of Holder in Global Warrant (if different from name of Holder of Warrants in form of Warrant Certificates):                                 

3. Number of Warrants in name of Holder in form of Warrant Certificates:                            

4. Number of Warrants for which Global Warrant shall be issued:                            

5. Number of Warrants in name of Holder in form of Warrant Certificates after issuance of Global Warrant, if any:                            

6. Global Warrant shall be delivered to the following address:

The undersigned hereby acknowledges and agrees that, in connection with this Global Warrant Exchange and the issuance of the Global Warrant, the Holder is deemed to have surrendered the number of Warrants in form of Warrant Certificates in the name of the Holder equal to the number of Warrants evidenced by the Global Warrant.

[SIGNATURE OF HOLDER]

Name of Investing Entity:

Signature of Authorized Signatory of Investing Entity:

Name of Authorized Signatory:

Title of Authorized Signatory:

Date:

Exhibit 4

Warrant Agent Fee Schedule

Acceptance Fee for Agreement review	$5,000.00
Monthly Administration Fee: per Warrant Register	$400.00
Per Warrant Exercise	$50.00

EX-10.7

DMK Pharmaceuticals Corporation 10-Q

Exhibit 10.7

EXECUTIVE EMPLOYMENT AGREEMENT

THIS EXECUTIVE EMPLOYMENT AGREEMENT (this “Agreement”) is dated as of October 23, 2023 (the “Effective Date”) and is entered into by and between DMK Pharmaceuticals Inc., a Delaware corporation (the “Company”), and John Dorbin (“Executive”).

1.Employment. The Company hereby employs Executive as General Counsel and Corporate Secretary assigned with responsibilities to do and perform all services, acts, or things necessary or advisable to manage and conduct the business of the Company, subject at all times to the policies set by the Board of Directors of the Company (the “Board”), and to the consent of the Board when required by the terms of this contract. Executive hereby accepts such employment and agrees to devote such time and energies as appropriate to fulfill all responsibilities to the Company. Executive shall be employed on an at-will basis.

2.Compensation. In consideration for all services rendered by Executive under this Agreement, Executive shall receive the compensation described in this Section 2. All such compensation shall be paid subject to appropriate tax withholding and similar deductions.

 (a)          Salary. Executive shall be paid an initial annual salary at a rate of two hundred and thirty thousand dollars ($230,000.00) per annum, payable in substantially equal installments in accordance with the Company’s normal salary and wages practices, but not less than 24 installments annually. The Board (or the Compensation Committee) may, without limitation, in its discretion review Executive’s base salary and may increase base salary from time to time based on such considerations as the Board or a duly authorized committee may deem appropriate.

(b)Executive Benefit and Incentive Compensation Plans. Executive shall be eligible to receive such discretionary cash or equity bonus compensation as the Board of Directors of the Company (or the Compensation Committee thereof) may approve from time to time. In addition, during employment hereunder, Executive shall be eligible to receive those benefits which are routinely made available to executive officers of the Company, including participation in any executive stock ownership plan, profit sharing plan, incentive compensation or bonus plan, retirement plan, Company-provided life insurance, directors and officers (D&O) insurance (naming Executive as an Additional Insured), and similar executive benefit plans maintained or sponsored by the Company, including without limitation eligibility to receive an annual cash bonus under the Company’s Bonus Plan at the target percentage of annual base salary applicable to the general counsel, currently thirty-five percent (35%) of annual base salary (and appropriately and proportionately prorated for the year of the Effective Date based on the number of days that Executive serves as chief general counsel officer during such year). The Company shall not take any action that would materially diminish the aggregate value of Executive’s fringe benefits as they exist as of the Effective Date of this Agreement or as the same may be increased from time to time, except for actions taken with respect to officers or employees generally. Payment of any discretionary or incentive bonus is subject to Executive’s continued employment by the Company through the payment date.

(c)Long-Term Incentive Plan. In addition, as an inducement that you have indicated is material to your willingness to accept this offer and join the Company as an employee, the Company will recommend that the Compensation Committee of the Board of Directors approve the grant to you of a nonqualified stock option to purchase 70,000 shares of common stock, with the option vesting with respect to 1/8 of the total number of shares subject to the option on the 6-month anniversary of the grant date or vesting start date (if different) and thereafter monthly as to 1/48 of the total number of shares subject to the option, provided that you continue to provide services to the Company and that your service as an employee has not terminated, and subject to other terms and conditions to be described in the option grant and related option agreement. The exercise price of any option that may be granted will be equal to the fair market value of the common stock on the date of grant. Any such grant will be made only upon approval of the compensation committee of the Board (or the independent director members of the board of directors).

1

(d)Expense Reimbursement. The Company shall promptly reimburse Executive for all reasonable expenses necessarily incurred during conduct of Company business, and for which adequate documentation is presented, but in no event later than the end of the calendar quarter following the calendar quarter in which the expense was incurred. Furthermore, if any reimbursements or in-kind benefits provided by the Company pursuant to this Agreement would constitute deferred compensation for purposes of Section 409A of the Internal Revenue Code of 1986, as amended (the “Code”), such reimbursements or in-kind benefits shall be subject to the following rules: (i) the amounts to be reimbursed, or the in-kind benefits to be provided, shall be determined pursuant to the terms of the applicable benefit plan, policy or agreement and shall be limited to Executive’s lifetime and the lifetime of Executive’s eligible dependents; (ii) the amounts eligible for reimbursement, or the in-kind benefits provided, during any calendar year may not affect the expenses eligible for reimbursement, or the in-kind benefits provided, in any other calendar year; (iii) any reimbursement of an eligible expense shall be made on or before the earlier of: (A) the last day of the calendar month following the calendar month in which the expense report and any required documentation were submitted, or (B) the last day of the calendar year following the calendar year in which the expense was incurred; and (iv) Executive’s right to an in-kind benefit or reimbursement is not subject to liquidation or exchange for cash or another benefit.

(e)Personal Time Off. Executive shall be entitled to paid time off in accordance with the Company’s policies applicable to executives.

3.             Termination. Executive’s employment may be terminated as follows, with the following effects:

(a)Death. Executive’s employment shall terminate immediately upon the Executive’s death, in which event the Company’s only obligations hereunder shall be to pay all compensation and expense reimbursements owing for services rendered and reasonable business expenses incurred by the Executive prior to the date of his death. If Executive’s employment ceases as a result of death, then all unvested options to purchase common stock, of the Company (“Common Stock”) held by Executive as of the date of Executive’s death shall immediately terminate and become unexercisable and all vested options held by Executive as of the date of Executive’s death shall remain exercisable by the executor of the Executive’s estate until the one (1) year anniversary of the date of cessation of service.

2

(b)Disability. In the event the Executive is disabled from performing his assigned duties under this Agreement due to illness or injury for a period in excess of sixty (60) consecutive days or a period or periods of more than one hundred and twenty (120) days in the aggregate in any twelve (12) month period, the Board, in its sole discretion, may terminate Executive’s employment immediately upon written notice to Executive, in which event the Company’s only obligations hereunder shall be to pay all compensation and expense reimbursements owing for services rendered and reasonable business expenses incurred by the Executive prior to the effective date of termination. If Executive’s employment ceases as a result of disability, then all unvested options to purchase Common Stock held by Executive on the date of Executive’s termination shall immediately terminate and become unexercisable and all vested options held by Executive on the date of Executive’s termination shall remain exercisable until the one (1) year anniversary of the date of cessation of service.

(c)For Cause. The Company may terminate Executive’s employment for Cause immediately upon written notice from the Board to Executive. For purposes of this Agreement, “Cause” means the occurrence of any one or more of the following: (i) Executive’s conviction of or plea of nolo contendere to any felony crime involving fraud, dishonesty or moral turpitude under the laws of the United States or any state thereof; (ii) Executive’s attempted commission of, or participation in, a material fraud or a material act of dishonesty against the Company; (iii) Executive’s intentional, material violation of any contract or agreement between Executive and the Company or of any statutory duty owed to the Company; (iv) Executive’s unauthorized use or disclosure of the Company’s confidential information or trade secrets; or (v) Executive’s gross misconduct provided however that, such termination by the Board shall only be deemed for gross misconduct if: (A) the Board gives the Executive written notice of the intent to terminate for gross misconduct, which notice shall describe such conduct; and (B) the Executive fails to remedy such conduct, if such conduct is capable of being cured, within seven (7) days following the receipt of the written notice. In the event Executive’s employment is terminated for Cause, the Company shall have no further obligations to Executive other than to pay all compensation and expense reimbursements owing for services rendered and reasonable business expenses incurred by Executive prior to the effective date of such termination. If Executive’s employment ceases as a result of a termination for Cause, then all unvested options to purchase Common Stock held by Executive on the date of his termination shall immediately terminate and become unexercisable and all vested options held by Executive on the date of Executive’s termination shall remain exercisable for the period of time provided for in the agreements relating to such options.

3

(d)           Without Cause; Termination for Good Reason. The Company in its sole discretion may terminate Executive’s employment without Cause (as defined above) immediately upon written notice from the Board to Executive. In such event, or if Executive terminates Executive’s employment for Good Reason (as defined below), the Company shall pay to Executive all compensation and expense reimbursements owing for services rendered and reasonable business expenses incurred by Executive prior to the effective date of termination, and provided such termination is a “separation from service” as such term is defined in Code Section 409A(a)(2)(A)(i) and the applicable guidance thereunder, contingent upon Executive’s delivery to the Company of an effective Release and Waiver as provided in Section 3(e) below, the Company shall also provide the following benefits to Executive: (i) severance consisting of continued payment of Executive’s base salary at the rate in effect as of the effective date of termination, less standard deductions and withholdings, for a period of six (6) months following the effective date of termination, to be paid in accordance with the Company’s normal payroll practices (provided, that the initial payment will include a catch-up payment to cover the period between Executive’s termination date and the date such first payment); (ii) to the extent that Executive is eligible to continue medical benefits under the Consolidated Omnibus Budget Reconciliation Act (“COBRA”), and upon timely election by Executive complying with COBRA and to the extent it does not result in a penalty to the Company, the Company will pay the same portion of premiums for such coverage that it had paid for similarly situated employees prior to the termination for the same level of group medical coverage, as in effect as of the day before the effective date of termination, for the period from the effective date of termination through the earliest of: (A) eighteen (18) months after the effective date of termination; (B) the date that Executive becomes eligible for group medical care coverage through other employment; or (C) the end of Executive’s eligibility under COBRA for continuation coverage for medical care. Executive agrees to notify the Company promptly if Executive becomes eligible for group medical care coverage through another employer. Executive also agrees to respond promptly and fully to any reasonable written requests for information (email to suffice) by the Company concerning Executive’s eligibility for such coverage. Notwithstanding the foregoing, if the Company’s making COBRA premium payments under this section of the Agreement would violate any applicable law or result in the imposition of penalties under applicable law, the parties agree to reform this paragraph regarding payment of a portion of COBRA premiums in such manner as is necessary to comply with applicable law; and (iii) immediate acceleration of the vesting of all options to purchase Common Stock granted to Executive prior to the effective date of such termination (the “Options”) such that Executive shall be deemed vested as to the same number of shares as if Executive had continued to be employed by the Company for a period of nine (9) months following the effective date of such termination (and, if any Options have been early exercised by Executive, the reacquisition or repurchase rights held by the Company with respect to the shares of Common Stock subject to such acceleration shall lapse to the same extent), and all vested options held by Executive shall remain exercisable until the one (1) year anniversary of the date of cessation of service (but in all events not beyond the original term of the applicable Options). As a condition to receiving the continuing benefits specified in this Section 3(d), to the maximum extent permitted by applicable law, during the six (6) month period following the Executive’s termination date, Executive shall not engage in any employment or business activity that is directly competitive with the Company’s business activities as of such termination date and Executive shall not induce any employee of the Company to leave the employ of the Company. Each payment under this Section 3(d) shall be considered a separate payment and not one of a series of payments for Code Section 409A. Subject to Section 5, any amount due to Executive pursuant to this Section 3(d) during the 60-day period following Executive’s termination without Cause shall be paid to Executive in a single lump sum on the first payroll date immediately after the end of the 60-day period.

(e)Release and Waiver. As a condition to receiving the benefits specified in Sections 3(d) and 4(b) of this Agreement, Executive must deliver to the Company a waiver and release of claims in the form attached hereto as Exhibit A or in other form reasonably satisfactory to the Company (the “Release and Waiver”) within the time frame set forth therein, but in no event later than sixty (60) days following the Executive’s termination date, and any applicable revocation period must expire during the 60-day period following Executive’s termination as described in Section 3(d) or 4(b) without Executive revoking such release.

4

(f)Voluntary Termination by Executive. Executive may terminate his employment hereunder at any time, whether with or without cause, effective after delivery of written notice of such termination to the Company. Upon voluntary termination pursuant to this Section, the Company shall have no further obligations to Executive other than to pay all compensation and expense reimbursements owing for services rendered and reasonable business expenses incurred by Executive prior to effective date of termination as determined by the Company. If Executive voluntarily terminates Executive’s employment, then all unvested options to purchase Common Stock of the Company held by Executive as of the date of Executive’s termination shall immediately terminate and become unexercisable and all vested options held by Executive as of the date of Executive’s termination shall remain exercisable for the period of time provided for in the agreements relating to such options.

(g)Resignation as a Director. In the event of any termination of employment pursuant to this Agreement, Executive shall be deemed to have resigned voluntarily from the Board and any Committee of the Board, and from the board of directors (and any committee thereof) of all subsidiaries of the Company, upon the effective date of termination or such earlier date as may be agreed in writing between the Company and Executive, and Executive’s signature on this Agreement shall, without the need to any further action, constitute Executive’s resignation from such boards of directors in such circumstance.

(h)Returning Company Documents. In the event of any termination of Executive’s employment hereunder, Executive shall, prior to or on such termination deliver to the Company (and will not maintain possession of or deliver to anyone else) any and all devices, records, data, data bases software, software documentation, laboratory notebooks, notes, reports, proposals, lists, customer lists, correspondence, specifications, drawings, blueprints, sketches, materials, equipment, other documents or property, or reproductions of any of the above aforementioned items belonging to the Company, its successors or assigns.

4.            Change in Control.

(a)Option Acceleration Upon a Change in Control. Effective immediately upon the closing of a Change in Control (as defined below), the vesting of all of the then unvested shares of Common Stock subject to the Options shall be accelerated in full and the Options shall become fully vested and immediately exercisable as to such additional vested shares (and, if any Options have been early exercised by Executive, the reacquisition or repurchase rights held by the Company with respect to the shares of Common Stock subject to such acceleration shall lapse in full, as appropriate).

(b)Restricted Stock Units Acceleration Upon a Change in Control. Effective immediately upon the closing of a Change in Control (as defined below), the vesting of all of the then unvested restricted stock units (“RSUs”) shall be accelerated to the extent provided in the agreements relating to such RSUs.

5

(c)Change in Control. “Change in Control” means the occurrence, in a single transaction or in a series of related transactions, of any one or more of the following events:

(i)any Exchange Act Person (as defined below) becomes the beneficial owner, directly or indirectly, of securities of the Company representing more than fifty percent (50%) of the combined voting power of the Company’s then outstanding securities other than by virtue of a merger, consolidation or similar transaction. Notwithstanding the foregoing, a Change in Control shall not be deemed to occur (A) on account of the acquisition of securities of the Company by an investor, any affiliate thereof or any other Exchange Act Person from the Company in a transaction or series of related transactions the primary purpose of which is to obtain financing for the Company through the issuance of equity securities or (B) solely because the level of beneficial ownership held by any Exchange Act Person (the “Subject Person”) exceeds the designated percentage threshold of the outstanding voting securities as a result of a repurchase or other acquisition of voting securities by the Company reducing the number of shares outstanding, provided that if a Change in Control would occur (but for the operation of this sentence) as a result of the acquisition of voting securities by the Company, and after such share acquisition, the Subject Person becomes the beneficial owner of any additional voting securities that, assuming the repurchase or other acquisition had not occurred, increases the percentage of the then outstanding voting securities beneficially owned by the Subject Person over the designated percentage threshold, then a Change in Control shall be deemed to occur (for purposes of this Section 4(c), “Exchange Act Person” means any natural person, entity or “group” (within the meaning of Section 13(d) or 14(d) of the Securities Exchange Act of 1934, as amended (“Exchange Act”)), except that “Exchange Act Person” shall not include (A) the Company or any subsidiary of the Company, (B) any employee benefit plan of the Company or any subsidiary of the Company or any trustee or other fiduciary holding securities under an employee benefit plan of the Company or any subsidiary of the Company, (C) an underwriter temporarily holding securities pursuant to an offering of such securities, (D) an entity beneficially owned, directly or indirectly, by the stockholders of the Company in substantially the same proportions as their beneficial ownership of stock of the Company; or (E) any natural person, entity or “group” (within the meaning of Section 13(d) or 14(d) of the Exchange Act) that, as of the date of this Agreement, is the beneficial owner, directly or indirectly, of securities of the Company representing more than fifty percent (50%) of the combined voting power of the Company’s then outstanding securities); and provided, that for purposes of this paragraph, the acquisition of additional stock by any one Exchange Act Person who is considered to own more than fifty percent (50%) of the total voting power of the stock of the Company will not be considered a Change in Control; there is consummated a merger, consolidation or similar transaction involving (directly or indirectly) the Company and, immediately after the consummation of such merger, consolidation or similar transaction, the stockholders of the Company immediately prior thereto do not beneficially own, directly or indirectly, either (A) outstanding voting securities representing more than fifty percent (50%) of the combined outstanding voting power of the surviving entity in such merger, consolidation or similar transaction or (B) more than fifty percent (50%) of the combined outstanding voting power of the parent of the surviving entity in such merger, consolidation or similar transaction, in each case in substantially the same proportions relative to each other as their beneficial ownership of the outstanding voting securities of the Company immediately prior to such transaction;

(ii)the stockholders of the Company approve or the Board approves a plan of complete dissolution or liquidation of the Company, or a complete dissolution or liquidation of the Company shall otherwise occur, except for a liquidation into a parent corporation;

6

(iii)a change in the ownership of a substantial portion of the Company’s assets which occurs on the date that any Exchange Act Person acquires (or has acquired during the 12 month period ending on the date of the most recent acquisition by such Exchange Act Person), by means of a sale, lease, exclusive license or other disposition, all or substantially all of the consolidated assets of the Company and its subsidiaries (and which have a total gross fair market value equal to or more than 50% of the total gross fair market value of all of the assets of the Company immediately prior to such acquisition or acquisitions), other than a sale, lease, license or other disposition of all or substantially all of the consolidated assets of the Company and its subsidiaries to an entity, more than fifty percent (50%) of the combined voting power of the voting securities of which are beneficially owned by stockholders of the Company in substantially the same proportions relative to each other as their beneficial ownership of the outstanding voting securities of the Company immediately prior to such sale, lease, license or other disposition; provided, that for purposes of this subparagraph, the following will not constitute a change in the ownership of a substantial portion of the Company’s assets: (A) a transfer to an entity that is controlled by the Company’s stockholders immediately after the transfer, or (B) a transfer of assets by the Company to: (1) a stockholder of the Company (immediately before the asset transfer) in exchange for or with respect to the Company’s stock, (2) an entity, fifty percent (50%) or more of the total value or voting power of which is owned, directly or indirectly, by the Company, (3) an Exchange Act Person, that owns, directly or indirectly, fifty percent (50%) or more of the total value or voting power of all the outstanding stock of the Company, or (4) an entity, at least fifty percent (50%) of the total value or voting power of which is owned, directly or indirectly, by an Exchange Act Person described in this subparagraph. For purposes of this subparagraph, gross fair market value means the value of the assets of the Company, or the value of the assets being disposed of, determined without regard to any liabilities associated with such assets; or

(iv)a change in the effective control of the Company which occurs on the date that individuals who, on the date of this Agreement, are members of the Board (the “Incumbent Board”) cease for any reason to constitute during any 12-month period at least a majority of the members of the Board; (provided, however, that if the appointment or election (or nomination for election) of any new Board member was approved or recommended by a majority vote of the members of the Incumbent Board then still in office, such new member shall, for purposes of the Plan, be considered as a member of the Incumbent Board). For purposes of this subparagraph, if any Exchange Act Person is considered to be in effective control of the Company, the acquisition of additional control of the Company by the same Exchange Act Person will not be considered a Change of Control;

Notwithstanding the foregoing, a transaction will not be deemed a Change of Control unless the transaction qualifies as a change in control event within the meaning of Code Section 409A, as it has been and may be amended from time to time, and any proposed or final Treasury Regulations and Internal Revenue Service guidance that has been promulgated or may be promulgated thereunder from time to time.

(d)          Good Reason. “Good Reason” for the Executive to terminate the Executive’s employment hereunder shall mean the occurrence of any of the following events without the Executive’s consent:

(i)a material adverse change in the nature of the Executive’s authority, duties, direct reports, or responsibilities, as they exist on the Effective Date of this Agreement;

7

(ii)a material adverse change in the Executive’s reporting level requiring that the Executive report to a corporate officer or executive other than the chief executive officer;

(iii)a material reduction by the Company of the Executive’s base salary as initially set forth herein or as the same may be increased from time to time, except for across-the-board salary reductions based on the Company’s financial performance similarly affecting all or substantially all senior officers of the Company and does not exceed 15% of Executive’s base salary.

Provided however that, such termination by the Executive shall only be deemed for Good Reason pursuant to the foregoing definition if: (i) the Executive gives the Company written notice of the intent to terminate for Good Reason within thirty (30) days following reasonable knowledge by the Executive of the condition(s) that the Executive believes constitutes Good Reason, which notice shall describe such condition(s); (ii) the Company fails to remedy such condition(s), if such condition(s) is/are capable of being cured, within thirty (30) days following receipt of the written notice (the “Cure Period”); and (iii) the Executive terminates employment within thirty (30) days following the end of the Cure Period.

5.       Application of Internal Revenue Code Section 409A. (a) Notwithstanding anything to the contrary contained in this Agreement, if any payment or reimbursement, or the provision of any benefit under this Agreement that is paid or provided upon Executive’s “separation from service” with the Company within the meaning of Code Section 409A(a)(2)(A)(i) would constitute a “deferral of compensation” under Code Section 409A and Executive is a “specified employee” (as determined pursuant to procedures adopted by the Company in compliance with Code Section 409A) on the date of Executive’s “separation from service” with the Company within the meaning of Code Section 409A(a)(2)(A)(i), Executive will receive payment or reimbursement of such amounts or the provision of such benefits upon the earlier of (i) the first day of the seventh (7^th) month following the date of Executive’s “separation from service” with the Company within the meaning of Section 409A(a)(2)(A)(i) of the Code or (ii) Executive’s death.

(b)           To the extent applicable, it is intended that this Agreement comply with the provisions of Code Section 409A, so that the income inclusion provisions of Code Section 409A(a)(1) do not apply to Executive. This Agreement shall be administered in a manner consistent with this intent. Reference to Code Section 409A is to Section 409A of the Internal Revenue Code of 1986, as amended, and will also include any regulations or any other formal guidance promulgated with respect to such Section by the U.S. Department of the Treasury or the Internal Revenue Service.

6.            Code Section 280G. If any payment or benefit Executive would receive pursuant to a Corporate Transaction from the Company or otherwise (“Payment”) would (i) constitute a “parachute payment” within the meaning of Code Section 280G, and (ii) but for this sentence, be subject to the excise tax imposed by Code Section 4999 (the “Excise Tax”), then the Company shall cause to be determined, before any amounts of the Payment are paid to Executive, which of the following two amounts would maximize Executive’s after-tax proceeds: (i) payment in full of the entire amount of the Payment (a “Full Payment”), or (ii) payment of only a part of the Payment so that Executive receives the largest payment possible without the imposition of the Excise Tax (a “Reduced Payment”), whichever amount results in Executive’s receipt, on an after-tax basis, of the greater amount of the Payment notwithstanding that all or some portion of the Payment may be subject to the Excise Tax. For purposes of determining whether to make a Full Payment or a Reduced Payment, the Company shall cause to be taken into account all applicable federal, state and local income and employment taxes and the Excise Tax (all computed at the highest applicable marginal rate, net of the maximum reduction in federal income taxes which could be obtained from a deduction of such state and local taxes). If a Reduced Payment is made, (i) the Payment shall be paid only to the extent permitted under the Reduced Payment alternative, and Executive shall have no rights to any additional payments and/or benefits constituting the Payment, and (ii) reduction in payments and/or benefits shall occur in the following order: reduction of cash payments, cancellation of accelerated vesting of stock awards, and reduction of other benefits. In the event that acceleration of compensation from Executive’s equity awards is to be reduced, such acceleration of vesting shall be canceled in the reverse order of the date of grant unless Executive elects in writing a different order for cancellation.

8

The independent registered public accounting firm engaged by the Company for general audit purposes as of the day prior to the effective date of the Corporate Transaction shall make all determinations required to be made under this Section 6. If the independent registered public accounting firm so engaged by the Company is serving as accountant or auditor for the individual, entity or group effecting the Corporate Transaction, the Company shall appoint a different nationally recognized independent registered public accounting firm to make the determinations required hereunder. The Company shall bear all expenses with respect to the determinations by such independent registered public accounting firm required to be made hereunder. The independent registered public accounting firm engaged to make the determinations hereunder shall provide its calculations, together with detailed supporting documentation, to the Company and Executive within fifteen (15) calendar days after the date on which Executive’s right to a Payment is triggered (if requested at that time by the Company or Executive) or at such other time as requested by the Company. If the independent registered public accounting firm determines that no Excise Tax is payable with respect to a Payment, either before or after the application of the Reduced Amount, it shall furnish the Company and Executive with an opinion reasonably acceptable to Executive that no Excise Tax will be imposed with respect to such Payment. Any good faith determinations of the accounting firm made hereunder shall be final, binding and conclusive upon the Company and Executive.

7.Conflict of Interest. During the Employment Period, Executive shall devote such time and energies as appropriate to fulfill all responsibilities to the Company in the capacity set forth in Section 1. Executive shall be free to pursue business activities which do not interfere with the performance of his duties and responsibilities under this Agreement; provided, however, Executive shall not engage in any outside business activity which involves actual or potential competition with the business of the Company, except with the written consent of the Board.

8.Executive Benefit Plans. All of the Executive benefit plans referred to or contemplated by this Agreement shall be governed solely by the terms of the underlying plan documents and applicable law. Nothing in this Agreement shall impair the Company’s right to amend, modify, replace, and terminate any and all such plans in its sole discretion as provided by law. This Agreement is for the sole benefit of Executive and the Company, and is not intended to create an Executive benefit plan or to modify existing terms of existing plans.

9

9.Assignment. This Agreement may not be assigned by Executive. This Agreement shall bind and inure to the benefit of the Company’s successors and assigns, as well as Executive’s heirs, executors, administrators, and legal representatives. The Company shall obtain from any successor, before the succession takes place, an agreement to assume the obligations and perform all of the terms and conditions of this Agreement.

10.Notices. All notices required by this Agreement may be delivered by first class mail at the following addresses:

To Company:

DMK Pharmaceuticals, Inc.
11682 El Camino Real, Suite 300
San Diego, CA 92130

To Executive:

John Dorbin

[at the address for Executive contained in the Company’s records]

11.Amendment. This Agreement may be modified only by written agreement signed by both the Company and Executive.

12.Choice of Law; Arbitration. This Agreement shall be governed by the laws of the State of California, without regard to choice of law principles. To provide a mechanism for rapid and economical dispute resolution, Executive and the Company agree that any and all disputes, claims, or causes of action, in law or in equity, arising from or relating to this Agreement (including the Release and Waiver) and its enforcement, performance, breach or interpretation, will be resolved, to the fullest extent permitted by law, by final, binding and confidential arbitration before a single arbitrator held in San Diego, California and conducted by JAMS, under its then-existing employment rules and procedures. The parties shall be entitled to conduct adequate discovery, and they may obtain all remedies available to the parties as if the matter had been tried in court. The arbitrator shall issue a written decision which specifies the findings of fact and conclusions of law on which the arbitrator’s decision is based. Judgment upon the award rendered by the arbitrator may be entered by any court having jurisdiction thereof. Unless a different allocation is required by law, the parties shall each pay one-half (1/2) of all fees and costs of the arbitration. Punitive damages shall not be awarded. Unless otherwise required by law, the arbitrator will award reasonable attorney fees and expenses (including reimbursement of the assigned arbitration costs) to the prevailing party. Nothing in this Section or in this Agreement is intended to prevent either Executive or the Company from obtaining injunctive relief in a court of competent jurisdiction to prevent irreparable harm pending the conclusion of any such arbitration. Notwithstanding the above, both Executive and the Company retain the right to seek or obtain, and shall not be prohibited, limited or in any other way restricted from seeking or obtaining, equitable relief from a court having jurisdiction over the parties in order to enforce the non-solicitation and noncompetition provisions of this Agreement or any disputes or claims relating to or arising out of the misuse or misappropriation of the Company’s intellectual property.

10

13.Partial Invalidity. In the event any provision of this Agreement is void or unenforceable, the remaining provisions shall continue in full force and effect.

14.Waiver. No waiver of any breach of this Agreement shall constitute a waiver of any subsequent breach.

15.Complete Agreement. As of the Effective Date, this Agreement, together with the stock option agreements and equity incentive plans governing the Options, constitutes the entire agreement between the parties in connection with the subject matter hereof and supersedes any and all prior or contemporaneous oral and written agreements or understandings between the parties, including the Prior Agreement.

16.Headings. Headings in this Agreement are included herein for convenience of reference only and shall not constitute a part of this Agreement for any other purpose.

17.Miscellaneous. Executive acknowledges full understanding of the matters set forth herein and the obligations undertaken upon the execution hereof.

18.Recoupment of Compensation. Executive agrees that the compensation and benefits provided by the Company under this Agreement or otherwise, including any cash compensation or equity compensation and including incentive compensation, is subject to recoupment or clawback by the Company as may be required or provided by applicable federal or state law, rule or regulation, including without limitation The Dodd–Frank Wall Street Reform and Consumer Protection Act and any implementing regulations thereunder, and/or any recoupment or clawback rules, regulations or policies adopted by the Securities and Exchange Commission or the listing standards of any stock market, stock exchange, association or trading platform on which the Company’s Common Stock is listed or traded, and/or any recoupment, clawback or compensation recovery policy that the Company is required to adopt or may adopt (whether or not required by applicable law), in addition to any other remedies that may be available under such policies, requirements or laws (including cancellation of outstanding cash or equity awards and the recoupment of any gains realized with respect to awards); and Executive agrees to comply with any such policies that the Company may adopt or may be required to adopt. Executive agrees that no such recovery of compensation, including pursuant to such a recoupment or clawback policy, will be an event giving rise to a right to resign for “Good Reason” under this Agreement.

[REMAINDER OF PAGE INTENTIONALLY LEFT BLANK]

11

IN WITNESS WHEREOF, the parties have executed this EXECUTIVE EMPLOYMENT AGREEMENT as of the date first written above.

DMK PHARMACEUTICALS CORPORATION

/s/ Eboo Versi

Name: Eboo Versi, MD, PhD

Title: CEO, Chairman of the Board

EXECUTIVE

/s/ John Dorbin

John Dorbin

12

EXHIBIT A

RELEASE AND WAIVER OF CLAIMS

In consideration of the payments and other benefits set forth in the Executive Employment Agreement dated as of [DATE] (the “Employment Agreement”), to which this form is attached, I, John Dorbin, hereby furnish DMK Pharmaceuticals, Inc. (the “Company”), with the following release and waiver (“Release and Waiver”). Terms used herein but not otherwise defined shall have the meanings given to them in the Employment Agreement.

1.        In exchange for the consideration provided to me by the Employment Agreement that I am not otherwise entitled to receive, I hereby generally and completely release and forever discharge the Company and its present, former and future directors, officers, executives, shareholders, partners, agents, attorneys, predecessors, successors, parent and subsidiary entities, insurers, affiliates, and assigns (collectively, the “Released Parties”) from any and all claims, suits, controversies, actions, causes of action, cross-claims, counter claims, demands, debts, damages of any kind, claims for costs and attorneys’ fees, or other liabilities and obligations of any nature whatsoever, both past and present (through the date that this Release and Waiver becomes effective and enforceable) and whether known or unknown, suspected or claimed, fixed or contingent, and whether in law or in equity, that I, my spouse, or any of my heirs, executors, administrators or assigns may have, or may ever have had, against any of the Released Parties, that are predicted upon, arise out of or are in any way related to, directly or indirectly, events, acts, conduct, or omissions occurring prior to my signing this Release and Waiver. This general release includes, but is not limited to all claims arising out of or relating in any way to: (1) my employment with the Company or the termination of that employment; (2) my compensation or benefits from the Company, including, but not limited to, salary, bonuses, commissions, vacation pay, expense reimbursements, severance pay, fringe benefits, stock, stock options, or any other ownership interests in the Company; (3) breach of contract, wrongful termination or retaliatory discharge, breach of the implied covenant of good faith and fair dealing, discrimination, harassment, improper wage payment, any other unlawful employment practice under federal, state, municipal, local, or foreign law, or arising under any other federal, state, municipal, local, or foreign law, rule, or regulation, including but not limited to civil rights laws, wage-hour, wage-payment, pension, or labor laws, rules, regulations, constitutions, or ordinances; (4) any and all tort claims, including, but not limited to, claims for fraud, defamation, emotional distress, and discharge in violation of public policy; and (5) any and all federal, state, and local statutory claims, including, but not limited to, claims for discrimination, harassment, retaliation, attorneys’ fees, or other claims arising under: the federal Civil Rights Act of 1964 (as amended) (including Title VII thereunder); the Civil Rights Act of 1991; the federal Age Discrimination in Employment Act of 1967 (as amended) (“ADEA”); the Older Workers Benefit Protection Act; the Civil Rights Acts of 1966 and 1967; the Fair Labor Standards Act; the Equal Pay Act of 1963, as amended; the Americans with Disabilities Act; the Americans with Disabilities Act Amendments Act of 2008; the Family and Medical Leave Act of 1993; the Occupational Safety and Health Act; the Fair Credit Reporting Act; the Labor Management Relations Act; the Worker Adjustment Retraining and Notification Act; the Employee Retirement Income Security Act of 1974; the Sarbanes-Oxley Act of 2002; any applicable Executive Order Programs; the Consolidated Omnibus Budget Reconciliation Act; or their state or local counterparts, including without limitation the California Fair Employment and Housing Act (as amended), the California Worker Adjustment and Retraining Notification Act, the California Family Rights Act, the California Labor Code and Industrial Welfare Commission Orders, the California Constitution, the California Family Rights Act, and the California Business and Professions Code; (6) any and all federal, state and local claims under any other federal, state or local law, regulation or ordinance; and (7) any and all claims arising under any policies, practices or procedures of the Company (collectively, “Claims” or the “Released Claims”). I agree that I hereby waive all rights to sue or obtain equitable, remedial or punitive relief from any or all Released Parties of any kind whatsoever in respect of any Claim, including, without limitation, reinstatement, back pay, and any form of injunctive relief. I acknowledge and agree that my separation from employment with the Company shall not serve as the basis for any claim or action (including, without limitation, any claim under the ADEA). The Released Parties are intended to be third-party beneficiaries of this Release and Waiver, and this Release and Waiver may be enforced by each of them in accordance with the terms hereof in respect of the rights granted to such Released Parties hereunder.

13

2.       I also expressly acknowledge that this Release and Waiver is also intended to include in its effect, without limitation, any and all claims which I do not know of or suspect may exist in my favor at the time of execution of this Release and Waiver, and that this Release and Waiver will also extinguish any such claim. I acknowledge that this is a full, complete and final general release of any and all claims described as aforesaid, and that I agree that it shall apply to all unknown, unanticipated, unsuspected and undisclosed claims, demands, liabilities, actions or causes of action, in law, equity or otherwise, as well as those which are now known, anticipated, suspected or disclosed. This release includes a release under § 1542 of the Civil Code of the State of California. I acknowledge that I have read and understand Section 1542 of the California Civil Code which reads as follows: “A general release does not extend to claims which the creditor or releasing party does not know or suspect to exist in his or her favor at the time of executing the release and that, if known by him or her, would have materially affected his or her settlement with the debtor or released party.” I hereby expressly waive and relinquish all rights and benefits under that section and any law of any jurisdiction of similar effect with respect to any claims I may have against the Company. I represent that I am not aware of any claim by me against any Released Party of the type described in Section 1 above. I acknowledge that I may hereafter discover claims or facts in addition to or different than those which I now know or believe to exist with respect to the subject matter of this Release and Waiver and which, if known or suspected at the time of entering into this Release and Waiver, may have materially affected this Release and Waiver and my decision to enter into it. In signing this Release and Waiver, I acknowledge and intend that it shall be effective as a bar to each and every one of the Claims hereinabove mentioned or implied. I expressly consent that this Release and Waiver shall be given full force and effect according to each and all of its terms and provisions. I acknowledge and agree that this waiver is an essential and material term of this Release and Waiver and that without such waiver the Company would not have agreed to the terms of the Employment Agreement. I further agree that in the event I should bring a claim seeking damages against the Company, or in the event I should seek to recover against the Company in any claim brought by a Government Agency on my behalf, this Release and Waiver shall serve as a complete defense to such Claims to the maximum extent permitted by law.

14

3.By signing this Release and Waiver, I represent and agree that I have read it carefully, I understand all of its terms and know that I am giving up important rights, including but not limited to, rights under the ADEA, Title VII of the Civil Rights Act of 1964, as amended, the Equal Pay Act of 1963, the Americans With Disabilities Act of 1990, and the Employee Retirement Income Security Act of 1974, as amended. I acknowledge that, among other rights, I am waiving and releasing any rights I may have under ADEA, that this Release and Waiver is knowing and voluntary, and that the consideration given for this Release and Waiver is in addition to anything of value to which I was already entitled as an executive of the Company. I understand that any severance payments or benefits paid or granted to me under the Employment Agreement represent, in part, consideration for signing this Release and Waiver and are not salary, wages or benefits to which I was already entitled. I further acknowledge that I have been advised, as required by the Older Workers Benefit Protection Act, that: (a) the release and waiver granted herein does not relate to claims under the ADEA which may arise after this Release and Waiver is executed; (b) I should consult with an attorney prior to executing this Release and Waiver and have done so or, after careful reading and consideration, I have chosen not to do so of my own volition; (c) I have been given at least 21 days (or, if required by applicable law, 45 days) to consider this Release and Waiver and whether or not to sign (although I may choose voluntarily to execute this Release and Waiver earlier, and if I decide to shorten this time period for signing, my decision was knowing and voluntary), and that any changes made since my receipt of this Release and Waiver are not material, were made at my request, and whether or not material in all events will not restart the required 21 (or 45) day period; (d) I have seven (7) days following the execution of this Release and Waiver to revoke my consent to this Release and Waiver; and (e) this Release and Waiver shall not be effective until the seven (7) day revocation period has expired unexercised and no benefits will be paid unless and until this Release and Waiver has become effective. If the last day of such 7-day revocation period falls on a Saturday, Sunday, or holiday, then the last day of the revocation period shall be deemed to be the next business day. Any such revocation must be in writing and received by the Company’s Corporate Secretary (or, if I am the Corporate Secretary, then Chief Financial Officer) on or before such 7^th day in order to be effective. In the event that this Release and Waiver is requested in connection with an exit incentive or other employment termination program offered to a group or class of employees, I have 45 days to consider this Release and Waiver and I shall be provided with the information required by 29 U.S.C. Section 626 (f)(1)(H). I understand and agree that I will not receive certain of the payments and benefits specified in the Employment Agreement unless I execute this Release and Waiver and do not revoke this Release and Waiver within the time period permitted hereafter. Such payments and benefits will not be considered compensation for purposes of any employee benefit plan, program, policy or arrangement maintained or hereafter established by the Company or its affiliates.

15

4.I represent and warrant that: (a) I have made no assignment or transfer of any right, claim, demand, cause of action, or other matter covered by any of the Released Claims and will not make any such assignment or transfer; (b) I am the lawful owner of all Claims released through this Release and Waiver; (c) I have not commenced, maintained, or prosecuted, any action, claim, lawsuit, grievance, complaint, or proceeding of any kind against any of the Released Parties in any court or arbitral forum, or before any administrative or investigative body or agency; and to the extent that I have, except for claims that cannot by law be released, I agree that I shall promptly withdraw or dismiss, and shall undertake all measures necessary to effectuate the withdrawal or dismissal of, any such action, claim, lawsuit, grievance, complaint, or proceeding, with prejudice. In the event that any such action, claim, lawsuit, grievance, complaint, or proceeding is commenced by me or on my behalf, I hereby waive any right to compensation, recovery, monetary relief, damages, settlement, or other individual relief. I acknowledge and understand that I am waiving any right I may have to sue any of the Released Parties for any of the claims I have released, or to receive any compensation, recovery, monetary relief, damages, settlement, or other individual relief arising as a result of any action, claim, lawsuit, grievance, complaint, or proceeding commenced by anyone else against any of the Released Parties.

5.I also acknowledge and affirm that, except for the severance payments and benefits set forth in the Employment Agreement to be paid after the date of this Release and waiver, I have been fully paid all wages and other compensation owed to me by the Company, including all overtime wages, incentive compensation, expense reimbursement payments, equity compensation, separation compensation, severance compensation, bonuses, and commissions, and to the extent I ever claim or allege that I have not been fully paid all such wages and other compensation, I hereby waive and forfeit, through this Release and Waiver, my entitlement to any and all such wages and other compensation. To the extent any other compensation and/or benefits other than under this Release and Waiver may exist or be claimed to exist for or by me, this Release and Waiver and the consideration hereunder expressly are agreed to and shall constitute an accord and satisfaction of any and all such claims and/or obligations. In addition, I also acknowledge and affirm that, as of the date of my execution of this Release and Waiver, I have been afforded all required periods of family, medical, and other leave, as well as any right to reinstatement upon conclusion of any leave taken. I further acknowledge and affirm that I have no known workplace injuries or occupational diseases.

16

Notwithstanding the above or anything else in this Release and Waiver, nothing in this Release and Waiver shall be deemed to require the waiver or release of any claim that may not be released or waived under applicable federal or state law. I acknowledge that I am not waiving and am not being required to waive any right that cannot be waived under law, including the right to file or initiate a charge, claim, or complaint of discrimination or any other unlawful employment practice that cannot legally be waived, or to communicate with any federal, state, or local government agency charged with the enforcement and/or investigation of claims of unlawful conduct, including but not necessarily limited to the California Department of Fair Housing and Employment or the U.S. Equal Employment Opportunity Commission and any other state or city fair employment practices agency; provided, however, that I disclaim and waive any right to share or participate in any monetary award resulting from the prosecution of such charge or investigation or proceeding. Additionally, I am not waiving (i) any right to the severance benefits to which I am entitled under the Employment Agreement, (ii) any claim relating to directors’ and officers’ liability insurance coverage or any right of indemnification under the Company’s organizational documents or otherwise, (iii) claims under the Consolidated Omnibus Budget Reconciliation Act of 1985, as amended, (iv) claims relating to any outstanding equity-based award on the date of termination in accordance with the terms thereof, (v) claims for the enforcement of this Release and Waiver, (vi) claims that arise after the date of this Release and Waiver, or (vii) any rights or claims I may have to receive workers’ compensation or unemployment insurance benefits or under California Labor Code section 2802. Further, nothing in this Release and Waiver shall prevent me (or my attorneys) from exercising my rights under the Older Workers Benefit Protection Act to challenge the validity of my above waiver of claims under the Age Discrimination in Employment Act of 1967, nor does this Release and Waiver impose any condition precedent, penalties, or costs for doing so, unless specifically authorized by applicable law. In addition, I understand that nothing in this Release and Waiver is intended to or shall prevent, impede or interfere with my rights, to the extent non-waivable, to file a charge or complaint with the Equal Employment Opportunity Commission, the Occupational Safety and Health Review Commission (“OSH”), the National Labor Relations Board, the Securities and Exchange Commission (“SEC”), the Department of Justice, any other federal agency, labor board or commission, any state or local fair employment practices agency, the Financial Industry Regulatory Authority, any other self regulatory organization or any governmental entity or any other state or local agency, labor board or commission (collectively, the “Government Agencies”). I also understand that nothing in this Release and Waiver, my Employment Agreement or other written agreement between the Company and me limits, interferes with or restricts my ability, without prior authorization from or notification to the Company, to provide information and/or documents to or otherwise communicate with any Government Agencies, participate in or cooperate with any investigation or proceeding conducted by any Government Agency, communicate directly with, respond to any inquiry from, testify or otherwise participate in any proceeding that may be conducted by any Government Agencies concerning the Company’s past or future conduct, to report possible violations of federal, state or local law or regulation to any Government Agency, or engage in any activities now or in the future that are protected under whistleblower provisions of federal, state or local law or regulation, without notice to the Company, including regarding this Release and Waiver or its underlying facts or circumstances. My right and ability to engage and participate in the activities described in this paragraph shall not be limited or abridged, in any way, by any term, condition, or provision of, or obligation imposed by, this Release and Waiver. To the extent that any other term or condition of the Release and Waiver is inconsistent with this paragraph, this paragraph shall supersede and invalidate such term or condition to the extent necessary to give effect to the provisions of this paragraph. Notwithstanding the foregoing, I understand that the waivers and releases in this Release and Waiver shall be construed and enforced to the maximum extent permitted by law. I agree that notwithstanding the foregoing, I am completely waiving any right to recover money, receive any individual relief, share in or participate in any monetary award in connection with or resulting from the prosecution of any charge, investigation or proceeding by any Government Agency, and if I am awarded individual relief and/or monetary damages in connection therewith, I hereby unconditionally assign to the Company, and agree to undertake any and all measures necessary to effectuate such assignment of, any right or interest that I may have to receive such individual relief and/or monetary damages. Notwithstanding the foregoing, this Release and Waiver does not limit my right to receive an award for information provided to the SEC, and this Agreement does not limit the right to receive and fully retain a monetary reward from any government-administered whistleblower award or other incentive program for providing information directly to any Government Agencies (such as those administered by the OSH or the SEC). I acknowledge that any non-disclosure provision in this Release and Waiver or in the Employment Agreement or other written agreement between the Company and me does not prohibit or restrict me (or my attorney from responding to any inquiry about this Release and Waiver or its underlying facts and circumstances by the SEC, the Financial Industry Regulatory Authority (FINRA), any other self regulatory organization or any governmental entity.

17

6.I agree that if I violate this Release and Waiver by suing the Company or the other Released Parties, I will pay all costs and expenses of defending against the suit incurred by the Released Parties, including reasonable attorneys’ fees.

7.Whenever possible, each provision of this Release and Waiver shall be interpreted in, such manner as to be effective and valid under applicable law, but if any provision of this Release and Waiver is held to be invalid, illegal or unenforceable in any respect under any applicable law or rule in any jurisdiction, such invalidity, illegality or unenforceability shall not affect any other provision or any other jurisdiction, but this Release and Waiver shall be reformed, construed and enforced in such jurisdiction as if such invalid, illegal or unenforceable provision had never been contained herein.

8.Without limitation of any of my obligations set forth in any agreements or documents, or sections thereof, that survive the execution of this Release and Waiver, I agree that, prior to my execution of this Release and Waiver, I have returned all of the Company’s property and equipment in my possession or under my control, including but not limited to any and all computers, laptops, computer hardware or software, cell phones, iPads, credit cards, keys, manuals, notebooks, financial statements, reports, passwords, company IDs, and any other property of the Company, including any and all copies of Company documents, materials, and information not specifically addressed and relating to you.

9.I agree that neither this Release and Waiver, nor the furnishing of the consideration for this Release and Waiver, shall be deemed or construed at any time to be an admission by the Company, any Released Party or me of any improper or unlawful conduct. In fact, I understand that the Released Parties specifically deny that they have violated any federal, state or local law or ordinance or any right or obligation that they owe or might have owed to me at any time and maintain that they have at all times treated me in a fair, lawful, nondiscriminatory and nonretaliatory manner.

10.Except as provided for in and subject to Section 6 of this Release and Waiver, I agree that I will not make any false, negative, or disparaging comments about, and will refrain from directly or indirectly making any comments or engaging in publicity or any other action or activity which reflects adversely upon, the Company or any of the Released Parties. This non-disparagement provision applies to comments made verbally, in writing, electronically, or by any other means, including but not limited to blogs, postings, message boards, texts, video, or audio files, and all other forms of communication. For the avoidance of doubt, nothing in this Release and Waiver prevents me from discussing or disclosing information about unlawful acts in the workplace, such as harassment or discrimination or any other conduct that I have reason to believe is unlawful. This paragraph shall be in addition to, and shall not be considered or construed as superseding or in conflict with, any other obligation, whether contractual or otherwise, that I owe or may owe to the Company. For the avoidance of doubt, the parties further acknowledge and agree that this Section is subject to the terms, conditions, and exceptions set forth in Section 6 above. Nothing in this Agreement prevents me from discussing or disclosing information about unlawful acts in the workplace, such as harassment, discrimination, or any other conduct that I have reason to believe is unlawful or shall otherwise operate to prevent me from exercising rights under Section 7 of the NLRA, participating in activity permitted by Section 7 of the NLRA, filing charges with the NLRB or any comparable state or local agency, or otherwise cooperating in the NLRB’s investigative process.

18

11.Except as provided for in and subject to Section 6, I agree that I will cooperate with the Company regarding any investigation, or the defense or prosecution of any claims, proceedings, arbitrations, or actions now pending or in existence, or which may be brought in the future, against or on behalf of the Company, which relate to events or occurrences that transpired during my employment with the Company. My cooperation shall include, but not necessarily be limited to: (i) attending meetings with and truthfully answering questions posed by representatives and/or attorneys of the Company; (ii) providing or producing documents relevant to such claim, proceeding, arbitration, or action, as applicable, to the extent that such documents are in my possession, custody, or control and as may be requested, from time to time, by representatives and/or attorneys of the Company; (iii) executing truthful and complete declarations or affidavits; and (iv) appearing as a witness at depositions, trials, arbitration hearings, or other proceedings without the necessity of a subpoena and testifying truthfully and completely, provided that the Company agrees to pay me a fee equivalent to the hourly rate I was paid in my last paycheck (based on my base salary divided by 2,000 hours) for all time in excess of ten (10) cumulative hours required and reimburse me for all of my reasonable, out-of-pocket expenses associated with such cooperation, including reasonable travel expenses, in accordance with any applicable Company policy as in effect from time to time, so long as I provide advance written notice of my request for reimbursement and provide satisfactory documentation of the expenses. Nothing in this provision shall be construed or applied so as to obligate me to violate any law or legal obligation. Nothing herein is intended to unduly interfere with my other business or personal activities.

This Release and Waiver constitutes the complete, final, and exclusive embodiment of the entire agreement between the Company and me with regard to the subject matter hereof. I am not relying on any promise or representation by the Company that is not expressly stated herein. This Release and Waiver may only be modified by a writing signed by both me and a duly authorized member of the Board of Directors of the Company.

IN WITNESS WHEREOF, the parties have executed this RELEASE AND WAIVER OF CLAIMS as of the date first written above.

DMK PHARMACEUTICALS CORPORATION EXECUTIVE

Name: John Dorbin

Title: Date:

Date:

19

EX-31.1

DMK Pharmaceuticals Corporation 10-Q

Exhibit 31.1

CERTIFICATION PURSUANT TO SECTION 302 OF THE 

SARBANES-OXLEY ACT OF 2002

I, Ebrahim Versi, certify that:

1. I have reviewed this Quarterly Report on Form 10-Q of DMK Pharmaceuticals Corporation;

2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this quarterly report;

3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

4. The registrant’s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and (15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and we have:

a) Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

b) Designed such internal control over financial reporting, or caused such internal control over financial reporting disclosure to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

c) Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

d) Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and

5. The registrant’s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):

a) All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial data; and

b) Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

Date:	November 14, 2023	By:	/s/ Ebrahim Versi
			Chief Executive Officer

EX-31.2

DMK Pharmaceuticals Corporation 10-Q

Exhibit 31.2

CERTIFICATION PURSUANT TO SECTION 302 OF THE 

SARBANES-OXLEY ACT OF 2002

I, Seth A. Cohen, certify that:

1. I have reviewed this Quarterly Report on Form 10-Q of DMK Pharmaceuticals Corporation;

2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this quarterly report;

3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

4. The registrant’s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and (15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and we have:

a) Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

b) Designed such internal control over financial reporting, or caused such internal control over financial reporting disclosure to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

c) Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

d) Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and

5. The registrant’s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):

a) All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial data; and

b) Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

Date:	November 14, 2023	By:	/s/ Seth A. Cohen
			Chief Financial Officer

EX-32.1

DMK Pharmaceuticals Corporation 10-Q

Exhibit 32.1

CERTIFICATION OF CHIEF EXECUTIVE OFFICER

PURSUANT TO SECTION 906 OF THE SARBANES-OXLEY ACT

The undersigned, Ebrahim Versi, the Chief Executive Officer of DMK Pharmaceuticals Corporation (the “Company”), pursuant to 18 U.S.C. 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, hereby certifies that, to the best of my knowledge:

(1) the Company’s Quarterly Report on Form 10-Q for the quarter ended September 30, 2023 (the “Report”) fully complies with the requirements of Section 13(a) of the Securities Exchange Act of 1934; and

(2) the information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

/s/ Ebrahim Versi

Ebrahim Versi

Chief Executive Officer

Dated: November 14, 2023

This certification is being furnished to the SEC with this Quarterly Report on Form 10-Q pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 and shall not, except to the extent required by such Act, be deemed filed by the Company for purposes of Section 18 of the Securities Exchange Act of 1934.

EX-32.2

DMK Pharmaceuticals Corporation 10-Q

Exhibit 32.2

CERTIFICATION OF CHIEF FINANCIAL OFFICER

PURSUANT TO SECTION 906 OF THE SARBANES-OXLEY ACT

The undersigned, Seth A. Cohen, as Chief Financial Officer of DMK Pharmaceuticals, Corporation (the “Company”), pursuant to 18 U.S.C. 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, hereby certifies that, to the best of my knowledge:

(1) the Company’s Quarterly Report on Form 10-Q for the quarter ended September 30, 2023 (the “Report”) fully complies with the requirements of Section 13(a) of the Securities Exchange Act of 1934; and

(2) the information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

/s/ Seth A. Cohen

Seth A. Cohen

Chief Financial Officer

Dated: November 14, 2023

This certification is being furnished to the SEC with this Quarterly Report on Form 10-Q pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 and shall not, except to the extent required by such Act, be deemed filed by the Company for purposes of Section 18 of the Securities Exchange Act of 1934.

XML

Cover - shares	9 Months Ended
	Sep. 30, 2023	Nov. 13, 2023
Cover [Abstract]
Document Type	10-Q
Amendment Flag	false
Document Quarterly Report	true
Document Transition Report	false
Document Period End Date	Sep. 30, 2023
Document Fiscal Period Focus	Q3
Document Fiscal Year Focus	2023
Current Fiscal Year End Date	--12-31
Entity File Number	001-36242
Entity Registrant Name	DMK PHARMACEUTICALS CORPORATION
Entity Central Index Key	0000887247
Entity Tax Identification Number	82-0429727
Entity Incorporation, State or Country Code	DE
Entity Address, Address Line One	11622 El Camino Real
Entity Address, Address Line Two	Suite 100
Entity Address, City or Town	San Diego
Entity Address, State or Province	CA
Entity Address, Postal Zip Code	92130
City Area Code	(858)
Local Phone Number	997-2400
Title of 12(b) Security	Common Stock
Trading Symbol	DMK
Security Exchange Name	NASDAQ
Entity Current Reporting Status	Yes
Entity Interactive Data Current	Yes
Entity Filer Category	Non-accelerated Filer
Entity Small Business	true
Entity Emerging Growth Company	false
Entity Shell Company	false
Entity Common Stock, Shares Outstanding		10,102,050

XML

UNAUDITED CONDENSED CONSOLIDATED BALANCE SHEETS - USD ($)	Sep. 30, 2023	Dec. 31, 2022
CURRENT ASSETS
Cash and Cash Equivalents	$ 6,663,921	$ 1,081,364
Restricted Cash		30,068
Accounts Receivable, net		1,054,058
Inventories	662,962	1,238,778
Prepaid Expenses and Other Current Assets	539,772	1,914,966
Current Assets of Discontinued Operations	5,406	3,952,916
Total Current Assets	7,872,061	9,272,150
LONG TERM ASSETS
Fixed Assets, net	1,075,676	1,288,894
Right-of-Use Assets		317,622
Other Non-Current Assets	9,674	52,174
Total Assets	8,957,411	10,930,840
CURRENT LIABILITIES
Accounts Payable	9,973,413	7,937,493
Deferred Revenue, current portion (including $145,000 and $0 associated with variable interest entity at September 30, 2023 and December 31, 2022, respectively)	172,779	27,779
Accrued Other Expenses	2,323,738	1,510,053
Product Recall Liability		305,806
Lease Liabilities, current portion	63,209	342,562
Current Liabilities of Discontinued Operations	929,328	1,272,173
Total Current Liabilities	13,462,467	11,395,866
LONG TERM LIABILITIES
Deferred Revenue, net of current portion	157,413	178,247
Warrant Liabilities, at fair value	302,170	7,492
Total Liabilities	13,922,050	11,581,605
MEZZANINE EQUITY
Convertible Preferred Stock - Par Value $0.0001;  10,000,000 Shares Authorized: Series C Preferred Stock 3,000 Shares Authorized, liquidation preference $110 per share; 3,000 Issued and Outstanding at September 30, 2023 and December 31, 2022, respectively.	330,000	157,303
STOCKHOLDERS’ DEFICIT
Convertible Preferred Stock - Par Value $0.0001; 10,000,000 Shares Authorized; Series E Preferred Stock 1,941.2 Shares Authorized, 1,212 Issued and Outstanding at September 30, 2023 and no Shares Authorized, Issued and Outstanding at December 31, 2022
Common Stock - Par Value $0.0001; 200,000,000 Shares Authorized; 10,102,050 and 2,150,051 Issued, 10,094,580 and 2,142,581 Outstanding at September 30, 2023 and December 31, 2022, respectively.	1,010	215
Additional Paid-in Capital	318,178,762	303,761,053
Accumulated Deficit	(323,469,161)	(304,564,086)
Treasury Stock - 7,470 Shares, at cost	(5,250)	(5,250)
Total Stockholders’ Deficit	(5,294,639)	(808,068)
Total Liabilities, Mezzanine Equity and Stockholders’ Deficit	$ 8,957,411	$ 10,930,840

XML

UNAUDITED CONDENSED CONSOLIDATED BALANCE SHEETS (Parenthetical) - USD ($)	Sep. 30, 2023	Dec. 31, 2022
Deferred Revenue	$ 172,779	$ 27,779
Convertible Preferred Stock, par value (in dollars per share)	$ 0.0001	$ 0.0001
Convertible Preferred Stock, authorized	10,000,000	10,000,000
Convertible Preferred Stock, par value (in dollars per share)	$ 0.0001	$ 0.0001
Convertible Preferred Stock, authorized	10,000,000	10,000,000
Common stock, par value (in dollars per share)	$ 0.0001	$ 0.0001
Common stock, authorized	200,000,000	200,000,000
Common stock, issued	10,102,050	2,150,051
Common stock, outstanding	10,094,580	2,142,581
Treasury stock, shares	7,470	7,470
Series C Preferred Stock [Member]
Convertible Preferred Stock, authorized	3,000	3,000
Convertible Preferred Stock, liquidation preference (in dollars per share)	$ 110	$ 110
Convertible Preferred Stock, issued	3,000	3,000
Convertible Preferred Stock, outstanding	3,000	3,000
Series E Preferred Stock [Member]
Convertible Preferred Stock, authorized	1,941.2	0
Convertible Preferred Stock, issued	1,212	0
Convertible Preferred Stock, outstanding	1,212	0
Variable Interest Entity, Primary Beneficiary [Member]
Deferred Revenue	$ 145,000	$ 0

XML

UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS - USD ($)	3 Months Ended		9 Months Ended
	Sep. 30, 2023	Sep. 30, 2022	Sep. 30, 2023	Sep. 30, 2022
Income Statement [Abstract]
Revenue, net	$ 9,062	$ 1,505,683	$ 1,469,007	$ 2,605,396
Costs of goods sold	338,488	1,647,585	2,487,948	3,705,697
Gross Loss	(329,426)	(141,902)	(1,018,941)	(1,100,301)
OPERATING EXPENSES
Selling, General and Administrative	2,517,161	2,508,176	11,332,333	10,096,807
Research and Development	418,518	1,977,939	2,106,004	9,520,118
Acquired In-Process Research and Development (IPR&D)			6,539,675
Loss from Operations	(3,265,105)	(4,628,017)	(20,996,953)	(20,717,226)
OTHER INCOME (EXPENSE)
Interest Income	13,835	19,699	14,549	40,021
Interest Expense	(29,465)		(135,808)
Other Income (Expense)	773,764	278,419	1,183,781	(419,413)
Loss on PPP2 loan				(1,787,417)
Excess of March 2023 Warrant Fair Value over Offering Proceeds			(2,476,109)
Change in Fair Value of Warrants	770,723	58,690	4,656,292	87,618
Total Other Income (Expense), net	1,528,857	356,808	3,242,705	(2,079,191)
Net Loss from Continuing Operations	(1,736,248)	(4,271,209)	(17,754,248)	(22,796,417)
DISCONTINUED OPERATIONS
Net Income(Loss) from Discontinued Operations	348,202	(127,692)	(1,150,827)	(354,320)
Net Loss Applicable to Common Stock	$ (1,388,046)	$ (4,398,901)	$ (18,905,075)	$ (23,150,737)
Basic and Diluted Loss Per Share:
Continuing Operations, Basic Loss Per Share	$ (0.25)	$ (1.99)	$ (4.53)	$ (10.65)
Continuing Operations, Diluted Loss Per Share	(0.25)	(1.99)	(4.53)	(10.65)
Discontinued Operations, Basic Loss Per Share	0.05	(0.06)	(0.29)	(0.17)
Discontinued Operations, Diluted Loss Per Share	0.05	(0.06)	(0.29)	(0.17)
Basic Loss Per Share	(0.20)	(2.05)	(4.82)	(10.82)
Diluted Loss Per Share	$ (0.20)	$ (2.05)	$ (4.82)	$ (10.82)
Basic Weighted Average Shares Outstanding	7,065,673	2,142,618	3,957,733	2,140,097
Diluted Weighted Average Shares Outstanding	7,065,673	2,142,618	3,957,733	2,140,097

XML

UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF MEZZANINE EQUITY AND STOCKHOLDERS' DEFICIT - USD ($)	Preferred Stock [Member]	Common Stock [Member]	Additional Paid-in Capital [Member]	Treasury Stock, Common [Member]	Retained Earnings [Member]	Total	Convertible Preferred Stock [Member]
Beginning balance, value at Dec. 31, 2021		$ 214	$ 303,973,627	$ (5,250)	$ (278,085,813)	$ 25,882,778
Beginning balance, shares at Dec. 31, 2021		2,144,494		7,470
Beginning balance, Convertible Preferred Stock at Dec. 31, 2021
Accretion of Series C Preferred Stock
Issuance of Series C Preferred Stock, net of issuance costs of $8,300							$ 157,303
Issuance of Series C Preferred Stock, net of issuance costs of $8,300 (in shares)							3,000
Issuance of 750,000 Warrants, pursuant to the Series C Preferred Stock issuance, net of issuance costs of $6,700			127,697			127,697
Issuance of Common Stock upon Vesting of Restricted Stock Units (RSUs)		$ 1	(1)
Issuance of Common Stock upon Vesting of Restricted Stock Units (RSUs) (in shares)		5,557
Share Based Compensation			(14,311)			(14,311)
Net Loss					(23,150,737)	(23,150,737)
Ending balance, value at Sep. 30, 2022		$ 215	304,087,012	$ (5,250)	(301,236,550)	2,845,427
Ending balance, shares at Sep. 30, 2022		2,150,051		7,470			3,000
Ending balance, Convertible Preferred Stock at Sep. 30, 2022							$ 157,303
Beginning balance, value at Jun. 30, 2022		$ 215	303,884,827	$ (5,250)	(296,837,649)	7,042,143
Beginning balance, shares at Jun. 30, 2022		2,150,051		7,470
Beginning balance, Convertible Preferred Stock at Jun. 30, 2022
Issuance of Series C Preferred Stock, net of issuance costs of $8,300							$ 157,303
Issuance of Series C Preferred Stock, net of issuance costs of $8,300 (in shares)							3,000
Issuance of 750,000 Warrants, pursuant to the Series C Preferred Stock issuance, net of issuance costs of $6,700			127,697			127,697
Share Based Compensation			74,488			74,488
Net Loss					(4,398,901)	(4,398,901)
Ending balance, value at Sep. 30, 2022		$ 215	304,087,012	$ (5,250)	(301,236,550)	2,845,427
Ending balance, shares at Sep. 30, 2022		2,150,051		7,470			3,000
Ending balance, Convertible Preferred Stock at Sep. 30, 2022							$ 157,303
Beginning balance, value at Dec. 31, 2022		$ 215	303,761,053	$ (5,250)	(304,564,086)	(808,068)
Beginning balance, shares at Dec. 31, 2022		2,150,051		7,470			3,000
Beginning balance, Convertible Preferred Stock at Dec. 31, 2022						157,303	$ 157,303
March 2023 Offering		$ 24	(24)
March 2023 Offering, shares		235,714
Accretion of Series C Preferred Stock			(172,697)			(172,697)
Accretion of Series C Preferred Stock							$ 172,697
Issuance of Series E Preferred Stock pursuant to DMK Merger			4,853,000			4,853,000
Issuance of Series E Preferred Stock pursuant to DMK Merger, shares	1,941.2
Common Stock Issuance pursuant to DMK Merger		$ 30	757,008			757,038
Common Stock Issuance pursuant to DMK Merger, shares		302,815
Assumption of DMK options pursuant to DMK Merger			415,809			415,809
Issuance of Common Stock and Warrants in the August 2023 Financing, net of issuance costs of $912,751		$ 480	7,092,156			7,092,636
Issuance of Common Stock and Warrants in the August 2023 Financing, net of issuance costs of $912,731, shares		4,800,000
Conversion of Series E Preferred Stock into Common Stock		$ 73	(73)
Conversion of Series E Preferred Stock into Common Stock, shares	(729.2)	729,200
Issuance of Common Stock upon Exercise of Pre-funded Warrants		$ 124	525,045			525,169
Issuance of Common Stock upon Exercise of Prefunded Warrants, shares		1,237,127
Issuance of Common Stock upon Exercise of Common Stock Warrants		$ 64	870,686			870,750
Issuance of Common Stock upon exercise of Common Stock Warrants, shares		645,000
Issuance of Common Stock upon Vesting of Restricted Stock Units (RSUs)
Issuance of Common Stock upon Vesting of Restricted Stock Units (RSUs) (in shares)		2,143
Share Based Compensation			76,799			76,799
Net Loss					(18,905,075)	(18,905,075)
Ending balance, value at Sep. 30, 2023		$ 1,010	318,178,762	$ (5,250)	(323,469,161)	(5,294,639)
Ending balance, shares at Sep. 30, 2023	1,212	10,102,050		7,470			3,000
Ending balance, Convertible Preferred Stock at Sep. 30, 2023						330,000	$ 330,000
Beginning balance, value at Jun. 30, 2023		$ 280	310,260,759	$ (5,250)	(322,081,115)	(11,825,326)
Beginning balance, shares at Jun. 30, 2023	1,941.2	2,797,865		7,470			3,000
Beginning balance, Convertible Preferred Stock at Jun. 30, 2023							$ 330.00
Accretion of Series C Preferred Stock
Issuance of Common Stock and Warrants in the August 2023 Financing, net of issuance costs of $912,751		$ 480	7,092,156			7,092,636
Issuance of Common Stock and Warrants in the August 2023 Financing, net of issuance costs of $912,731, shares		4,800,000
Conversion of Series E Preferred Stock into Common Stock		$ 73	(73)
Conversion of Series E Preferred Stock into Common Stock, shares	(729.2)	729,200
Issuance of Common Stock upon Exercise of Pre-funded Warrants		$ 113	(73)			40
Issuance of Common Stock upon Exercise of Prefunded Warrants, shares		1,129,985
Issuance of Common Stock upon Exercise of Common Stock Warrants		$ 64	870,686			870,750
Issuance of Common Stock upon exercise of Common Stock Warrants, shares		645,000
Share Based Compensation			(44,693)			(44,693)
Net Loss					(1,388,046)	(1,388,046)
Ending balance, value at Sep. 30, 2023		$ 1,010	$ 318,178,762	$ (5,250)	$ (323,469,161)	(5,294,639)
Ending balance, shares at Sep. 30, 2023	1,212	10,102,050		7,470			3,000
Ending balance, Convertible Preferred Stock at Sep. 30, 2023						$ 330,000	$ 330,000

XML

UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF MEZZANINE EQUITY AND STOCKHOLDERS' DEFICIT (Parenthetical) - USD ($)	3 Months Ended		9 Months Ended
	Sep. 30, 2023	Sep. 30, 2022	Sep. 30, 2023	Sep. 30, 2022
Statement of Stockholders' Equity [Abstract]
Issuance of Common Stock and Warrants in August 2023 Financing, issuance costs	$ 912,751		$ 912,751
Issuance of Series C Preferred Stock, issuance costs		$ 8,300		$ 8,300
Issuance of Warrants, pursuant to the Series C Preferred Stock issuance		750,000		750,000
Issuance of 750,000 Warrants, pursuant to the Series C Preferred Stock issuance, issuance costs		$ 6,700		$ 6,700

XML

UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS - USD ($)	9 Months Ended
	Sep. 30, 2023	Sep. 30, 2022
CASH FLOWS FROM OPERATING ACTIVITIES
Net Loss	$ (18,905,075)	$ (23,150,737)
Less: Loss from Discontinued Operations	1,150,827	354,320
Adjustments to Reconcile Net Loss to Net Cash Used in Operating Activities:
Acquired IPR&D	6,539,675
Stock Based Compensation	76,799	(14,311)
Excess of March 2023 Warrant Fair Value over Offering Proceeds	2,476,109
Change in Fair Value of Warrant Liability	(4,656,292)	(87,618)
Cash Payments in Excess of Lease Expense	(78,665)	(12,081)
Impairment of Right-of-Use Assets	116,934
Depreciation Expense	264,012	1,111,495
Receivable from Fagron		919,413
Change in Operating Assets and Liabilities:
Accounts Receivable	1,054,058	(490,940)
Inventories	575,816	(673,838)
Prepaid Expenses and Other Current & Non-Current Assets	1,318,090	567,094
Accounts Payable	1,580,139	1,319,707
Product Recall Liability	(305,806)	(1,591,870)
Deferred Revenue (including $145,000 and $0 associated with variable interest entity for the nine months ended September 30, 2023 and 2022, respectively)	(22,952)	(637,030)
Accrued Other Expenses	1,108,448	(1,552,766)
Net Cash Used in Operating Activities of Continuing Operations	(7,707,883)	(23,939,162)
Net Cash Used in Operating Activities of Discontinued Operations	(145,429)	(439,301)
Net Cash Used in Operating Activities	(7,853,312)	(24,378,463)
CASH FLOWS FROM INVESTING ACTIVITIES
Purchase of Equipment		(588,923)
Cash Acquired in DMK Acquisition	136,089
Proceeds from Receivable from Fagron	12,104	3,917,530
Net Cash Provided by Investing Activities of Continuing Operations	148,193	3,328,607
Net Cash Provided by Investing Activities of Discontinued Operations	2,599,267
Net Cash Provided by Investing Activities	2,747,460	3,328,607
CASH FLOWS FROM FINANCING ACTIVITIES
Proceeds from March 2023 Offering related to Common Stock Warrant	2,099,862
Proceeds from March 2023 Offering related to Prefunded Warrant	899,388
March 2023 Offering Issuance Costs	(275,000)
Proceeds from Exercise of Prefunded Warrant	790
Proceeds from August 2023 Financing	8,005,387
August 2023 Financing Issuance Costs	(912,751)
Proceeds from Exercise of August 2023 Common Stock Warrants	870,750
Proceeds from Issuance of Preferred Stock and Warrants, net		285,000
Net Cash Provided by Financing Activities of Continuing Operations	10,688,426	285,000
Net Cash Provided by Financing Activities of Discontinued Operations
Net Cash Provided by Financing Activities	10,688,426	285,000
Increase (Decrease) in Cash and Cash Equivalents and Restricted Cash	5,582,574	(20,764,856)
Cash and Cash Equivalents, and Restricted Cash
Beginning Balance	1,111,432	23,250,793
Decrease in Cash and Restricted Cash Equivalents of Discontinued Operations	(30,085)	(35,921)
Ending Balance	6,663,921	2,450,016
RECONCILIATION OF CASH & CASH EQUIVALENTS AND RESTRICTED CASH
Cash & Cash Equivalents	6,663,921	2,419,960
Restricted Cash		(30,056)
SUPPLEMENTAL DISCLOSURE OF CASH FLOW INFORMATION
Cash Paid for Income Taxes		3,625
SUPPLEMENTAL DISCLOSURE OF NONCASH INVESTING ACTIVITIES
Liabilities of DMK assumed from DMK Merger	157,461
Issuance of common stock for DMK Merger	(757,038)
Issuance of Series E preferred stock for DMK Merger	(4,853,000)
DMK options assumed and replaced by the Company in connection with the DMK Merger	(415,809)
Fixed asset additions included in accrued expenses		217,340
SUPPLEMENTAL DISCLOSURE OF NONCASH FINANCING ACTIVITIES
Accretion on Series C Preferred Stock	172,697
Conversion of Series E Preferred Stock to Common Stock	73
Cashless Exercise of August 2023 Prefunded Warrants	73
Exercise of March 2023 Prefunded Warrants	$ 524,379

XML

UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (Parenthetical) - USD ($)	9 Months Ended
	Sep. 30, 2023	Sep. 30, 2022
Deferred Revenue	$ (22,952)	$ (637,030)
Variable Interest Entity, Primary Beneficiary [Member]
Deferred Revenue	$ 145,000	$ 0

XML

Organization and Description of the Business

9 Months Ended

Sep. 30, 2023

Organization, Consolidation and Presentation of Financial Statements [Abstract]

Organization and Description of the Business

Note 1: Organization and Description of the Business

DMK Pharmaceuticals Corporation (“DMK” or the “Company”) is a specialty biopharmaceutical company focused on developing and commercializing products in the substance use disorder space including treatment of opioid use disorder. Effective September 6, 2023, pursuant to a certificate of amendment to the Company’s restated certificate of incorporation, the Company changed its name from Adamis Pharmaceuticals Corporation to DMK Pharmaceuticals Corporation.

Reverse Stock Split

Effective May 22, 2023, the Company effected a 1-for-70 reverse stock split of its outstanding common stock (the “Reverse Stock Split”). Pursuant to the Reverse Stock Split, every 70 shares of issued and outstanding common stock were automatically combined into one share of common stock, without any change in the par value per share. The Company did not issue any fractional shares in the Reverse Stock Split. The number of authorized shares of common stock under the Company’s restated certificate of incorporation remained unchanged at 200,000,000 shares. Unless otherwise indicated, share numbers, per share data and earnings per share data throughout this Report have been recast retroactively to reflect the Reverse Stock Split.

DMK Merger

On February 24, 2023, the Company entered into an Agreement and Plan of Reorganization (the “Merger Agreement”) with DMK Pharmaceuticals Corporation, a New Jersey corporation (“Legacy DMK”), and Aardvark Merger Sub, Inc. (“Merger Sub”), a Delaware corporation and a wholly-owned subsidiary of the Company (“Merger Sub”). The Merger Agreement provided for the merger (the “Merger”) of Legacy DMK with and into Merger Sub, with Merger Sub surviving as a wholly-owned subsidiary of the Company. Prior to the Merger, Legacy DMK was a privately-held, clinical stage biotechnology company focused on the development and commercialization of potential products for a variety of central nervous disorders. Pursuant to the Merger, each share of common stock of Legacy DMK was converted into the right to receive a number of shares of the Company’s common stock and, in the case of certain Legacy DMK stockholders, shares of our Series E Convertible Preferred Stock, or Series E Preferred.

On May 25, 2023, following a special meeting of stockholders of the Company, the Merger was completed in accordance with the terms of the Merger Agreement. In connection with the Merger, the name of Merger Sub as the surviving corporation was changed to DMK Pharmaceuticals Corporation. In connection with the September 2023 change of the Company’s corporate name, Merger Sub’s corporate name was changed to Adamis Pharmaceuticals Corporation.

As a result of the consummation of the Merger, and after giving effect to the Reverse Stock Split, effective at the closing of the Merger (the “Effective Time”), the shares of Legacy DMK common stock then outstanding were canceled and automatically converted into and became the right to receive a total of 302,815 shares of the Company’s common stock and, with respect to certain former Legacy DMK stockholders, 1,941.2 shares of Series E Convertible Preferred Stock (“Series E Preferred”) of the Company. The Series E Preferred is convertible into shares of the Company’s common stock at a conversion rate of 1,000 common shares for one Series E Preferred share (subject to beneficial ownership limitations of 9.99%).

XML

Summary of Significant Accounting Policies

9 Months Ended

Sep. 30, 2023

Accounting Policies [Abstract]

Summary of Significant Accounting Policies

Note 2: Summary of Significant Accounting Policies

Basis of Presentation and Principles of Consolidation

The accompanying unaudited interim condensed consolidated financial statements have been prepared in accordance with U.S. generally accepted accounting principles for interim financial information and with the instructions to Form 10-Q and Article 8 of Regulation S-X promulgated by the Securities and Exchange Commission (“SEC”). Accordingly, certain information and footnote disclosures normally included in annual financial statements have been condensed or omitted. In the opinion of management, the accompanying unaudited interim condensed consolidated financial statements reflect all adjustments (including normal recurring adjustments and the elimination of intercompany accounts) considered necessary for a fair statement of all periods presented. The results of operations of the Company for any interim periods are not necessarily indicative of the results of operations for any other interim periods or for a full fiscal year. These unaudited interim condensed consolidated financial statements should be read in conjunction with the audited consolidated financial statements and footnotes thereto included in the Company’s Annual Report on Form 10-K for the year ended December 31, 2022 (the “2022 Form 10-K”).

Principles of Consolidation

The condensed consolidated financial statements include the accounts of DMK and its wholly-owned and controlled subsidiaries, Merger Sub (a variable interest entity wherein the Company is the primary beneficiary) and US Compounding, Inc (a discontinued operation) (“USC”). All significant intercompany accounts and transactions have been eliminated in consolidation.

Prior Periods Reclassifications

Certain amounts in prior periods have been reclassified to conform with current period presentation related to the receivable from Fagron included in prepaid expenses and other current assets in the accompanying condensed consolidated balance sheets. Such reclassification had no effect on the total current assets as of December 31, 2022. The reclassification had no effect on the condensed consolidated statement of operations or condensed consolidated statement of cash flows for the periods ended September 30, 2022.

Certain amounts in prior periods have been reclassified to conform with current period presentation related to interest income which was presented separately from the other income (expenses) on the accompanying condensed consolidated statements of operations. Such reclassification had no effect on the total other income (expense), net for the three and nine months ended September 30, 2022. The reclassification had no effect on the condensed consolidated balance sheet as of December 31, 2022 or condensed consolidated statement of cash flows for the periods ended September 30, 2022.

Variable Interest Entity

The purpose of the Merger with Legacy DMK is to expand the Company’s potential product pipeline. The Company intends to focus on developing therapies with novel mechanisms of action to treat conditions, including substance abuse disorders.

The Company has 100% ownership of Merger Sub. In the event Merger Sub requires additional funding to support its operations, the Company would provide such financial support; and any benefits from the development of any of the potential product candidates would be realized by the Company. Additionally, as with any product development program there are risks that could materially impact the Company’s financial condition negatively. Conversely, positive outcomes during product development and/or achieving regulatory approval on a product or drug could materially impact the Company’s financial condition positively. See Note 3, DMK Merger for additional information regarding the VIE.

Assets recognized as a result of consolidating Merger Sub do not represent additional assets that could be used to satisfy claims against the Company’s general assets. Cash specifically must be utilized based on the specific terms of the respective grant in which the monies were received; and any unspent grant funds would be required to be returned at the end of the respective grant term. Conversely, liabilities recognized as a result of consolidating Merger Sub do not represent additional claims of the Company’s general assets; they represent claims against the specific assets of Merger Sub. 

               Assets Held for Sale

The Company considers assets to be held for sale when management approves and commits to a plan to actively market the assets for sale at a reasonable price in relation to its fair value, the assets are available for immediate sale in their present condition, an active program to locate a buyer and other actions required to complete the sale have been initiated, the sale of the assets is expected to be completed within one year and it is unlikely that significant changes will be made to the plan. Upon designation as held for sale, the Company ceases to record depreciation and amortization expenses and measures the assets at the lower of their carrying value or estimated fair value less costs to sell. Assets held for sale are included as other current assets in the Company’s consolidated balance sheets and the gain or loss from sale of assets held for sale is included in the Company’s general and administrative expenses. 

Accrued Other Expenses

Accrued Other Expenses consists of the following as of September 30, 2023 and December 31, 2022:

	September 30, 2023		December 31, 2022
Accrued Expenses – R&D	$	145,806	$	42,400
Accrued Expenses – COGS		1,392,810		1,099,571
Accrued Expenses - Other		601,000		200,363
Accrued PTO		184,122		167,719
Total Accrued Other Expenses	$	2,323,738	$	1,510,053

                Going Concern

The Company’s cash and cash equivalents were approximately $6.7 million and $1.1 million at September 30, 2023 and December 31, 2022, respectively.  

The condensed consolidated financial statements were prepared under the assumption that the Company will continue operations as a going concern, which contemplates the realization of assets and the satisfaction of liabilities during the normal course of business. In preparing these condensed consolidated financial statements, consideration was given to the Company’s future business as described below, which may preclude the Company from realizing the value of certain assets.    

The Company has incurred substantial recurring losses from continuing operations, negative cash flows from operations, and is dependent on additional financing to fund operations. The Company incurred a net loss of approximately $1.4 million and $18.9 million for the three months and nine months ended September 30, 2023, respectively. As of September 30, 2023, the Company had an accumulated deficit of approximately $323.5 million. These conditions raise substantial doubt about the Company’s ability to continue as a going concern within one year after the date the financial statements are issued. The accompanying unaudited condensed consolidated financial statements do not include any adjustments relating to the recoverability and classification of recorded asset amounts and classification of liabilities that might be necessary should the Company be unable to continue in existence.

Management’s plans include attempting to secure additional required funding through equity or debt financing, if available, seeking to enter into a partnership or other strategic agreement regarding, or sales or out-licensing of, its commercial products, product candidates or intellectual property assets or other assets, revenues relating to supply and sale of SYMJEPI and ZIMHI products and share of net profits received relating to sales in the U.S. of our SYMJEPI and ZIMHI products, seeking partnerships or commercialization agreements with other pharmaceutical companies or third parties to co-develop and fund research and development or commercialization efforts of its products.  There can be no assurance that we will be able to obtain required funding in the future. If the Company does not obtain required funding, the Company’s cash resources will be depleted in the near term and the Company would be required to materially reduce or suspend operations, which would likely have a material adverse effect on the Company’s business, stock price and our relationships with third parties with whom the Company have business relationships. If the Company does not have sufficient funds to continue operations, the Company could be required to seek bankruptcy protection, dissolution or liquidation, or other alternatives that could result in the Company’s stockholders losing some or all of their investment in us. The Company has implemented expense reduction measures including, without limitation, employee headcount reductions and the reduction or discontinuation of certain product development programs. Additionally, the Company is not in compliance with certain listing standards of the Nasdaq National Market and there can be no assurance that the Company will be successful in curing the deficiencies and regaining compliance by the applicable cure dates. (See Note 11 for additional information).

 Basic and Diluted Loss per Share 

Under ASC 260, the Company is required to apply the two-class method to compute earnings per share (“EPS”). Under the two-class method both basic and diluted EPS are calculated for each class of common stock and participating security considering both dividends declared (or accumulated) and participation rights in undistributed earnings. The two-class method results in an allocation of all undistributed earnings as if all those earnings were distributed. Considering the Company has generated losses in each reporting period since its inception through September 30, 2023, the Company also considered the guidance related to the allocation of the undistributed losses under the two-class method. The contractual rights and obligations of the preferred stock shares and the warrants were evaluated to determine if they have an obligation to share in the losses of the Company. As there is no obligation for the preferred stock shareholders or the holders of the warrants to fund the losses of the Company nor is the contractual principal or redemption amount of the preferred stock shares or the warrants reduced as a result of losses incurred by the Company, under the two-class method, the undistributed losses are allocated entirely to the common stock securities.

The Company computes basic loss per share by dividing the loss attributable to holders of common stock for the period by the weighted average number of shares of common stock outstanding during the period. Adjustments to the loss attributable to holders of common stock include the accretion on Series C Preferred treated as a dividend. During the three and nine months ended September 30, 2023, the Series C Preferred was accreted $0 and $172,697, respectively. As of September 30, 2023, the carrying value of the Series C Preferred stock represents its full redemption value of $330,000. The numerator in calculating the loss attributable to the holders of common stock was adjusted as follows:

	Three Months Ended September 30, 2023			Nine Months Ended September 30, 2023
Net loss	$	(1,388,046	)	$	(18,905,075	)
Accretion on Series C Preferred		—			(172,697	)
Adjusted Net Loss	$	(1,388,046	)	$	(19,077,772	)

The Series E common stock equivalents are not included in the calculation of diluted EPS as this would be anti-dilutive (since the Company generates net losses). The diluted loss per share calculation is based on the if-converted method for convertible preferred shares and gives effect to dilutive if-converted shares and the treasury stock method and gives effect to dilutive options, warrants and other potentially dilutive common stock. The preferred stock is not considered potentially dilutive due to the contingency on the conversion feature not being tied to stock price or price of the convertible instrument.

Common share equivalents outstanding, determined using the treasury stock method, are comprised of shares that may be issued under the Company’s stock option and warrant agreements. For the warrants accounted as liabilities, at each reporting period the Company evaluates the combined effect of the adjustment to the numerator (assumed beginning of the period exercise) and inclusion of the warrants in the denominator, with the warrants included for the purposes of diluted EPS calculation if such effect is dilutive. The warrants and options were determined to be anti-dilutive for all periods presented.

Potentially dilutive securities, which are not included in diluted weighted average shares outstanding for the period ended September 30, 2023 and 2022, consist of the following (in common stock equivalents):

	September 30,  2023		September 30, 2022
Outstanding Warrants		6,184,323		213,612
Outstanding Options		33,886		63,377
Legacy DMK Options assumed by the Company		231,490		—
Outstanding Restricted Stock Units		7,143		9,286
Series C Preferred stock (if converted)		697,674		—
Series E Preferred stock (if converted)		1,212,000		—

Stock-based compensation

The Company accounts for transactions in which the Company receives services in exchange for restricted stock units (“RSUs”) or options to purchase common stock as stock-based compensation cost based on estimated fair value. Stock-based compensation cost for RSUs is measured based on the closing fair market value of the Company’s common stock on the date of grant. Stock-based compensation cost for stock options is estimated at the grant date based on each option’s fair-value as calculated by the Black-Scholes option-pricing model. The Company accounts for forfeitures as they occur and will reduce compensation cost at the time of forfeiture.

Discontinued Operations

In accordance with ASC 205-20 Presentation of Financial Statements: Discontinued Operations, the Company reports a disposal of a component of an entity or a group of components of an entity as discontinued operations if the disposal represents a strategic shift that has (or will have) a major effect on the Company’s operations and financial results when the component/s meets the criteria in paragraph 205-20-45-10. In the period in which the component meets held-for-sale or discontinued operations criteria, the Company reports the major current assets, noncurrent assets, current liabilities, and noncurrent liabilities as components of total assets and liabilities separate from those balances of the continuing operations. At the same time, the Company reports the results of all discontinued operations, less applicable income taxes, as components of net loss separate from the net loss of continuing operations.

XML

DMK Merger

9 Months Ended

Sep. 30, 2023

Business Combination and Asset Acquisition [Abstract]

DMK Merger

 Note 3: DMK Merger

On May 25, 2023, the Company completed the merger transaction with Legacy DMK. The Company determined that the acquired group, Legacy DMK, is a variable interest entity, or VIE, as Legacy DMK's total equity at risk is not sufficient to permit Legacy DMK to finance its activities without additional subordinated financial support. In accordance with FASB Accounting Standards Codification (“ASC”) Topic 805 “Business Combinations”, the consolidation of Legacy DMK was considered an asset acquisition as substantially all of the fair value of the gross assets acquired were concentrated in DPI-125, a single identifiable asset. The Company was determined to be the primary beneficiary of Legacy DMK (as the Company holds 100% equity ownership in Legacy DMK post-merger, will receive the returns from its operations and is also obligated to absorb any losses of Legacy DMK). Based on applicable accounting guidance, the Company was required to record Legacy DMK's assets and liabilities at fair value. At acquisition date, based on the provisions of ASC Topic 730 "Research and Development", the Company expensed the purchase consideration allocated to the early-stage acquired in-process research and development (acquired IPR&D) because there is no alternative future use related to DPI-125 asset in IPR&D stage. The Company incurred approximately $1.4 million of transaction costs that were included within selling, general and administrative expenses on the condensed consolidated statement of operations.

           The fair value of the acquired IPR&D was determined based upon the income approach using a multi period excess earnings model which included a forecast of the expected cash flows of DPI-125. The discount rate associated with this forecast was 27%.

           The purchase price, or total consideration transferred, to acquire Legacy DMK in the Merger was comprised of the following:

Fair Value of the Company's Common Stock issued to Legacy DMK shareholders	$	757,038
Fair Value of the Company's Series E Preferred issued to Legacy DMK shareholders		4,853,000
Fair Value of Legacy DMK options assumed and replaced by the Company		415,809
Legacy DMK incurred Merger-related costs paid for by the Company		492,456
Total Consideration Transferred	$	6,518,303

The fair value of the  302,815 shares of common stock issued in connection with the Merger is based on the closing price of the Company's common stock on the date of acquisition multiplied by the number of common shares issued.

The fair value of the  1,941.2 shares of Series E Preferred issued in connection with the Merger is based on inputs that are observable or can be corroborated by observable market data (the Company’s closing stock price), and, as such, qualify as Level 2 measurement. The fair value of the Series E Preferred is based on the closing price of the Company's common stock as the Series E Preferred have no preferences over common stock.

Pursuant to the Merger Agreement, at the effective time, the outstanding Legacy DMK stock options to purchase shares of Legacy DMK common stock were assumed by the Company and became options to purchase a total of  231,490 shares of the Company’s common stock, with proportionate adjustments to the exercise prices per share of such options based on the exchange ratio determined pursuant to the Merger Agreement. The assumed options continue to be governed by the terms of the Legacy DMK 2016 Stock Plan, which was assumed by the Company in connection with the closing of the Merger. The assumed options were fully vested and the fair value of the replacement awards was treated as additional purchase price consideration.

The fair value of the replacement awards is based primarily on inputs that are observable or can be corroborated by observable market data (such as the Company’s closing stock price and the published treasury par yield curves from the US Department of the Treasury). The estimated fair value of the replacement options of  $415,809 at the merger closing date was calculated using the Black Scholes Option Pricing Model. The valuation assumptions include the volatility of  119.5%, the Company’s stock price on the date of closing of  $2.50, expected dividend yield of  0.0%, and the terms ranging from  2.37 years to  4.37 years and average risk-free interest rate of 4.06%.

The allocation of the total purchase price is estimated as follows:

Assets Acquired:
Cash	$	136,089
Total assets acquired		136,089
Liabilities Assumed:
Accounts Payable		30
Due to Related Party		1,698
Accrued Expenses		8,615
Deferred Grant Revenue		147,118
Total liabilities assumed		157,461
Net Liabilities acquired		(21,372	)
Acquired IPR&D (DPI-125)		6,539,675
Total Purchase Price	$	6,518,303

XML

Discontinued Operations

9 Months Ended

Sep. 30, 2023

DISCONTINUED OPERATIONS

Discontinued Operations

Note 4: Discontinued Operations

In July 2021, the Company approved a restructuring process to wind down and cease the remaining operations at USC, with the remaining USC assets to be sold, liquidated or otherwise disposed of.

In August 2021, the Company entered into a purchase agreement with Fagron Compounding Services, LLC (“Fagron”) to sell to Fagron certain assets of USC, related to its human compounding pharmaceutical business including certain customer information and information on products sold to such customers by USC, including related formulations, know-how, and expertise regarding the compounding of pharmaceutical preparations, clinical support knowledge and other data and certain other information relating to the customers and products. Fagron made monthly payments to the Company based on formulas related to the amounts actually collected by Fagron or its affiliates for sales of products or services made through July 30, 2022. As of September 30, 2023, the total amount received in connection with this purchase agreement was approximately $5.5 million. At September 30, 2023, the remaining receivable from Fagron was approximately $19,000.

Discontinued operations comprise those activities that were disposed of during the period, abandoned or which were classified as held for sale at the end of the period and represent a separate major line of business or geographical area that was previously distinguished as Compounded Pharmaceuticals segment for operational and financial reporting purposes in prior reported financial statements.

The major assets and liabilities associated with discontinued operations included in our condensed consolidated balance sheets are as follows:

	September 30, 2023		December 31, 2022
Cash and Cash Equivalents	$	—	$	30,085
Fixed Assets held for sale		—		6,719,252
Other assets		5,406		5,407
Loss recognized on classification as held for sale		—		(2,801,828	)
Total assets of the disposal group classified as held for sale in the statement of financial position	$	5,406	$	3,952,916
Carrying amounts of major classes of liabilities included as part of discontinued operations
Accounts Payable	$	673,335	$	649,633
Accrued Other Expenses		55,959		75,602
Lease Liabilities		200,034		243,008
Contingent Loss Liability		—		50,000
Other Current Liabilities		—		208,000
Deferred Tax Liability		—		45,930
Total liabilities of the disposal group classified as held for sale in the statement of financial position	$	929,328	$	1,272,173

In January 2023, the Company received approximately $832,000 from the sale of certain fixed assets to a third party. This amount plus the $208,000 of earnest money received as a deposit in December 2022 (previously recorded as other current liability), resulted in the recognition of a gain of $68,339 which was recorded as a gain on sale of fixed assets in discontinued operations during the three month period ended March 31, 2023.

During the second quarter of 2023, in connection with a third party’s offer to purchase USC’s land and building (the “USC Property”) for $1,525,000, the Company recorded an impairment charge of approximately $1.5 million (inclusive of broker commissions) to bring the carrying value of the USC property down to its net sales price. On July 25, 2023, the Company received net proceeds of approximately $1.5 million from the sale of USC’s land and building. On July 25, 2023, the Company sold previously impaired USC equipment and received the net proceeds of approximately $349,000. During the three months ended September 30, 2023, the Company recorded the gain on disposal of fixed assets in discontinued operations of $20,500 and $348,500, on the sale of the USC Property and USC equipment, respectively, representing the excess of the net proceeds over the carrying value of the equipment.

               The revenues and expenses associated with discontinued operations included in our consolidated statements of operations were as follows:

	Three Months Ended September 30,
	2023			2022
Major line items constituting pretax loss of discontinued operations:
Selling, General and Administrative Expenses	$	(20,798	)	$	(125,722	)
Interest Income		—			22
Gain (Loss) on Disposal of Assets		369,000			(1,992	)
Gain (Loss) from discontinued operations before income taxes		348,202			(127,692	)
Income Tax Benefit		—			—
Gain (Loss) from discontinued operations	$	348,202		$	(127,692	)

	Nine Months Ended September 30,
	2023			2022
Major line items constituting pretax loss of discontinued operations:
Selling, General and Administrative Expenses	$	(83,721	)	$	(390,105	)
Impairment Expense - USC Property		(1,512,263	)		—
Other Income		7,818			8,647
Gain on Disposal of Assets		437,339			27,138
Loss from discontinued operations before income taxes		(1,150,827	)		(354,320	)
Income tax benefit		—			—
Loss from discontinued operations	$	(1,150,827	)	$	(354,320	)

XML

Revenues

9 Months Ended

Sep. 30, 2023

Revenue from Contract with Customer [Abstract]

Revenues

Note 5: Revenues 

Revenues are related to the sales of the Company's commercial products which include: ZIMHI^® (naloxone HCL Injection, USP) 5 mg/0.5 mL, which was approved by the U.S. Food and Drug Administration, or FDA, for the treatment of opioid overdose; SYMJEPI^® (epinephrine) Injection 0.3mg, which was approved by the FDA for use in the emergency treatment of acute allergic reactions, including anaphylaxis, for patients weighing 66 pounds or more; and SYMJEPI (epinephrine) Injection 0.15mg, which was approved by the FDA for use in the treatment of anaphylaxis for patients weighing 33-65 pounds.

            Exclusive Distribution and Commercialization Agreement for SYMJEPI^™ and ZIMHI^™ with US WorldMeds (“USWM”)

             On May 11, 2020 (the “Effective Date”) the Company entered into an exclusive distribution and commercialization agreement (the “USWM Agreement”) with USWM for the United States commercial rights for the SYMJEPI products, as well as for the Company’s ZIMHI (naloxone HCI Injection, USP) 5mg/0.5mL product intended for the emergency treatment of opioid overdose. The Company’s revenues relating to its FDA approved products SYMJEPI and ZIMHI are dependent on the USWM Agreement.

            Under the terms of the USWM Agreement, the Company appointed USWM as the exclusive (including as to the Company) distributor of SYMJEPI in the United States and related territories (“Territory”) effective upon the termination of a Distribution and Commercialization Agreement previously entered into with Sandoz Inc., and of the ZIMHI product approved by the U.S. Food and Drug Administration (“FDA”) for marketing, and granted USWM an exclusive license under the Company’s patent and other intellectual property rights and know-how to market, sell, and otherwise commercialize and distribute the products in the Territory, subject to the provisions of the USWM Agreement, in partial consideration of an initial payment by USWM and potential regulatory and commercial based milestone payments totaling up to $26 million, if the milestones are achieved. There can be no assurances that any of these milestones will be met or that any milestone payments will be paid to the Company. The Company retains rights to the intellectual property subject to the USWM Agreement and to commercialize both products outside of the Territory. In addition, the Company may continue to use the licensed intellectual property (excluding certain of the licensed trademarks) to develop and commercialize other products (with certain exceptions), including products that utilize the Company’s Symject™ syringe product platform.

            The initial term for the USWM Agreement began on the Effective Date and continues for a period of 10 years from the launch by USWM of the first product in the United States pursuant to the agreement, unless terminated earlier in accordance with its terms.

Revenue Recognition

            The Company evaluated the USWM Agreement under ASC Topic 606, “Revenue from Contracts with Customers” (ASC 606). 

           The Company has determined that there are multiple performance obligations in the contract which are the following: the manufacture and supply of SYMJEPI™ and ZIMHI™ products to USWM, the license to distribute and commercialize SYMJEPI™ and ZIMHI™ products in the United States and the clinical development of ZIMHI™.

            The Company utilized significant judgement to develop estimates of the stand-alone selling price for each distinct performance obligation based upon the relative stand-alone selling price. The transaction price allocated to the clinical development of ZIMHI was immaterial.

            Revenues from the manufacture and supply of SYMJEPI™ and ZIMHI™ are recognized at a point in time upon delivery to the carrier. The licenses to distribute and commercialize SYMJEPI™ and ZIMHI™ products in the United States is distinct from the other performance obligations identified in the arrangement and has stand-alone functionality; the Company recognizes revenues from non-refundable, upfront fees allocated to the license when the license is transferred to the licensee and the licensee is able to benefit from the license.

        Payments received under USWM Agreement may include non-refundable fees at the inception of the arrangements, milestone payments for specific achievements and net-profit sharing payments based on certain percentages of net profit generated from the sales of products over a given quarter. At the inception of arrangements that include milestone payments, the Company uses judgement to evaluate whether the milestones are probable of being achieved and estimates the amount to include in the transaction price utilizing the most likely amount method. If it is probable that a significant revenue reversal will not occur, the estimated amount is included in the transaction price. Milestone payments that are not within the Company or the licensee’s control, such as regulatory approvals are not included in the transaction price until those approvals are received. At the end of each reporting period, the Company re-evaluates the probability of achievement of development milestones and any related constraint and adjusts the estimate of the overall transaction price, if necessary. The Company recognizes aggregate sales-based milestones, and net-profit sharing as royalties from product sales at the later of when the related sales occur or when the performance obligation to which the sales-based milestone or royalty has been allocated has been satisfied. The amounts receivable from USWM have a payment term of Net 30.

            Revenues do not include any state or local taxes collected from customers on behalf of governmental authorities. The Company made the accounting policy election to continue to exclude these amounts from revenues. 

Product Recall   

           On March 21, 2022, the Company announced a voluntary recall of four lots of SYMJEPI (epinephrine) Injection 0.15 mg (0.15 mg/0.3 mL) and 0.3 mg (0.3 mg/0.3 mL) Pre-Filled Single-Dose Syringes to the consumer level, due to the potential clogging of the needle preventing the dispensing of epinephrine. In February 2023, the Company received notice from the FDA that the FDA considers the voluntary recall of our SYMJEPI products to be terminated. Such notice does not preclude the FDA from taking action in the future related to the recall, and the Company remains responsible for compliance with applicable laws relating to the product and the recall.

          As of September 30, 2023 and December 31, 2022, the recall liability was $0 and $0.3 million, respectively. During the three and nine months ended September 30, 2023, the Company expensed $25,000 and $81,000, respectively, in product recall costs, which were included in selling, general and administrative expenses. During the three and nine months ended September 30, 2022, the Company expensed $388,000 and $2.4 million, respectively, in product recall costs, which were included in selling, general and administrative expenses. Total product recall costs from inception of the recall through September 30, 2023, were approximately $2.6 million.

XML

Inventories

9 Months Ended

Sep. 30, 2023

Inventory Disclosure [Abstract]

Inventories

Note 6: Inventories

Inventories at September 30, 2023 and December 31, 2022 were as follows: 

	September 30, 2023		December 31, 2022
Finished Goods	$	—	$	267,554
Work-in-Process		—		261,720
Raw Materials		662,962		709,504
Inventories	$	662,962	$	1,238,778

XML

Fixed Assets, net

9 Months Ended

Sep. 30, 2023

Property, Plant and Equipment [Abstract]

Fixed Assets, net

Note 7: Fixed Assets, net

Fixed assets, net at September 30, 2023 and December 31, 2022 were as follows: 

Description	Useful Life (Years)		September 30,  2023			December 31, 2022
Machinery and Equipment		3 - 7	$	5,156,377		$	5,209,575
Less: Accumulated Depreciation				(4,080,701	)		(4,665,067	)
Construction In Progress - Equipment				—			744,386
Fixed Assets, net			$	1,075,676		$	1,288,894

Depreciation expense for the three months ended September 30, 2023 and 2022 was approximately $67,000 and $399,000, respectively, included in costs of goods sold and Selling, General and Administrative in the accompanying condensed consolidated statements of operations. Depreciation expense for the nine months ended September 30, 2023 and 2022 was approximately $264,000 and $1,111,000, respectively, included in costs of goods sold and Selling, General and Administrative in the accompanying condensed consolidated statements of operations.  

XML

Paycheck Protection Program (PPP) Loan

9 Months Ended

Sep. 30, 2023

Debt Disclosure [Abstract]

Paycheck Protection Program (PPP) Loan

Note 8: Paycheck Protection Program (PPP) Loan    

On March 15, 2021, the Company entered into a Note (the “PPP2 Note”) in favor of Arvest Bank (the “Bank”), as lender, in the principal amount of $1,765,495 relating to funding under a Second Draw loan (the “Second PPP Loan”) pursuant to the terms of the Paycheck Protection Program (the “PPP”), established pursuant to the Coronavirus Aid, Relief, and Economic Security Act (the “CARES Act”) and administered by the U.S. Small Business Administration (“SBA”), and the Economic Aid to Hard-Hit Small Businesses, Nonprofits, and Venues Act enacted in December 2020. The Company applied for forgiveness and received notification through the Bank that as of September 28, 2021, the Second Draw PPP Loan, including principal and interest thereon, was fully forgiven by the SBA. The Company recognized $1,765,495, the amount forgiven, as other income in the third quarter of 2021. In March 2022 the Company was informed that the Civil Division of the U.S. Attorney’s Office for the Southern District of New York was investigating the Company’s Second Draw PPP Loan and eligibility for that loan. In June 2022, following the inquiry, the Company paid a total of $1,787,417 in repayment of the Second Draw PPP Loan principal and such related interest and fees.

XML

Fair Value Measurement

9 Months Ended

Sep. 30, 2023

Fair Value Disclosures [Abstract]

Fair Value Measurement

Note 9: Fair Value Measurement

Fair value is defined as the exchange price that would be received for an asset or an exit price paid to transfer a liability in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. Valuation techniques used to measure fair value must maximize the use of observable inputs and minimize the use of unobservable inputs.

The fair value hierarchy defines a three-level valuation hierarchy for disclosure of fair value measurements as follows: 

Level 1:	Unadjusted quoted prices in active markets for identical assets or liabilities;
Level 2:	Inputs other than quoted prices included within Level 1 that are observable, unadjusted quoted prices in markets that are not active, or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the related assets or liabilities; and
Level 3:	Unobservable inputs that are supported by little or no market activity for the related assets or liabilities.

The carrying value of the Company’s cash and cash equivalents, prepaid expenses and other current assets, accounts payable and accrued liabilities, approximate fair value due to the short-term nature of these items. 

The categorization of a financial instrument within the valuation hierarchy is based upon the lowest level of input that is significant to the fair value measurement.

The following table sets forth the Company’s financial instruments that were measured at fair value on a recurring basis by level within the fair value hierarchy: 

		Fair Value Measurements at September 30, 2023
	Total		Level 1		Level 2		Level 3
Liabilities
2020 Warrant Liability	$	Less than $1	$	—	$	Less than $1	$	—
March 2023 Common Stock Warrants		302,170		—		302,170		—
Total Common Stock Warrants Liabilities	$	302,170	$	—	$	302,170	$	—

		Fair Value Measurements at December 31, 2022
	Total		Level 1		Level 2		Level 3
Liabilities
2020 Warrant Liability	$	7,492	$	—	$	7,492	$	—

The fair value measurement of the warrants issued by the Company in February 2020 (“2020 Warrant Liability”) and March 16, 2023 Common Stock Warrant ("March 2023 Common Stock Warrants") are based on inputs that are observable or can be corroborated by observable market data (such as the Company’s daily closing stock price and the published treasury par yield curves from the US Department of the Treasury), and, as such, qualify as Level 2 measurement. The fair value of the warrant liabilities was calculated using the Black Scholes Option Pricing Model.

As of September 30, 2023, the valuation assumptions include the expected volatility of the Company’s stock ranging from approximately 70% - 134.65%, the Company’s stock price at valuation date of $0.69, expected dividend yield of 0.0%, expected term ranging from 1.93 to 4.96 years and average risk-free interest rate ranging from 4.721% - 5.253%.

As of December 31, 2022, the valuation assumptions include the expected volatility of the Company’s stock of approximately 70% (based on calculated volatility and management’s judgement), the Company’s stock price at valuation date of $11.90, expected dividend yield of 0.0%, expected term of 2.68 years and risk-free interest rate of approximately 4.362%. 

XML

Prepaid Expenses and Other Current Assets

9 Months Ended

Sep. 30, 2023

Prepaid Expenses And Other Current Assets

Prepaid Expenses and Other Current Assets

Note 10: Prepaid Expenses and Other Current Assets

Prepaid expenses and other current assets were as follows:

	September 30, 2023		December 31, 2022
Employee Retention Credit	$	—	$	875,307
Prepaid Insurance		86,436		323,143
Prepaid - Research and Development		326,854		588,354
Other Prepaid		59,275		78,590
Other Current Assets		67,207		49,572
	$	539,772	$	1,914,966

Employee Retention Credit

The Company applied for the Employee Retention Credit (ERC) which was available under the CARES Act. The ERC is a fully refundable tax credit for employers equal to 50 percent of qualified wages (including allocable qualified health plan expenses) that eligible employers paid their employees. The ERC applied to wages paid after March 12, 2020 and before January 1, 2021. The Company received the full amount from the original ERC from the Department of Treasury in January 2023. The Company amended its ERC application due to its repayment of the PPP loans (discussed in Note 7) and was subsequently awarded an additional refund of approximately $463,000, which the Company received in full during the second quarter of 2023, and is included in other income in the condensed consolidated statement of operations for the nine months ended September 30, 2023.

XML

Legal Proceedings

9 Months Ended

Sep. 30, 2023

Commitments and Contingencies Disclosure [Abstract]

Legal Proceedings

Note 11: Legal Proceedings

The Company may from time to time become party to actions, claims, suits, investigations or proceedings arising from the ordinary course of business, including actions with respect to intellectual property claims, breach of contract claims, labor and employment claims and other matters. The Company may also become party to litigation in federal and state courts relating to opioid drugs. Any litigation could divert management time and attention from the Company, could involve significant amounts of legal fees and other fees and expenses, or could result in an adverse outcome having a material adverse effect on the Company’s financial condition, cash flows or results of operations. Actions, claims, suits, investigations and proceedings are inherently uncertain and their results cannot be predicted with certainty. Except as described below, the Company is not currently involved in any legal proceedings that the Company believes are, individually or in the aggregate, material to our business, results of operations or financial condition. However, regardless of the outcome, litigation can have an adverse impact on the Company because of associated cost and diversion of management time.

            Investigations 

           On May 11, 2021, each of the Company and its USC subsidiary received a grand jury subpoena from the U.S. Attorney’s Office for the Southern District of New York (the “USAO”) issued in connection with a criminal investigation, requesting a broad range of documents and materials relating to, among other matters, certain veterinary products sold by the Company’s USC subsidiary, certain practices, agreements and arrangements relating to products sold by USC, including veterinary products, and certain regulatory and other matters relating to the Company and USC. The Audit Committee of the Board engaged outside counsel to conduct an independent internal investigation to review these and other matters. The Company has also received requests from the Securities and Exchange Commission (“SEC”) that the Company voluntarily provide documents and information in connection with the SEC’s investigation relating to certain matters including matters arising from the subject matter of the subpoenas from the USAO. The Company has produced and will continue to produce and provide documents in response to the subpoenas and requests as needed. Additionally, on March 16, 2022, the Company was informed that the Civil Division of the USAO (“Civil Division”) is investigating the Company’s Second Draw PPP Loan application disclosed in previous reports. The Audit Committee of the Board engaged outside counsel to conduct an internal inquiry into the matter. In June 2022, following the inquiry the Company paid a total of $1,787,417 in repayment of the Second Draw PPP Loan principal and such related interest and fees. The Company intends to continue cooperating with the USAO and the SEC, and has continued to engage in communications with the SEC and USAO regarding their investigations. The Company has received additional requests for production of documents from the SEC and the USAO, have responded to those requests, could receive additional requests from the USAO, SEC, or other authorities, and continue to engage in communications with the SEC and the USAO regarding their investigations.  Additional issues or facts could arise or be determined, which may expand the scope, duration, or outcome of the investigation. The Company is unable to predict the duration, scope, or final outcome of the investigations by the USAO, SEC, or other agencies; what, if any, proceedings the USAO, SEC, or other federal or state authorities may initiate; what penalties, payments, by the Company, remedies or remedial measures the USAO, SEC, or other federal or state authorities may seek or may require in order to resolve the investigations; what, if any, impact the foregoing matters may have on the Company’s business, financial condition, previously reported financial results, financial results included in this Report, or future financial results; or what proceedings the USAO, SEC, or other federal or state authorities may initiate if the foregoing matters are not resolved. However, in connection with resolution of these matters, the Company or its USC subsidiary may be found to have violated one or more laws arising from the subject matter of the subpoenas, and to resolve the matters and investigations with the USAO and the SEC the Company may be required to pay material amounts in penalties or other payments, and to agree to other remedies or remedial measures. Payment of material amounts in connection with resolution of the foregoing matters would reduce the amount of financial resources that the Company has available to support product development programs and commercialization activities and would adversely impact the Company’s development programs. Depending in part on the amount and timing of any payments that the Company may be required to make or other remedial measures that may be implemented in connection with resolution of these matters, a resolution of these matters with the USAO or SEC could have a material and adverse impact on the company. The foregoing matters have diverted and will likely continue to divert management’s attention, have caused the company to suffer reputational harm, have required and will continue to require the company to devote significant financial resources, could subject the company, one or more of its subsidiaries, or its officers and directors to civil or criminal proceedings, and depending on the resolution of the matters or any proceedings, could result in fines, penalties, payments, or financial remedies in amounts that would have a material adverse effect on the Company’s financial condition, or equitable remedies, and adversely affect the company’s business, previously reported financial results, financial results included or incorporated by reference herein, or future financial results.

Nasdaq Compliance     

              On October 4, 2023, the Company received notice (the “Prior Notice”) from the Listing Qualifications Department (the “Staff”) of The Nasdaq Stock Market LLC (“Nasdaq”) notifying the Company that it failed to evidence a minimum closing bid price of $1.00 per share, as required by Nasdaq Listing Rule 5550(a)(2) (the “Bid Price Rule”), for the previous 30 consecutive days and that the Company was provided a grace period of 180 calendar days from the date of the Prior Notice, or until April 1, 2024, to regain compliance with the Bid Price Rule, in accordance with Listing Rule 5810(c)(3)(A).  Also as previously disclosed, on October 11, 2023, the Company received notice from the Staff that, due to the Company’s failure to regain compliance with the minimum $35 million market value of listed securities (“MVLS”) requirement set forth in Nasdaq Listing Rule 5550(b)(2) (the “MVLS Rule”) during the 180-day grace period previously granted to the Company that expired on October 9, 2023, the Company’s common stock was subject to delisting unless the Company timely requested a hearing before the Nasdaq Hearings Panel (the “Panel”).

                In response, the Company timely requested a hearing before the Panel, which request stayed any further action by Nasdaq at least until the hearing is held and any extension the Panel may grant to the Company following the hearing expires.

              On October 18, 2023, the Company received a superseding notice from the Staff (the “Subsequent Notice”), indicating that the Prior Notice was issued in error. The Subsequent Notice indicated that because the Company was subject to a one-year Mandatory Panel Monitor as a result of a prior hearing before the Panel, the Company was not eligible for the automatic 180-day compliance grace period provided by Listing Rule 5810(c)(3)(A) and that the Company’s non-compliance with the Bid Price Rule serves as an additional basis for delisting from Nasdaq.

At the hearing before the Panel, the Company will address its plan to regain compliance with both the Bid Price Rule and the MVLS Rule as well as its continued compliance with all other applicable criteria for continued listing on The Nasdaq Capital Market. There can be no assurance, however, that the Panel will grant the Company’s request for continued listing or that the Company will evidence compliance with the listing rules prior to the expiration of any extension that may be granted by the Panel following the hearing.

 Jerald Hammann       

On June 8, 2021, Jerald Hammann filed a complaint against the Company and each of its directors in the Court of Chancery of the State of Delaware, captioned Jerald Hammann v. Adamis Pharmaceuticals Corporation et al., C.A. No. 2021-0506-PAF (the “Complaint”), seeking injunctive and declaratory relief.  The Complaint alleges, among other things, that the defendants (i) violated Rule 14a-5(f) and 14a-9(a) of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), in connection with the Company’s 2021 annual meeting of stockholders—which was subsequently held on July 16, 2021 (the “2021 annual meeting”)—and disseminated false and misleading information in the Company’s proxy materials relating to the 2021 annual meeting, (ii) violated certain provisions of the Company’s bylaws relating to the 2021 annual meeting, (iii) violated section 220 of the Delaware General Corporation Law (“DGCL”) in connection with a request for inspection of books and records submitted by the plaintiff, and (iv) breached their fiduciary duties of disclosure and loyalty, including relating to establishing and disclosing the date of the Company’s 2021 annual meeting and to the Company’s determination that a solicitation notice delivered to the Company by plaintiff was not timely and was otherwise deficient.  On April 4, 2022, the plaintiff filed a motion to amend the Complaint. The proposed amended Complaint added additional allegations relating to the manner in which the defendants established and disclosed the date of the Company’s 2021 annual meeting of stockholders and to statements the defendants made about the plaintiff to the Company’s stockholders. On April 28, 2022, the Court granted the motion. Trial on the merits of the plaintiff’s claims was held on March 16, 2023.  On August 23, 2023, the Court entered its opinion rendering judgment in favor of the Company and the other defendants and against the plaintiff as to all of the plaintiff’s claims.  On August 30, 2023, the plaintiff filed a motion for re-argument.  On October 16, 2023, the Court denied the plaintiff’s motion except with respect to an issue of nominal damages but concluded that nominal damages were not warranted.  On October 9, 2023, the plaintiff filed a motion for a temporary restraining order seeking to enjoin the defendants from distributing proxy materials and holding the Company’s 2023 annual meeting of stockholders.  On October 12, 2023, the Court denied the plaintiff’s motion for a temporary restraining order, and on October 16, 2023, the Court issued an order denying the plaintiff’s motion for re-argument. On November 3, 2023, plaintiff filed a notice of appeal to the Supreme Court of the State of Delaware.

CVI Investments

On October 19, 2023, a purported shareholder of the Company filed a complaint against the Company in the Supreme Court of the State of New York, County of New York, captioned CVI Investments vs. DMK Pharmaceuticals Corporation f/k/a Adamis Pharmaceuticals Corporation, Index No. 655184/2023 (the “Complaint”).  The Complaint alleges that the Company breached two warrant agreements that Plaintiff entered into with the Company in connection with Plaintiff’s previous purchases of shares of Adamis stock.  Specifically, the Complaint alleges that the Company failed to repurchase two warrants previously issued to the Plaintiff for the repurchase price specified in the warrants, allegedly in violation of the terms of the warrants that provide for the repurchase of the warrants following timely notice from the warrant holder following the occurrence of certain specified events. The Complaint seeks (i) actual and compensatory damages from the purported breaches, (ii) reasonable attorneys’ fees and other costs and expenses incurred in connection with the Complaint, and (iii) pre- and post-judgment interest.  The Company’s deadline to respond to the Complaint is November 22, 2023. The Company disputes that it was obligated to repurchase the warrants and intends to vigorously dispute the claim.

Arbitration

On October 20, 2023, David J. Marguglio, a former executive officer of the Company, filed a demand for arbitration with Judicial Arbitration and Mediation Services, Inc. (JAMS) challenging the grounds of the separation of his employment, alleging that he is entitled to severance under the terms of his employment agreement, and demanding that the Company pay the costs of the arbitration.  The Company contends that Mr. Marguglio is not entitled to severance under the terms of his employment agreement.

Turbare Real Estate Holdings

On May 26, 2023, Turbare Real Estate Holdings, LLC filed a complaint against the Company in the Circuit Court of Faulkner County Arkansas, captioned Turbare Real Estate Holdings, LLC v Adamis Pharmaceutical Corporation 23CV-23-796. The suit alleges breach of contract, seeking $1,414,943.08, with additional amounts still being incurred, plus costs and attorney fees, for alleged required repairs under a lease agreement between the parties.  The Company has filed a counter suit, alleging as to Turbare Real Estate Holdings, LLC, claims for breach of lease agreement, conversion, civil conspiracy for conversion, replevin, and unjust enrichment.  Additionally, the Company has added, as third party defendant, Turbare Manufacturing, LLC, alleging claims of breach of an access agreement for the leased real estate, conversion, civil conspiracy for conversion, replevin, tortious interference with contract, and unjust enrichment. On November 3, 2023, plaintiff filed a notice of appeal to the Supreme Court of the State of Delaware.

Supplemental Proxy Disclosures

On April 11, 2023, a purported stockholder of the Company filed a complaint against the Company and each of its directors in the United States District Court for the Southern District of New York, captioned Lapin vs. Adamis Pharmaceuticals Corporation, Case No. 1:23-cv-03023 (the “Complaint”). The Complaint alleged that the defendants violated Sections 14(a) and 20(a) of the Securities Exchange Act of 1934, as amended, by causing a materially incomplete and misleading Preliminary Proxy Statement to be filed with the SEC. Specifically, the Complaint alleged that the Preliminary Proxy Statement contains materially incomplete and misleading information concerning the sales process, financial projections prepared by management, as well as the financial analysis conducted by Raymond James & Associates, Inc., the Company’s financial advisor. The Complaint sought, among other things, (i) injunctive relief preventing the consummation of the transactions contemplated by the Merger Agreement or the filing of a definitive proxy statement with the SEC or causing a definitive proxy statement to be disseminated to the Company’s stockholders unless and until the material information described in the Complaint is included in the definitive proxy statement or otherwise disseminated to the Company’s stockholders, and (ii) in the event that the Merger transaction is consummated without the alleged material omissions referenced in the Complaint being remedied, damages and costs and disbursements of the action including reasonable plaintiff’s attorneys’ and experts’ fees and expenses. On July 6, 2023, the plaintiff filed a notice of voluntary dismissal, dismissing the claims in the complaint without prejudice, which was entered by the court on July 7, 2023.

In addition, the Company has received additional demand letters from counsel (the “Demand Letters”), each representing a purported stockholder of the Company, asserting that the Preliminary Proxy Statement and/or Proxy Statement was deficient and demanding that the alleged deficiencies be rectified. The Demand Letters allege, among other matters, that the Proxy Statements contain materially incomplete and misleading information concerning the sales process, financial projections prepared by the Company's management, and the financial analysis conducted by Raymond James & Associates, Inc. In addition, each purported shareholder has reserved his or her rights, including the right to alter or amend the demands at any time, and/or seek monetary damages following the consummation of the Merger.

The Company believes that the allegations in the Complaint and the Demand Letters are without merit and that the disclosures set forth in the Proxy Statement comply fully with applicable law. However, in order to moot the unmeritorious claims, avoid nuisance and possible expense and delay, and to provide additional information to the Company’s shareholders, the Company provided a voluntary supplement to the Proxy Statement with the supplemental disclosures filed with the SEC on May 5, 2023. Nothing in the Supplemental Disclosures shall be deemed an admission of the legal necessity or materiality under applicable laws of any of the disclosures set forth in the Supplemental Disclosures. To the contrary, the Company specifically denies all allegations that any additional disclosure was or is required. Nevertheless, resolution of these matters may involve payments by the Company to the parties submitting the Demand Letters or other claims.

The Company records accruals for loss contingencies associated with legal matters when the Company determines it is probable that a loss has been or will be incurred and the amount of the loss can be reasonably estimated. Where a material loss contingency is reasonably possible and the reasonably possible loss or range of possible loss can be reasonably estimated, U.S. GAAP requires the Company to disclose an estimate of the reasonably possible loss or range of loss or make a statement that such an estimate cannot be made. The Company has not accrued any amount in respect of the matters described under the headings “Investigation,” “Jerald Hammann,” “Supplemental Proxy Disclosures,” “CVI Investments,” “Arbitration,” or “Turbare Real Estate Holdings,” as the Company cannot estimate the probable loss or the range of probable losses that the Company may incur. The Company is unable to make such an estimate because (i) with respect to the matters described under the heading “Investigation,” the Company is unable to predict whether any proceedings will be initiated by the USAO, SEC or other authorities arising from such matters, what, if any, relief, remedies or remedial measures the USAO, SEC, or other authorities may seek if proceedings are commenced, and the duration, scope, or outcome of any such proceedings, if they are commenced, (ii) litigation, arbitration, and other proceedings are inherently uncertain and unpredictable, and (iii) with respect to the “Supplemental Proxy Disclosures” the Demand Letters have not specified any amount for monetary damages and a reasonably possible loss or range of loss cannot be estimated. Because legal proceedings and investigations are uncertain and unpredictable and unfavorable results could occur, assessing contingencies is highly subjective and requires significant judgments about future events, including determining both the probability and reasonably estimated amount of a possible loss or range of loss. The amount of any ultimate loss may differ from any accruals or estimates that the Company may make.

XML

Stockholders' Equity

9 Months Ended

Sep. 30, 2023

Equity [Abstract]

Stockholders' Equity

Note 12: Stockholders' Equity

Common Stock

             On March 14, 2023, the Company entered into a Securities Purchase Agreement or, SPA, with an investor providing for the purchase and sale of (i) an aggregate of 235,714 common stock shares, at a price of $8.75 per share, (ii) a warrant to purchase up to an aggregate of 685,714 shares of the Company’s common stock at an exercise price of $9.66 per share (the “Common Stock Warrants”), and (iii) a prefunded warrant at a price of $8.74 per share to purchase up to an aggregate of 107,143 shares of the Company’s common stock (the “Prefunded Warrants” and, collectively with the Common Stock Warrant, the “Warrants”), which represents the per share price for the shares less the $0.0007 per share exercise price for the Prefunded Warrant, pursuant to a previously filed and effective registration statement in a registered direct offering (the “March 2023 Offering”). Gross proceeds from the March 2023 Offering were approximately $3.0 million, before deducting offering expenses of approximately $0.3 million.

The Prefunded Warrants are immediately exercisable and will expire five years from the date of issuance. The Common Stock Warrants are exercisable on or after the six month and one day anniversary of the date of issuance and will expire five years and six months from the date of issuance. The terms of the Warrants provide that at the request of the holder following a change of control or certain other fundamental transactions, the Company or the successor entity, has to purchase the Warrant from the holder for an amount in cash equal to the Black Scholes Value (as defined in the Warrant). Due to this cash redemption feature, the Company determined that the Warrants should be classified as liabilities based on the authoritative guidance in ASC 480 “Distinguishing Liabilities from Equity” (“ASC 480”). The liability-classified Warrants are measured initially and subsequently at fair value each reporting period, with the changes in fair value recorded in the income statement.

             At the closing of the Offering on March 16, 2023, the Company determined the fair value of the Warrants (based on the Black Scholes Option Pricing Model) was in excess of the proceeds and, as such, a day-one loss was recognized in earnings. The issuance costs of $225,000 were fully allocated to the Warrants and expensed in the condensed consolidated statement of operations.

The following table provides the initial allocation of the offering proceeds between the common stock and the Warrants issued:

	Allocation
235,714 Common Stock Issued	$	—
107,142 Prefunded Warrant Issued		899,388
685,714 Common Stock Warrant Issued		4,575,971
Day-one Loss due to Excess Warrant Fair Value		(2,476,109	)
Gross Proceeds	$	2,999,250

In May 2023, the Prefunded Warrants were exercised in full, which resulted in the reclassification of the fair value of the Prefunded Warrants of $524,379, net of the cash proceeds of $750, at the exercise date into equity.

August 2023 Offering

On August 4, 2023, the Company completed an offering of (i) 4,800,000 shares of the common stock, (ii) pre-funded warrants to purchase up to 1,130,000 shares of Common Stock (the “August 2023 Prefunded Warrants”), and (iii) common stock purchase warrants to purchase up to 5,930,000 shares of the Company’s common stock (the “August 2023 Common Stock Warrants” and together with the August 2023 Prefunded Warrants, the “August 2023 Warrants”) (the “August 2023 Offering”). The Company received net proceeds of approximately $7.1 million from the August 2023 Offering, net of approximately $0.9 million of placement agent commissions and other offering expenses.

The August 2023 Prefunded Warrants are immediately exercisable at $0.0001 per share and do not expire until exercised in full. All August 2023 Prefunded Warrants were exercised in full on August 4, 2023. Of the 1,130,000 August 2023 Prefunded Warrants exercised on August 4, 2023, 395,000 resulted in cash proceeds of approximately $40, representing the par value of the 395,000 Common Stock shares issued. The remaining 735,000 of the August 2023 Prefunded Warrants were exercised on a cashless basis, resulting in the issuance of 734,985 Common Stock shares. 

The August 2023 Common Stock Warrants are exercisable at $1.35 per share beginning on the issuance date, and expire five years from the issuance date. During the three months ended September 30, 2023, 645,000 August 2023 Common Stock Warrants were exercised, resulting in cash proceeds of $870,750. 

The August 2023 Warrants were accounted for as equity instruments as they meet all of the requirements for equity classification under ASC Topic 815 “Derivatives and Hedging” (“ASC 815").

Series C Convertible Preferred Stock

On July 5, 2022, the Company entered into a private placement transaction with Lincoln Park Capital Fund, LLC, (“Lincoln Park”) pursuant to which the Company issued an aggregate of 3,000 shares of Series C Convertible Preferred Stock, par value $0.0001 per share (the “Series C Preferred”), together with warrants (the “July Warrants”) to purchase up to an aggregate of 10,714 shares of common stock of the Company, at an exercise price of $32.90 per share (subject to adjustment as provided in the July Warrants). Gross proceeds were $300,000, excluding transaction costs, fees and expenses of $15,000. The July Warrants become exercisable commencing January 3, 2023 and have a term ending on January 5, 2028.

Subsequent to the issuance of the Series C Preferred, in connection with the Company’s 2022 annual meeting of stockholders, in September 2022 the Company’s stockholders voted on a reverse stock split proposal, and the proposal was not approved. Pursuant to the Series C Preferred transaction agreements, the Company paid $15,000 to Lincoln Park resulting from the failure of the reverse stock split proposal to be approved at the meeting.  In connection the approval of the Reverse Stock Split in May 2023 at the Company's special meeting of stockholders, redemption of the Series C Preferred became probable. As a result, the Company recorded accretion of approximately $173,000 in the second quarter of 2023, which is reflected in the accompanying condensed consolidated statements of mezzanine equity and stockholders’ deficit for the nine months ended September 30, 2023. As of September 30, 2023, neither the holder nor the Company have elected to redeem the Series C Preferred and the Series C Preferred stock is reflected on the condensed consolidated balance sheet at the 110% redemption value of $330,000.

Series E Preferred Stock

Pursuant to the DMK Merger, 1,941.2 shares of Series E Preferred were issued to former Legacy DMK shareholders. The Series E Preferred is convertible into shares of the Company’s common stock at a conversion rate of 1,000 common shares for 1 Series E Preferred share, and conversion is subject to certain beneficial ownership limitations. During the three and nine months ended September 30, 2023, 729.2 Series E Preferred shares have been converted into 729,200 shares of Common Stock.

Stock Options

The Company’s 2020 Equity Incentive Plan (the “2020 Plan”) provides for the grant of incentive stock options, non-statutory stock options, restricted stock awards, restricted stock unit awards, stock appreciation rights, performance stock awards, and other forms of equity compensation (collectively “stock awards”). In addition, the 2020 Plan provides for the grant of cash awards. The initial aggregate number of shares of common stock that may be issued initially pursuant to stock awards under the 2020 Plan is 28,571 shares. The number of shares of common stock reserved for issuance automatically increases on January 1 of each calendar year during the term of the 2020 Plan, commencing January 1, 2021, by 5.0% of the total number of shares of common stock outstanding on December 31 of the preceding calendar year, or a lesser number of shares of common stock determined by the Company’s board of directors before the start of a calendar year for which an increase applies. In December 2022, the Board determined and resolved, that the 2020 Plan share reserve shall not be increased effective January 1, 2023, and that there shall not be any increase in share reserve for the 2023 year by virtue of the annual share reserve increase. No awards had been made pursuant to the 2020 Plan as of September 30, 2023.

The Company had a 2009 Equity Incentive Plan (the “2009 Plan”). The 2009 Plan terminated effective February 2019 and no new awards may be made under the 2009 Plan. The maximum contractual term for options is 10 years.

The following table summarizes the outstanding stock option activity under the 2009 Equity Incentive Plan for the nine months ended September 30, 2023:

	2009 Equity Incentive Plan			Weighted-Average Exercise Price		Weighted-Average Remaining Contract Life
Outstanding Vested and Expected to Vest as of December 31, 2022		61,525		$	291.41		2.09 years
Cancelled/Expired		(29,068	)		280.26		—
Outstanding and Vested as of September 30, 2023		32,457			306.44		2.44 years

As of September 30, 2023, the unamortized compensation expense related to 2009 Plan awards was $0.

The aggregate intrinsic value (the difference between the Company’s closing stock price on the last trading day of the period and the exercise price, multiplied by the number of in-the-money options) of all options outstanding at September 30, 2023 and December 31, 2022 was $0.

The following table summarizes the outstanding stock option activity for the non-plan awards for the nine months ended September 30, 2023:

	Non-Plan Awards			Weighted-Average Exercise Price			Weighted-Average Remaining Contract Life
Outstanding as of December 31, 2022		1,857			$	43.40		9.13 years
Cancelled		(429	)			43.40		—
Outstanding as of September 30, 2023		1,428				43.40		8.38 years
Vested and Expected to Vest at September 30, 2023		952				43.40		8.38 years

Non-plan awards are granted pursuant to Rule 5635(c)(4) of the Nasdaq Listing Rules, as a material inducement to the willingness of such person to join the Company as a new employee, effective upon the effective date of Board of Director-approved resolutions to grant nonqualified stock options to such person (an inducement grant). Inducement grants, although granted outside of the Company’s 2020 Plan, are subject to the terms and conditions set forth in that plan. The terms of inducement grants are generally the same as terms would be under the 2020 Plan, wherein the exercise price of the options is equal to the fair value of the Company’s common stock at date of grant, with vesting commencing on date of grant, and a vesting schedule consisting of one-sixth (1/6) of the options becoming exercisable six (6) months after vesting commences, and one thirty-sixth (1/36) of the options on becoming exercisable each subsequent monthly anniversary of the vesting commencement date, such that the option is exercisable in full after three years from the vesting commencement date of the option grant, subject to the option holder providing continuous service.

As of September 30, 2023, the unamortized compensation expense related to non-plan awards was $0.

              Pursuant to the Merger Agreement with Legacy DMK, the Company assumed the outstanding options of Legacy DMK.  Based on the conversion mechanism in the Merger Agreement, the Company assumed 231,490 options with an exercise price of $2.90. The assumed options were fully vested and will continue to be governed by the terms of the DMK 2016 Stock Plan, which was assumed by the Company in connection with the closing of the Merger. Additionally, the assumed options were converted into an equivalent option to acquire shares of the Company’s common stock. The DMK 2016 Stock Plan provides for the grant of incentive stock options ("ISOs"), nonstatutory stock options, stock bonus and opportunities to make direct purchase of the Company’s common stock to employees and directors. The total number of shares of common stock reserved for the Stock Plan is 249,501.

The aggregate intrinsic value (the difference between the Company’s closing stock price on the last trading day of the period and the exercise price, multiplied by the number of in-the-money options) of all options outstanding at September 30, 2023 and December 31, 2022, was $0.

 Restricted Stock Units

The following table summarizes the RSUs outstanding at September 30, 2023: 

	Number of Shares/Units			Weighted Average Grant Date Fair Value
Non-vested as of December 31, 2022		9,286		$	325.13
Vested during the period		(2,143	)		592.20
Forfeited during the period		—			—
Non-vested as of September 30, 2023		7,143			245.00
Expected to vest as of September 30, 2023		7,143		$	245.00

The RSU's have cliff vesting after seven years of continuous service or upon change of control from date of grant or upon death or disability. As of September 30, 2023, the unamortized compensation expense related to RSUs was approximately $42,000 and will be recognized over 0.42 years.

Stock-Based Compensation

The following summarizes stock-based compensation recognized for the three months ended September 30, 2023 and 2022:

	For the Three Months Ended September 30,
	2023			2022
Research and Development	$	(69,835	)	$	3,654
Selling, General and Administrative		25,142			70,834
Total	$	(44,693	)	$	74,488

The following summarizes stock-based compensation recognized as R&D costs and SG&A costs for the nine months ended September 30, 2023 and 2022:

	For the Nine Months Ended September 30,
	2023			2022
Research and Development	$	(69,835	)	$	122,746
Selling, General and Administrative		146,634			(137,057	)
Total	$	76,799		$	(14,311	)

     Warrants 

The following table summarizes warrants issued and outstanding as of September 30, 2023:   

	Warrant   Shares		Exercise Price   Per Share		Date   Issued	Expiration   Date
Old Adamis Warrants		840	$	595.00	November 15, 2007	November 15, 2023
2019 Warrants		197,055	$	80.50	August 5, 2019	August 5, 2024
2020 Warrants		5,000	$	49.00	February 25, 2020	September 3, 2025
Series C Preferred Warrants		10,714	$	32.90	July 5, 2022	January 5, 2028
March 2023 Common Stock Warrants		685,714	$	9.66	March 16, 2023	September 16, 2028
August 2023 Common Stock Warrants		5,285,000	$	1.35	August 4, 2023	August 4, 2028
Total		6,184,323

Shares Reserved

As of September 30, 2023, the Company has reserved shares of common stock for issuance upon exercise of outstanding options, warrants including all of the warrants in the table above and restricted stock units, as follows:

Warrants	6,184,323
Restricted Stock Units	7,143
Non-Plan Awards	1,428
2009 Equity Incentive Plan	32,457
Legacy DMK Options Assumed by the Company	231,490
Conversion of Series C Preferred stock	697,674
Conversion of Series E Preferred stock	1,212,000
Total Shares Reserved	8,366,515

XML

Commitments and Contingencies

9 Months Ended

Sep. 30, 2023

Commitments and Contingencies Disclosure [Abstract]

Commitments and Contingencies

 Note 13: Commitments and Contingencies

Firm Purchase Commitments

The Company has a production threshold commitment to a manufacturer of our SYMJEPI Products where the Company would be required to pay for maintenance fees if it does not meet certain periodic purchase order minimums. Any such maintenance fees would be prorated as a percentage of the required minimum production threshold. For the three and nine month periods ended September 30, 2023 and 2022, there were no purchases under firm purchase commitments. The maintenance fees for the three and nine months ended September 30, 2023 were approximately $268,000 and $804,000, respectively, and were recorded as cost of sales in the condensed consolidated statement of operations. There were no maintenance fees incurred during the three and nine months ended September 30, 2022.

Abandonment of ROU Assets

The Company has one operating lease for an office space in San Diego, CA with the lease term through November 30, 2023 and base rent of $32,000 per month. The Company ceased the use of this space in August 2023 and the related right-of-use asset was deemed abandoned. The ROU asset was reduced to its salvage value of zero as of its cease-use date which resulted in an impairment charge of $116,934 included in general and administrative expenses in the condensed consolidated statements of operations for the three and nine months ended September 30, 2023.

XML

Income Taxes

9 Months Ended

Sep. 30, 2023

Income Tax Disclosure [Abstract]

Income Taxes

 Note 14: Income Taxes

The Company did not record any income tax provision or benefit for the three and nine months ended September 30, 2023 and 2022. The Company has evaluated the positive and negative evidence bearing upon its ability to realize the deferred tax assets. Management has considered the Company’s history of cumulative net losses incurred since inception and its history of gross losses and has concluded that it is not more likely than not that the Company will realize the benefits of the deferred tax assets. Accordingly, a full valuation allowance has been established against the deferred tax assets as of September 30, 2023 and December 31, 2022. Management reevaluates the positive and negative evidence at each reporting period.

XML

Summary of Significant Accounting Policies (Policies)

9 Months Ended

Sep. 30, 2023

Accounting Policies [Abstract]

Basis of Presentation and Principles of Consolidation

Basis of Presentation and Principles of Consolidation

The accompanying unaudited interim condensed consolidated financial statements have been prepared in accordance with U.S. generally accepted accounting principles for interim financial information and with the instructions to Form 10-Q and Article 8 of Regulation S-X promulgated by the Securities and Exchange Commission (“SEC”). Accordingly, certain information and footnote disclosures normally included in annual financial statements have been condensed or omitted. In the opinion of management, the accompanying unaudited interim condensed consolidated financial statements reflect all adjustments (including normal recurring adjustments and the elimination of intercompany accounts) considered necessary for a fair statement of all periods presented. The results of operations of the Company for any interim periods are not necessarily indicative of the results of operations for any other interim periods or for a full fiscal year. These unaudited interim condensed consolidated financial statements should be read in conjunction with the audited consolidated financial statements and footnotes thereto included in the Company’s Annual Report on Form 10-K for the year ended December 31, 2022 (the “2022 Form 10-K”).

Principles of Consolidation

Principles of Consolidation

The condensed consolidated financial statements include the accounts of DMK and its wholly-owned and controlled subsidiaries, Merger Sub (a variable interest entity wherein the Company is the primary beneficiary) and US Compounding, Inc (a discontinued operation) (“USC”). All significant intercompany accounts and transactions have been eliminated in consolidation.

Prior Periods Reclassifications

Prior Periods Reclassifications

Certain amounts in prior periods have been reclassified to conform with current period presentation related to the receivable from Fagron included in prepaid expenses and other current assets in the accompanying condensed consolidated balance sheets. Such reclassification had no effect on the total current assets as of December 31, 2022. The reclassification had no effect on the condensed consolidated statement of operations or condensed consolidated statement of cash flows for the periods ended September 30, 2022.

Certain amounts in prior periods have been reclassified to conform with current period presentation related to interest income which was presented separately from the other income (expenses) on the accompanying condensed consolidated statements of operations. Such reclassification had no effect on the total other income (expense), net for the three and nine months ended September 30, 2022. The reclassification had no effect on the condensed consolidated balance sheet as of December 31, 2022 or condensed consolidated statement of cash flows for the periods ended September 30, 2022.

Variable Interest Entity

Variable Interest Entity

The purpose of the Merger with Legacy DMK is to expand the Company’s potential product pipeline. The Company intends to focus on developing therapies with novel mechanisms of action to treat conditions, including substance abuse disorders.

The Company has 100% ownership of Merger Sub. In the event Merger Sub requires additional funding to support its operations, the Company would provide such financial support; and any benefits from the development of any of the potential product candidates would be realized by the Company. Additionally, as with any product development program there are risks that could materially impact the Company’s financial condition negatively. Conversely, positive outcomes during product development and/or achieving regulatory approval on a product or drug could materially impact the Company’s financial condition positively. See Note 3, DMK Merger for additional information regarding the VIE.

Assets recognized as a result of consolidating Merger Sub do not represent additional assets that could be used to satisfy claims against the Company’s general assets. Cash specifically must be utilized based on the specific terms of the respective grant in which the monies were received; and any unspent grant funds would be required to be returned at the end of the respective grant term. Conversely, liabilities recognized as a result of consolidating Merger Sub do not represent additional claims of the Company’s general assets; they represent claims against the specific assets of Merger Sub. 

Assets Held for Sale

               Assets Held for Sale

The Company considers assets to be held for sale when management approves and commits to a plan to actively market the assets for sale at a reasonable price in relation to its fair value, the assets are available for immediate sale in their present condition, an active program to locate a buyer and other actions required to complete the sale have been initiated, the sale of the assets is expected to be completed within one year and it is unlikely that significant changes will be made to the plan. Upon designation as held for sale, the Company ceases to record depreciation and amortization expenses and measures the assets at the lower of their carrying value or estimated fair value less costs to sell. Assets held for sale are included as other current assets in the Company’s consolidated balance sheets and the gain or loss from sale of assets held for sale is included in the Company’s general and administrative expenses. 

Accrued Other Expenses

Accrued Other Expenses

Accrued Other Expenses consists of the following as of September 30, 2023 and December 31, 2022:

	September 30, 2023		December 31, 2022
Accrued Expenses – R&D	$	145,806	$	42,400
Accrued Expenses – COGS		1,392,810		1,099,571
Accrued Expenses - Other		601,000		200,363
Accrued PTO		184,122		167,719
Total Accrued Other Expenses	$	2,323,738	$	1,510,053

Going Concern

                Going Concern

The Company’s cash and cash equivalents were approximately $6.7 million and $1.1 million at September 30, 2023 and December 31, 2022, respectively.  

The condensed consolidated financial statements were prepared under the assumption that the Company will continue operations as a going concern, which contemplates the realization of assets and the satisfaction of liabilities during the normal course of business. In preparing these condensed consolidated financial statements, consideration was given to the Company’s future business as described below, which may preclude the Company from realizing the value of certain assets.    

The Company has incurred substantial recurring losses from continuing operations, negative cash flows from operations, and is dependent on additional financing to fund operations. The Company incurred a net loss of approximately $1.4 million and $18.9 million for the three months and nine months ended September 30, 2023, respectively. As of September 30, 2023, the Company had an accumulated deficit of approximately $323.5 million. These conditions raise substantial doubt about the Company’s ability to continue as a going concern within one year after the date the financial statements are issued. The accompanying unaudited condensed consolidated financial statements do not include any adjustments relating to the recoverability and classification of recorded asset amounts and classification of liabilities that might be necessary should the Company be unable to continue in existence.

Management’s plans include attempting to secure additional required funding through equity or debt financing, if available, seeking to enter into a partnership or other strategic agreement regarding, or sales or out-licensing of, its commercial products, product candidates or intellectual property assets or other assets, revenues relating to supply and sale of SYMJEPI and ZIMHI products and share of net profits received relating to sales in the U.S. of our SYMJEPI and ZIMHI products, seeking partnerships or commercialization agreements with other pharmaceutical companies or third parties to co-develop and fund research and development or commercialization efforts of its products.  There can be no assurance that we will be able to obtain required funding in the future. If the Company does not obtain required funding, the Company’s cash resources will be depleted in the near term and the Company would be required to materially reduce or suspend operations, which would likely have a material adverse effect on the Company’s business, stock price and our relationships with third parties with whom the Company have business relationships. If the Company does not have sufficient funds to continue operations, the Company could be required to seek bankruptcy protection, dissolution or liquidation, or other alternatives that could result in the Company’s stockholders losing some or all of their investment in us. The Company has implemented expense reduction measures including, without limitation, employee headcount reductions and the reduction or discontinuation of certain product development programs. Additionally, the Company is not in compliance with certain listing standards of the Nasdaq National Market and there can be no assurance that the Company will be successful in curing the deficiencies and regaining compliance by the applicable cure dates. (See Note 11 for additional information).

Basic and Diluted Loss per Share

 Basic and Diluted Loss per Share 

Under ASC 260, the Company is required to apply the two-class method to compute earnings per share (“EPS”). Under the two-class method both basic and diluted EPS are calculated for each class of common stock and participating security considering both dividends declared (or accumulated) and participation rights in undistributed earnings. The two-class method results in an allocation of all undistributed earnings as if all those earnings were distributed. Considering the Company has generated losses in each reporting period since its inception through September 30, 2023, the Company also considered the guidance related to the allocation of the undistributed losses under the two-class method. The contractual rights and obligations of the preferred stock shares and the warrants were evaluated to determine if they have an obligation to share in the losses of the Company. As there is no obligation for the preferred stock shareholders or the holders of the warrants to fund the losses of the Company nor is the contractual principal or redemption amount of the preferred stock shares or the warrants reduced as a result of losses incurred by the Company, under the two-class method, the undistributed losses are allocated entirely to the common stock securities.

The Company computes basic loss per share by dividing the loss attributable to holders of common stock for the period by the weighted average number of shares of common stock outstanding during the period. Adjustments to the loss attributable to holders of common stock include the accretion on Series C Preferred treated as a dividend. During the three and nine months ended September 30, 2023, the Series C Preferred was accreted $0 and $172,697, respectively. As of September 30, 2023, the carrying value of the Series C Preferred stock represents its full redemption value of $330,000. The numerator in calculating the loss attributable to the holders of common stock was adjusted as follows:

	Three Months Ended September 30, 2023			Nine Months Ended September 30, 2023
Net loss	$	(1,388,046	)	$	(18,905,075	)
Accretion on Series C Preferred		—			(172,697	)
Adjusted Net Loss	$	(1,388,046	)	$	(19,077,772	)

The Series E common stock equivalents are not included in the calculation of diluted EPS as this would be anti-dilutive (since the Company generates net losses). The diluted loss per share calculation is based on the if-converted method for convertible preferred shares and gives effect to dilutive if-converted shares and the treasury stock method and gives effect to dilutive options, warrants and other potentially dilutive common stock. The preferred stock is not considered potentially dilutive due to the contingency on the conversion feature not being tied to stock price or price of the convertible instrument.

Common share equivalents outstanding, determined using the treasury stock method, are comprised of shares that may be issued under the Company’s stock option and warrant agreements. For the warrants accounted as liabilities, at each reporting period the Company evaluates the combined effect of the adjustment to the numerator (assumed beginning of the period exercise) and inclusion of the warrants in the denominator, with the warrants included for the purposes of diluted EPS calculation if such effect is dilutive. The warrants and options were determined to be anti-dilutive for all periods presented.

Potentially dilutive securities, which are not included in diluted weighted average shares outstanding for the period ended September 30, 2023 and 2022, consist of the following (in common stock equivalents):

	September 30,  2023		September 30, 2022
Outstanding Warrants		6,184,323		213,612
Outstanding Options		33,886		63,377
Legacy DMK Options assumed by the Company		231,490		—
Outstanding Restricted Stock Units		7,143		9,286
Series C Preferred stock (if converted)		697,674		—
Series E Preferred stock (if converted)		1,212,000		—

Stock-based compensation

Stock-based compensation

The Company accounts for transactions in which the Company receives services in exchange for restricted stock units (“RSUs”) or options to purchase common stock as stock-based compensation cost based on estimated fair value. Stock-based compensation cost for RSUs is measured based on the closing fair market value of the Company’s common stock on the date of grant. Stock-based compensation cost for stock options is estimated at the grant date based on each option’s fair-value as calculated by the Black-Scholes option-pricing model. The Company accounts for forfeitures as they occur and will reduce compensation cost at the time of forfeiture.

Discontinued Operations

Discontinued Operations

In accordance with ASC 205-20 Presentation of Financial Statements: Discontinued Operations, the Company reports a disposal of a component of an entity or a group of components of an entity as discontinued operations if the disposal represents a strategic shift that has (or will have) a major effect on the Company’s operations and financial results when the component/s meets the criteria in paragraph 205-20-45-10. In the period in which the component meets held-for-sale or discontinued operations criteria, the Company reports the major current assets, noncurrent assets, current liabilities, and noncurrent liabilities as components of total assets and liabilities separate from those balances of the continuing operations. At the same time, the Company reports the results of all discontinued operations, less applicable income taxes, as components of net loss separate from the net loss of continuing operations.

XML

Summary of Significant Accounting Policies (Tables)

9 Months Ended

Sep. 30, 2023

Accounting Policies [Abstract]

Accrued Other Expenses consists of the following as of September 30, 2023 and December 31, 2022:

Accrued Other Expenses consists of the following as of September 30, 2023 and December 31, 2022:

	September 30, 2023		December 31, 2022
Accrued Expenses – R&D	$	145,806	$	42,400
Accrued Expenses – COGS		1,392,810		1,099,571
Accrued Expenses - Other		601,000		200,363
Accrued PTO		184,122		167,719
Total Accrued Other Expenses	$	2,323,738	$	1,510,053

The numerator in calculating the loss attributable to the holders of common stock was adjusted as follows:

The Company computes basic loss per share by dividing the loss attributable to holders of common stock for the period by the weighted average number of shares of common stock outstanding during the period. Adjustments to the loss attributable to holders of common stock include the accretion on Series C Preferred treated as a dividend. During the three and nine months ended September 30, 2023, the Series C Preferred was accreted $0 and $172,697, respectively. As of September 30, 2023, the carrying value of the Series C Preferred stock represents its full redemption value of $330,000. The numerator in calculating the loss attributable to the holders of common stock was adjusted as follows:

	Three Months Ended September 30, 2023			Nine Months Ended September 30, 2023
Net loss	$	(1,388,046	)	$	(18,905,075	)
Accretion on Series C Preferred		—			(172,697	)
Adjusted Net Loss	$	(1,388,046	)	$	(19,077,772	)

Potentially dilutive securities, which are not included in diluted weighted average shares outstanding for the period ended September 30, 2023 and 2022, consist of the following (in common stock equivalents):

Potentially dilutive securities, which are not included in diluted weighted average shares outstanding for the period ended September 30, 2023 and 2022, consist of the following (in common stock equivalents):

	September 30,  2023		September 30, 2022
Outstanding Warrants		6,184,323		213,612
Outstanding Options		33,886		63,377
Legacy DMK Options assumed by the Company		231,490		—
Outstanding Restricted Stock Units		7,143		9,286
Series C Preferred stock (if converted)		697,674		—
Series E Preferred stock (if converted)		1,212,000		—

XML

DMK Merger (Tables)

9 Months Ended

Sep. 30, 2023

Business Combination and Asset Acquisition [Abstract]

The purchase price, or total consideration transferred, to acquire Legacy DMK in the Merger was comprised of the following:

           The purchase price, or total consideration transferred, to acquire Legacy DMK in the Merger was comprised of the following:

Fair Value of the Company's Common Stock issued to Legacy DMK shareholders	$	757,038
Fair Value of the Company's Series E Preferred issued to Legacy DMK shareholders		4,853,000
Fair Value of Legacy DMK options assumed and replaced by the Company		415,809
Legacy DMK incurred Merger-related costs paid for by the Company		492,456
Total Consideration Transferred	$	6,518,303

The allocation of the total purchase price is estimated as follows:

The allocation of the total purchase price is estimated as follows:

Assets Acquired:
Cash	$	136,089
Total assets acquired		136,089
Liabilities Assumed:
Accounts Payable		30
Due to Related Party		1,698
Accrued Expenses		8,615
Deferred Grant Revenue		147,118
Total liabilities assumed		157,461
Net Liabilities acquired		(21,372	)
Acquired IPR&D (DPI-125)		6,539,675
Total Purchase Price	$	6,518,303

XML

Discontinued Operations (Tables)

9 Months Ended

Sep. 30, 2023

DISCONTINUED OPERATIONS

The major assets and liabilities associated with discontinued operations included in our condensed consolidated balance sheets are as follows:

The major assets and liabilities associated with discontinued operations included in our condensed consolidated balance sheets are as follows:

	September 30, 2023		December 31, 2022
Cash and Cash Equivalents	$	—	$	30,085
Fixed Assets held for sale		—		6,719,252
Other assets		5,406		5,407
Loss recognized on classification as held for sale		—		(2,801,828	)
Total assets of the disposal group classified as held for sale in the statement of financial position	$	5,406	$	3,952,916
Carrying amounts of major classes of liabilities included as part of discontinued operations
Accounts Payable	$	673,335	$	649,633
Accrued Other Expenses		55,959		75,602
Lease Liabilities		200,034		243,008
Contingent Loss Liability		—		50,000
Other Current Liabilities		—		208,000
Deferred Tax Liability		—		45,930
Total liabilities of the disposal group classified as held for sale in the statement of financial position	$	929,328	$	1,272,173

The revenues and expenses associated with discontinued operations included in our consolidated statements of operations were as follows:

               The revenues and expenses associated with discontinued operations included in our consolidated statements of operations were as follows:

	Three Months Ended September 30,
	2023			2022
Major line items constituting pretax loss of discontinued operations:
Selling, General and Administrative Expenses	$	(20,798	)	$	(125,722	)
Interest Income		—			22
Gain (Loss) on Disposal of Assets		369,000			(1,992	)
Gain (Loss) from discontinued operations before income taxes		348,202			(127,692	)
Income Tax Benefit		—			—
Gain (Loss) from discontinued operations	$	348,202		$	(127,692	)

	Nine Months Ended September 30,
	2023			2022
Major line items constituting pretax loss of discontinued operations:
Selling, General and Administrative Expenses	$	(83,721	)	$	(390,105	)
Impairment Expense - USC Property		(1,512,263	)		—
Other Income		7,818			8,647
Gain on Disposal of Assets		437,339			27,138
Loss from discontinued operations before income taxes		(1,150,827	)		(354,320	)
Income tax benefit		—			—
Loss from discontinued operations	$	(1,150,827	)	$	(354,320	)

XML

Inventories (Tables)

9 Months Ended

Sep. 30, 2023

Inventory Disclosure [Abstract]

Inventories at September 30, 2023 and December 31, 2022 were as follows:

Inventories at September 30, 2023 and December 31, 2022 were as follows: 

	September 30, 2023		December 31, 2022
Finished Goods	$	—	$	267,554
Work-in-Process		—		261,720
Raw Materials		662,962		709,504
Inventories	$	662,962	$	1,238,778

XML

Fixed Assets, net (Tables)

9 Months Ended

Sep. 30, 2023

Property, Plant and Equipment [Abstract]

Fixed assets, net at September 30, 2023 and December 31, 2022 were as follows:

Fixed assets, net at September 30, 2023 and December 31, 2022 were as follows: 

Description	Useful Life (Years)		September 30,  2023			December 31, 2022
Machinery and Equipment		3 - 7	$	5,156,377		$	5,209,575
Less: Accumulated Depreciation				(4,080,701	)		(4,665,067	)
Construction In Progress - Equipment				—			744,386
Fixed Assets, net			$	1,075,676		$	1,288,894

XML

Fair Value Measurement (Tables)

9 Months Ended

Sep. 30, 2023

Fair Value Disclosures [Abstract]

The following table sets forth the Company’s financial instruments that were measured at fair value on a recurring basis by level within the fair value hierarchy:

The following table sets forth the Company’s financial instruments that were measured at fair value on a recurring basis by level within the fair value hierarchy: 

		Fair Value Measurements at September 30, 2023
	Total		Level 1		Level 2		Level 3
Liabilities
2020 Warrant Liability	$	Less than $1	$	—	$	Less than $1	$	—
March 2023 Common Stock Warrants		302,170		—		302,170		—
Total Common Stock Warrants Liabilities	$	302,170	$	—	$	302,170	$	—

		Fair Value Measurements at December 31, 2022
	Total		Level 1		Level 2		Level 3
Liabilities
2020 Warrant Liability	$	7,492	$	—	$	7,492	$	—

XML

Prepaid Expenses and Other Current Assets (Tables)

9 Months Ended

Sep. 30, 2023

Prepaid Expenses And Other Current Assets

Prepaid expenses and other current assets were as follows:

Prepaid expenses and other current assets were as follows:

	September 30, 2023		December 31, 2022
Employee Retention Credit	$	—	$	875,307
Prepaid Insurance		86,436		323,143
Prepaid - Research and Development		326,854		588,354
Other Prepaid		59,275		78,590
Other Current Assets		67,207		49,572
	$	539,772	$	1,914,966

XML

Stockholders' Equity (Tables)

9 Months Ended

Sep. 30, 2023

Equity [Abstract]

The following table provides the initial allocation of the offering proceeds between the common stock and the Warrants issued:

The following table provides the initial allocation of the offering proceeds between the common stock and the Warrants issued:

	Allocation
235,714 Common Stock Issued	$	—
107,142 Prefunded Warrant Issued		899,388
685,714 Common Stock Warrant Issued		4,575,971
Day-one Loss due to Excess Warrant Fair Value		(2,476,109	)
Gross Proceeds	$	2,999,250

The following table summarizes the outstanding stock option activity under the 2009 Equity Incentive Plan for the nine months ended September 30, 2023:

The following table summarizes the outstanding stock option activity under the 2009 Equity Incentive Plan for the nine months ended September 30, 2023:

	2009 Equity Incentive Plan			Weighted-Average Exercise Price		Weighted-Average Remaining Contract Life
Outstanding Vested and Expected to Vest as of December 31, 2022		61,525		$	291.41		2.09 years
Cancelled/Expired		(29,068	)		280.26		—
Outstanding and Vested as of September 30, 2023		32,457			306.44		2.44 years

The following table summarizes the outstanding stock option activity for the non-plan awards for the nine months ended September 30, 2023:

The following table summarizes the outstanding stock option activity for the non-plan awards for the nine months ended September 30, 2023:

	Non-Plan Awards			Weighted-Average Exercise Price			Weighted-Average Remaining Contract Life
Outstanding as of December 31, 2022		1,857			$	43.40		9.13 years
Cancelled		(429	)			43.40		—
Outstanding as of September 30, 2023		1,428				43.40		8.38 years
Vested and Expected to Vest at September 30, 2023		952				43.40		8.38 years

The following table summarizes the RSUs outstanding at September 30, 2023:

The following table summarizes the RSUs outstanding at September 30, 2023: 

	Number of Shares/Units			Weighted Average Grant Date Fair Value
Non-vested as of December 31, 2022		9,286		$	325.13
Vested during the period		(2,143	)		592.20
Forfeited during the period		—			—
Non-vested as of September 30, 2023		7,143			245.00
Expected to vest as of September 30, 2023		7,143		$	245.00

The following summarizes stock-based compensation recognized for the three months ended September 30, 2023 and 2022:

The following summarizes stock-based compensation recognized for the three months ended September 30, 2023 and 2022:

	For the Three Months Ended September 30,
	2023			2022
Research and Development	$	(69,835	)	$	3,654
Selling, General and Administrative		25,142			70,834
Total	$	(44,693	)	$	74,488

The following summarizes stock-based compensation recognized as R&D costs and SG&A costs for the nine months ended September 30, 2023 and 2022:

	For the Nine Months Ended September 30,
	2023			2022
Research and Development	$	(69,835	)	$	122,746
Selling, General and Administrative		146,634			(137,057	)
Total	$	76,799		$	(14,311	)

The following table summarizes warrants issued and outstanding as of September 30, 2023:

The following table summarizes warrants issued and outstanding as of September 30, 2023:   

	Warrant   Shares		Exercise Price   Per Share		Date   Issued	Expiration   Date
Old Adamis Warrants		840	$	595.00	November 15, 2007	November 15, 2023
2019 Warrants		197,055	$	80.50	August 5, 2019	August 5, 2024
2020 Warrants		5,000	$	49.00	February 25, 2020	September 3, 2025
Series C Preferred Warrants		10,714	$	32.90	July 5, 2022	January 5, 2028
March 2023 Common Stock Warrants		685,714	$	9.66	March 16, 2023	September 16, 2028
August 2023 Common Stock Warrants		5,285,000	$	1.35	August 4, 2023	August 4, 2028
Total		6,184,323

As of September 30, 2023, the Company has reserved shares of common stock for issuance upon exercise of outstanding options, warrants including all of the warrants in the table above and restricted stock units, as follows:

As of September 30, 2023, the Company has reserved shares of common stock for issuance upon exercise of outstanding options, warrants including all of the warrants in the table above and restricted stock units, as follows:

Warrants	6,184,323
Restricted Stock Units	7,143
Non-Plan Awards	1,428
2009 Equity Incentive Plan	32,457
Legacy DMK Options Assumed by the Company	231,490
Conversion of Series C Preferred stock	697,674
Conversion of Series E Preferred stock	1,212,000
Total Shares Reserved	8,366,515

XML

Organization and Description of the Business (Details Narrative) - shares			9 Months Ended
	May 25, 2023	May 22, 2023	Sep. 30, 2023	Dec. 31, 2022
Reverse stock split		1-for-70
Common stock, authorized		200,000,000	200,000,000	200,000,000
Series E Preferred Stock [Member]
Issuance of Series E Preferred Stock pursuant to DMK Merger, shares	1,941.2
Shares issuable upon conversion	1,000
Beneficial ownership limitation	9.99%
Common Stock [Member]
Issuance of Common Stock pursuant to DMK Merger, shares	302,815		302,815

XML

Summary of Significant Accounting Policies (Details Narrative) - USD ($)		3 Months Ended		9 Months Ended
	Sep. 30, 2023	Sep. 30, 2023	Sep. 30, 2022	Sep. 30, 2023	Sep. 30, 2022	Dec. 31, 2022
Cash and cash equivalents	$ 6,663,921	$ 6,663,921	$ 2,419,960	$ 6,663,921	$ 2,419,960	$ 1,081,364
Net loss		(1,388,046)	$ (4,398,901)	(18,905,075)	(23,150,737)
Accumulated deficit	(323,469,161)	(323,469,161)		(323,469,161)		(304,564,086)
Accretion on Series C Preferred				172,697
Convertible Preferred Stock	330,000	330,000		330,000		$ 157,303
Series C Preferred Stock [Member]
Accretion on Series C Preferred		0		172,697
Convertible Preferred Stock	$ 330,000	$ 330,000		$ 330,000
Merger Sub [Member]
Ownership percentage	100.00%

XML

Accrued Other Expenses consists of the following as of September 30, 2023 and December 31, 2022: (Details) - USD ($)	Sep. 30, 2023	Dec. 31, 2022
Accounting Policies [Abstract]
Accrued Expenses – R&D	$ 145,806	$ 42,400
Accrued Expenses – COGS	1,392,810	1,099,571
Accrued Expenses - Other	601,000	200,363
Accrued PTO	184,122	167,719
Total Accrued Other Expenses	$ 2,323,738	$ 1,510,053

XML

The numerator in calculating the loss attributable to the holders of common stock was adjusted as follows: (Details) - USD ($)	3 Months Ended		9 Months Ended
	Sep. 30, 2023	Sep. 30, 2022	Sep. 30, 2023	Sep. 30, 2022
Accounting Policies [Abstract]
Net loss	$ (1,388,046)	$ (4,398,901)	$ (18,905,075)	$ (23,150,737)
Accretion on Series C Preferred			(172,697)
Adjusted Net Loss	$ (1,388,046)		$ (19,077,772)

XML

Potentially dilutive securities, which are not included in diluted weighted average shares outstanding for the period ended September 30, 2023 and 2022, consist of the following (in common stock equivalents): (Details) - shares	9 Months Ended
	Sep. 30, 2023	Sep. 30, 2022
Warrant [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Potentially dilutive securities, which are not included in diluted weighted average shares outstanding	6,184,323	213,612
Share-Based Payment Arrangement, Option [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Potentially dilutive securities, which are not included in diluted weighted average shares outstanding	33,886	63,377
DMK Options assumed by Adamis [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Potentially dilutive securities, which are not included in diluted weighted average shares outstanding	231,490
Restricted Stock Units (RSUs) [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Potentially dilutive securities, which are not included in diluted weighted average shares outstanding	7,143	9,286
Series C Preferred Stock [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Potentially dilutive securities, which are not included in diluted weighted average shares outstanding	697,674
Series E Preferred Stock [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Potentially dilutive securities, which are not included in diluted weighted average shares outstanding	1,212,000

XML

DMK Merger (Details Narrative)			9 Months Ended
	Sep. 30, 2023	May 25, 2023 USD ($) $ / shares shares	Sep. 30, 2023 shares
DMK Options assumed by Adamis [Member]
Asset Acquisition [Line Items]
Options | shares		231,490
Fair value		$ 415,809
Expected volatility		119.50%
Stock price | $ / shares		$ 2.50
Dividend yield		0.00%
Risk-free interest rate		4.06%
DMK Options assumed by Adamis [Member] | Minimum [Member]
Asset Acquisition [Line Items]
Expected term		2 years 4 months 13 days
DMK Options assumed by Adamis [Member] | Maximum [Member]
Asset Acquisition [Line Items]
Expected term		4 years 4 months 13 days
Series E Preferred Stock [Member]
Asset Acquisition [Line Items]
Issuance of Series E Preferred Stock pursuant to DMK Merger, shares | shares		1,941.2
Common Stock [Member]
Asset Acquisition [Line Items]
Issuance of Common Stock pursuant to DMK Merger, shares | shares		302,815	302,815
Measurement Input, Discount Rate [Member]
Asset Acquisition [Line Items]
Acquired IPR&D, measurement input		0.27
DMK Pharmaceuticals Corporation [Member]
Asset Acquisition [Line Items]
Transaction costs		$ 1,400,000
DMK Pharmaceuticals Corporation [Member] | DMK Options assumed by Adamis [Member]
Asset Acquisition [Line Items]
Fair value		415,809
DMK Pharmaceuticals Corporation [Member] | Series E Preferred Stock [Member]
Asset Acquisition [Line Items]
Fair value		4,853,000
DMK Pharmaceuticals Corporation [Member] | Common Stock [Member]
Asset Acquisition [Line Items]
Fair value		$ 757,038
Legacy DMK [Member]
Asset Acquisition [Line Items]
Ownership percentage	100.00%

XML

The purchase price, or total consideration transferred, to acquire Legacy DMK in the Merger was comprised of the following: (Details)	May 25, 2023 USD ($)
DMK Options assumed by Adamis [Member]
Asset Acquisition [Line Items]
Fair Value	$ 415,809
DMK Pharmaceuticals Corporation [Member]
Asset Acquisition [Line Items]
Legacy DMK incurred Merger-related costs paid for by the Company	492,456
Total Consideration Transferred	6,518,303
DMK Pharmaceuticals Corporation [Member] | DMK Options assumed by Adamis [Member]
Asset Acquisition [Line Items]
Fair Value	415,809
DMK Pharmaceuticals Corporation [Member] | Series E Preferred Stock [Member]
Asset Acquisition [Line Items]
Fair Value	4,853,000
DMK Pharmaceuticals Corporation [Member] | Common Stock [Member]
Asset Acquisition [Line Items]
Fair Value	$ 757,038

XML

The allocation of the total purchase price is estimated as follows: (Details) - USD ($)		3 Months Ended		9 Months Ended
	May 25, 2023	Sep. 30, 2023	Sep. 30, 2022	Sep. 30, 2023	Sep. 30, 2022
Liabilities Assumed:
Acquired IPR&D (DPI-125)				$ 6,539,675
DMK Pharmaceuticals Corporation [Member]
Assets Acquired:
Cash	$ 136,089
Total assets acquired	136,089
Liabilities Assumed:
Accounts Payable	30
Due to Related Party	1,698
Accrued Expenses	8,615
Deferred Grant Revenue	147,118
Total liabilities assumed	157,461
Net Liabilities acquired	(21,372)
Acquired IPR&D (DPI-125)	6,539,675
Total Purchase Price	$ 6,518,303

XML

The major assets and liabilities associated with discontinued operations included in our condensed consolidated balance sheets are as follows: (Details) - USD ($)	Sep. 30, 2023	Dec. 31, 2022
Disposal Group, Including Discontinued Operation, Assets [Abstract]
Cash and Cash Equivalents		$ 30,085
Fixed Assets held for sale		6,719,252
Other assets	5,406	5,407
Loss recognized on classification as held for sale		(2,801,828)
Total assets of the disposal group classified as held for sale in the statement of financial position	5,406	3,952,916
Carrying amounts of major classes of liabilities included as part of discontinued operations
Accounts Payable	673,335	649,633
Accrued Other Expenses	55,959	75,602
Lease Liabilities	200,034	243,008
Contingent Loss Liability		50,000
Other Current Liabilities		208,000
Deferred Tax Liability		45,930
Total liabilities of the disposal group classified as held for sale in the statement of financial position	$ 929,328	$ 1,272,173

XML

The revenues and expenses associated with discontinued operations included in our consolidated statements of operations were as follows: (Details) - USD ($)	3 Months Ended		9 Months Ended
	Sep. 30, 2023	Sep. 30, 2022	Sep. 30, 2023	Sep. 30, 2022
Major line items constituting pretax loss of discontinued operations:
Selling, General and Administrative Expenses	$ (20,798)	$ (125,722)	$ (83,721)	$ (390,105)
Impairment Expense - USC Property			(1,512,263)
Other Income			7,818	8,647
Interest Income		22
Gain (Loss) on Disposal of Assets	369,000	(1,992)	437,339	27,138
Gain (Loss) from discontinued operations before income taxes	348,202	(127,692)	(1,150,827)	(354,320)
Income tax benefit
Gain (Loss) from discontinued operations	$ 348,202	$ (127,692)	$ (1,150,827)	$ (354,320)

XML

Discontinued Operations (Details Narrative) - USD ($)		1 Months Ended		3 Months Ended			9 Months Ended
	Jul. 25, 2023	Jan. 31, 2023	Dec. 31, 2022	Sep. 30, 2023	Jun. 30, 2023	Mar. 31, 2023	Sep. 30, 2023	Sep. 30, 2022
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Impairment of Fixed Assets, Held for Sale							$ 1,512,263
USC [Member]
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Proceeds from sale of assets		$ 832,000	$ 208,000
Gain on Sale of Fixed Assets						$ 68,339
USC [Member] | Land and Building [Member]
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Proceeds from sale of assets	$ 1,500,000
Gain on Sale of Fixed Assets				$ 20,500
Offer to Purchase Fixed Assets, Held for Sale					$ 1,525,000
Impairment of Fixed Assets, Held for Sale					$ 1,500,000
USC [Member] | Equipment [Member]
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Proceeds from sale of assets	$ 349,000
Gain on Sale of Fixed Assets				348,500
Fagron Compounding Services LLC [Member]
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Consideration received from purchase agreement				5,500,000			5,500,000
Remaining receivables				$ 19,000			$ 19,000

XML

Revenues (Details Narrative) - USD ($) $ in Thousands		3 Months Ended		9 Months Ended		18 Months Ended
	May 11, 2020	Sep. 30, 2023	Sep. 30, 2022	Sep. 30, 2023	Sep. 30, 2022	Sep. 30, 2023	Dec. 31, 2022
Product recall liability		$ 0		$ 0		$ 0	$ 300
Inventory Recall Expense						$ 2,600
Selling, General and Administrative Expenses [Member]
Inventory Recall Expense		$ 25	$ 388	$ 81	$ 2,400
USWM Agreement [Member]
Milestone payments	$ 26,000
Term of agreement	10 years

XML

Inventories at September 30, 2023 and December 31, 2022 were as follows: (Details) - USD ($)	Sep. 30, 2023	Dec. 31, 2022
Inventory Disclosure [Abstract]
Finished Goods		$ 267,554
Work-in-Process		261,720
Raw Materials	662,962	709,504
Inventories	$ 662,962	$ 1,238,778

XML

Fixed assets, net at September 30, 2023 and December 31, 2022 were as follows: (Details) - USD ($)	Sep. 30, 2023	Dec. 31, 2022
Property, Plant and Equipment [Line Items]
Machinery and Equipment, Gross	$ 5,156,377	$ 5,209,575
Less: Accumulated Depreciation	(4,080,701)	(4,665,067)
Construction In Progress - Equipment		744,386
Fixed Assets, net	$ 1,075,676	$ 1,288,894
Machinery and Equipment [Member] | Minimum [Member]
Property, Plant and Equipment [Line Items]
Property, Plant and Equipment, Useful Life	3 years
Machinery and Equipment [Member] | Maximum [Member]
Property, Plant and Equipment [Line Items]
Property, Plant and Equipment, Useful Life	7 years

XML

Fixed Assets, net (Details Narrative) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2023	Sep. 30, 2022	Sep. 30, 2023	Sep. 30, 2022
Property, Plant and Equipment [Abstract]
Depreciation	$ 67	$ 399	$ 264	$ 1,111

XML

Paycheck Protection Program (PPP) Loan (Details Narrative) - USD ($)	1 Months Ended	3 Months Ended			9 Months Ended
	Jun. 30, 2022	Sep. 30, 2023	Sep. 30, 2022	Sep. 30, 2021	Sep. 30, 2023	Sep. 30, 2022	Mar. 15, 2021
Debt Instrument [Line Items]
Gain (Loss) on Extinguishment of Debt						$ (1,787,417)
Paycheck Protection Plan Second Draw Loan [Member]
Debt Instrument [Line Items]
Gain (Loss) on Extinguishment of Debt				$ 1,765,495
Repayments of Other Long-Term Debt	$ 1,787,417
Paycheck Protection Plan Second Draw Loan [Member]
Debt Instrument [Line Items]
Long-Term Debt, Gross							$ 1,765,495

XML

The following table sets forth the Company’s financial instruments that were measured at fair value on a recurring basis by level within the fair value hierarchy: (Details) - USD ($)	Sep. 30, 2023	Dec. 31, 2022
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Total common stock warrant liabilities	$ 302,170	$ 7,492
Fair Value, Recurring [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Total common stock warrant liabilities	302,170
Fair Value, Recurring [Member] | Fair Value, Inputs, Level 1 [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Total common stock warrant liabilities
Fair Value, Recurring [Member] | Fair Value, Inputs, Level 2 [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Total common stock warrant liabilities	302,170
Fair Value, Recurring [Member] | Fair Value, Inputs, Level 3 [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Total common stock warrant liabilities
Fair Value, Recurring [Member] | Warrants 2020 [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Total common stock warrant liabilities		7,492
Fair Value, Recurring [Member] | Warrants 2020 [Member] | Fair Value, Inputs, Level 1 [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Total common stock warrant liabilities
Fair Value, Recurring [Member] | Warrants 2020 [Member] | Fair Value, Inputs, Level 2 [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Total common stock warrant liabilities		7,492
Fair Value, Recurring [Member] | Warrants 2020 [Member] | Fair Value, Inputs, Level 3 [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Total common stock warrant liabilities
Fair Value, Recurring [Member] | Warrants 2020 [Member] | Maximum [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Total common stock warrant liabilities	1
Fair Value, Recurring [Member] | Warrants 2020 [Member] | Maximum [Member] | Fair Value, Inputs, Level 1 [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Total common stock warrant liabilities
Fair Value, Recurring [Member] | Warrants 2020 [Member] | Maximum [Member] | Fair Value, Inputs, Level 2 [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Total common stock warrant liabilities	1
Fair Value, Recurring [Member] | Warrants 2020 [Member] | Maximum [Member] | Fair Value, Inputs, Level 3 [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Total common stock warrant liabilities
Fair Value, Recurring [Member] | March 2023 Common Stock Warrants [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Total common stock warrant liabilities	302,170
Fair Value, Recurring [Member] | March 2023 Common Stock Warrants [Member] | Fair Value, Inputs, Level 1 [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Total common stock warrant liabilities
Fair Value, Recurring [Member] | March 2023 Common Stock Warrants [Member] | Fair Value, Inputs, Level 2 [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Total common stock warrant liabilities	302,170
Fair Value, Recurring [Member] | March 2023 Common Stock Warrants [Member] | Fair Value, Inputs, Level 3 [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Total common stock warrant liabilities

XML

Fair Value Measurement (Details Narrative)	Sep. 30, 2023 $ / shares yr	Dec. 31, 2022 $ / shares yr
Measurement Input, Price Volatility [Member]
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Derivative Liability, Measurement Input		0.70
Measurement Input, Price Volatility [Member] | Minimum [Member]
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Derivative Liability, Measurement Input	0.70
Measurement Input, Price Volatility [Member] | Maximum [Member]
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Derivative Liability, Measurement Input	1.3465
Measurement Input, Share Price [Member]
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Derivative Liability, Measurement Input | $ / shares	0.69	11.90
Measurement Input, Expected Dividend Rate [Member]
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Derivative Liability, Measurement Input	0.000	0.000
Measurement Input, Expected Term [Member]
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Derivative Liability, Measurement Input		2.68
Measurement Input, Expected Term [Member] | Minimum [Member]
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Derivative Liability, Measurement Input	1.93
Measurement Input, Expected Term [Member] | Maximum [Member]
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Derivative Liability, Measurement Input	4.96
Measurement Input, Risk Free Interest Rate [Member]
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Derivative Liability, Measurement Input		0.04362
Measurement Input, Risk Free Interest Rate [Member] | Minimum [Member]
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Derivative Liability, Measurement Input	0.04721
Measurement Input, Risk Free Interest Rate [Member] | Maximum [Member]
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Derivative Liability, Measurement Input	0.05253

XML

Prepaid expenses and other current assets were as follows: (Details) - USD ($)	Sep. 30, 2023	Dec. 31, 2022
Prepaid Expenses And Other Current Assets
Employee Retention Credit		$ 875,307
Prepaid Insurance	86,436	323,143
Prepaid - Research and Development	326,854	588,354
Other Prepaid	59,275	78,590
Other Current Assets	67,207	49,572
	$ 539,772	$ 1,914,966

XML

Prepaid Expenses and Other Current Assets (Details Narrative) $ in Thousands	9 Months Ended
	Sep. 30, 2023 USD ($)
Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure [Abstract]
Other income	$ 463

XML

Legal Proceedings (Details Narrative) - USD ($)				1 Months Ended	9 Months Ended
	Oct. 18, 2023	Oct. 11, 2023	Oct. 04, 2023	Jun. 30, 2022	Sep. 30, 2023
Loss contingency, alleged repairs amount					$ 1,414,943.08
Subsequent Event [Member]
Minimum bid price per share requirement			$ 1.00
Period of consecutive business days below minimum bid price			30 days
Period to regain compliance with minimum bid price			180 days
Minimum market value of listed securities		$ 35,000,000
Period to regain compliance with minimum market value		180 days
Mandatory Panel Monitor period	1 year
Ineligible period to regain compliance with minimum bid price	180 days
Paycheck Protection Plan Second Draw Loan [Member]
Repayment of debt				$ 1,787,417

XML

Stockholders' Equity (Details Narrative) - USD ($)						1 Months Ended	3 Months Ended			9 Months Ended		12 Months Ended
	Aug. 04, 2023	May 25, 2023	Mar. 16, 2023	Mar. 16, 2023	Jul. 05, 2022	May 31, 2023	Sep. 30, 2023	Jun. 30, 2023	Dec. 31, 2022	Sep. 30, 2023	Sep. 30, 2022	Dec. 31, 2020
Class of Stock [Line Items]
Gross proceeds from offering			$ 2,999,250	$ 3,000,000.0
Offering expenses				$ 300,000						$ 275,000
Proceeds from Warrant Exercises										790
Net proceeds from offering	$ 7,100,000
Placement agent commissions and other offering expenses	$ 900,000									$ 912,751
Convertible Preferred Stock, par value (in dollars per share)							$ 0.0001		$ 0.0001	$ 0.0001
Gross proceeds											$ 285,000
Convertible Preferred Stock							$ 330,000		$ 157,303	$ 330,000
Shares reserved							8,366,515			8,366,515
DMK Options assumed by Adamis [Member]
Class of Stock [Line Items]
Options		231,490
Options, exercise price		$ 2.90
Shares reserved							231,490			231,490
Share-Based Payment Arrangement, Option [Member]
Class of Stock [Line Items]
Stock options outstanding aggregate intrinsic value							$ 0		$ 0	$ 0
Restricted Stock Units (RSUs) [Member]
Class of Stock [Line Items]
Shares reserved							7,143			7,143
Service period										7 years
Unamortized compensation expense							$ 42,000			$ 42,000
Period for recognition										5 months 1 day
Equity Incentive Plan 2020 [Member]
Class of Stock [Line Items]
Number of shares authorized												28,571
Increase in shares reserved, percentage												5.00%
2009 Equity Incentive Plan [Member]
Class of Stock [Line Items]
Options							32,457		61,525	32,457
Options, exercise price							$ 306.44		$ 291.41	$ 306.44
Shares reserved							32,457			32,457
2009 Equity Incentive Plan [Member] | Share-Based Payment Arrangement, Option [Member]
Class of Stock [Line Items]
Stock options outstanding aggregate intrinsic value							$ 0		$ 0	$ 0
2009 Equity Incentive Plan [Member] | Share-Based Payment Arrangement, Option [Member] | Maximum [Member]
Class of Stock [Line Items]
Contractual term										10 years
Equity Incentive Plan 2009 [Member]
Class of Stock [Line Items]
Unamortized compensation expense							0			$ 0
Non Plan Awards [Member]
Class of Stock [Line Items]
Unamortized compensation expense							$ 0			$ 0
Options							1,428		1,857	1,428
Options, exercise price							$ 43.40		$ 43.40	$ 43.40
Shares reserved							1,428			1,428
Non Plan Awards [Member] | Share-Based Payment Arrangement, Tranche One [Member]
Class of Stock [Line Items]
Vesting percentage										16.67%
Vesting period										6 months
Non Plan Awards [Member] | Share-Based Payment Arrangement, Tranche Two [Member]
Class of Stock [Line Items]
Vesting percentage										2.78%
DMK 2016 Stock Plan [Member]
Class of Stock [Line Items]
Shares reserved							249,501			249,501
Series C Preferred Stock [Member]
Class of Stock [Line Items]
Offering expenses					$ 15,000
Number of shares issued					3,000
Convertible Preferred Stock, par value (in dollars per share)					$ 0.0001
Gross proceeds					$ 300,000
Payment for preferred stock transaction agreement									$ 15,000
Temporary Equity, Accretion to Redemption Value								$ 173,000
Temporary Equity, redemption percentage by holder after reverse stock split								110.00%
Convertible Preferred Stock							$ 330,000			$ 330,000
Shares reserved							697,674			697,674
Series E Preferred Stock [Member]
Class of Stock [Line Items]
Issuance of Series E Preferred Stock pursuant to DMK Merger, shares		1,941.2
Shares issuable upon conversion		1,000
Shares reserved							1,212,000			1,212,000
Common Stock Warrants [Member]
Class of Stock [Line Items]
Number of warrants issued	5,930,000		685,714	685,714
Warrants exercise price	$ 1.35		$ 9.66	$ 9.66
Warrant expiration period	5 years		5 years 6 months	5 years 6 months
Warrants and Rights Outstanding, Exercisable Period				6 months
Proceeds from Warrant Exercises							$ 870,750
Number of Warrants Exercised							645,000
Prefunded Warrants [Member]
Class of Stock [Line Items]
Price per share			$ 8.74	$ 8.74
Number of warrants issued	1,130,000		107,143	107,143
Warrants exercise price	$ 0.0001		$ 0.0007	$ 0.0007
Warrant expiration period			5 years	5 years
Fair Value of Warrants Exercised						$ 524,379
Proceeds from Warrant Exercises	$ 40					$ 750
Number of Warrants Exercised	1,130,000
Number of Warrants Exercised Cash Basis	395,000
Stock Issued During Period, Shares, Exercise of Warrants	395,000
Number of Warrants Exercised Cashless Basis	735,000
Stock Issued During Period, Shares, Cashless Exercise of Warrants	734,985
Warrants [Member]
Class of Stock [Line Items]
Offering expenses				$ 225,000
Series C Preferred Warrants [Member]
Class of Stock [Line Items]
Number of warrants issued					10,714
Warrants exercise price					$ 32.90		$ 32.90			$ 32.90
Warrants exercisable date					Jan. 03, 2023
Warrants term end date					Jan. 05, 2028		Jan. 05, 2028			Jan. 05, 2028
Common Stock [Member]
Class of Stock [Line Items]
Number of shares issued	4,800,000		235,714	235,714						235,714
Price per share			$ 8.75	$ 8.75
Stock Issued During Period, Shares, Exercise of Warrants							1,129,985			1,237,127

XML

The following table provides the initial allocation of the offering proceeds between the common stock and the Warrants issued: (Details) - USD ($)				3 Months Ended		9 Months Ended
	Aug. 04, 2023	Mar. 16, 2023	Mar. 16, 2023	Sep. 30, 2023	Sep. 30, 2022	Sep. 30, 2023	Sep. 30, 2022	Dec. 31, 2022
Class of Stock [Line Items]
Common Stock Issued, value
Warrants Issued				6,184,323		6,184,323
Warrants Issued, value				$ 302,170		$ 302,170		$ 7,492
Day 1 Loss due to Excess Warrant Fair Value		$ (2,476,109)				$ (2,476,109)
Gross Proceeds		$ 2,999,250	$ 3,000,000.0
Prefunded Warrants [Member]
Class of Stock [Line Items]
Warrants Issued		107,142	107,142
Warrants Issued, value		$ 899,388	$ 899,388
Common Stock Warrants [Member]
Class of Stock [Line Items]
Warrants Issued		685,714	685,714
Warrants Issued, value		$ 4,575,971	$ 4,575,971
Common Stock [Member]
Class of Stock [Line Items]
Common Stock Issued	4,800,000	235,714	235,714			235,714
Common Stock Issued, value						$ 24

XML

The following table summarizes the outstanding stock option activity under the 2009 Equity Incentive Plan for the nine months ended September 30, 2023: (Details) - 2009 Equity Incentive Plan [Member]	9 Months Ended
	Sep. 30, 2023 $ / shares shares
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Total outstanding and vested and expected to vest at beginning | shares	61,525
Total outstanding and vested and expected to vest at beginning | $ / shares	$ 291.41
Options outstanding, weighted average remaining contractual term at beginning	2 years 1 month 2 days
Options cancelled/expired | shares	(29,068)
Options cancelled/expired, weighted average exercise price | $ / shares	$ 280.26
Total outstanding at ending | shares	32,457
Options outstanding, weighted average exercise price, ending balance | $ / shares	$ 306.44
Options outstanding, weighted average remaining contractual term at ending	2 years 5 months 8 days

XML

The following table summarizes the outstanding stock option activity for the non-plan awards for the nine months ended September 30, 2023: (Details) - Non Plan Awards [Member]	9 Months Ended
	Sep. 30, 2023 $ / shares shares
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Total outstanding and vested and expected to vest at beginning | shares	1,857
Total outstanding and vested and expected to vest at beginning | $ / shares	$ 43.40
Options outstanding, weighted average remaining contractual term at beginning	9 years 1 month 17 days
Options cancelled | shares	(429)
Options cancelled, weighted average exercise price | $ / shares	$ 43.40
Total outstanding at ending | shares	1,428
Options outstanding, weighted average exercise price, ending balance | $ / shares	$ 43.40
Options outstanding, weighted average remaining contractual term at ending	8 years 4 months 17 days
Vested and expected to vest at ending | shares	952
Options vested, weighted average exercise price at ending | $ / shares	$ 43.40
Options vested, weighted average remaining contractual term	8 years 4 months 17 days

XML

The following table summarizes the RSUs outstanding at September 30, 2023: (Details) - Restricted Stock Units (RSUs) [Member]	9 Months Ended
	Sep. 30, 2023 $ / shares shares
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Non-vested RSUs, beginning | shares	9,286
Weighted average grant date fair value, beginning | $ / shares	$ 325.13
RSUs vested during the period | shares	(2,143)
Weighted average grant date fair value, vested | $ / shares	$ 592.20
RSUs forfeited during the period | shares
Weighted average grant date fair value, forfeited | $ / shares
Non-vested RSUs, ending | shares	7,143
Weighted average grant date fair value, ending | $ / shares	$ 245.00
RSUs expected to vest | shares	7,143
Weighted average grant date fair value, RSUs expected to vest | $ / shares	$ 245.00

XML

The following summarizes stock-based compensation recognized for the three months ended September 30, 2023 and 2022: (Details) - USD ($)	3 Months Ended		9 Months Ended
	Sep. 30, 2023	Sep. 30, 2022	Sep. 30, 2023	Sep. 30, 2022
Total	$ (44,693)	$ 74,488	$ 76,799	$ (14,311)
Research and Development Expense [Member]
Total	(69,835)	3,654	(69,835)	122,746
Selling, General and Administrative Expenses [Member]
Total	$ 25,142	$ 70,834	$ 146,634	$ (137,057)

XML

The following table summarizes warrants issued and outstanding as of September 30, 2023: (Details) - $ / shares	9 Months Ended
	Sep. 30, 2023	Jul. 05, 2022
Class of Warrant or Right [Line Items]
Number of warrants outstanding	6,184,323
Old Adamis Warrants [Member]
Class of Warrant or Right [Line Items]
Number of warrants outstanding	840
Warrant exercise price (in dollars per share)	$ 595.00
Date issued	Nov. 15, 2007
Warrants expiration date	Nov. 15, 2023
Warrants 2019 [Member]
Class of Warrant or Right [Line Items]
Number of warrants outstanding	197,055
Warrant exercise price (in dollars per share)	$ 80.50
Date issued	Aug. 05, 2019
Warrants expiration date	Aug. 05, 2024
Warrants 2020 [Member]
Class of Warrant or Right [Line Items]
Number of warrants outstanding	5,000
Warrant exercise price (in dollars per share)	$ 49.00
Date issued	Feb. 25, 2020
Warrants expiration date	Sep. 03, 2025
Series C Preferred Warrants [Member]
Class of Warrant or Right [Line Items]
Number of warrants outstanding	10,714
Warrant exercise price (in dollars per share)	$ 32.90	$ 32.90
Date issued	Jul. 05, 2022
Warrants expiration date	Jan. 05, 2028	Jan. 05, 2028
March 2023 Common Stock Warrants [Member]
Class of Warrant or Right [Line Items]
Number of warrants outstanding	685,714
Warrant exercise price (in dollars per share)	$ 9.66
Date issued	Mar. 16, 2023
Warrants expiration date	Sep. 16, 2028
August 2023 Common Stock Warrants [Member]
Class of Warrant or Right [Line Items]
Number of warrants outstanding	5,285,000
Warrant exercise price (in dollars per share)	$ 1.35
Date issued	Aug. 04, 2023
Warrants expiration date	Aug. 04, 2028

XML

As of September 30, 2023, the Company has reserved shares of common stock for issuance upon exercise of outstanding options, warrants including all of the warrants in the table above and restricted stock units, as follows: (Details)	Sep. 30, 2023 shares
Class of Stock [Line Items]
Number of common stock reserved for future issuance	8,366,515
Series C Preferred Stock [Member]
Class of Stock [Line Items]
Number of common stock reserved for future issuance	697,674
Series E Preferred Stock [Member]
Class of Stock [Line Items]
Number of common stock reserved for future issuance	1,212,000
DMK Options assumed by Adamis [Member]
Class of Stock [Line Items]
Number of common stock reserved for future issuance	231,490
Non Plan Awards [Member]
Class of Stock [Line Items]
Number of common stock reserved for future issuance	1,428
2009 Equity Incentive Plan [Member]
Class of Stock [Line Items]
Number of common stock reserved for future issuance	32,457
Restricted Stock Units (RSUs) [Member]
Class of Stock [Line Items]
Number of common stock reserved for future issuance	7,143
Warrant [Member]
Class of Stock [Line Items]
Number of common stock reserved for future issuance	6,184,323

XML

Commitments and Contingencies (Details Narrative) - USD ($)	3 Months Ended	9 Months Ended
	Sep. 30, 2023	Sep. 30, 2023	Sep. 30, 2022	Aug. 01, 2023
Other Commitments [Line Items]
Maintenance fees	$ 268,000	$ 804,000
Impairment of Right-of-Use Assets		116,934
Operating Lease [Member]
Other Commitments [Line Items]
Monthly rent				$ 32,000
Impairment of Right-of-Use Assets	$ 116,934	$ 116,934